<SEC-DOCUMENT>0001615774-18-011677.txt : 20181031
<SEC-HEADER>0001615774-18-011677.hdr.sgml : 20181031
<ACCEPTANCE-DATETIME>20181031155719
ACCESSION NUMBER:		0001615774-18-011677
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		8
FILED AS OF DATE:		20181031
DATE AS OF CHANGE:		20181031

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Eton Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001710340
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				371858472
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-226774
		FILM NUMBER:		181150228

	BUSINESS ADDRESS:	
		STREET 1:		12264 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		858-704-4040

	MAIL ADDRESS:	
		STREET 1:		12264 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>s113558_s1a.htm
<DESCRIPTION>S-1/A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>As filed with the Securities and
Exchange Commission on October 31, 2018</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-226774</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>UNITED
STATES</B></FONT><BR>
<FONT STYLE="font-size: 12pt"><B>SECURITIES AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Amendment
No. 3</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>to&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>FORM S-1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REGISTRATION STATEMENT</B><BR>
<B>UNDER</B><BR>
<B>THE SECURITIES ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>ETON PHARMACEUTICALS,
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified
in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 34%; text-align: center"><FONT STYLE="font-size: 10pt"><B>2834</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>37-1858472</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Primary Standard Industrial</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">incorporation or organization)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Classification Code Number)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>21925 W. Field Parkway, Suite 235</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Deer Park, Illinois 60010</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(847) 787-7361</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address, including zip code, and telephone
number, including area code, of registrant&rsquo;s principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Sean E. Brynjelsen</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>President and Chief Executive Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Eton Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>21925 W. Field Parkway, Suite 235</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Deer Park, Illinois 60010</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(847) 787-7361</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name, address, including zip code, and
telephone number, including area code, of agent for service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Copies to:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Daniel
                                         K. Donahue, Esq.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Christopher M. Piazza, Esq.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Greenberg Traurig, LLP</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>3161 Michelson Drive, Suite 1000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Irvine, California 92612</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Telephone: (949) 732-6557</B></P></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 34%; text-align: center"></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 32%; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Martin
                                         C. Glass, Esq.</B><BR>
                                         <B>Jenner &amp; Block LLP</B><BR>
                                         <B>919 Third Avenue</B><BR>
                                         <B>New York, New York 10022</B><BR>
                                         <B>Telephone: (212) 891-1600</B></P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Approximate date of commencement of proposed sale to the
public: As soon as practicable after this registration statement becomes effective.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">If any of the
securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities
Act of 1933 check the following box. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">If this Form
is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the
same offering. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">If this Form
is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">If this Form
is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company.
See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company&rdquo;
and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act (check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%; text-indent: 0in"><FONT STYLE="font-size: 10pt">Large accelerated filer</FONT></TD>
    <TD STYLE="width: 4%; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 24%; text-indent: 0in"><FONT STYLE="font-size: 10pt">Accelerated filer</FONT></TD>
    <TD STYLE="width: 23%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in"><FONT STYLE="font-size: 10pt">Non-accelerated filer</FONT></TD>
    <TD STYLE="text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD></TD>
    <TD STYLE="text-indent: 0in"><FONT STYLE="font-size: 10pt">Smaller reporting company</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" NOWRAP STYLE="text-indent: 0in"></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</FONT></TD>
    <TD>&#9746;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CALCULATION OF REGISTRATION FEE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> Title&nbsp;of&nbsp;Each&nbsp;Class&nbsp;of<BR>
    Securities&nbsp;to&nbsp;be&nbsp;Registered </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> Proposed&nbsp;Maximum<BR>
    Aggregate&nbsp;Offering&nbsp;Price<SUP>(1)</SUP> </TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> Amount&nbsp;of<BR> Registration&nbsp;Fee<SUP>(5)</SUP> </TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 65%; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"> Common Stock, $0.001 par value per
    share </TD><TD STYLE="width: 1%; padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 15%; text-align: right"> 20,700,000 </TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%; padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 14%; text-align: right"> 2,577.15 </TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left"> &nbsp; </TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0in"> Underwriter Warrant (2)(3)(4) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 100 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &mdash; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in"> Shares of Common Stock underlying Underwriter
    Warrant </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2,587,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 322.15 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Estimated solely for the purpose of computing the amount of
    the registration fee pursuant to Rule&nbsp;457(o)&nbsp;under the Securities Act of 1933, as amended. Includes the aggregate
    offering price of additional shares that the underwriter has the option to purchase to cover over-allotments, if any.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">No registration
                                         fee required pursuant to Rule 457(g) under the Securities Act of 1933.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(3)</TD><TD STYLE="text-align: justify">Registers
                                         a warrant to be granted to the underwriter for an amount equal to 10% of the number of
                                         the shares sold to the public.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: left">(4)</TD><TD STYLE="text-align: justify">Pursuant to Rule 416 under the Securities
                                         Act of 1933, this registration statement shall be deemed to cover the additional securities
                                         (i) to be offered or issued in connection with any provision of any securities purported
                                         to be registered hereby to be offered pursuant to terms which provide for a change in
                                         the amount of securities being offered or issued to prevent dilution resulting from stock
                                         splits, stock dividends, or similar transactions and (ii) of the same class as the securities
                                         covered by this registration statement issued or issuable prior to completion of the
                                         distribution of the securities covered by this registration statement as a result of
                                         a split of, or a stock dividend on, the registered securities.</TD>
</TR>     <TR STYLE="vertical-align: top">
<TD STYLE="text-align: left"> (5) </TD><TD STYLE="text-align: justify"> Of which, $2,886.41 has been previously paid. </TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><B>The Registrant hereby amends this Registration
Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment,
which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a)&nbsp;of
the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Securities and Exchange
Commission, acting pursuant to said Section&nbsp;8(a), may determine.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: red">THE INFORMATION
IN THIS PROSPECTUS IS NOT COMPLETE AND MAY BE CHANGED. THESE SECURITIES MAY NOT BE SOLD UNTIL THE REGISTRATION STATEMENT FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION IS EFFECTIVE. THIS PROSPECTUS IS NOT AN OFFER TO SELL THESE SECURITIES AND WE ARE
NOT SOLICITING AN OFFER TO BUY THESE SECURITIES IN ANY STATE WHERE THE OFFER OR SALE IS NOT PERMITTED.</P>

<P STYLE="color: red; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="color: red; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> SUBJECT TO COMPLETION,
DATED OCTOBER 31, 2018 </P>

<P STYLE="color: red; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">3,000,000 Shares of Common Stock</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt">ETON
PHARMACEUTICALS, INC.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Eton Pharmaceuticals,
Inc. is offering shares of common stock on a firm commitment basis. This is an initial public offering of our common stock and
there is presently no public market for our common stock. The initial public offering price is $6.00 per share. We intend to apply
for listing of our common stock on the NASDAQ Global Market under the symbol &ldquo;ETON.&rdquo; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>We are an &ldquo;emerging
growth company&rdquo; under the federal securities laws and will have the option to use reduced public company reporting requirements.
Please see &ldquo;Risk Factors&rdquo; beginning on page 6 to read about certain factors you should consider before buying our
securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Neither the Securities
and Exchange Commission nor any other regulatory body has approved or disapproved these securities or passed upon the accuracy
or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP> &nbsp; </TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> Price to Public </TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> Underwriting<BR> Discounts
    and <BR> Commissions (1) </TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> Proceeds to<BR> Eton<BR>
    &nbsp;Pharmaceuticals,<BR> Inc. </TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; padding-bottom: 1pt"> Per Share </TD><TD STYLE="width: 1%; padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1pt solid"> $ </TD><TD STYLE="width: 10%; text-align: right; border-bottom: Black 1pt solid"> 6.00 </TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="width: 1%; padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1pt solid"> $ </TD><TD STYLE="width: 10%; text-align: right; border-bottom: Black 1pt solid"> 0.49 </TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="width: 1%; padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1pt solid"> $ </TD><TD STYLE="width: 10%; text-align: right; border-bottom: Black 1pt solid"> 5.51 </TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 1pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"> Total Offering </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double"> $ </TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double"> 18,000,000 </TD><TD STYLE="text-align: left; padding-bottom: 2.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double"> $ </TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double"> 1,476,000 </TD><TD STYLE="text-align: left; padding-bottom: 2.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double"> $ </TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double"> 16,524,000 </TD><TD STYLE="text-align: left; padding-bottom: 2.5pt"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Does not
                                         include our obligation to reimburse the underwriter for its expenses in an amount not
                                         to exceed $200,000. See &ldquo;Underwriting&rdquo; for a description of the compensation
                                         payable to the underwriter.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The underwriter may
also purchase an additional&nbsp;450,000 shares of our common stock amounting to 15% of the number of shares offered to the public,
within 45 days of the date of this prospectus, to cover over-allotments, if any, on the same terms set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The underwriter expects to deliver the
shares on or about , 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>National
Securities Corporation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Table of
Contents</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%; text-align: right; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right; font-weight: bold; vertical-align: bottom">Page</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right; font-weight: bold"></TD>
    <TD STYLE="text-align: right; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-transform: uppercase"><A HREF="#a_001">Prospectus Summary</A></TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom"><A HREF="#a_001">1</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-transform: uppercase"><A HREF="#a_002">RISK FACTORS</A></TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom"><A HREF="#a_002">6</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-transform: uppercase"><A HREF="#a_003">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom"><A HREF="#a_003">28</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-transform: uppercase"><A HREF="#a_004">OUR BUSINESS</A></TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom"><A HREF="#a_004">29</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-transform: uppercase"><A HREF="#a_005">MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
    RESULTS OF OPERATIONS</A></TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom"><A HREF="#a_005">41</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-transform: uppercase"><A HREF="#a_006">MANAGEMENT</A></TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom"><A HREF="#a_006">44</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-transform: uppercase"><A HREF="#a_007">PRINCIPAL STOCKHOLDERS</A></TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom"><A HREF="#a_007">55</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-transform: uppercase"><A HREF="#a_008">ESTIMATED USE OF PROCEEDS</A></TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom"><A HREF="#a_008">56</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-transform: uppercase"><A HREF="#a_009">CAPITALIZATION</A></TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom"><A HREF="#a_009">57</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-transform: uppercase"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif">DILUTION</FONT></A></TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom"><A HREF="#a_010">59</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-transform: uppercase"><A HREF="#a_011">DESCRIPTION OF SECURITIES</A></TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom"><A HREF="#a_011">61</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-transform: uppercase"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif">SHARES ELIGIBLE
    FOR FUTURE SALE</FONT></A></TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom"><A HREF="#a_012">64</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-transform: uppercase"><A HREF="#a_013">UNDERWRITING</A></TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom"><A HREF="#a_013">66</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-transform: uppercase"><A HREF="#a_014">LEGAL MATTERS</A></TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom"><A HREF="#a_014">71</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-transform: uppercase"><A HREF="#a_015">EXPERTS</A></TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom"><A HREF="#a_015">71</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-transform: uppercase"><A HREF="#a_016">WHERE YOU CAN FIND MORE INFORMATION</A></TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom"><A HREF="#a_016">71</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-transform: uppercase"><A HREF="#a_017">INDEX TO FINANCIAL STATEMENTS</A></TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom"><A HREF="#a_017">72</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither we nor the underwriter has authorized
anyone to provide any information or make any representations other than those contained in this prospectus or in any free writing
prospectus prepared by or on behalf of us or to which we have referred you. Neither we nor the underwriter takes responsibility
for, and can provide no assurance as to the reliability of, any other information that others may give you. We are offering to
sell, and seeking offers to buy, shares of common stock only in jurisdictions where offers and sales are permitted. The information
contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus
or of any sale of the common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Through and including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
, 2018 (the 25th&nbsp;day after the date of this prospectus), all dealers effecting transactions in these securities, whether
or not participating in this offering, may be required to deliver a prospectus. This is in addition to a dealer&rsquo;s obligation
to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For investors outside of the United States:
Neither we nor the underwriter has done anything that would permit this offering or possession or distribution of this prospectus
in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States
are required to inform themselves about, and to observe any restrictions relating to, this offering and the distribution of this
prospectus outside of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">(<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence -->)</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<center><div STYLE="BORDER:solid BLACK 1pt;padding-left:1%;padding-Right:1%;width:98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_001"></A>Prospectus
Summary</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Investing in our
common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together
with all of the other information in this prospectus, including our financial statements and related notes, before investing in
our common stock. If any of the following risks materialize, our business, financial condition, operating results and prospects
could be materially and adversely affected. In that event, the price of our common stock could decline, and you could lose part
or all of your investment.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Our Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Eton Pharmaceuticals,
Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative pharmaceutical products utilizing
the FDA&rsquo;s 505(b)(2) regulatory pathway. Our business model is to develop proprietary innovative products that fulfill an
unmet patient need.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The 505(b)(2) pathway
is intended for molecules that have been previously approved by the FDA or have already been proven to be safe and effective.
A 505(b)(2) product typically reformulates the known molecule in a new strength or dosage form. 505(b)(2) products have the advantage
of potentially significantly lower development costs and shorter development timelines versus traditional new molecular entities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A 505(b)(2) NDA is an
application that contains full reports of investigations of safety and effectiveness, but where at least some of the information
required for approval comes from studies not conducted by or for the applicant. This alternate regulatory pathway enables the
applicant to rely, in part, on the FDA&rsquo;s findings of safety and efficacy for an existing product, or published literature,
in support of its application. A 505(b)(2) product candidate might rely on the clinical studies or literature of a previously
FDA-approved drug, or rely on the literature and physician usage of an FDA-unapproved drug. We believe there is a significant
opportunity to pursue alternative formulations of off-patent drugs using the 505(b)(2) regulatory pathway.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"> <B>Our Products</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have established
a diversified pipeline of product candidates in various stages of development. Our six lead products include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"> <B>Innovative Formula Products</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Three innovative formula products
for which we have developed unique formulations of already approved molecules that we believe will provide a significant safety,
efficacy, or cost benefit to patients and practitioners:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.3pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54.3pt"></TD><TD STYLE="width: 18pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">EM-100
                                         is an ophthalmic product with a unique preservative-free formulation of the active ingredient
                                         ketotifen, and is indicated for the treatment of allergic conjunctivitis. EM-100 is expected
                                         to be the first preservative-free ophthalmic product approved for allergic conjunctivitis.
                                         According to IRI, a market research organization, the market for ketotifen ophthalmic
                                         anti-allergy products is more than $55 million annually. We believe our EM-100 product
                                         candidate will address the entire $55 million market for ketotifen ophthalmic anti-allergy products and we expect to capture a small percentage of the market
with our EM-100 product candidate. An ANDA for EM-100 has been filed
                                         with the FDA and we anticipate receiving marketing approval in 2019.</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.3pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54.3pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">ET-103
                                         is an oral liquid formulation of levothyroxine, which is widely used in tablet and capsule
                                         form, and is indicated for the treatment of hypothyroidism. According to IQVIA, an independent
                                         pharmaceutical data company, the market for ET-103&rsquo;s active ingredient in tablet
                                         and capsule form is greater than $2.6 billion annually, and we expect to convert a small
                                         percentage of the tablet market to our liquid product. We believe our innovative formula
                                         will provide a significant benefit to geriatric and pediatric patients that have trouble
                                         swallowing pills.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.3pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54.3pt"></TD><TD STYLE="width: 18pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">CT-100
                                         is our patent-pending synthetic corticotropin therapeutic candidate that mimics the amino
                                         acid chain of injectable product H.P. Acthar Gel. H.P Acthar Gel currently sells for
                                         a list price of over $38,000 per vial and is currently approved for 19 indications,
                                         including as a prescription add-on medicine for the short-term administration of rheumatoid
                                         arthritis to tide patients over an acute episode or exacerbation. We believe that the
                                         annual sales of H.P. Acthar Gel for all 19 indications exceed $1 billion, and that 10% to 20% of the patients using H.P. Acthar Gel are
being treated for the rheumatoid arthritis indication. We intend to pursue one indication for CT-100, as a prescription add-on medicine
                                         for the short-term administration of rheumatoid arthritis to tide patients over an acute
                                         episode or exacerbation. We believe our CT-100 product candidate will address the
                                         entire market presently served by H.P. Acthar Gel for the rheumatoid arthritis indication and we expect to capture a small percentage of the market with our CT-100 product candidate.
                                         We believe CT-100 would provide patients with an alternative treatment option at a discounted
                                         price.</FONT> </TD></TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We have held two written response
meetings with the FDA regarding CT-100 and we are currently working with a clinical research organization to analyze the cost
and protocol for CT-100&rsquo;s clinical program based on the FDA&rsquo;s feedback. If the project is determined to be cost prohibitive
for us, we may seek to partner with or license the product to a larger or more well-capitalized company. For this reason, as of
the date of this prospectus, we are unable to estimate the amount required to fund CT-100 through regulatory approval and we do
not intend to allocate a meaningful amount of our cash on hand or net proceeds of this offering towards CT-100. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> <B>DESI Conversion Products</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Three products
that are reformulations of currently unapproved, or DESI drugs, by which we will seek to convert the market from the DESI product
to our product candidate for which we are seeking FDA approval: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">DS-300
                                         is a patent-pending injectable product candidate indicated to treat nutritional deficiencies in neonates.
                                         The DESI product we are targeting with DS-300 has annual sales of approximately $19 million.
                                         Our DS-300 product candidate has been granted Fast Track Designation and an NDA for the
                                         product has been filed under a rolling review. We expect the product to be approved in
                                         2019.</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">DS-200
                                         is an injectable product candidate indicated to treat nutritional deficiencies. The DESI
                                         product we are targeting with DS-200 has annual sales of approximately $6 million. Our
                                         DS-200 product candidate was also granted Fast Track Designation and we expect the product&rsquo;s
                                         NDA will be filed in 2019.</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">DS-100
                                         is an injectable product candidate indicated for therapeutic neurolysis for the relief
                                         of intractable pain, generally defined as <FONT STYLE="font-size: 10pt">severe, constant
                                         pain that is not curable by any known means. The DESI product we are targeting with DS-100
                                         has annual sales of approximately $11 million. </FONT> We expect the product&rsquo;s NDA
                                         will be filed in 2019.</FONT> </TD></TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We will seek
to convert the market from the current DESI products to our product candidates for which we are seeking FDA approval. DESI
products, also known as &ldquo;grandfathered&rdquo; or &ldquo;unapproved&rdquo; products, are products that were marketed
prior to 1962 when the FDA began requiring proof of efficacy, in addition to safety, in order to gain approval. The FDA has
allowed DESI products to remain on the market until someone receives formal FDA approval for the molecule. We will pursue a
formal approval via the 505(b)(2) NDA pathway for our products. Based on the FDA&rsquo;s published guidance document, we
would expect the currently marketed DESI product to exit the market within one year of our product&rsquo;s approval. However,
none of our DESI conversion products are subject to patent protection or market exclusivity under the provisions of the
Federal Food, Drug and Cosmetic Act, or FDCA. Following FDA approval of our product candidates for which we have no patent
protection or market exclusivity, our competitors may seek to develop a competing product pursuant to the 505(j) pathway,
which is an abbreviated pathway used for the regulatory approval of generic product candidates. As a result of the foregoing,
and the fact that 505(b)(2) product candidates generally have shorter timelines to, and lower cost of, regulatory approval,
we may find that the market opportunity for our product candidates that target DESI products and for which we have no patent
protection or market exclusivity is relatively small due to the fact that barriers to entry are low and generic competition
may follow within relatively short time periods after our product is approved. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0"> <B>Early Stage Products</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">We also have two early stage
products under development:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">ET-101.
                                         ET-101 is an innovative oral liquid product for use in the treatment of epilepsy. The
                                         active ingredient in ET-101 is FDA-approved in an oral solid dosage form but is not approved
                                         in oral liquid form. We anticipate submitting a patent application on our unique formulation
                                         and expect to file the NDA for ET-101 in 2020. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">ET-102.
                                         ET-102 is an innovative oral liquid product for use as a muscle relaxant in the treatment
                                         of muscle contractions due to multiple sclerosis. The active ingredient in ET-102 is
                                         FDA-approved in an oral solid dosage form but is not approved in an oral liquid form.
                                         We expect to file the NDA for ET-102 in 2020.</FONT></TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to focus
on product candidates that are liquid in formulation, including injections, oral liquids and ophthalmics, and qualify under the
FDA&rsquo;s 505(b)(2) regulatory pathway. Our corporate strategy is to pursue what we perceive to be low-risk 505(b)(2) candidates
where existing published literature, historical clinical trials, or physician usage has established safety and/or efficacy of
the molecule, thereby reducing the incremental clinical burden required for us to bring the product to patients. We intend to
focus on product candidates that we believe will offer innovative and proprietary functional advantages to currently available
alternatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to pursue
product candidates that require a single small Phase 3 trial, a bio-equivalence trial, or literature-based filings. Prior to initiating
significant development activities on a product candidate, we typically meet with the FDA to establish a defined clinical and
regulatory path to approval. We intend to pursue product opportunities where patient demand is not being met by current FDA-approved
pharmaceutical products. This may include products that are being supplied on an unapproved basis, products that are currently
being compounded, internationally approved products that are widely used offshore but not approved in the United States, or approved
products where we believe we can provide a lower-cost alternative to an existing high-priced branded product. While we may opportunistically
pursue 505(b)(2) opportunities across all dosage forms, we are primarily focused on liquid products, including injectables, oral
liquids and ophthalmics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2017 Private Placement of Series A Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 20, 2017,
we completed the private placement of 6,685,082 shares of our Series A preferred stock, at an offering price of $3.00 per share,
for the gross proceeds of approximately $20.1 million. Pursuant to the terms of our current amended and restated certificate of
incorporation, the Series A preferred stock accumulates dividends at the rate of 6% per annum. The shares of Series A preferred
stock plus all accrued but unpaid dividends on the Series A preferred stock will automatically convert into shares of our common
stock concurrent with the completion of this offering, at the conversion price of 50% of the initial public offering price, provided,
however, in no event shall the conversion price be greater than $3.00 nor less than $2.25 per share. Assuming that this offering
was completed on June 30, 2018 at a price of $6.00 per share, and based on dividends accrued through such date in the amount of
$1,242,875, the Series A preferred stock would have converted into&nbsp;7,099,374 shares of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</div>
</center>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<center><div STYLE="BORDER:solid BLACK 1pt;padding-left:1%;padding-Right:1%;width:98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>Risks Related
to Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business is subject
to numerous risks, which are highlighted in the section &ldquo;Risk Factors&rdquo; immediately following this prospectus summary.
Some of those risks include:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         future financial and operating results;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         report of our independent registered public accounting firm as of and for the period
                                         ended December 31, 2017 states that due to our accumulated deficit and negative operating
                                         cash flows and potential redemption demands under our redeemable convertible preferred
                                         stock there is substantial doubt about our ability to continue as a going concern;</FONT></TD></TR></TABLE>



<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         intentions, expectations and beliefs regarding anticipated growth, market penetration
                                         and trends in our business;</FONT></TD></TR></TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         timing and success of our plan of commercialization;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         ability to successfully develop and clinically test our product candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         ability to file for FDA approval of our product candidates through the 505(b)(2) regulatory
                                         pathway;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         ability to obtain FDA approval for any of our product candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         ability to comply with all U.S. and foreign regulations concerning the development, manufacture
                                         and sale of our product candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         adequacy of the net proceeds of this offering;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         effects of market conditions on our stock price and operating results;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         ability to maintain, protect and enhance our intellectual property and the risks associated
                                         with the fact that we hold only two patent applications at this time and no issued patents;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         effects of increased competition in our market and our ability to compete effectively;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         plans to use the proceeds from this offering;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">costs
                                         associated with initiating and defending intellectual property infringement and other
                                         claims;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         attraction and retention of qualified employees and key personnel;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">future
                                         acquisitions of or investments in complementary companies or technologies; and</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         ability to comply with evolving legal standards and regulations, particularly concerning
                                         requirements for being a public company.</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were incorporated
under the laws of the state of Delaware in April 2017. We were initially a wholly-owned subsidiary of Imprimis Pharmaceuticals,
Inc., or Imprimis. On June 20, 2017, we completed a Series A preferred stock financing with third-party investors and, as of December
31, 2017, Imprimis owned 3,500,000 shares of our common stock, or approximately 27% of our capital stock on an as-converted to
common stock basis. We are no longer a subsidiary of Imprimis. Our principal executive offices are located at 21925 W. Field Parkway,
Suite 235, Deer Park, Illinois, 60010, and our telephone number is (847) 787-7361. Our website address is www.etonpharma.com.
The information contained in, or accessible through, our website is not incorporated by reference into this prospectus, and you
should not consider any information contained in, or that can be accessed through, our website as part of this prospectus or in
deciding whether to purchase our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We own two U.S. federal
trademark applications and unregistered trademarks, including our company name. All other trademarks or trade names referred to
in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this
prospectus are referred to without the symbols &reg; and &trade;, but such references should not be construed as any indication
that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Emerging Growth Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Jumpstart Our
Business Startups Act, or the JOBS Act, was enacted in April 2012 with the intention of encouraging capital formation in the United
States and reducing the regulatory burden on newly public companies that qualify as &ldquo;emerging growth companies.&rdquo; We
are an emerging growth company within the meaning of the JOBS Act. As an emerging growth company, we may take advantage of certain
exemptions from various public reporting requirements, including:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
</div>
</center>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<center><div STYLE="BORDER:solid BLACK 1pt;padding-left:1%;padding-Right:1%;width:98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         requirement that our internal control over financial reporting be attested to by our
                                         independent registered public accounting firm pursuant to Section&nbsp;404 of the Sarbanes-Oxley
                                         Act of 2002;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">certain
                                         requirements related to the disclosure of executive compensation in this prospectus and
                                         in our periodic reports and proxy statements;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         requirement that we hold a nonbinding advisory vote on executive compensation and any
                                         golden parachute payments; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">the
                                         ability to delay compliance with new or revised financial accounting standards until
                                         private companies are required to comply with the new or revised financial accounting
                                         standard.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may take advantage
of the exemptions under the JOBS Act discussed above until we are no longer an emerging growth company. We will remain an emerging
growth company until the earliest to occur of (1)&nbsp;the last day of the fiscal year in which we have $1.07&nbsp;billion or
more in annual revenue; (2)&nbsp;the date we qualify as a &ldquo;large accelerated filer,&rdquo; with at least $700&nbsp;million
of equity securities held by non-affiliates; (3)&nbsp;the date on which we have issued, in any three-year period, more than $1.0&nbsp;billion
in non-convertible debt securities; or (4)&nbsp;the last day of the fiscal year ending after the fifth anniversary of our initial
public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may choose to take
advantage of some, but not all, of the available benefits under the JOBS Act. We are choosing to irrevocably &ldquo;opt out&rdquo;
of the extended transition periods available under the JOBS Act for complying with new or revised accounting standards, but we
intend to take advantage of the other exemptions discussed above. Accordingly, the information contained herein and in our subsequent
filing with the Securities and Exchange Commission may be different than the information you receive from other public companies
in which you hold stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For certain risks
related to our status as an emerging growth company, see the disclosure elsewhere in this prospectus under &ldquo;Risk Factors
&mdash; Risks Related to this Offering and Owning Our Common Stock &mdash; We are an &lsquo;emerging growth company&rsquo; under
the JOBS Act of 2012 and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will
make our common stock less attractive to investors.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36%; text-align: justify">Common stock offered by us</TD>
    <TD STYLE="width: 3%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 61%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3,000,000 shares</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Common stock to be outstanding after this</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;&nbsp;offering</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">16,318,354 shares</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Over-allotment option offered by us</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">450,000 shares</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Proposed NASDAQ symbol</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&ldquo;ETON&rdquo;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> Use of proceeds </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> We estimate that the net proceeds from the sale of the shares of common stock in this offering
    will be approximately $15.8 million, or approximately $18.3 million if the underwriter exercises its option to purchase additional
    shares in full, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable
    by us. We intend to use the net proceeds from this offering for clinical trials and product development, FDA filing fees,
    laboratory expansion, as well as for other general corporate purposes, including general and administrative expenses and working
    capital. See &ldquo;Estimated Use of Proceeds&rdquo;. </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify; text-indent: -3in">&nbsp;</P>
</div>
</center>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0; text-align: justify">&nbsp;</P>
<center><div STYLE="BORDER:solid BLACK 1pt;padding-left:1%;padding-Right:1%;width:98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The number of shares
of our common stock to be outstanding after this offering is based on 13,318,354 shares of common stock outstanding as of the
date of this prospectus (including preferred stock on an as-converted basis as of June 30, 2018 assuming a conversion price of
$3.00&nbsp;per share of the Series A preferred stock), and excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,225,000
                                         shares of our common stock issuable upon exercise of outstanding options, with a weighted
                                         average exercise price of $1.43 per share, granted pursuant to our 2017 Equity Incentive
                                         Plan, or the 2017 Plan;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">100,000
                                         shares of common stock issuable upon the settlement of outstanding restricted stock units
                                         pursuant to the 2017 Plan;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">approximately
                                         <FONT STYLE="font-family: Times New Roman, Times, Serif">1,289,548 shares of our common
                                         stock issuable upon exercise of outstanding warrants, with a weighted average exercise
                                         price of $1.61 per share, which includes an estimated 689,548 shares of our common stock
                                         issuable upon exercise of a warrant issued to the underwriter as placement agent compensation
                                         in connection with the offering of our Series A preferred stock;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">up
                                         to 450,000 shares issuable pursuant to the underwriter&rsquo;s over-allotment option;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">300,000
    shares issuable upon exercise of a warrant to be issued to the underwriter as part of its compensation in connection with
    this offering (up to 345,000 shares if the overallotment option is exercised) at an exercise price of $7.50 per share;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">956,020
                                         shares of our common stock to be reserved for future issuance under our 2018 Equity Incentive
                                         Plan, or 2018 Plan, which will become effective at the time of execution of the underwriting
                                         agreement for this offering and contains provisions that automatically increase its share
                                         reserve each year, as more fully described in &ldquo;Executive Compensation&mdash;Equity
                                         Incentive Plans;&rdquo; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">150,000
                                         shares of common stock reserved for issuance under our 2018 Employee Stock Purchase Plan,
                                         or 2018 ESPP, which will become effective at the time of execution of the underwriting
                                         agreement for this offering and which contains provisions that automatically increase
                                         its share reserve each year, as more fully described in &ldquo;Executive Compensation&mdash;Equity
                                         Incentive Plans.&rdquo;</FONT></TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0; text-align: justify">Except as otherwise indicated,
all information in this prospectus assumes:</p>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         automatic conversion of all outstanding shares of our redeemable convertible preferred
                                         stock into an aggregate of 7,099,374&nbsp;shares of common stock in connection with the
                                         closing of this offering (assuming a conversion as of June 30, 2018 at a conversion price
                                         of $3.00 per share of the Series A preferred stock);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">no
                                         exercise of outstanding warrants or options described above;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         filing and effectiveness of our amended and restated certificate of incorporation and
                                         the effectiveness of our amended and restated bylaws, each of which will occur in connection
                                         with the closing of this offering; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">no
                                         exercise of the underwriter&rsquo;s over-allotment option.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>
</div>
</center>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
<center><div STYLE="BORDER:solid BLACK 1pt;padding-left:1%;padding-Right:1%;width:98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Summary Financial Data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following tables
summarize our financial data. You should read this summary financial data together with the section entitled &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and our financial statements and related notes
that are included elsewhere in this prospectus. The financial information for the period from April 27, 2017 (inception) to December
31, 2017 is derived from the audited financial statements that are included elsewhere in this prospectus. The statement of operations
data for the periods ended June 30, 2017 and 2018 and the balance sheet data as of June 30, 2018 have been derived from our unaudited
financial statements that are included elsewhere in this prospectus. The unaudited financial statements were prepared on a basis
consistent with our audited financial statements and include, in management&rsquo;s opinion, all adjustments, consisting only
of normal recurring adjustments that we consider necessary for a fair presentation of the financial information set forth in those
statements. Our historical results are not necessarily indicative of the results that may be expected in the future, and our interim
results are not necessarily indicative of the results to be expected for the full year or any other period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Period from <BR>
    April 27, 2017<BR> (Inception) to <BR>
    December 31, 2017</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Period from <BR>
    April 27, 2017<BR> to <BR> June 30, <BR>
    2017</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six<BR> Months<BR>
    Ended<BR> June 30,<BR> 2018</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center"><B>Statement of Operations Data (in thousands)</B></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>(unaudited)</B></FONT></TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>(unaudited)</B></FONT></TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; text-align: left">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(7,156</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(2,184</TD><TD STYLE="width: 1%; text-align: left">)&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(6,100</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net loss per share attributable to common shareholders - basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(2.50</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.69</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1.80</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif">June
    30, 2018</FONT> </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif">(in thousands)</FONT> </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif">Actual</FONT> </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif">Pro
    Forma <SUP>(1)</SUP></FONT> </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif">Pro
    Forma</FONT><BR> <FONT STYLE="font-family: Times New Roman, Times, Serif">as Adjusted <SUP>(2)</SUP></FONT> </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif">(unaudited)</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD><TD STYLE="font-weight: bold"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif">(unaudited)</FONT> </TD><TD STYLE="font-weight: bold"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD><TD STYLE="font-weight: bold"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif">(unaudited)</FONT> </TD><TD STYLE="font-weight: bold"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">Balance Sheet
    Data:</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">Cash and cash equivalents</FONT> </TD><TD STYLE="width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT> </TD><TD STYLE="width: 10%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">8,946</FONT> </TD><TD STYLE="width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD><TD STYLE="width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="width: 10%; text-align: right"> 8,946 </TD><TD STYLE="width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD><TD STYLE="width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT> </TD><TD STYLE="width: 10%; text-align: right"> 24,952 </TD><TD STYLE="width: 1%; text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">Working capital </FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT> </TD><TD STYLE="text-align: right"> 8,028 </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="text-align: right"> 8,028 </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT> </TD><TD STYLE="text-align: right"> 24,034 </TD><TD STYLE="text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">Total assets</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">9,646</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="text-align: right"> 9,646 </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT> </TD><TD STYLE="text-align: right"> 25,450 </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">Total redeemable convertible preferred
    stock &ndash; Series A</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">20,432</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> &mdash; </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT> </TD><TD STYLE="text-align: right"> &mdash; </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">Total common stock</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">6</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="text-align: right"> 13 </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT> </TD><TD STYLE="text-align: right"> 16 </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">Additional paid-in capital</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">3,225</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="text-align: right"> 46,830 </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT> </TD><TD STYLE="text-align: right"> 62,631 </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">Total shareholders&rsquo; (deficit)
    equity</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">(12,936</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="text-align: right"> 8,512 </TD><TD STYLE="text-align: left"></TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT> </TD><TD STYLE="text-align: right"> 24,316 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><SUP>(1)</SUP> The
pro forma column reflects the automatic conversion of 6,685,082 shares of our Series A preferred stock at the close of this offering
into 7,099,374 shares of our common stock and reclassified into common stock and additional paid-in capital and the reclassification
of the warrant liability into additional paid-in capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><SUP>(2)</SUP> The
pro forma as adjusted column reflects all adjustments included in the pro forma column and gives effect to the sale by us of 3,000,000
shares of common stock offered by this prospectus at the public offering price of $6.00 and deducting estimated underwriting discounts
and commissions and estimated offering expenses payable by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</div>
</center>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_002"></A>RISK
FACTORS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Investing in our
common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together
with all of the other information in this prospectus, including our financial statements and related notes, before investing in
our common stock. If any of the following risks materialize, our business, financial condition, operating results and prospects
could be materially and adversely affected. In that event, the price of our common stock could decline, and you could lose part
or all of your investment.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Relating to Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We are a specialty
pharmaceutical company with a limited operating history, and it is difficult for potential investors to evaluate our business</I></B>.
We are a specialty pharmaceutical company founded in April 2017 and have not commenced revenue-producing operations. To date,
our operations have consisted of the preliminary formulation, testing and development of our initial product candidates. Our limited
operating history makes it difficult for potential investors to evaluate our initial product candidates or our prospective operations.
As an early stage company, we are subject to all the risks inherent in the initial organization, financing, expenditures, complications
and delays in a new business. Further, biopharmaceutical product development is a highly speculative undertaking, involves a substantial
degree of risk, and is a capital-intensive business. Accordingly, you should consider our prospects in light of the costs, uncertainties,
delays and difficulties frequently encountered by companies in the early stages of development, especially clinical-stage biopharmaceutical
companies such as ours. Potential investors should carefully consider the risks and uncertainties that a company with a limited
operating history will face. In particular, potential investors should consider that we may be unable to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">successfully implement
                                         or execute our current business plan, or develop a business plan that is sound;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">successfully complete
                                         clinical trials and obtain regulatory approval for the marketing of our product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">successfully contract
                                         for the manufacture of our clinical drug products and establish a commercial drug supply;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">secure market exclusivity
                                         or adequate intellectual property protection for our product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">attract and retain
                                         an experienced management and advisory team; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">raise sufficient funds
                                         in the capital markets to effectuate our business plan, including clinical development,
                                         regulatory approval and commercialization for our product candidates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Investors should evaluate
an investment in us in light of the uncertainties encountered by developing companies in a competitive environment. There can
be no assurance that our efforts will be successful or that we will ultimately be able to attain profitability. If we cannot successfully
execute any one of the foregoing, our business may not succeed and your investment will be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We have a history
of significant operating losses and anticipate continued operating losses for the foreseeable future.</I></B> From our inception
in April 2017 through December 31, 2017 and for the six months ended June 30, 2018, we incurred a net loss of $7.2&nbsp;million
and $6.1 million, respectively, and our operations used $4.7 million and $4.1 million of cash and cash equivalents, respectively.
Following completion of this offering, we expect to incur substantial expenses without any corresponding revenues unless and until
we are able to obtain regulatory approval and successfully commercialize a product candidate. We expect to incur significant expense
to complete our clinical programs for our product candidates in the United States and elsewhere. We may never be able to obtain
regulatory approval for the marketing of our product candidates in any indication in the United States or internationally. Even
if we are able to commercialize our product candidates, there can be no assurance that we will generate significant revenues or
ever achieve profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to have
significant research, regulatory and development expenses as we advance our product candidates. As a result, we expect to incur
substantial losses for the foreseeable future, and these losses will be increasing. We are uncertain when or if we will be able
to achieve or sustain profitability. If we achieve profitability in the future, we may not be able to sustain profitability in
subsequent periods. Failure to become and remain profitable may impair our ability to sustain operations and adversely affect
our business and our ability to raise capital. If we are unable to generate positive cash flow within a reasonable period of time,
we may be unable to further pursue our business plan or continue operations, in which case you may lose your entire investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The report of our
independent registered public accounting firm as of and for the period ended December 31, 2017 states that due to our accumulated
deficit and negative operating cash flows and potential redemption demands under our redeemable convertible preferred stock there
is substantial doubt about our ability to continue as a going concern.<B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We expect we
will need additional financing to execute our business plan and fund operations, which additional financing may not be available
on reasonable terms or at all.</I></B> As of June 30, 2018, we had total assets of $9.6 million and working capital of $8.0 million.
We believe that we require a minimum of $10&nbsp;million of additional capital in order to fund our current business plan <FONT STYLE="font-family: Times New Roman, Times, Serif">over,
at least, the 12 months following the date of this prospectus, </FONT>including the securing of regulatory approval and commencement
commercial sales of at least one drug product candidate. We further believe that the net proceeds of this offering, along with
our cash on hand, will allow us to fund our business plan over the 24 months following the date of this prospectus without the
need for internally or externally generated capital. We have undertaken this initial public offering of our common shares to acquire
the necessary capital. However, we may require additional capital, the receipt of which there can be no assurance. In the event
we require additional capital, we will endeavor to seek additional funds through various financing sources, including the sale
of our equity and debt securities, licensing fees for our technology and joint ventures with industry partners. In addition, we
will consider alternatives to our current business plan that may enable to us to achieve revenue producing operations and meaningful
commercial success with a smaller amount of capital. However, there can be no guarantees that such funds will be available on
commercially reasonable terms, if at all. If such financing is not available on satisfactory terms, we may be unable to further
pursue our business plan and we may be unable to continue operations, in which case you may lose your entire investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We will need
to grow the size of our organization, and we may experience difficulties in managing this growth</I></B>. As our development and
commercialization plans and strategies develop, we will need to expand the size of our employee and consultant/contractor base.
Future growth would impose significant added responsibilities on members of management, including the need to identify, recruit,
maintain, motivate and integrate additional employees. In addition, our management may have to divert a disproportionate amount
of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities.
Our future financial performance and our ability to commercialize our product candidates and any other future product candidates
and our ability to compete effectively will depend, in part, on our ability to effectively manage our future growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>If we are not
successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.
In addition, the loss of the services of our senior management would adversely impact our business prospects</I></B>. Our management
team has expertise in many different aspects of drug development and commercialization. However, our ability to compete in the
highly competitive pharmaceuticals industry depends in large part upon our ability to attract and retain highly qualified managerial,
scientific and medical personnel. We will need to hire additional personnel as we further develop our product candidates. Competition
for skilled personnel in our market is intense and competition for experienced scientists may limit our ability to hire and retain
highly qualified personnel on acceptable terms. Despite our efforts to retain valuable employees, members of our management, scientific
and medical teams may terminate their employment with us on short notice. The loss of the services of any of our executive officers
or other key employees, or our inability to hire targeted executives, could potentially harm our business, operating results or
financial condition. In particular, we believe that the loss of the services of our chief executive officer would have a material
adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other pharmaceutical
companies with which we compete for qualified personnel have greater financial and other resources, different risk profiles, and
a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement.
Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable to
continue to attract and retain high-quality personnel, the rate and success at which we can develop and commercialize product
candidates would be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>If product liability
lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product
candidates</I></B>. We face a potential risk of product liability as a result of the clinical testing of our product candidates
and will face an even greater risk if we commercialize any of our product candidates or any other future product. For example,
we may be sued if any product we develop, including any of our product candidates, or any materials that we use in our products
allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such
product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers
inherent in the product, negligence, strict liability and a breach of warranties. In the US, claims could also be asserted under
state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial
liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant
financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">decreased demand for
                                         any of our product candidates or any future products that we may develop;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">injury to our reputation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">withdrawal of clinical
                                         trial participants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">costs to defend the
                                         related litigation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">a diversion of management&rsquo;s
                                         time and our resources;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">substantial monetary
                                         awards to trial participants or patients;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">product recalls, withdrawals
                                         or labeling, marketing or promotional restrictions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the inability to commercialize
                                         some or all of our product candidates; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">a decline in the value
                                         of our stock.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of
this prospectus, we carry product liability insurance we consider adequate for our current level of clinical testing and development.
However, we will need additional product liability coverage at the time we commence commercial sale of our initial product. Our
inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product
liability claims could prevent or inhibit the commercialization of products we develop. Although we will endeavor to obtain and
maintain such insurance in coverage amounts we deem adequate, any claim that may be brought against us could result in a court
judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits
of our insurance coverage. Our insurance policies also have various exclusions, and we may be subject to a product liability claim
for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our
coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to
pay such amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We may acquire
businesses or products, or form strategic alliances, in the future, and we may not realize the benefits of such acquisitions</I></B><I>.
</I>We may acquire additional businesses or products, form strategic alliances or create joint ventures with third parties that
we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies,
we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our
existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any
new products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits
or enhancing our business. We cannot assure you that, following any such acquisition, we will achieve the expected synergies to
justify the transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Our business
operations could suffer in the event of information technology systems&rsquo; failures or security breaches. </I></B>While we
believe that we have implemented adequate security measures within our internal information technology and networking systems,
our information technology systems may be subject to security breaches, damages from computer viruses, natural disasters, terrorism,
and telecommunication failures. Any system failure or security breach could cause interruptions in our operations in addition
to the possibility of losing proprietary information and trade secrets. To the extent that any disruption or security breach results
in inappropriate disclosure of our confidential information, our competitive position may be adversely affected and we may incur
liability or additional costs to remedy the damages caused by these disruptions or security breaches.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Sales of counterfeits
of any of our product candidates, as well as unauthorized sales of any of our product candidates, may have adverse effects on
our revenues, business, results of operations and damage our brand and reputation</I></B><I>. </I>Our product candidates may become
subject to competition from counterfeit pharmaceutical products, which are pharmaceutical products sold under the same or very
similar brand names and/or having a similar appearance to genuine products, but which are sold without proper licenses or approvals.
Such products divert sales from genuine products, often are of lower cost, often are of lower quality (having different ingredients
or formulations, for example), and have the potential to damage the reputation for quality and effectiveness of the genuine product.
Obtaining regulatory approval for our product candidates is a complex and lengthy process. If during the period while the regulatory
approval is pending illegal sales of counterfeit products begin, consumers may buy such counterfeit products, which could have
an adverse impact on our revenues, business and results of operations. In addition, if illegal sales of counterfeits result in
adverse side effects to consumers, we may be associated with any negative publicity resulting from such incidents. Although pharmaceutical
regulation, control and enforcement systems throughout the world have been increasingly active in policing counterfeit pharmaceuticals,
we may not be able to prevent third parties from manufacturing, selling or purporting to sell counterfeit products competing with
our product candidates. Such sales may also be occurring without our knowledge. The existence and any increase in production or
sales of counterfeit products or unauthorized sales could negatively impact our revenues, brand reputation, business and results
of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We have
entered into several arrangements with related parties for the development and marketing of certain product candidates and
these arrangements present potential conflicts of interest.</I></B> Our Chief Executive Officer, Sean Brynjelsen, has a
material ownership interest in several companies from which we have licensed or acquired product development and marketing
rights. See, &ldquo;Management &mdash; Related Party Transactions.&rdquo; We are required to pay these entities a combination
of licensing fees, milestone payments and royalty payments. The transactional agreements also subject us to a loss of our
rights to the product candidates in the event we breach any of our representations, warranties or covenants included in the
agreements. While we believe the terms of the transactional agreements, including the licensing fees, milestone payments and
royalty payments, approximate the terms and payments we could have obtained in an arms&rsquo; length transaction with an
unaffiliated party, these arrangements may present Mr. Brynjelsen with a conflict of interest in the event of dispute between
the parties. Although we believe we have mechanisms in place to protect the interests of our stockholders, including a board
of directors, a majority of which are independent and have no interest in these related parties, there can be no assurance
that a conflict of interest will not arise or that any such conflict will not adversely impact the interests of our
stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Product Development,
Regulatory Approval, Manufacturing and Commercialization</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We depend entirely
on the success of our product candidates, which have not yet demonstrated efficacy for their target or any other indications.
If we are unable to generate revenues from our product candidates, our ability to create stockholder value will be limited.</I></B>
Our product candidates are in the early stages of clinical development and as of the date of this prospectus we do not generate
revenues from any FDA approved drug products. An ANDA was submitted for our EM-100 product candidate and an NDA was submitted
for our DS-300 product candidate in January 2018. We expect to submit an Investigational New Drug Applications, or IND, or foreign
equivalent to the FDA or international regulatory authorities for our CT-100 product candidate, and may be required to submit
INDs for our other product candidates, seeking approval to initiate our clinical trials in humans in the United States or other
countries yet to be determined. We plan on submitting our clinical trial protocols and receive approvals from the FDA and international
regulatory authorities before we commence any clinical trials. We may not be successful in obtaining acceptance from the FDA or
comparable foreign regulatory authorities to start our clinical trials. If we do not obtain such acceptance, the time in which
we expect to commence clinical programs for any product candidate will be extended and such extension will increase our expenses
and increase our need for additional capital. Moreover, there is no guarantee that our clinical trials will be successful or that
we will continue clinical development in support of an approval from the FDA or comparable foreign regulatory authorities for
any indication. We note that most product candidates never reach the clinical development stage and even those that do commence
clinical development have only a small chance of successfully completing clinical development and gaining regulatory approval.
Therefore, our business currently depends entirely on the successful development, regulatory approval and commercialization of
our product candidates, which may never occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
face competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete
effectively. </I></B>The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant
technological change. We have existing competitors and potential new competitors in a number of jurisdictions, many of which have
or will have substantially greater name recognition, commercial infrastructures and financial, technical and personnel resources
than we have. Established competitors may invest heavily to quickly discover and develop novel compounds that could make any of
our product candidates obsolete or uneconomical. In addition, mergers and acquisitions in the biotechnology and pharmaceutical
industries may result in even more resources being concentrated among a smaller number of our competitors, potentially reducing
or eliminating our commercial opportunity. Furthermore, such potential competitors may enter the market before us, and their products
may be designed to circumvent our pending patent applications and any patents we may receive. They may also challenge, narrow
or invalidate any granted patents or our patent applications, and such patents and patent applications may fail to provide adequate
protection for our product candidates. Any new product that competes with an approved product may need to demonstrate compelling
advantages in efficacy, cost, convenience, tolerability and safety to be commercially successful. Other competitive factors, including
generic competition, could force us to lower prices or could result in reduced sales. In addition, new products developed by others
could emerge as competitors to our product candidates. If we are not able to compete effectively against our current and future
competitors, our business will not grow and our financial condition and operations will suffer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We face substantial
competition, which may result in others discovering, developing and commercializing products before or more successfully than
our product candidates</I></B>. The development and commercialization of new drugs is highly competitive. We face competition
(from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide) with respect to
our current product candidates and will face competition with respect to any product candidates that we may seek to develop or
commercialize in the future. We compete directly with companies that focus on 505(b)(2) and generic drugs, and companies dedicating
their resources to novel forms of therapies for these indications. Many of these competitors are attempting to develop products
for our target indications. We face the risk that our competitors will develop a competing product using the same 505(b)(2) pathway
that we intend to pursue. Our business model is to focus on product candidates that we consider to have a shorter timeline to,
and lower cost of, regulatory approval.&nbsp; These attributes can also be taken advantage of by our competitors to develop and
obtain marketing approval of a competing product. In addition, following FDA approval of our product candidates for which we have
no patent protection, our competitors may seek to develop a competing product pursuant to the 505(j) pathway, which is an abbreviated
pathway used for the regulatory approval of generic product candidates.&nbsp; As a result of the foregoing, we may find that the
market opportunity for our product candidates for which we have no patent protection is relatively small due to the fact that
barriers to entry are low and generic competition may follow within relatively short time periods after our product is approved.
With the proliferation of new drugs and therapies in these areas, we expect to face increasingly intense competition as new technologies
become available. Any product candidates that we successfully develop and commercialize will compete with existing products and
new products that may become available in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are products
already approved for all of the indications we are targeting. Many of these approved products are well established therapies and
are widely accepted by physicians, patients and third-party payors. This may make it difficult for us to achieve our business
strategy of replacing existing products with our product candidates. In addition, where we are able to offer benefits over existing
products offered by our competitors, those competitors may reformulate their drugs in a manner that mimics the benefits offered
by our product candidates. As noted below, many of our product candidates are not eligible for patent protection or the market
and data exclusivity provisions under the Federal Food, Drug and Cosmetic Act, or FDCA. Consequently, our commercial operations
face significant direct competition and our competitors may develop products that are similar to ours and perhaps safer, more
effective, more convenient or less costly than any that we are developing or that would render our product candidates obsolete
or non-competitive. Our inability to successfully compete could negatively impact our business, results of operations and stock
price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Our competitors
may obtain FDA or other regulatory approval for comparable products more rapidly than we may obtain approval for ours, and the
risk of our competitors doing so may lead us to develop drug candidates without disclosing certain information with regard to
such candidates.</I></B> We hold one patent application for our CT-100 product candidate and one provisional patent application
for our DS-300 product candidate. In addition, we expect that we or our development partner will file a patent application covering
our ET-103 product candidate in the fourth quarter of 2018. Other than any protection that may be afforded by the issuance of
a patent with respect to such applications, of which there can be no assurance, we do not believe that any of our current product
candidates are eligible for patent protection or the market and data exclusivity provisions under the FDCA. The FDCA provides
three years of marketing exclusivity for an NDA, 505(b)(2) NDA, or supplement to an existing NDA or 505(b)(2) NDA if new clinical
investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to
be essential to the approval of the application, for example (for new indications, dosages, strengths or dosage forms of an existing
drug). Many of our competitors have significantly greater financial, manufacturing, marketing, drug development, technical and
human resources than we do. As a result, many of our competitors have the ability to bring a product candidate to market more
rapidly than we can and depending on the nature of their product candidate they could substantially delay the introduction of
our product candidate into the market if their products qualifies for the market and data exclusivity provisions under the FDCA.
In order to preserve any competitive advantage, we will, at times, make the decision to pursue a product candidate for which we
will not disclose the API, dosage or reference drug until such time as we believe that any competitive advantage would not be
materially compromised by public disclosure of such information, which in some cases may be as a late as our receipt of marketing
approval from the FDA. Our business currently depends on our ability to bring our product candidates to market in a manner that
preserves our perceived competitive advantage and any loss of that competitive advantage could negatively impact our business,
results of operations and stock price.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>If we are not
able to obtain any required regulatory approvals for our product candidates, we will not be able to commercialize our product
candidate and our ability to generate revenue will be limited</I></B>. We may be required to successfully complete clinical trials
for our product candidates before we can apply for marketing approval. Even if we complete any such clinical trials, it does not
assure marketing approval. Any such clinical trials may be unsuccessful, which would materially harm our business. Even if such
initial clinical trials are successful, we may be required to conduct additional clinical trials to establish our product candidates&rsquo;
safety and efficacy, before an NDA or Biologics License Application, or BLA, or their foreign equivalents can be filed with the
FDA or comparable foreign regulatory authorities for marketing approval of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical testing is
expensive, is difficult to design and implement, can take many years to complete and is uncertain as to outcome. Success in early
phases of pre-clinical and clinical trials does not ensure that later clinical trials will be successful, and interim results
of a clinical trial do not necessarily predict final results. A failure of one or more of our clinical trials can occur at any
stage of testing. We may experience numerous unforeseen events during, or as a result of, the clinical trial process that could
delay or prevent our ability to receive regulatory approval or commercialize our product candidates. The research, testing, manufacturing,
labeling, packaging, storage, approval, sale, marketing, advertising and promotion, pricing, export, import and distribution of
drug products are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries,
which regulations differ from country to country. We are not permitted to market our product candidates as prescription pharmaceutical
products in the United States until we receive approval of an NDA from the FDA, or in any foreign countries until we receive the
requisite approval from such countries. In the United States, the FDA generally requires the completion of clinical trials of
each drug to establish its safety and efficacy and extensive pharmaceutical development to ensure its quality before an NDA is
approved. Regulatory authorities in other jurisdictions impose similar requirements. Of the large number of drugs in development,
only a small percentage result in the submission of an NDA to the FDA and even fewer are eventually approved for commercialization.
As of the date of this prospectus, an ANDA has been submitted for our EM-100 product candidate and an NDA has been submitted to
the FDA for our DS-300 product candidate, however, there can be no assurance our NDA will be approved by the FDA. If our development
efforts for our product candidates, including regulatory approval, are not successful for their planned indications, or if adequate
demand for our product candidates is not generated, our business will be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success depends
on the receipt of regulatory approval and the issuance of such regulatory approvals is uncertain and subject to a number of risks,
including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the results of any
                                         required toxicology studies may not support the filing of an IND for our product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the FDA or comparable
                                         foreign regulatory authorities or Institutional Review Boards, or IRB, may disagree with
                                         the design or implementation of our clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">we may not be able
                                         to provide acceptable evidence of our product candidates&rsquo; safety and efficacy;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the results of our
                                         clinical trials may not be satisfactory or may not meet the level of statistical or clinical
                                         significance required by the FDA, European Medicines Agency, or EMA, or other regulatory
                                         agencies for marketing approval;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the dosing of our product
                                         candidates in any required clinical trial may not be at an optimal level;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">patients in our clinical
                                         trials may suffer adverse effects for reasons that may or may not be related to our product
                                         candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the data collected
                                         from clinical trials may not be sufficient to support the submission of an NDA, BLA or
                                         other submission or to obtain regulatory approval in the United States or elsewhere;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the FDA or comparable
                                         foreign regulatory authorities may fail to approve the manufacturing processes or facilities
                                         of third-party manufacturers with which we contract for clinical and commercial supplies;
                                         and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the approval policies
                                         or regulations of the FDA or comparable foreign regulatory authorities may significantly
                                         change in a manner rendering our clinical data insufficient for approval.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Failure to obtain
regulatory approval for our product candidates for the foregoing, or any other reasons, will prevent us from commercializing our
product candidates, and our ability to generate revenue will be materially impaired. We cannot guarantee that regulators will
agree with our assessment of the results of the clinical trials we intend to conduct in the future or that such trials will be
successful. The FDA, EMA and other regulators have substantial discretion in the approval process and may refuse to accept any
application or may decide that our data is insufficient for approval and require additional clinical trials, or pre-clinical or
other studies. In addition, varying interpretations of the data obtained from pre-clinical and clinical testing could delay, limit
or prevent regulatory approval of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical
stage company and as of the date of this prospectus only one ANDA and one NDA have been submitted for our product candidates and
we have not received regulatory approval to market any product candidates in any jurisdiction. We have only limited experience
in filing the applications necessary to gain regulatory approvals and expect to rely on consultants and third party contract research
organizations, or CROs, with expertise in this area to assist us in this process. Securing regulatory approvals to market a product
requires the submission of clinical, and pharmacokinetic data, information about product manufacturing processes and inspection
of facilities and supporting information to the appropriate regulatory authorities for each therapeutic indication to establish
a product candidate&rsquo;s safety and efficacy for each indication. Our product candidates may prove to have undesirable or unintended
side effects, toxicities or other characteristics that may preclude us from obtaining regulatory approval or prevent or limit
commercial use with respect to one or all intended indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The process of obtaining
regulatory approvals is expensive, often takes many years, if approval is obtained at all, and can vary substantially based upon,
among other things, the type, complexity and novelty of the product candidates involved, the jurisdiction in which regulatory
approval is sought and the substantial discretion of the regulatory authorities. Changes in regulatory approval policies during
the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for
a submitted product application may cause delays in the approval or rejection of an application. Regulatory approval obtained
in one jurisdiction does not necessarily mean that a product candidate will receive regulatory approval in all jurisdictions in
which we may seek approval, but the failure to obtain approval in one jurisdiction may negatively impact our ability to seek approval
in a different jurisdiction. Failure to obtain regulatory marketing approval for our product candidates will prevent us from commercializing
the product candidate, and our ability to generate revenue will be materially impaired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>If the FDA does
not conclude that our product candidates satisfy the requirements for the 505(b)(2) regulatory approval pathway, or if the requirements
for approval of any of our product candidates under Section&nbsp;505(b)(2) are not as we expect, the approval pathway for our
product candidates will likely take significantly longer, cost significantly more and encounter significantly greater complications
and risks than anticipated, and in any case may not be successful. </I></B>We intend to seek FDA approval through the 505(b)(2)
regulatory pathway for seven of our eight current product candidates described in this prospectus. The Drug Price Competition
and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act, added Section&nbsp;505(b)(2) to the Federal Food,
Drug and Cosmetic Act, or FDCA. Section&nbsp;505(b)(2) permits the filing of an NDA where at least some of the information required
for approval comes from studies that were not conducted by or for the applicant. If the FDA does not allow us to pursue the 505(b)(2)
regulatory pathway for our product candidates as anticipated, we may need to conduct additional clinical trials, provide additional
data and information and meet additional standards for regulatory approval. If this were to occur, the time and financial resources
required to obtain FDA approval for our product candidates would likely substantially increase. Moreover, the inability to pursue
the 505(b)(2) regulatory pathway could result in new competitive products reaching the market faster than our product candidates,
which could materially adversely impact our competitive position and prospects. Even if we are allowed to pursue the 505(b)(2)
regulatory pathway for a product candidate, we cannot assure you that we will receive the requisite or timely approvals for commercialization
of such product candidate. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For example, we had under
development a patented injectable pentoxifylline therapeutic candidate, which we believed would satisfy the requirements of the
505(b)(2) regulatory pathway. However, based on a pre-IND meeting with the FDA in March 2018 to discuss the clinical and regulatory
pathway for the product, we have decided to suspend all further development activities for this candidate indefinitely due to
extraordinarily high costs of the clinical trials that would be required by the FDA.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Notwithstanding the approval
of many products by the FDA pursuant to Section 505(b)(2), over the last few years some pharmaceutical companies and others have
objected to the FDA&rsquo;s interpretation of Section 505(b)(2) to allow reliance on the FDA&rsquo;s prior findings of safety
and effectiveness. If the FDA changes its interpretation of Section 505(b)(2), or if the FDA&rsquo;s interpretation is successfully
challenged in court, this could delay or even prevent the FDA from approving any Section 505(b)(2) application that we submit.
In addition, we expect that our competitors will file citizens&rsquo; petitions with the FDA in an attempt to persuade the FDA
that our product candidate, or the clinical studies that support their approval, contain deficiencies. Such actions by our competitors
could delay or even prevent the FDA from approving any NDA that we submit under Section 505(b)(2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Moreover, the FDA recently
adopted an interpretation of the three-year exclusivity provisions whereby a 505(b)(2) application can be blocked by exclusivity
even if does not rely on the previously-approved drug that has exclusivity (or any safety or effectiveness information regarding
that drug). Under the FDA&rsquo;s new interpretation, approval may be blocked by exclusivity awarded to a previously-approved
drug product that shares certain innovative features with our product, even if our 505(b)(2) application does not identify the
previously-approved drug product as a listed drug or rely upon any of its safety or efficacy data. Any failure to obtain regulatory
approval of our product candidates would significantly limit our ability to generate revenues, and any failure to obtain such
approval for all of the indications and labeling claims we deem desirable could reduce our potential revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>An NDA submitted
under Section&nbsp;505(b)(2) subjects us to the risk that we may be subject to a patent infringement lawsuit that would delay
or prevent the review or approval of our product candidate. </I></B>The 505(b)(2) application would enable us to reference published
literature or the FDA&rsquo;s previous findings of safety and effectiveness for the branded reference drug. For NDAs submitted
under Section&nbsp;505(b)(2) of the FDCA, the patent certification and related provisions of the Hatch-Waxman Act apply. In accordance
with Hatch-Waxman Act, in seeking approval for a drug through such an NDA, applicants are required to list with the FDA each patent
whose claims cover the applicant&rsquo;s product. Upon approval of a drug, each of the patents listed in the application for the
drug is then published in the FDA&rsquo;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the
Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential generic competitors in support of approval of
an abbreviated new drug application, or ANDA. An ANDA provides for marketing of a drug product that has the same active ingredients
in the same strengths and dosage form as the listed drug and has been shown to be bioequivalent to the listed drug. Other than
the requirement for bioequivalence testing, ANDA applicants are not required to conduct, or submit results of, pre-clinical or
clinical tests to prove the safety or effectiveness of their drug product. Drugs approved in this way are commonly referred to
as &ldquo;generic equivalents&rdquo; to the listed drug, and can often be substituted by pharmacists under prescriptions written
for the original listed drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The ANDA applicant is
required to certify to the FDA concerning any patents listed for the approved product in the FDA&rsquo;s Orange Book. Specifically,
the applicant must certify that either: (i) the required patent information has not been filed; (ii) the listed patent has expired;
(iii) the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration;
or (iv) the listed patent is invalid or will not be infringed by the new product. The ANDA applicant may also elect to submit
a section viii statement certifying that its proposed ANDA label does not contain (or carves out) any language regarding the patented
method-of-use rather than certify to a listed method-of-use patent. If the applicant does not challenge the listed patents, the
ANDA application will not be approved until all the listed patents claiming the referenced product have expired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A certification that the
new product will not infringe the already approved product&rsquo;s listed patents, or that such patents are invalid or unenforceable,
is called a Paragraph IV certification. If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant
must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing
by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph
IV certification. Under the Hatch-Waxman Act, the holder of patents that the 505 (b)(2) application references may file a patent
infringement lawsuit after receiving notice of the Paragraph IV certification. Filing of a patent infringement lawsuit against
the filer of the 505(b)(2) applicant within 45 days of the patent owner&rsquo;s receipt of notice triggers a one-time, automatic,
30-month stay of the FDA&rsquo;s ability to approve the 505(b)(2) NDA, unless patent litigation is resolved in the favor of the
Paragraph IV filer or the patent expires before that time. Accordingly, we may invest a significant amount of time and expense
in the development of one or more product candidates only to be subject to significant delay and patent litigation before such
product candidates may be commercialized, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, a 505(b)(2)
application will not be approved until any non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical
entity, or NCE, listed in the Orange Book for the referenced product has expired. The FDA may also require us to perform one or
more additional clinical studies or measurements to support the change from the branded reference drug, which could be time consuming
and could substantially delay our achievement of regulatory approvals for such product candidates. The FDA may also reject our
future 505(b)(2) submissions and require us to file such submissions under Section 505(b)(1) of the FDCA, which would require
us to provide extensive data to establish safety and effectiveness of the drug for the proposed use and could cause delay and
be considerably more expensive and time consuming. These factors, among others, may limit our ability to successfully commercialize
our product candidates.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Companies that produce
branded reference drugs routinely bring litigation against ANDA or 505(b)(2) applicants that seek regulatory approval to manufacture
and market generic and reformulated forms of their branded products. These companies often allege patent infringement or other
violations of intellectual property rights as the basis for filing suit against an ANDA or 505(b) (2) applicant. Likewise, patent
holders may bring patent infringement suits against companies that are currently marketing and selling their approved generic
or reformulated products. Litigation to enforce or defend intellectual property rights is often complex and often involves significant
expense and can delay or prevent introduction or sale of our product candidates. If patents are held to be valid and infringed
by our product candidates in a particular jurisdiction, we would, unless we could obtain a license from the patent holder, be
required to cease selling in that jurisdiction and may need to relinquish or destroy existing stock in that jurisdiction. There
may also be situations where we use our business judgment and decide to market and sell our approved products, notwithstanding
the fact that allegations of patent infringement(s) have not been finally resolved by the courts, which is known as an &ldquo;at-risk
launch.&rdquo; The risk involved in doing so can be substantial because the remedies available to the owner of a patent for infringement
may include, among other things, damages measured by the profits lost by the patent owner and not necessarily by the profits earned
by the infringer. In the case of a willful infringement, the definition of which is subjective, such damages may be increased
up to three times. Moreover, because of the discount pricing typically involved with bioequivalent and, to a lesser extent, 505(b)(2)
products, patented branded products generally realize a substantially higher profit margin than bioequivalent and, to a lesser
extent, 505(b)(2) products, resulting in disproportionate damages compared to any profits earned by the infringer. An adverse
decision in patent litigation could have a material adverse effect on our business, financial position and results of operations
and could cause the market value of our common stock to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Even if we receive
regulatory approval for any of our product candidates, we may not be able to successfully commercialize the product and the revenue
that we generate from its sales, if any, may be limited. </I></B>If approved for marketing, the commercial success of our product
candidates will depend upon each product&rsquo;s acceptance by the medical community, including physicians, patients and health
care payors. The degree of market acceptance for any of our product candidates will depend on a number of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">demonstration of clinical
                                         safety and efficacy;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">relative convenience,
                                         dosing burden and ease of administration;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the prevalence and
                                         severity of any adverse effects;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the willingness of
                                         physicians to prescribe our product candidates, and the target patient population to
                                         try new therapies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">efficacy of our product
                                         candidates compared to competing products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the introduction of
                                         any new products that may in the future become available targeting indications for which
                                         our product candidates may be approved;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">new procedures or therapies
                                         that may reduce the incidences of any of the indications in which our product candidates
                                         may show utility;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">pricing and cost-effectiveness;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the inclusion or omission
                                         of our product candidates in applicable therapeutic and vaccine guidelines;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the effectiveness of
                                         our own or any future collaborators&rsquo; sales and marketing strategies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">limitations or warnings
                                         contained in approved labeling from regulatory authorities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our ability to obtain
                                         and maintain sufficient third-party coverage or reimbursement from government health
                                         care programs, including Medicare and Medicaid, private health insurers and other third-party
                                         payors or to receive the necessary pricing approvals from government bodies regulating
                                         the pricing and usage of therapeutics; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the willingness of
                                         patients to pay out-of-pocket in the absence of third-party coverage or reimbursement
                                         or government pricing approvals.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of our product
candidates are approved, but do not achieve an adequate level of acceptance by physicians, health care payors, and patients, we
may not generate sufficient revenue and we may not be able to achieve or sustain profitability. Our efforts to educate the medical
community and third-party payors on the benefits of our product candidates may require significant resources and may never be
successful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, even
if we obtain regulatory approvals, the timing or scope of any approvals may prohibit or reduce our ability to commercialize our
product candidates successfully. For example, if the approval process takes too long, we may miss market opportunities and give
other companies the ability to develop competing products or establish market dominance. Any regulatory approval we ultimately
obtain may be limited or subject to restrictions or post-approval commitments that render our product candidates not commercially
viable. For example, regulatory authorities may approve any of our product candidates for fewer or more limited indications than
we request, may not approve the price we intend to charge for any of our product candidates, may grant approval contingent on
the performance of costly post-marketing clinical trials, or may approve any of our product candidates with a label that does
not include the labeling claims necessary or desirable for the successful commercialization of that indication. Further, the FDA
or comparable foreign regulatory authorities may place conditions on approvals or require risk management plans or a Risk Evaluation
and Mitigation Strategy, or REMS, to assure the safe use of the drug. If the FDA concludes a REMS is needed, the FDA will not
approve the NDA without an approved REMS, if required. A REMS could include medication guides, physician communication plans,
or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools.
The FDA may also require a REMS for an approved product when new safety information emerges. Any of these limitations on approval
or marketing could restrict the commercial promotion, distribution, prescription or dispensing of our product candidates. Moreover,
product approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following the initial marketing
of the product. Any of the foregoing scenarios could materially harm the commercial success of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Even if we obtain
marketing approval for any of our product candidates, we will be subject to ongoing obligations and continued regulatory review,
which may result in significant additional expense. Additionally, our product candidates could be subject to labeling and other
restrictions and withdrawal from the market and we may be subject to penalties if we fail to comply with regulatory requirements
or if we experience unanticipated problems with our product candidates. </I></B>Even if we obtain regulatory approval for any
of our product candidates for an indication, the FDA or foreign equivalent may still impose significant restrictions on their
indicated uses or marketing or the conditions of approval, or impose ongoing requirements for potentially costly and time-consuming
post-approval studies, including Phase&nbsp;4 clinical trials, and post-market surveillance to monitor safety and efficacy. Our
product candidates will also be subject to ongoing regulatory requirements governing the manufacturing, labeling, packaging, storage,
distribution, safety surveillance, advertising, promotion, recordkeeping and reporting of adverse events and other post-market
information. These requirements include registration with the FDA, as well as continued compliance with current Good Clinical
Practices regulations, or cGCPs, for any clinical trials that we conduct post-approval. In addition, manufacturers of drug products
and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for
compliance with current Good Manufacturing Processes, or cGMP, requirements relating to quality control, quality assurance and
corresponding maintenance of records and documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA has the authority
to require a REMS as part of an NDA or after approval, which may impose further requirements or restrictions on the distribution
or use of an approved drug, such as limiting prescribing to certain physicians or medical centers that have undergone specialized
training, limiting treatment to patients who meet certain safe-use criteria or requiring patient testing, monitoring and/or enrollment
in a registry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With respect to sales
and marketing activities by us or any future partner, advertising and promotional materials must comply with FDA rules in addition
to other applicable federal, state and local laws in the United States and similar legal requirements in other countries. In the
United States, the distribution of product samples to physicians must comply with the requirements of the U.S. Prescription Drug
Marketing Act. Application holders must obtain FDA approval for product and manufacturing changes, depending on the nature of
the change. We may also be subject, directly or indirectly through our customers and partners, to various fraud and abuse laws,
including, without limitation, the U.S. Anti-Kickback Statute, U.S. False Claims Act, and similar state laws, which impact, among
other things, our proposed sales, marketing, and scientific/educational grant programs. If we participate in the U.S. Medicaid
Drug Rebate Program, the Federal Supply Schedule of the U.S. Department of Veterans Affairs, or other government drug programs,
we will be subject to complex laws and regulations regarding reporting and payment obligations. All of these activities are also
potentially subject to U.S. federal and state consumer protection and unfair competition laws. Similar requirements exist in many
of these areas in other countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if any
of our product candidates are approved for a particular indication, our product labeling, advertising and promotion would be subject
to regulatory requirements and continuing regulatory review. The FDA strictly regulates the promotional claims that may be made
about prescription products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected
in the product&rsquo;s approved labeling. If we receive marketing approval for our product candidates, physicians may nevertheless
legally prescribe our products to their patients in a manner that is inconsistent with the approved label. If we are found to
have promoted such off-label uses, we may become subject to significant liability and government fines. The FDA and other agencies
actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly
promoted off-label uses may be subject to significant sanctions. The federal government has levied large civil and criminal fines
against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The
FDA has also requested that companies enter into consent decrees of permanent injunctions under which specified promotional conduct
is changed or curtailed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we or a regulatory
agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, problems
with the facility where the product is manufactured, or we or our manufacturers fail to comply with applicable regulatory requirements,
we may be subject to the following administrative or judicial sanctions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">restrictions on the
                                         marketing or manufacturing of the product, withdrawal of the product from the market,
                                         or voluntary or mandatory product recalls;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">issuance of warning
                                         letters or untitled letters;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">clinical holds;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">injunctions or the
                                         imposition of civil or criminal penalties or monetary fines;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">suspension or withdrawal
                                         of regulatory approval;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">suspension of any ongoing
                                         clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">refusal to approve
                                         pending applications or supplements to approved applications filed by us, or suspension
                                         or revocation of product license approvals;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">suspension or imposition
                                         of restrictions on operations, including costly new manufacturing requirements; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">product
                                         seizure or detention or refusal to permit the import or export of product.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The occurrence of
any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue. Adverse
regulatory action, whether pre- or post-approval, can also potentially lead to product liability claims and increase our product
liability exposure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Obtaining and
maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining
regulatory approval of our product candidates in other jurisdictions. </I></B>Obtaining and maintaining regulatory approval of
our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in
any other jurisdiction, but a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect
on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable
regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate
in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods
different from those in the United States, including additional preclinical studies or clinical trials, as clinical studies conducted
in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United
States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some
cases, the price that we intend to charge for our products is also subject to approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Obtaining foreign
regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and
costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory
requirements in international markets and/or to receive applicable marketing approvals, our target market will be reduced and
our ability to realize the full market potential of our product candidates will be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We currently
have a limited sales and marketing organization. If we are unable to secure a sales and marketing partner or establish satisfactory
sales and marketing capabilities, we may not successfully commercialize any of our product candidates</I></B>. As of the date
of this prospectus, we have limited sales and marketing personnel. In order to commercialize products that are approved for commercial
sales, we must either collaborate with third parties that have such commercial infrastructure or develop our own sales and marketing
infrastructure. If we are not successful entering into appropriate collaboration arrangements, or recruiting sufficient sales
and marketing personnel or in building a sales and marketing infrastructure, we will have difficulty successfully commercializing
our product candidates, which would adversely affect our business, operating results and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not be able
to enter into collaboration agreements on terms acceptable to us or at all. In addition, even if we enter into such relationships,
we may have limited or no control over the sales, marketing and distribution activities of these third parties. Our future revenues
may depend heavily on the success of the efforts of these third parties. If we elect to establish a sales and marketing infrastructure
we may not realize a positive return on this investment. In addition, we will have to compete with established and well-funded
pharmaceutical and biotechnology companies to recruit, hire, train and retain sales and marketing personnel. Factors that may
inhibit our efforts to commercialize our product candidates without strategic partners or licensees include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our inability to recruit
                                         and retain adequate numbers of effective sales and marketing personnel;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the inability of sales
                                         personnel to obtain access to or persuade adequate numbers of physicians to prescribe
                                         any of our product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the lack of complementary
                                         products to be offered by sales personnel, which may put us at a competitive disadvantage
                                         relative to companies with more extensive product lines; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">unforeseen costs and
                                         expenses associated with creating an independent sales and marketing organization.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Current and
future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates
and affect the prices we may obtain</I></B>. In the United States and some foreign jurisdictions, there have been a number of
legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing
approval for our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell our
product candidates. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales
and promotional activities for pharmaceutical products. We do not know whether additional legislative changes will be enacted,
or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing
approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&rsquo;s approval
process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing
testing and other requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States,
the Medicare Modernization Act, or MMA, changed the way Medicare covers and pays for pharmaceutical products. The legislation
expanded Medicare coverage for drug purchases by the elderly and introduced a new reimbursement methodology based on average sales
prices for drugs. In addition, this legislation authorized Medicare Part&nbsp;D prescription drug plans to use formularies where
they can limit the number of drugs that will be covered in any therapeutic class. As a result of this legislation and the expansion
of federal coverage of drug products, we expect that there will be additional pressure to contain and reduce costs. These cost
reduction initiatives and other provisions of this legislation could decrease the coverage and price that we receive for our product
candidates and could seriously harm our business. While the MMA applies only to drug benefits for Medicare beneficiaries, private
payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates, and any reduction
in reimbursement that results from the MMA may result in a similar reduction in payments from private payors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In March 2010, the Patient
Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively referred to as
the Health Care Reform Law, was enacted, which substantially changes the way health care is financed by both governmental and
private insurers, and significantly impacts the U.S. pharmaceutical industry. The Health Care Reform Law, among other things,
imposed reporting requirements on manufacturers related to drug samples and financial relationships with physicians and teaching
hospitals, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the
rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees on manufacturers of certain
branded prescription drugs, and established a Medicare Part D coverage gap discount program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, other legislative
changes have been proposed and adopted in the United States since the Health Care Reform Law was enacted. These changes include,
among others, aggregate reductions of Medicare payments to providers of up to 2% per fiscal year. We expect that additional state
and federal healthcare reform measures will be adopted in the future, which may alter or completely replace the existing healthcare
financing structure. Any of these reform measures could limit the amounts that federal and state governments will pay for healthcare
products and services, which could result in reduced demand for any such product candidate that we may have developed or additional
pricing pressures on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
healthcare regulatory environment in the U.S. is still in flux, and judicial challenges and legislative initiatives to modify,
limit, or repeal the Health Care Reform Law continue, and may increase in light of the change in administration following the
2016 U.S. presidential election.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Since January 2017, President
Trump has signed two executive orders and other directives designed to delay, circumvent, or loosen certain requirements mandated
by the Health Care Reform Law. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or
part of the Health Care Reform Law. While Congress has not passed repeal legislation, the Tax Cuts and Jobs Act of 2017 includes
a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the Health Care Reform
Law on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred
to as the &ldquo;individual mandate.&rdquo; Additionally, on January 22, 2018, President Trump signed a continuing resolution
on appropriations for fiscal year 2018 that delayed the implementation of certain Health Care Reform Law-mandated fees, including
the so-called &ldquo;Cadillac&rdquo; tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain
health insurance providers based on market share, and the medical device excise tax on non-exempt medical devices. Congress may
consider other legislation to repeal or replace elements of the Health Care Reform Law. We cannot predict the impact on our business
of changes to current laws and regulations. However, any changes that lower reimbursements for products for which we may obtain
regulatory approval, or that impose administrative and financial burdens on us, could adversely affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The policies of the FDA
or similar regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or
delay regulatory approval of our product candidates. For example, in December 2016, the 21st Century Cures Act, was signed into
law. The 21st Century Cures Act, among other things, is intended to modernize the regulation of drugs and biologics and spur innovation,
but it has not yet been fully implemented and its ultimate implementation is unclear. Furthermore, the Trump administration has
taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens
on, or otherwise materially delay, the FDA&rsquo;s ability to engage in routine regulatory and oversight activities such as implementing
statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. If these executive actions
impose constraints on FDA&rsquo;s ability to engage in oversight and implementation activities in the normal course, our business
may be negatively impacted. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements
or policies, or if we are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval
that may have been obtained and we may not achieve or sustain profitability, which would adversely affect our business.&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Our future growth
may depend, in part, on our ability to penetrate international markets, where we would be subject to additional regulatory burdens
and other risks and uncertainties. </I></B>Our future profitability may depend, in part, on our ability to commercialize our product
candidates in international markets for which we intend to rely on collaborations with third parties. If we commercialize any
of our product candidates in international markets, we would be subject to additional risks and uncertainties, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our customers&rsquo;
                                         ability to obtain reimbursement for our product candidates in international markets;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our inability to directly
                                         control commercial activities because we are relying on third parties;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the burden of complying
                                         with complex and changing international regulatory, tax, accounting and legal requirements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">different medical practices
                                         and customs in foreign countries affecting acceptance in the marketplace;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">import or export licensing
                                         requirements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">longer accounts receivable
                                         collection times;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">longer lead times for
                                         shipping;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">language barriers for
                                         technical training;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">reduced protection
                                         of intellectual property rights in some foreign countries;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">foreign currency exchange
                                         rate fluctuations; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the interpretation
                                         of contractual provisions governed by foreign laws in the event of a contract dispute.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">International sales of our product candidates
could also be adversely affected by the imposition of governmental controls, political and economic instability, trade restrictions
and changes in tariffs, any of which may adversely affect our results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>If we market
any of our product candidates in a manner that violates healthcare fraud and abuse laws, or if we violate government price reporting
laws, we may be subject to civil or criminal penalties</I></B>. The FDA enforces laws and regulations which require that the promotion
of pharmaceutical products be consistent with the approved prescribing information. While physicians may prescribe an approved
product for a so-called &ldquo;off label&rdquo; use, it is unlawful for a pharmaceutical company to promote its products in a
manner that is inconsistent with its approved label and any company which engages in such conduct can be subject to significant
liability. Similarly, industry codes in the EU and other foreign jurisdictions prohibit companies from engaging in off-label promotion
and regulatory agencies in various countries enforce violations of the code with civil penalties. While we intend to ensure that
our promotional materials are consistent with our label, regulatory agencies may disagree with our assessment and may issue untitled
letters, warning letters or may institute other civil or criminal enforcement proceedings. In addition to FDA restrictions on
marketing of pharmaceutical products, several other types of state and federal healthcare fraud and abuse laws have been applied
in recent years to restrict certain marketing practices in the pharmaceutical industry. These laws include the U.S. Anti-Kickback
Statute, U.S. False Claims Act and similar state laws. Because of the breadth of these laws and the narrowness of the safe harbors,
it is possible that some of our business activities could be subject to challenge under one or more of these laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The U.S. Anti-Kickback
Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce,
or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service
reimbursable under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted broadly
to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers
on the other. Although there are several statutory exemptions and regulatory safe harbors protecting certain common activities
from prosecution, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce
prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Our
practices may not, in all cases, meet all of the criteria for safe harbor protection from anti-kickback liability. Moreover, recent
health care reform legislation has strengthened these laws. For example, the Health Care Reform Law, among other things, amends
the intent requirement of the U.S. Anti-Kickback Statute and criminal health care fraud statutes; a person or entity no longer
needs to have actual knowledge of this statute or specific intent to violate it. In addition, the Health Care Reform Law provides
that the government may assert that a claim including items or services resulting from a violation of the U.S. Anti-Kickback Statute
constitutes a false or fraudulent claim for purposes of the U.S. False Claims Act. Federal false claims laws prohibit any person
from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making,
or causing to be made, a false statement to get a false claim paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Over the past few
years, several pharmaceutical and other healthcare companies have been prosecuted under these laws for a variety of alleged promotional
and marketing activities, such as: allegedly providing free trips, free goods, sham consulting fees and grants and other monetary
benefits to prescribers; reporting to pricing services inflated average wholesale prices that were then used by federal programs
to set reimbursement rates; engaging in off-label promotion that caused claims to be submitted to Medicare or Medicaid for non-covered,
off-label uses; and submitting inflated best price information to the Medicaid Rebate Program to reduce liability for Medicaid
rebates. Most states also have statutes or regulations similar to the U.S. Anti-Kickback Statute and the U.S. False Claims Act,
which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless
of the payor. Sanctions under these federal and state laws may include substantial civil monetary penalties, exclusion of a manufacturer&rsquo;s
products from reimbursement under government programs, substantial criminal fines and imprisonment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We will be completely
dependent on third parties to manufacture our product candidates, and our commercialization of our product candidates could be
halted, delayed or made less profitable if those third parties fail to obtain manufacturing approval from the FDA or comparable
foreign regulatory authorities, fail to provide us with sufficient quantities of our product candidates or fail to do so at acceptable
quality levels or prices.</I></B> We do not currently have, nor do we plan to acquire, the capability or infrastructure to manufacture
the active pharmaceutical ingredient, or API, in our product candidates for use in our clinical trials or for commercial product,
if any. In addition, we do not have the capability to encapsulate any of our product candidates as a finished drug product for
commercial distribution. As a result, we will be obligated to rely on contract manufacturers, if and when any of our product candidates
are approved for commercialization. While we have entered into certain agreements with contract manufacturers for clinical and
commercial supply, there can be no assurance we will be able to maintain those relationships or engage additional contract manufacturers
for clinical or commercial supply of any of our product candidates on favorable terms to us, or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The facilities used
by our contract manufacturers to manufacture our product candidates must be approved by the FDA or comparable foreign regulatory
authorities pursuant to inspections that will be conducted after we submit an NDA or BLA to the FDA or their equivalents to other
relevant regulatory authorities. We will not control the manufacturing process of, and will be completely dependent on, our contract
manufacturing partners for compliance with cGMPs for manufacture of both active drug substances and finished drug products. These
cGMP regulations cover all aspects of the manufacturing, testing, quality control and record keeping relating to our product candidates.
If our contract manufacturers do not successfully manufacture material that conforms to our specifications and the strict regulatory
requirements of the FDA or others, they will not be able to secure or maintain regulatory approval for their manufacturing facilities.
If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates
or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly
impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our contract manufacturers
will be subject to ongoing periodic unannounced inspections by the FDA and corresponding state and foreign agencies for compliance
with cGMPs and similar regulatory requirements. We will not have control over our contract manufacturers&rsquo; compliance with
these regulations and standards. Failure by any of our contract manufacturers to comply with applicable regulations could result
in sanctions being imposed on us, including fines, injunctions, civil penalties, failure to grant approval to market any of our
product candidates, delays, suspensions or withdrawals of approvals, operating restrictions and criminal prosecutions, any of
which could significantly and adversely affect our business. In addition, we will not have control over the ability of our contract
manufacturers to maintain adequate quality control, quality assurance and qualified personnel. Failure by our contract manufacturers
to comply with or maintain any of these standards could adversely affect our ability to develop, obtain regulatory approval for
or market any of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If, for any reason,
these third parties are unable or unwilling to perform, we may not be able to terminate our agreements with them, and we may not
be able to locate alternative manufacturers or formulators or enter into favorable agreements with them and we cannot be certain
that any such third parties will have the manufacturing capacity to meet future requirements. If these manufacturers or any alternate
manufacturer of finished drug product experiences any significant difficulties in its respective manufacturing processes for our
API or finished products or should cease doing business with us, we could experience significant interruptions in the supply of
any of our product candidates or may not be able to create a supply of our product candidates at all. Were we to encounter manufacturing
issues, our ability to produce a sufficient supply of any of our product candidates might be negatively affected. Our inability
to coordinate the efforts of our third party manufacturing partners, or the lack of capacity available at our third party manufacturing
partners, could impair our ability to supply any of our product candidates at required levels. Because of the significant regulatory
requirements that we would need to satisfy in order to qualify a new bulk or finished product manufacturer, if we face these or
other difficulties with our current manufacturing partners, we could experience significant interruptions in the supply of any
of our product candidates if we decided to transfer the manufacture of any of our product candidates to one or more alternative
manufacturers in an effort to deal with the difficulties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any manufacturing
problem or the loss of a contract manufacturer could be disruptive to our operations and result in lost sales. Additionally, we
rely on third parties to supply the raw materials needed to manufacture our potential products. Any reliance on suppliers may
involve several risks, including a potential inability to obtain critical materials and reduced control over production costs,
delivery schedules, reliability and quality. Any unanticipated disruption to a future contract manufacturer caused by problems
at suppliers could delay shipment of any of our product candidates, increase our cost of goods sold and result in lost sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot guarantee
that our future manufacturing and supply partners will be able to reduce the costs of commercial scale manufacturing of any of
our product candidates over time. If the commercial-scale manufacturing costs of any of our product candidates are higher than
expected, these costs may significantly impact our operating results. In order to reduce costs, we may need to develop and implement
process improvements. However, in order to do so, we will need, from time to time, to notify or make submissions with regulatory
authorities, and the improvements may be subject to approval by such regulatory authorities. We cannot be sure that we will receive
these necessary approvals or that these approvals will be granted in a timely fashion. We also cannot guarantee that we will be
able to enhance and optimize output in our commercial manufacturing process. If we cannot enhance and optimize output, we may
not be able to reduce our costs over time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>We may not be able
to establish agreements with third parties with whom we wish to collaborate and, if we are able to establish them, we may not
be able to establish them on commercially reasonable terms, which could result in alterations or delays of our development and
commercialization plans. </I></B>We face significant competition in seeking appropriate third parties. Whether we reach a definitive
agreement will depend, among other things, upon our assessment of the third parties&rsquo; resources and expertise, the terms
and conditions of the proposed agreement, and the proposed parties&rsquo; evaluation of a number of factors. Those factors may
include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside
the United States, the potential market for the product candidate, the costs and complexities of manufacturing and delivering
the product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership
of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry
and market conditions generally. Potential third parties may also consider alternative product candidates or technologies for
similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the
one with us for our product candidate. The terms of any arrangements that we may establish may also not be favorable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Agreements with third
parties are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent
business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future third parties.
We may not be able to negotiate agreements on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may
have to curtail the development of the product candidate, reduce or delay its development program, delay its potential commercialization
or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization
activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on
our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not
have sufficient funds, we may not be able to further develop our product candidate or bring it to market and generate product
revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, any future
agreements that we enter into may not be successful. The success of our arrangements will depend heavily on the efforts and activities
of our third party collaborators. Collaborators generally have significant discretion in determining the efforts and resources
that they will apply to these collaborations. Disagreements between parties to an agreement regarding clinical development and
commercialization matters can lead to delays in the development process or commercializing the applicable product candidate and,
in some cases, termination of the agreement. These disagreements can be difficult to resolve if neither of the parties has final
decision-making authority. Collaborations with pharmaceutical or biotechnology companies and other third parties often are terminated
or allowed to expire by the other party. Any such termination or expiration would adversely affect us financially and could harm
our business reputation.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We expect to
rely on third parties to conduct clinical trials for our product candidates. If these third parties do not successfully carry
out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize
any of our product candidates and our business would be substantially harmed</I></B>. We have entered into agreements with third-party
CROs to conduct and manage our clinical programs including contracting with clinical sites to perform our clinical studies. We
plan to rely heavily on these parties for execution of clinical studies for our product candidates and will control only certain
aspects of their activities. Nevertheless, we will be responsible for ensuring that each of our studies is conducted in accordance
with the applicable protocol, legal, regulatory and scientific standards, and our reliance on CROs and clinical sites will not
relieve us of our regulatory responsibilities. We and our CROs will be required to comply with cGCPs, which are regulations and
guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area and comparable foreign
regulatory authorities for any products in clinical development. The FDA and its foreign equivalents enforce these cGCP regulations
through periodic inspections of trial sponsors, principal investigators and trial sites. If we or our CROs fail to comply with
applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign
regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot
assure you that, upon inspection, the FDA or other regulatory authorities will determine that any of our clinical trials comply
with cGCPs. In addition, our clinical trials must be conducted with products produced under cGMP regulations and will require
a large number of test subjects. Our failure or the failure of our CROs or clinical sites to comply with these regulations may
require us to repeat clinical trials, which would delay the regulatory approval process and could also subject us to enforcement
action up to and including civil and criminal penalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we intend
to design the clinical trials for our product candidates in consultation with CROs, we expect that the CROs will manage all of
the clinical trials conducted at contracted clinical sites. As a result, many important aspects of our drug development programs
would be outside of our direct control. In addition, the CROs and clinical sites may not perform all of their obligations under
arrangements with us or in compliance with regulatory requirements. If the CROs or clinical sites do not perform clinical trials
in a satisfactory manner, breach their obligations to us or fail to comply with regulatory requirements, the development and commercialization
of any of our product candidates for the subject indication may be delayed or our development program materially and irreversibly
harmed. We cannot control the amount and timing of resources these CROs and clinical sites will devote to our program or any of
our product candidates. If we are unable to rely on clinical data collected by our CROs, we could be required to repeat, extend
the duration of, or increase the size of our clinical trials, which could significantly delay commercialization and require significantly
greater expenditures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of our relationships
with these third-party CROs or clinical sites terminate, we may not be able to enter into arrangements with alternative CROs or
clinical sites. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they
need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere
to our clinical protocols, regulatory requirements or for other reasons, any such clinical trials may be extended, delayed or
terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As
a result, our financial results and the commercial prospects for any of our product candidates would be harmed, our costs could
increase and our ability to generate revenue could be delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>We enter into various
contracts in the normal course of our business, some or all of which may require us to indemnify the other party to the contract.
In the event we have to perform under these indemnification provisions, it could have an adverse effect on our business, financial
condition and results of operations. </I></B>In the normal course of business, we periodically may enter into commercial, service,
collaboration, licensing, consulting and other agreements that contain indemnification provisions. With respect to our commercial
agreements, vendors typically ask for indemnification from any third-party product liability claims that could result from the
production, use or consumption of the product, as well as for alleged infringements of any patent or other intellectual property
right by a third party. Should our obligation under an indemnification provision exceed applicable insurance coverage or if we
were denied insurance coverage, our business, financial condition and results of operations could be adversely affected. Similarly,
if we are relying on a third party to indemnify us and the party is denied insurance coverage or the indemnification obligation
exceeds the applicable insurance coverage and does not have other assets available to indemnify us, our business, financial condition
and results of operations could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Our CEO holds ownership
interest in some of the third parties we have entered into agreements with. The terms and fee arrangements of these agreements,
we believe, approximate the terms and fee arrangements of an agreement that would have been obtained in an arm&rsquo;s length
and unaffiliated transaction. Nonetheless, this may expose us to claims of interested transactions and other fiduciary suits.
</I></B>Our Chief Executive Officer, Sean Brynjelsen, has a material ownership interest in several companies from which we have
licensed or acquired product development and marketing rights. These include a 27% stake in Andersen Pharma, LLC (license for
DS-100), 33% stake in Eyemax, LLC (license for EM-100), and 50% stake in Selenix, LLC (license for DS-200). We are required to
pay to these parties licensing fees, milestone payments and royalty payments. We believe the terms of the transactional agreements,
including the licensing fees, milestone payments and royalty payments, approximate the terms and payments we could have obtained
in an arms&rsquo; length transaction with an unaffiliated party. Nonetheless, a stockholder may seek to challenge these agreements
on grounds that they are not in the best interest of our company and our board breached its fiduciary duty by approving such agreements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Any termination
or suspension of, or delays in the commencement or completion of, any necessary studies of any of our product candidates for any
indications could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial
prospects</I></B>. The commencement and completion of clinical studies can be delayed for a number of reasons, including delays
related to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the FDA or a comparable
                                         foreign regulatory authority failing to grant permission to proceed and placing the clinical
                                         study on hold;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">subjects for clinical
                                         testing failing to enroll or remain in our trials at the rate we expect;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">a facility manufacturing
                                         any of our product candidates being ordered by the FDA or other government or regulatory
                                         authorities to temporarily or permanently shut down due to violations of cGMP requirements
                                         or other applicable requirements, or cross-contaminations of product candidates in the
                                         manufacturing process;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">any changes to our
                                         manufacturing process that may be necessary or desired;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">subjects choosing an
                                         alternative treatment for the indications for which we are developing our product candidates,
                                         or participating in competing clinical studies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">subjects experiencing
                                         severe or unexpected drug-related adverse effects;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">reports from clinical
                                         testing on similar technologies and products raising safety and/or efficacy concerns;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">third-party clinical
                                         investigators losing their license or permits necessary to perform our clinical trials,
                                         not performing our clinical trials on our anticipated schedule or employing methods consistent
                                         with the clinical trial protocol, cGMP requirements, or other third parties not performing
                                         data collection and analysis in a timely or accurate manner;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">inspections of clinical
                                         study sites by the FDA, comparable foreign regulatory authorities, or IRBs finding regulatory
                                         violations that require us to undertake corrective action, result in suspension or termination
                                         of one or more sites or the imposition of a clinical hold on the entire study, or that
                                         prohibit us from using some or all of the data in support of our marketing applications;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">third-party contractors
                                         becoming debarred or suspended or otherwise penalized by the FDA or other government
                                         or regulatory authorities for violations of regulatory requirements, in which case we
                                         may need to find a substitute contractor, and we may not be able to use some or any of
                                         the data produced by such contractors in support of our marketing applications;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">one or more IRBs refusing
                                         to approve, suspending or terminating the study at an investigational site, precluding
                                         enrollment of additional subjects, or withdrawing its approval of the trial; reaching
                                         agreement on acceptable terms with prospective CROs and clinical trial sites, the terms
                                         of which can be subject to extensive negotiation and may vary significantly among different
                                         CROs and trial sites;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">deviations of the clinical
                                         sites from trial protocols or dropping out of a trial;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">adding new clinical
                                         trial sites;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the inability of the
                                         CRO to execute any clinical trials for any reason; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">government
                                         or regulatory delays or &ldquo;clinical holds&rdquo; requiring suspension or termination
                                         of a trial.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Product development
costs for any of our product candidates will increase if we have delays in testing or approval or if we need to perform more or
larger clinical studies than planned. Additionally, changes in regulatory requirements and policies may occur and we may need
to amend study protocols to reflect these changes. Amendments may require us to resubmit our study protocols to the FDA, comparable
foreign regulatory authorities, and IRBs for reexamination, which may impact the costs, timing or successful completion of that
study. If we experience delays in completion of, or if we, the FDA or other regulatory authorities, the IRB, or other reviewing
entities, or any of our clinical study sites suspend or terminate any of our clinical studies of any of our product candidates,
its commercial prospects may be materially harmed and our ability to generate product revenues will be delayed. Any delays in
completing our clinical trials will increase our costs, slow down our development and approval process and jeopardize our ability
to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition and prospects
significantly. In addition, many of the factors that cause, or lead to, termination or suspension of, or a delay in the commencement
or completion of, clinical studies may also ultimately lead to the denial of regulatory approval of our product candidates. In
addition, if one or more clinical studies are delayed, our competitors may be able to bring products to market before we do, and
the commercial viability of any of our product candidates could be significantly reduced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Clinical drug
development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may
not be predictive of future trial results</I></B>. Clinical testing of drug product candidates is expensive and can take many
years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The
results of pre-clinical studies and early clinical trials may not be predictive of the results of later-stage clinical trials.
We cannot assure you that the FDA or comparable foreign regulatory authorities will view the results as we do or that any future
trials of any of our product candidates will achieve positive results. Product candidates in later stages of clinical trials may
fail to show the desired safety and efficacy traits despite having progressed through pre-clinical studies and initial clinical
trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials
due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Any future clinical trial
results for our product candidates may not be successful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, a number
of factors could contribute to a lack of favorable safety and efficacy results for any of our product candidates. For example,
such trials could result in increased variability due to varying site characteristics, such as local standards of care, differences
in evaluation period and surgical technique, and due to varying patient characteristics including demographic factors and health
status.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>We have not conducted
clinical trials for any of our product candidates, other than a bioequivalence trial for one product candidate, and we may be
delayed in commercializing or fail to find success in these trials. </I></B>Further, the results of any clinical trial may not
be predictive of future trial results. Positive results in preclinical testing and early clinical trials do not ensure that later
clinical trials will be successful. A number of pharmaceutical companies have suffered significant setbacks in clinical trials,
including in Phase 3, after promising results in preclinical testing and early clinical trials. These setbacks have included negative
safety and efficacy observations in later clinical trials, including previously unreported adverse events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To date, we have not conducted
any clinical trials other than a Phase 3 bioequivalence trial for our EM-100 product candidate. Our clinical trials may not be
successful, and even if they are, the FDA may not approve our NDA for products that are successful in the trial, may not agree
that the benefits outweigh its risks, or may raise new concerns regarding our clinical trial designs. The Phase 3 trial process
is often long, complex, costly and uncertain, and delays or failure is common. These clinical trials will be substantially broader
than a Phase 2 clinical trial and will require us to enlist a considerably larger number of patients in multiple clinics and medical
centers across a number of different countries. Before commencing Phase 3 clinical trials in the U.S. we will also need to agree
on a protocol with the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Phase 3 clinical trials
often produce unsatisfactory results even though prior clinical trials were successful. Moreover, the results of clinical trials
may be unsatisfactory to the FDA or foreign regulatory authorities even if we believe those clinical trials to be successful.
The FDA or applicable foreign regulatory agencies may suspend one or all of our clinical trials or require that we conduct additional
clinical, nonclinical, manufacturing, validation or drug product quality studies and submit that data before considering or reconsidering
any NDA or similar foreign regulatory application we may submit. Depending on the extent of these additional studies, approval
of any applications that we submit may be significantly delayed, or may require us to expend more resources than we have available.
It is also possible that additional studies we conduct may not be considered sufficient by the FDA or applicable foreign regulatory
agencies to provide regulatory approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If any of these outcomes
occur, we may not receive approval for our product candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Third-party
coverage and reimbursement and health care cost containment initiatives and treatment guidelines may constrain our future revenues</I></B>.
Our ability to successfully market our product candidates will depend in part on the level of reimbursement that government health
administration authorities, private health coverage insurers and other organizations provide for the cost of our products and
related treatments. Countries in which any of our product candidates are sold through reimbursement schemes under national health
insurance programs frequently require that manufacturers and sellers of pharmaceutical products obtain governmental approval of
initial prices and any subsequent price increases. In certain countries, including the United States, government-funded and private
medical care plans can exert significant indirect pressure on prices. We may not be able to sell our product candidates profitably
if adequate prices are not approved or coverage and reimbursement is unavailable or limited in scope. Increasingly, third-party
payors attempt to contain health care costs in ways that are likely to impact our development of products including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">failing to approve
                                         or challenging the prices charged for health care products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">introducing reimportation
                                         schemes from lower priced jurisdictions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">limiting both coverage
                                         and the amount of reimbursement for new therapeutic products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">denying or limiting
                                         coverage for products that are approved by the regulatory agencies but are considered
                                         to be experimental or investigational by third-party payors; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">refusing to provide
                                         coverage when an approved product is used in a way that has not received regulatory marketing
                                         approval.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Relating to Our Intellectual
Property Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.6in"><B><I>We will depend
on rights to certain pharmaceutical compounds that have been acquired by us. We do not have complete control over these pharmaceutical
compounds and any loss of our rights to them could prevent us from selling our products.</I></B> We are dependent on the assignment
and licensing from third parties for certain of our pharmaceutical compounds and potential product candidates. Our rights to use
the pharmaceutical compounds we were assigned are subject to the negotiation of, continuation of and compliance with the terms
of those assignments and licenses. Moreover, under these agreements, any related patents may remain under the control of the assignor
or licensor. Our rights to develop and commercialize the product candidates are subject to the validity of the intellectual property
rights. Enforcement of any assigned or licensed patents or defense or any claims asserting the invalidity of these patents is
often subject to the control or cooperation of the assignor or licensor. Legal action could be initiated against the original
owners of the intellectual property that we acquired and an adverse outcome in such legal action could harm our business because
it might prevent such companies or institutions from continuing to assign intellectual property that we may need to operate our
business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.6in">In addition, our rights
to practice the inventions claimed in any patents and patent applications are subject to our assignors and licensors abiding by
the terms of those agreements and not terminating them. These agreements may be terminated by the assignor or licensor if we are
in material breach of certain terms or conditions of the agreement or in certain other circumstances. Our rights under these agreements
are subject to our continued compliance with the terms of the agreements, including the payment of royalties and other payment
due under the agreements. Termination of these agreements could prevent us from marketing some or all of our products. Because
of the complexity of our products and the patents, determining the scope of the assignment or license and related royalty obligations
can be difficult and can lead to disputes between us and the assignor or licensor. An unfavorable resolution of such a dispute
could lead to an increase in the royalties payable pursuant to the agreement. If the assignor or licensor believed we were not
paying the royalties due under the agreement or were otherwise not in compliance with the terms of the agreement, the assignor
or licensor might attempt to revoke the agreement. If such an attempt were successful, we might be barred from producing and selling
some or all of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>It is difficult
and costly to protect our intellectual property rights, and we cannot ensure the protection of these rights</I></B>. Our commercial
success will depend, in part, on obtaining and maintaining patent protection for our technologies, products and processes, successfully
defending these patents against third-party challenges and successfully enforcing these patents against third party competitors.
As of the date of this prospectus, we hold one patent application for our CT-100 product candidate and one provisional patent
application for our DS-300 product candidate. In addition, we expect that we or our development partner will file a patent application
covering our ET-103 product candidate in the fourth quarter of 2018. The patent positions of pharmaceutical companies can be highly
uncertain and involve complex legal, scientific and factual questions for which important legal principles remain unresolved.
Changes in either the patent laws or in interpretations of patent laws may diminish the value of our intellectual property. Accordingly,
we cannot predict the breadth of claims that may be allowable or enforceable in our patents. Patent and patent applications relating
to our product candidates and related technologies may be challenged, invalidated or circumvented by third parties and might not
protect us against competitors with similar products or technologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The degree of future
protection for our proprietary rights is uncertain, because legal means afford only limited protection and may not adequately
protect our rights, permit us to gain or keep our competitive advantage, or provide us with any competitive advantage at all.
For example, others have filed, and in the future are likely to file, patent applications covering products and technologies that
are similar, identical or competitive to any of our product candidates, or important to our business. We cannot be certain that
any patent application owned by a third party will not have priority over patent applications filed by us, or that we will not
be involved in interference, opposition or invalidity proceedings before United States or foreign patent offices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Additionally, if we or
one of our licensing partners initiated legal proceedings against a third party to enforce a patent covering any product candidate,
the defendant could counterclaim that the patent covering any other product candidate is invalid and/or unenforceable. In patent
litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds
for a validity challenge include alleged failures to meet any of several statutory requirements, including lack of novelty, obviousness
or non-enablement. Grounds for unenforceability assertions include allegations that someone connected with prosecution of the
patent withheld relevant information from the U.S. PTO, or made a misleading statement, during prosecution. Third parties may
also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation.
Such mechanisms include re-examination, post grant review and equivalent proceedings in foreign jurisdictions, e.g. opposition
proceedings. Such proceedings could result in revocation or amendment of our patents or our licensors&rsquo; patents in such a
way that they no longer cover product candidates or competitive products. The outcome following legal assertions of invalidity
and unenforceability is unpredictable. With respect to validity, for example, we cannot be certain that there is no invalidating
prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion
of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on any product candidate.
Such a loss of patent protection would have a material adverse impact on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the future, we
may rely on know-how and trade secrets to protect technology, especially in cases when we believe patent protection is not appropriate
or obtainable. However, know-how and trade secrets are difficult to protect. While we intend to require employees, academic collaborators,
consultants and other contractors to enter into confidentiality agreements, we may not be able to adequately protect our trade
secrets or other proprietary or licensed information. Typically, research collaborators and scientific advisors have rights to
publish data and information in which we may have rights. If we cannot maintain the confidentiality of our proprietary technology
and other confidential information, our ability to receive patent protection and our ability to protect valuable information owned
by us may be imperiled. Enforcing a claim that a third-party entity illegally obtained and is using any of our trade secrets is
expensive and time consuming, and the outcome is unpredictable. In addition, courts are sometimes less willing to protect trade
secrets than patents. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We may not be
able to protect our intellectual property rights throughout the world. </I></B><FONT STYLE="font-weight: normal; font-style: normal">Filing,
prosecuting and defending patents on product candidates in all countries and jurisdictions throughout the world would be prohibitively
expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those
offered in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all
countries outside the United States, or from selling or importing products made using our inventions in and into the United States
or other jurisdictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Competitors may use our
technologies in jurisdictions where we do not have, or where we do not pursue and obtain, patent protection to develop their own
products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement
is not as strong as that in the United States. These products may compete with our product and our patents or other intellectual
property rights may not be effective or sufficient to prevent them from competing. Even if we pursue and obtain issued patents
in particular jurisdictions, our patent claims or other intellectual property rights may not be effective or sufficient to prevent
third parties from so competing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Further, the laws of some
foreign countries do not protect intellectual property rights to the same extent as the laws of the United States. Many companies
have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions.
The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual
property protection, especially those relating to biotechnology. This could make it difficult for us to stop the infringement
of our patents, if obtained, or the misappropriation of our other intellectual property rights. For example, many foreign countries
have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit
the enforceability of patents against third parties, including government agencies or government contractors. In these countries,
patents may provide limited or no benefit. Patent protection must ultimately be sought on a country-by-country basis, which is
an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain
countries, and we will not have the benefit of patent protection in such countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Moreover, proceedings
to enforce our patent rights, or those of our licensors or partners, in foreign jurisdictions could result in substantial costs
and divert our efforts and attention from other aspects of our business, could put our in-licensed patents, or any patents that
we may own in the future, at risk of being invalidated or interpreted narrowly, could put our owned or in-licensed patent applications
at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we
initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce
our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual
property that we develop or license.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we fail to obtain
or maintain patent protection or trade secret protection for our product candidates or our technologies, third parties could use
our proprietary information, which could impair our ability to compete in the market and adversely affect our ability to generate
revenues and attain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may also rely on
the trademarks we may develop to distinguish our products from the products of our competitors. We cannot guarantee that any trademark
applications filed by us or our business partners will be approved. Third parties may also oppose such trademark applications,
or otherwise challenge our use of the trademarks. In the event that the trademarks we use are successfully challenged, we could
be forced to rebrand our products, which could result in loss of brand recognition, and could require us to devote resources to
advertising and marketing new brands. Further, we cannot provide assurance that competitors will not infringe the trademarks we
use, or that we will have adequate resources to enforce these trademarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Changes in either
U.S. or foreign patent law or interpretation of such laws could diminish the value of patents in general, thereby impairing our
ability to protect our products. </I></B><FONT STYLE="font-weight: normal; font-style: normal">As is the case with other biotechnology
companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in
the biotechnology industry involve both technological and legal complexity, and it therefore is costly, time-consuming and inherently
uncertain. In addition, on September 16, 2011, the Leahy-Smith America Invents Act (AIA), was signed into law. The AIA includes
a number of significant changes to U.S. patent law, including provisions that affect the way patent applications will be prosecuted
and may also affect patent litigation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">An important change introduced
by the AIA is that, as of March 16, 2013, the United States transitioned to a &ldquo;first-to-file&rdquo; system for deciding
which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention.
A third party that files a patent application in the U.S. PTO after that date but before us could therefore be awarded a patent
covering an invention of ours even if we had made the invention before it was made by the third party. This will require us to
be cognizant going forward of the time from invention to filing of a patent application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Among some of the other
changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and providing opportunities
for third parties to challenge any issued patent in the U.S. PTO. This applies to all of our U.S. patents, even those issued before
March 16, 2013. Because of a lower evidentiary standard necessary to invalidate a patent claim in U.S. PTO proceedings compared
to the evidentiary standard in United States federal court, a third party could potentially provide evidence in a U.S. PTO proceeding
sufficient for the U.S. PTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim
if first presented in a district court action. Accordingly, a third party may attempt to use the U.S. PTO procedures to invalidate
our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court
action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Depending on decisions
by the United States Congress, the federal courts, the U.S. PTO, or similar authorities in foreign jurisdictions, the laws and
regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce
our existing in-licensed patents and patents that we might obtain in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Our product
candidates may infringe the intellectual property rights of others, which could increase our costs and delay or prevent our development
and commercialization efforts.</I></B> Our success depends in part on avoiding infringement of the proprietary technologies of
others. The pharmaceutical industry has been characterized by frequent litigation regarding patent and other intellectual property
rights. Identification of third party patent rights that may be relevant to our proprietary technology is difficult because patent
searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the
meaning of patent claims. Additionally, because patent applications are maintained in secrecy until the application is published,
we may be unaware of third-party patents that may be infringed by commercialization of any of our product candidates or any future
product candidate. There may be certain issued patents and patent applications claiming subject matter that we may be required
to license in order to research, develop or commercialize any of our product candidates, and we do not know if such patents and
patent applications would be available to license on commercially reasonable terms, or at all. Any claims of patent infringement
asserted by third parties would be time-consuming and may:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">result in costly litigation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">divert the time and
                                         attention of our technical personnel and management;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">prevent us from commercializing
                                         a product until the asserted patent expires or is held finally invalid or not infringed
                                         in a court of law;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">require us to cease
                                         or modify our use of the technology and/or develop non-infringing technology; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">require us to enter
                                         into royalty or licensing agreements.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Third parties may
hold proprietary rights that could prevent any of our product candidates from being marketed. Any patent-related legal action
against us claiming damages and seeking to enjoin commercial activities relating to any of our product candidates or our processes
could subject us to potential liability for damages and require us to obtain a license to continue to manufacture or market any
of our product candidates or any future product candidates. We cannot predict whether we would prevail in any such actions or
that any license required under any of these patents would be made available on commercially acceptable terms, if at all. In addition,
we cannot be sure that we could redesign our product candidates or any future product candidates or processes to avoid infringement,
if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary
licenses, could prevent us from developing and commercializing any of our product candidates or a future product candidate, which
could harm our business, financial condition and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that there
are other companies, including major pharmaceutical companies, working in the areas competitive to our proposed product candidates
which either has resulted, or may result, in the filing of patent applications that may be deemed related to our activities. If
we were to challenge the validity of these or any issued United States patent in court, we would need to overcome a statutory
presumption of validity that attaches to every issued United States patent. This means that, in order to prevail, we would have
to present clear and convincing evidence as to the invalidity of the patent&rsquo;s claims. If we were to challenge the validity
of these or any issued United States patent in an administrative trial before the Patent Trial and Appeal Board in the United
States Patent and Trademark Office, we would have to prove that the claims are unpatentable by a preponderance of the evidence.
There is no assurance that a jury and/or court would find in our favor on questions of infringement, validity or enforceability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Others may claim
an ownership interest in our intellectual property which could expose us to litigation and have an adverse effect on our prospects.
</I></B>A third party may claim an ownership interest in one or more of our or our licensors&rsquo; patents or other proprietary
or intellectual property rights. A third party could bring legal actions against us and seek monetary damages and/or enjoin clinical
testing, manufacturing and marketing of the affected product or products. We cannot guarantee that a third party will not assert
a claim or an interest in any of such patents or intellectual property. If we become involved in any litigation, it could consume
a substantial portion of our resources, and cause a significant diversion of effort by our technical and management personnel.
If any of these actions are successful, in addition to any potential liability for damages, we could be required to obtain a license
to continue to manufacture or market the affected product, in which case we may be required to pay substantial royalties or grant
cross-licenses to our patents. We cannot, however, assure you that any such license will be available on acceptable terms, if
at all. Ultimately, we could be prevented from commercializing a product candidate, or be forced to cease some aspect of our business
operations as a result of claims of patent infringement or violation of other intellectual property rights. Further, the outcome
of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance, including the
demeanor and credibility of witnesses and the identity of any adverse party. This is especially true in intellectual property
cases that may turn on the testimony of experts as to technical facts upon which experts may reasonably disagree.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We may be subject
to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed
alleged confidential information or trade secrets of their former employers</I></B>. As is commonplace in our industry, we will
employ individuals who were previously employed at other pharmaceutical companies, including our competitors or potential competitors.
Although no claims against us are currently pending, we may be subject in the future to claims that our employees or prospective
employees are subject to a continuing obligation to their former employers (such as non-competition or non-solicitation obligations)
or claims that our employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information
of their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending
against these claims, litigation could result in substantial costs and be a distraction to management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to this Offering and Owning Our Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <B><I>An active, liquid
and orderly trading market for our shares may not develop, which may inhibit the ability of our shareholders to sell shares following
this offering. </I></B>The offering under this prospectus is an initial public offering of our common shares. Prior to this offering
there has been no public market for our shares. Upon completion of this offering, our common stock will commence trading on the
<FONT STYLE="text-transform: uppercase">Nasdaq</FONT> Global Market under the symbol &ldquo;ETON.&rdquo; However, an active, liquid
or orderly trading market in our shares may not develop upon completion of this offering, or if it does develop, it may not be
sustained. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a
price that you consider reasonable. The lack of an active market may also reduce the fair market value of your shares. An inactive
market may also impair our ability to raise capital by selling shares and may impair our ability to acquire other companies by
using our shares as consideration. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Future capital
raises may dilute our existing stockholders&rsquo; ownership and/or have other adverse effects on our operations</I></B>. If we
raise additional capital by issuing equity securities, our existing stockholders&rsquo; percentage ownership will be reduced and
these stockholders may experience substantial dilution. If we raise additional funds by issuing debt securities, these debt securities
would have rights senior to those of our common stock and the terms of the debt securities issued could impose significant restrictions
on our operations, including liens on our assets. If we raise additional funds through collaborations and licensing arrangements,
we may be required to relinquish some rights to our technologies or candidate products, or to grant licenses on terms that are
not favorable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <B><I>The market price
of our shares may be subject to fluctuation and volatility. You could lose all or part of your investment. </I></B>The initial
public offering price for the shares will be determined by negotiations between us and representatives of the underwriters and
may not be indicative of prices that will prevail in the trading market. The price of our shares may decline following this offering.
The stock market in general, and early stage public companies in particular, has experienced extreme price and volume fluctuations
that have often been unrelated or disproportionate to the operating performance of such companies. The stock market in general
has been, and the market price of our shares in particular will likely be, subject to fluctuation, whether due to, or irrespective
of, our operating results and financial condition. The market price of our shares on the NASDAQ Global Market may fluctuate as
a result of a number of factors, some of which are beyond our control, including, but not limited to: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">actual
                                         or anticipated variations in our and our competitors&rsquo; results of operations and
                                         financial condition;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">market
                                         acceptance of our products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">the
                                         mix of products that we sell and related services that we provide;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">changes
                                         in earnings estimates or recommendations by securities analysts, if our shares are covered
                                         by analysts;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">development
                                         of technological innovations or new competitive products by others;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">announcements
                                         of technological innovations or new products by us;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">publication
                                         of the results of preclinical or clinical trials for our other product candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">failure
                                         by us to achieve a publicly announced milestone;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">delays
                                         between our expenditures to develop and market new or enhanced products and the generation
                                         of sales from those products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">developments
                                         concerning intellectual property rights, including our involvement in litigation brought
                                         by or against us;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">regulatory
                                         developments and the decisions of regulatory authorities as to the approval or rejection
                                         of new or modified products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">changes
                                         in the amounts that we spend to develop, acquire or license new products, technologies
                                         or businesses;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">changes
                                         in our expenditures to promote our products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">our
                                         sale or proposed sale, or the sale by our significant shareholders, of our shares or
                                         other securities in the future;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">changes
                                         in key personnel;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">success
                                         or failure of our research and development projects or those of our competitors;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">the
                                         trading volume of our shares; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">general
                                         economic and market conditions and other factors, including factors unrelated to our
                                         operating performance.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These factors and
any corresponding price fluctuations may materially and adversely affect the market price of our shares and result in substantial
losses being incurred by our investors. In the past, following periods of market volatility, public company shareholders have
often instituted securities class action litigation. If we were involved in securities litigation, it could impose a substantial
cost upon us and divert the resources and attention of our management from our business.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We are an &ldquo;emerging
growth company&rdquo; under the JOBS Act of 2012 and we cannot be certain if the reduced disclosure requirements applicable to
emerging growth companies will make our common stock less attractive to investors</I></B>. We are an &ldquo;emerging growth company,&rdquo;
as defined in the Jumpstart Our Business Startups Act of 2012 (&ldquo;JOBS Act&rdquo;), and we may take advantage of certain exemptions
from various reporting requirements that are applicable to other public companies that are not &ldquo;emerging growth companies&rdquo;
including, but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">not
                                         being required to comply with the auditor attestation requirements of Section 404 of
                                         the Sarbanes-Oxley Act;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">reduced
                                         disclosure obligations regarding executive compensation in our periodic reports and proxy
                                         statements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">exemptions
                                         from the requirements of holding a nonbinding advisory vote on executive compensation
                                         and stockholder approval of any golden parachute payments; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">extended
                                         transition periods available for complying with new or revised accounting standards.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have chosen to
&ldquo;opt out&rdquo; of the extended transition periods available for complying with new or revised accounting standards, but
we intend to take advantage of all of the other benefits available under the JOBS Act, including the exemptions discussed above.
We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors
find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock
price may be more volatile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will remain an
&ldquo;emerging growth company&rdquo; for up to five years, although we will lose that status sooner if our revenues exceed $1.07
billion, if we issue more than $1 billion in non-convertible debt in a three year period, or if the market value of our common
stock that is held by non-affiliates exceeds $700 million as of any June&nbsp;30.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>If we fail to maintain
an effective system of internal control over financial reporting, we may not be able to accurately report our financial results
or prevent fraud. As a result, shareholders could lose confidence in our financial and other public reporting, which would harm
our business and the trading price of our common shares. </I></B>Effective internal controls over financial reporting are necessary
for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent
fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause
us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404 of the Sarbanes-Oxley
Act, or the subsequent testing by our independent registered public accounting firm when required, may reveal deficiencies in
our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retrospective
changes to our consolidated financial statements or identify other areas for further attention or improvement. Inferior internal
controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect
on the trading price of our common shares. There is also a risk that neither we nor our independent registered public accounting
firm (when applicable in the future) will be able to conclude within the prescribed timeframe that internal controls over financial
reporting is effective as required by Section 404. This could result in an adverse reaction in the financial markets due to a
loss of confidence in the reliability of our financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Our status as
an &ldquo;emerging growth company&rdquo; under the JOBS Act may make it more difficult to raise capital as and when we need it</I></B>.
Because of the exemptions from various reporting requirements provided to us as an &ldquo;emerging growth company,&rdquo; we may
be less attractive to investors and it may be difficult for us to raise additional capital as and when we need it. Investors may
be unable to compare our business with other companies in our industry if they believe that our reporting is not as transparent
as other companies in our industry. If we are unable to raise additional capital as and when we need it, our financial condition
and results of operations may be materially and adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We have not
paid dividends in the past and have no immediate plans to pay dividends</I></B>. We plan to reinvest all of our earnings, to the
extent we have earnings, to cover operating costs and otherwise become and remain competitive. We do not plan to pay any cash
dividends with respect to our securities in the foreseeable future. We cannot assure you that we would, at any time, generate
sufficient surplus cash that would be available for distribution to the holders of our common stock as a dividend. Therefore,
you should not expect to receive cash dividends on the common stock we are offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>If equity research
analysts do not publish research or reports about our business or if they issue unfavorable commentary or downgrade our shares,
the price of our shares could decline. </I></B>The trading market for our shares will rely in part on the research and reports
that equity research analysts publish about us and our business, if at all. We do not have control over these analysts and we
do not have commitments from them to write research reports about us. The price of our shares could decline if no research reports
are published about us or our business, or if one or more equity research analysts downgrades our shares or if those analysts
issue other unfavorable commentary or cease publishing reports about us or our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We will
incur significant increased costs as a result of becoming a public company that reports to the Securities and Exchange
Commission and our management will be required to devote substantial time to meet compliance obligations</I></B>. As a public
company reporting to the Securities and Exchange Commission, we will incur significant legal, accounting and other expenses
that we did not incur as a private company. We will be subject to reporting requirements of the Securities Exchange Act of
1934, or Exchange Act, and the reporting and governance provisions of the Sarbanes-Oxley Act of 2002 and the Dodd-Frank Wall
Street Reform and Protection Act, as well as rules subsequently implemented by the Securities and Exchange Commission, that
impose significant requirements on public companies, including requiring establishment and maintenance of
effective disclosure and financial controls and changes in corporate governance practices. There are significant corporate
governance and reporting provisions in these laws that will increase our legal and financial compliance costs, make some
activities more difficult, time-consuming or costly and may also place undue strain on our personnel, systems and resources.
Our management and other personnel will need to devote a substantial amount of time to these regulations. In addition, we
expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer
liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs
to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified people
to serve on our board of directors, our board committees or as executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Assuming a market
for our common stock develops, shares eligible for future sale may adversely affect the market for our common stock</I></B>. All
of our common shares outstanding prior to this offering, including the common shares issuable upon conversion of our convertible
preferred stock, are subject to lock-up agreements whereby the holder has agreed not to sell, transfer or pledge, or offering
to do any of the same, directly or indirectly, any of our securities for a period of one year following the close of this offering,
except for the holders of common shares issuable upon conversion of our preferred stock and the holders of 218,980 shares of our
outstanding common stock who have agreed not to sell for 180 days following the close of this offering. Notwithstanding the lock-up
agreements, we have agreed to register for resale shares of common stock expected to be issued upon conversion of our preferred
stock and shares of common stock underlying warrants. Furthermore, commencing on the 90th day following the close of this offering,
certain of our stockholders may be eligible to sell all or some of their shares of common stock by means of ordinary brokerage
transactions in the open market pursuant to Rule 144, promulgated under the Securities Act, subject to certain limitations. In
general, pursuant to Rule 144, non-affiliate stockholders may sell freely after six months subject only to the current public
information requirement (which disappears after one year). Following the 180th&nbsp;day following the close of this offering,
certain stockholders will be eligible to begin publicly selling their shares under Rule&nbsp;144.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any substantial sale
of our common stock pursuant to Rule 144 or pursuant to any resale prospectus (including sales by investors of securities acquired
in connection with this offering) may have a material adverse effect on the market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <B><I>You will
experience immediate dilution in the book value per share of the common stock you purchase. </I></B>Because the price per share
of our common stock being offered is substantially higher than the book value per share of our common stock, you will experience
substantial dilution in the net tangible book value of the common stock you purchase in this offering. Based on the offering price
of $6.00 per share, if you purchase shares of common stock in this offering, you will experience immediate and substantial dilution
of $4.51 per share in the net tangible book value of the common stock at June 30, 2018. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>We may be at an
increased risk of securities class action litigation. </I></B>Historically, securities class action litigation has often been
brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because
biotechnology and pharmaceutical companies have experienced significant stock price volatility in recent years. If we were to
be sued, it could result in substantial costs and a diversion of management&rsquo;s attention and resources, which could harm
our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>We have broad discretion
in how we use the proceeds of this offering and may not use these proceeds effectively, which could affect our results of operations
and cause our stock price to decline. We may invest or spend these proceeds in ways with which you do not agree and in ways that
may not yield a return on your investment. </I></B>Our management will have considerable discretion in the application of the
net proceeds of this offering, including for any purpose described in the section of this prospectus entitled &ldquo;Estimated
Use of Proceeds&rdquo;. However, our needs may change as our business and industry evolve and, as a result, the proceeds we receive
from this offering may be used in a manner substantially different from our current expectations. We may use the net proceeds
for purposes that do not yield a significant return or any return at all for our shareholders. In addition, pending their use,
we may invest the net proceeds from this offering in a manner that does not produce income or that loses value. The failure by
our management to apply these funds effectively could result in financial losses that could harm our business, cause the price
of our common stock to decline and delay the development of our product candidates. You will not have the opportunity as part
of your investment decision to assess whether the net proceeds are being used appropriately and, as a result, you will be relying
on our management&rsquo;s judgment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Our charter
documents and Delaware law may inhibit a takeover that stockholders consider favorable. </I></B> Provisions in our amended and
restated certificate of incorporation and amended and restated bylaws to be effective in connection with this offering and applicable
provisions of Delaware law may delay or discourage transactions involving an actual or potential change in control or change in
our management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions
that our stockholders might otherwise deem to be in their best interests. The provisions in our amended and restated certificate
of incorporation and amended and restated bylaws:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD>authorize
                                         our board of directors to issue, without further action by the stockholders, shares of
                                         undesignated preferred stock with terms, rights, and preferences determined by our board
                                         of directors that may be senior to our common stock;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD>establish
                                         an advance notice procedure for stockholder proposals to be brought before an annual
                                         meeting, including proposed nominations of persons for election to our board of directors;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD>establish
                                         that our board of directors is divided into three classes, with each class serving three-year
                                         staggered terms;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD>require
                                         the approval of our board of directors or the holders of at least seventy-five percent
                                         (75%)&nbsp;of our outstanding shares of capital stock to amend our bylaws and certain
                                         provisions of our certificate of incorporation;</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">limit
                                         who may call stockholder meetings;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">do
                                         not provide for cumulative voting rights; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">provide
                                         that all vacancies may be filled by the affirmative vote of a majority of directors then
                                         in office, even if less than a quorum.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, once
we become a publicly traded corporation, Section 203 of the Delaware General Corporation Law may limit our ability to engage in
any business combination with a person who beneficially owns 15% or more of our outstanding voting stock unless certain conditions
are satisfied. This restriction lasts for a period of three years following the share acquisition. These provisions may have the
effect of entrenching our management team and may deprive you of the opportunity to sell your shares to potential acquirers at
a premium over prevailing prices. This potential inability to obtain a control premium could reduce the price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.95pt; text-align: justify; text-indent: 34.05pt"><B><I>Our
amended and restated certificate of incorporation designates the Court of Chancery of the State of Delaware as the sole and exclusive
forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders&rsquo; ability to obtain
a favorable judicial forum for disputes with us or our directors, officers or stockholders</I></B>. Provisions in our amended
and restated certificate of incorporation to be effective in connection with this offering provide that the Court of Chancery
of the State of Delaware will, to the fullest extent permitted by law, be the sole and exclusive forum for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                         derivative action or proceeding brought on our behalf; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                         action asserting a claim of breach of a fiduciary duty owed to us or our stockholders
                                         by any of our directors, officers or other employees; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                         action asserting a claim against us or any of our directors, officers or other employees
                                         arising pursuant to any provision of Delaware law or our charter documents; or </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol">&middot;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">any
action asserting a claim against us or any of our directors, officers or other employees governed by the internal affairs doctrine</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> , but excluding actions to enforce a duty or liability created
by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> In addition, unless
we consent in writing to the selection of an alternative forum, the Federal district courts of the United States of America shall
be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. However,
a court may determine that this provision is unenforceable. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> By becoming a stockholder
in our company, you will be deemed to have notice of and have consented to the provisions of our amended and restated certificate
of incorporation related to choice of forum, but will not be deemed to have waived our compliance with the federal securities
laws and the rules and regulations thereunder. The choice of forum provisions in our amended and restated certificate of incorporation
may limit our stockholders&rsquo; ability to obtain a favorable judicial forum for disputes with us or any of our directors, officers
or other employees, which may discourage lawsuits with respect to such claims. Alternatively, if a court were to find the choice
of forum provision contained in our restated charter to be inapplicable or unenforceable in an action, we may incur additional
costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations and financial
condition. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Ownership portions
held by our executives and directors, as well as by our former parent company, Imprimis Pharmaceuticals, Inc., may limit your
ability to influence corporate matters. </I></B>Following this offering, and after giving effect to the conversion of our Series
A preferred stock, our directors and executive officers will beneficially own approximately 12.4% of our common stock. Additionally,
Imprimis Pharmaceuticals, Inc., our former parent company, will hold approximately 21.4% of our outstanding common stock. Accordingly,
these parties, together, will be able to significantly influence, though not independently determine, the outcome of matters required
to be submitted to our shareholders for approval, including decisions relating to the election of our board of directors and the
outcome of any proposed merger or consolidation of our company. These interests may not be consistent with those of our other
shareholders. In addition, the significant interest held by these parties, and particularly by Imprimis, may discourage third
parties from seeking to acquire control of us, which may adversely affect the market price of our shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_003"></A>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus, including
the sections entitled &ldquo;Prospectus Summary,&rdquo; &ldquo;Risk Factors,&rdquo; &ldquo;Use of Proceeds,&rdquo; &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations,&rdquo; and &ldquo;Our Business,&rdquo; contains forward-looking
statements. The words &ldquo;believe,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;potentially,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;continue,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;project,&rdquo;
&ldquo;plan,&rdquo; &ldquo;expect&rdquo; and similar expressions that convey uncertainty of future events or outcomes are intended
to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning
the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         future financial and operating results;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         intentions, expectations and beliefs regarding anticipated growth, market penetration
                                         and trends in our business;</FONT></TD></TR></TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         timing and success of our plan of commercialization;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         ability to successfully develop and clinically test our product candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         ability to file for FDA approval of our product candidates through the 505(b)(2) regulatory
                                         pathway;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         ability to obtain FDA approval for any of our product candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         ability to comply with all U.S. and foreign regulations concerning the development, manufacture
                                         and sale of our product candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         adequacy of the net proceeds of this offering;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         effects of market conditions on our stock price and operating results;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         ability to maintain, protect and enhance our intellectual property;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         effects of increased competition in our market and our ability to compete effectively;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         plans to use the proceeds from this offering;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">costs
                                         associated with initiating and defending intellectual property infringement and other
                                         claims;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         attraction and retention of qualified employees and key personnel;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">future
                                         acquisitions of or investments in complementary companies or technologies; and</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         ability to comply with evolving legal standards and regulations, particularly concerning
                                         requirements for being a public company.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These forward-looking
statements are subject to a number of risks, uncertainties and assumptions, including those described in &ldquo;Risk Factors&rdquo;
and elsewhere in this prospectus. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge
from time to time. It is not possible for us to predict all risks, nor can we assess the impact of all factors on our business
or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained
in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events
and circumstances discussed in this prospectus may not occur and actual results could differ materially and adversely from those
anticipated or implied in our forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should not rely
upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in our forward-looking
statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances
described in the forward-looking statements will be achieved or occur. Moreover, neither we nor any other person assumes responsibility
for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any forward-looking
statements for any reason after the date of this prospectus to conform these statements to actual results or to changes in our
expectations, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should read this
prospectus and the documents that we reference in this prospectus and have filed with the Securities and Exchange Commission as
exhibits to the registration statement of which this prospectus is a part with the understanding that our actual future results,
levels of activity, performance and events and circumstances may be materially different from what we expect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_004"></A>OUR
BUSINESS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Eton Pharmaceuticals,
Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative pharmaceutical products utilizing
the FDA&rsquo;s 505(b)(2) regulatory pathway. Our business model is to develop proprietary innovative products that fulfill an
unmet patient need.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have established
a diversified pipeline of eight product candidates in various stages of development. Our corporate strategy is to pursue what
we perceive to be low-risk 505(b)(2) candidates where existing published literature, historical clinical trials, or physician
usage has established safety or efficacy of the molecule, thereby reducing the incremental clinical burden required for us to
bring the product to patients. We intend to focus on product candidates that are currently unapproved or product candidates that
we believe will offer innovative and proprietary functional advantages to currently available alternatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to pursue
product candidates that require a single small Phase 3 trial, a bio-equivalence trial, or literature-based filings. Prior to initiating
significant development activities on a product candidate, we intend to meet with the FDA to establish a defined clinical and
regulatory path to approval. We have conducted Pre-IND meetings with the FDA concerning all of our current product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Market Opportunity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe there is
a large market opportunity for developing drugs that offer improvements to currently approved treatments and address unmet patient
needs. We intend to pursue product opportunities where patient demand is not being met by current FDA-approved pharmaceutical
products. This may include products that are being supplied on an unapproved basis, products that are currently being compounded,
products that are approved and sold internationally but not available in the United States, or approved products where we believe
we can provide a lower-cost alternative to an existing high-priced branded product. While we may opportunistically pursue 505(b)(2)
opportunities across all dosage forms, we are primarily focused on liquid products, including injectables, oral liquids and ophthalmics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>505(b)(2) Pathway</B>.
The 505(b)(2) pathway is intended for molecules that have been previously approved by the FDA or have already been proven to be
safe and effective. A 505(b)(2) product typically reformulates the known molecule in a new strength or dosage form. 505(b)(2)
products have the advantage of potentially significantly lower development costs and shorter development timelines versus traditional
new molecular entities. We expect to utilize the 505(b)(2) pathway for all of our current product candidates, except for EM-100,
for which we intend to use the 505(j) pathway, which is typically utilized by generic drug candidates and generally requires only
a bioequivalence trial in order to prove safety and efficacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A 505(b)(2) NDA is
an application that contains full reports of investigations of safety and effectiveness, but where at least some of the information
required for approval comes from studies not conducted by or for the applicant. This alternate regulatory pathway enables the
applicant to rely, in part, on the FDA&rsquo;s findings of safety and efficacy for an existing product, or published literature,
in support of its application. A 505(b)(2) product candidate might rely on the clinical studies or literature of a previously
FDA-approved drug, or rely on the literature and physician usage of an FDA-unapproved, or DESI, drug. The clinical requirements
for a 505(b)(2) drug candidate can vary widely from product to product and may include new clinical trials, bioequivalence trials,
limited safety and efficacy trials, or full Phase 1 through 3 trials. Unless the FDA has released a guidance document, the clinical
requirement for a new product candidate is typically not known until the drug sponsor has a Pre-IND meeting with the FDA. We believe
there is a significant opportunity to pursue liquid or other alternative formulations of off-patent drugs using the 505(b)(2)
regulatory pathway.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The FDCA provides three
years of marketing exclusivity for an NDA, including an NDA under the 505(b)(2) pathway, if new clinical investigations, other
than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval
of the application, for example, for new indications, dosages, or strengths of an existing drug. This three-year exclusivity covers
only the conditions associated with the new clinical investigations. We believe that our current product candidates for which
we intend to pursue the 505(b)(2) pathway will not require clinical investigations, other than bioavailability studies, and, therefore,
we do not expect that any of our current product candidates will be eligible for marketing exclusivity under the FDCA.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to utilize
the 505(j) pathway for obtaining FDA approval for our EM-100 product candidate. The 505(j) pathway is used for product candidates
that are therapeutically equivalent to an approved product and requires an abbreviated new drug application, or ANDA, which relies
on the FDA&rsquo;s finding that the previously approved drug candidate is safe and effective. An ANDA generally must contain information
to show that the product candidate is the same as the approved product with respect to API, conditions of use, route of administration,
dosage form, strength and labeling, with certain permissible differences, and is the bioequivalent of the approved drug. The 505(j)
pathway typically requires no clinical testing other than a bioequivalence trial. While the 505(j) pathway is typically shorter
and less expensive than the 505(b)(2) pathway, the 505(b)(2) pathway allows greater flexibility as to the characteristics of the
product candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>DESI Program</B>.
Upon its enactment in 1938, the FDCA required new drugs to demonstrate that they were safe before they could be marketed. In 1962,
the FDCA was amended to require that new drugs demonstrate that they were effective as well as safe. Following the 1962 amendments
to the FDCA, the FDA adopted a program called the Drug Efficacy Study Implementation, or DESI, to review the efficacy of drugs
approved between 1938 and 1962, and the drugs approved between 1938 and 1962 are commonly referred to as DESI drugs. DESI drugs
were allowed to remain on the market until they were re-reviewed as long as they weren&rsquo;t substantially changed. The DESI
program removed many products that were deemed to not be effective, but there was no comprehensive list of drugs approved and
marketed at the time and not all drugs were re-reviewed. As a result, many DESI products remained marketed without a formal approval
for effectiveness. Based on the FDA&rsquo;s published guidance document, we would expect the currently marketed product to exit
the market within one year of our product&rsquo;s approval. We believe there is a significant opportunity to obtain FDA approval
of unapproved DESI drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Goals and Strengths</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our goal is to become
a leading specialty pharmaceutical company through the introduction of innovative medicines that are affordable and available
to all patients. We believe our competitive strengths include our:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">unique
                                         knowledge of the industry, including our ability to identify product opportunities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">management&rsquo;s
                                         regulatory and development experience, particularly within the 505(b)(2) pathway;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">our
                                         portfolio of attractive assets that we believe will enable us to compete effectively
                                         in the market;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">management&rsquo;s
                                         experience in business development, M&amp;A, licensing activities and broad industry
                                         connections;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">differentiated
                                         business model as compared to generic and branded specialty pharmaceutical drug companies,
                                         utilizing the 505(b)(2) pathway; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">patent
                                         rights, know-how, exclusive API and manufacturing relationships.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to grow
our business through opportunistic development and licensing of 505(b)(2) products. Our primary criteria for product candidates
are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><I>Low
                                         regulatory risk</I>: We focus on molecules where there is significant existing clinical
                                         data or literature to show that the product is safe and effective, creating a higher
                                         probability of clinical and regulatory success. Our product candidates do not typically
                                         require extensive clinical trials.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><I>Low
                                         commercial risk</I>: We select product candidates where patient demand is apparent, providing
                                         a high-degree of confidence in commercial success. We pursue products that are currently
                                         compounded, sold as unapproved products, or where we are providing a lower-cost alternative
                                         to high-price branded products with strong existing demand. Our candidates are typically
                                         well-known molecules that require minimal sales force promotion, so we able to pursue
                                         opportunities across most therapeutic areas.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><I>Short
                                         development timelines</I>: We believe that the product candidates internally developed
                                         by us typically have a path to approval of approximately 36 months from the time of product
                                         initiation. For product opportunities acquired or licensed by us, we primarily focus
                                         on opportunities where the NDA has been filed, or is near filing, and product could be
                                         less than 18 months away from the commercial market.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><I>Relatively
                                         low cost</I>: We prefer to develop numerous lower-cost projects, rather than a single
                                         high-cost candidate. We do not believe that development costs are necessarily correlated
                                         with the earnings potential of products.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><I>Protection
                                         from competition</I>. In the future, we will endeavor to acquire rights to or internally
                                         develop products that may receive Orange-book listed patents or FDA-granted exclusivity.
                                         We have also entered into exclusive agreements with manufacturing partners and API suppliers
                                         on most of our products.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to aggressively pursue value-creating
business development opportunities, including the licensing or acquisition of individual development-stage or commercial products,
as well as the acquisition of companies or subsidiaries of operating companies. Our management team has a track record of successfully
growing businesses through value-creating business development activities and has completed numerous transactions during their
careers. At any particular time, we are typically evaluating multiple acquisition or licensing opportunities of various sizes.
We believe management&rsquo;s business development experience and broad industry contacts provide us with a competitive advantage,
and as a public company we believe we will have greater access to capital with which to pursue transactions of all sizes.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Products&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have assembled
a diversified pipeline of high-value drug candidates in various stages of development. Two of our products have been filed with
the FDA and we anticipate receiving approval of both products in 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We source products
both internally, by contracting with third-parties for development of our internal candidates on a fee-for-service basis, and
externally, through the licensing or acquisition of existing development or commercial products. For products that we have licensed
or acquired from third parties, we typically are required to pay a combination of licensing fees, milestone payments, and/or profit
share/royalty payments to our partner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to continue
growing our pipeline of product candidates through value-creating business development activities, and we are in active discussions
with the FDA on additional internally developed products that may be added to our pipeline if we elect to proceed with the opportunity
after the outcome of our pre-IND meeting with the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our six lead product
candidates include three innovative formulation products and three product candidates where we are pursuing formal approval of
products that are currently sold as DESI or unapproved products. All of the FDA-approved products our candidates are referencing
are off-patent and have no form of FDA exclusivity. We do not anticipate any of our products requiring a paragraph four certification,
which is used by the FDA to confirm that a product candidate will not infringe patent rights held by an approved product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Innovative Formula Products</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20">For our
innovative formula products, we have developed improved versions of already FDA-approved products. We believe our unique formulas
will provide a significant benefit to patients or practitioners, in the form of improved safety, efficacy, or more affordable
costs. Our three lead innovative formula products are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20"><B>EM-100.
</B>EM-100 is an ophthalmic solution indicated for the treatment of allergic conjunctivitis. EM-100 is a unique preservative-free
formulation of ketotifen. Ketotifen is an FDA-approved molecule that is widely used and sold via the over-the-counter channel.
Ketotifen is an antihistamine for the eye that treats allergic symptoms. It is also a mast cell stabilizer that minimizes allergic
reactions by reducing the release of natural substances that cause an allergic reaction. Side effects associated with ketotifen
use include eye dryness, headache, and runny nose. All currently FDA-approved ketotifen ophthalmic products contain the preservative
benzalkonium chloride, which has been shown to cause irritation and negatively impact long-term eye health. We believe our unique
preservative-free formulation will successfully treat allergic conjunctivitis and, at the same time, provide an increased comfort
profile to patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20"> As
of the date of this prospectus, there are no FDA approved preservative-free ophthalmic products available for the treatment
of allergic conjunctivitis. We are not aware of any other companies working on preservative-free versions of ketotifen, or
any other allergic conjunctivitis treatment, so we expect EM-100 to be the first preservative-free product in its class.
While we expect EM-100 to primarily compete and take market share from the existing preservative-containing ketotifen
products, it may also compete against other leading allergic conjunctivitis products that contain preservatives, such as
Pazeo, an olopatadine-based product, Alrex, a loteprednol-based product and Bepreve, a bepotastine-based product. According
to IRI, an independent market research company, the current market for preservative-containing ketotifen ophthalmic products
is greater than $55 million annually. We believe our EM-100 product candidate will address the entire $55 million
market for ketotifen ophthalmic anti-allergy products and we expect to capture a small percentage of the market
with our EM-100 product candidate. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20">EM-100
will be sold via the over-the-counter, or OTC, channel, so patients will not require a prescription to purchase the product. We
expect to market the product ourselves or partner with an ophthalmic company that has an existing presence and well-known brand
in the OTC channel. As of the date of this prospectus, EM-100 is the only product candidate in our current portfolio that is targeting
the OTC channel, and all of our other products will be sold via the prescription channel. Going forward, we expect to primarily
focus on prescription products.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20">Our development
partner previously filed an ANDA for EM-100 and in response to a complete response letter, or CRL, from the FDA we ran a bioequivalence
trial in April 2018. The 65-patient clinical trial successfully showed statistically significant non-inferiority to ZADITOR (ketotifen
fumarate ophthalmic solution 0.035%) and statistically significant superiority to the placebo with no adverse events reported.
The FDA&rsquo;s request for a bioequivalence trial was the FDA&rsquo;s only material comment in the CRL, and we responded to the
CRL in September 2018. We expect to utilize the 505(j) pathway for FDA approval of EM-100. The 505(j) pathway is typically utilized
for generic drug candidates. We do not anticipate utilizing the 505(j) pathway for any other of our current product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20"><B>ET-103.
</B>ET-103 is a unique oral liquid formulation of levothyroxine for the treatment of hypothyroidism. Hypothyroidism, also called
underactive thyroid or low thyroid, is a disorder of the endocrine system in which the thyroid gland does not produce enough thyroid
hormone. Levothyroxine is a synthetic form of thyroxine, an endogenous hormone secreted by the thyroid gland, which is converted
to its active metabolite, L-triiodothyronine. Thyroxine and L-triiodothyronine bind to thyroid receptor proteins in the cell nucleus
and cause metabolic effects through the control of DNA transcription and protein synthesis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.95pt; text-align: justify; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.95pt; text-align: justify; text-indent: 0.5in; color: #231F20">As
of the date of this prospectus, levothyroxine is delivered primarily in tablet and capsule form. Levothyroxine is one of the most
frequently prescribed medications in the United States with sales of greater than $2.6 billion and more than 5.7 billion tablets
and capsules sold annually. It is estimated that 15% of Americans over the age of 55 take levothyroxine daily. Side effects reported
with oral use of levothyroxine include fatigue, weight loss, heat intolerance, fever and excessive sweating. We believe ET-103
will offer a significant benefit to the subset of levothyroxine patients that have challenges swallowing or need more flexible
dosing. As a result, we expect ET-103 to capture a small percentage of the overall levothyroxine tablet and capsule market.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20">As of
the date of this prospectus, there are no FDA-approved ready-to-use oral liquid levothyroxine products available in the market.
The FDA previously approved Tirosint-Sol, a liquid version of levothyroxine, in February 2017, however the product was never launched
and the product application has been designated as discontinued by the FDA. Patients unable to swallow pills must rely on liquids
created by compounding pharmacies, or patients must manually crush levothyroxine in tablet form, such as Synthroid, the leading
levothyroxine in the market, and mix them with a drink. We believe our product will offer significant benefits over the current
liquid options, including more accurate dosing, greater convenience, and better stability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20">We plan
to file a 505(b)(2) NDA application referencing Synthroid&reg;, the leading levothyroxine product in the market. We held a Pre-IND
meeting with the FDA in September 2018, and the agency agreed with our proposal to conduct a bridging study between ET-103 and
Synthroid as the principal means of proving safety and efficacy. The study is anticipated to be a 66-patient randomized, two treatment,
cross-over bioequivalence study. We plan to initiate the study in 2018 and, if successful, would plan to file the NDA in 2019.
We expect to file a patent on ET-103 in the near future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20">Upon approval,
we expect to use a targeted endocrinology salesforce to drive awareness and education of the product. We do not believe there
are any suitable molecule substitutes for levothyroxine, so we expect ET-103&rsquo;s primary competition to come from the numerous
levothyroxine tablet and capsule products in the market. We are not aware of any other companies seeking to bring a liquid form
of levothyroxine to the US market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20"> <B>CT-100. </B>CT-100
is our patent-pending synthetic corticotropin therapeutic candidate for the treatment of rheumatoid arthritis. Our
CT-100 product candidate mimics the amino acid chain of H.P. Acthar Gel. Our patent-pending technology stabilizes a known
unstable molecule of the approved drug. It is well documented that natural corticotropin is an unstable molecule and that
its instability leads to reduced potency over time or at higher temperatures. We believe that our synthetic corticotropin
is stable and retains its potency far longer that H.P. Acthar Gel. Our synthetic corticotropin is a 39-chain amino acid
peptide synthetic adrenocorticotrophic hormone, non-gelatin and preservative-free. CT-100 is an injectable product candidate
that could be administered in both the hospital and home settings. The exact mechanism of action of corticotropin is unknown,
but it is believed to stimulate the adrenal cortex to secrete cortisol and impact steroid-independent immunomodulatory
and anti-inflammatory pathways. Reported adverse events of H.P. Acthar Gel include weight increase, fatigue, injection
site bruising, insomnia, dyspnoea, stomach ulcers, headaches and dizziness, excessive sweating and skin disorders. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20"> H.P
Acthar Gel currently sells for a list price of over $38,000 per vial and is currently approved for 19 indications, including
as a prescription add-on medicine for the short-term administration of rheumatoid arthritis to tide patients over an acute
episode or exacerbation. We believe that the annual sales of H.P. Acthar Gel for all 19 indications exceed $1 billion, and
that 10% to 20% of the patients using H.P. Acthar Gel are being treated for the rheumatoid arthritis indication. We intend to
pursue one indication for CT-100, as a prescription add-on medicine for the short-term administration of rheumatoid arthritis
to tide patients over an acute episode or exacerbation. We believe our CT-100 product candidate will address the entire
market presently served by H.P. Acthar Gel for the rheumatoid arthritis indication and we expect to capture a small percentage of the market with our CT-100 product candidate. We believe CT-100 would provide
rheumatoid arthritis patients with a more stable treatment option at a discounted price. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20">ANI Pharmaceuticals
and Assertio Therapeutics have publicly disclosed development projects that would compete against H.P. Acthar and may impact the
market opportunity for CT-100. ANI Pharmaceuticals is seeking to revive a previously approved but now discontinued Cortrophin
Gel product. Assertio has begun enrolling patients in an infantile spasm clinical trial for its Cosyntropin drug candidate. Although
these two products may ultimately be approved for different indications than CT-100, and neither product is the same molecule
as CT-100, they may be viewed as competing treatments by patients and practitioners. If approved, these products may cause disruption
in the H.P. Acthar market, which could adversely impact the market opportunity for CT-100.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20">We have
held two written response meetings with the FDA regarding CT-100 and we are currently working with a clinical research organization
to analyze the cost and protocol for CT-100&rsquo;s clinical program based on the FDA&rsquo;s feedback. If the project is determined
to be cost prohibitive for us, we may seek to partner or license the product to a larger or more well-capitalized company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><B>DESI Conversion Products</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20">We have
three product candidates for which we are seeking formal FDA approval for molecules where the U.S market is currently relying
on a DESI product. We will seek to convert the market from the current DESI products to our formally approved products. DESI products,
also known as &ldquo;grandfathered&rdquo; or &ldquo;unapproved&rdquo; products, are products that were marketed prior to 1962
when the FDA began requiring proof of efficacy, in addition to safety, in order to gain approval. The FDA has allowed DESI products
to remain on the market until someone receives formal FDA approval for the molecule. Each of the three DESI markets is currently
served by a single DESI product and we do not expect any DESI products to reenter these markets. We will pursue a formal approval
via the 505(b)(2) NDA pathway for our products. Based on the FDA&rsquo;s published guidance document, we would expect the currently
marketed product to exit the market within one year of our product&rsquo;s approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20"> Currently,
the combined IQVIA sales of the DESI products we are referencing is approximately $40 million. With more consistent
supply and promotion of our product candidates, we believe our market opportunity is larger than the historic sales levels.
However, none of our DESI conversion products are subject to patent protection or market exclusivity under the provisions of
the FDCA. Following FDA approval of our product candidates for which we have no patent protection or market exclusivity,
our competitors may seek to develop a competing product pursuant to the 505(j) pathway, which is an abbreviated pathway used
for the regulatory approval of generic product candidates. As a result of the foregoing, and the fact that 505(b)(2)
product candidates generally have shorter timelines to, and lower cost of, regulatory approval, we may find that the
market opportunity for our product candidates that target DESI products and for which we have no patent protection or
market exclusivity is relatively small due to the fact that barriers to entry are low and generic competition may
follow within relatively short time periods after our product is approved. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Our three DESI conversion products
are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20"> <B>DS-300.
</B>DS-300 is a patent-pending injectable product intended for use as an additive to meet the nutritional requirements of neonates
requiring total parenteral nutrition. The product is administered in the hospital setting to patients that are unable to naturally
produce sufficient levels of needed nutrients. DS-300&rsquo;s active ingredient is naturally occurring in the body and has been
administered to patients as a supplement for decades with no reports of any meaningful adverse events besides occasional infusion
site reactions. The DESI product we are targeting with DS-300 has annual sales of approximately $19 million. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20">Based
on a Pre-IND meeting with the FDA, DS-300&rsquo;s NDA was submitted as a literature-based filing as the principal means of proving
safety and efficacy. The NDA references 24 studies published in well-respected medical publications, tracking more than 700 patients.
The product&rsquo;s NDA was filed with the FDA in January 2018. DS-300 has been granted Fast Track Designation by the FDA and
is being reviewed by the FDA as a rolling review, meaning we are allowed to submit sections of our NDA as they are completed rather
than waiting for completion of the entire NDA. All sections of the NDA have been submitted. However, the original manufacturing
site is no longer available, so the product is being transferred to a different FDA-approved manufacturing site. Registration
batches have been manufactured at the new site, and we anticipate providing the FDA with its requested data from the new manufacturer
by the end of 2018. As of the date of this prospectus, we are not aware of any drug companies that have publicly disclosed their
development of a product based on DS-300&rsquo;s active ingredient.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20"> <B>DS-200.
</B>DS-200 is an injectable nutrition product indicated for use as a supplement to intravenous solutions for total parenteral
nutrition. The product is administered in the hospital setting to patients that are unable to naturally produce sufficient levels
of needed nutrients and minerals. DS-200&rsquo;s active ingredient is naturally occurring in the body and has been administered
to patients as a supplement for decades with no reports of any meaningful adverse events besides occasional infusion site reactions.
The DESI product we are targeting with DS-200 has annual sales of approximately $6 million. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20">Based
on a Pre-IND meeting with the FDA, we expect DS-200 to be a literature-based filing as the principal means of proving safety and
efficacy. We expect to reference more than 15 published articles which showed safety and efficacy in studies involving more than
2,000 patients. DS-200 has been granted Fast Track Designation by the FDA, which we believe highlights the unmet need our product
is aiming to address. We expect DS-200&rsquo;s NDA to be submitted in 2019. As of the date of this prospectus, we are not aware
of any drug companies that have publicly disclosed their development of a product based on DS-200&rsquo;s active ingredient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20"> <B>DS-100. </B>DS-100
is an injectable nerve block indicated for therapeutic neurolysis for the relief of intractable pain, generally defined as <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">severe,
constant pain that is not curable by any known means. The DESI product we are targeting with DS-100 has annual sales of
approximately $11 million.</FONT> DS-100 produces neuritis and nerve degeneration, which blocks sensory, motor, and autonomic
function of the nerves. We are currently in discussions with the FDA regarding the exact indication we will pursue and
clinical requirements for DS-100, however as of the date of this prospectus it is our intention to seek FDA approval of
DS-100 for the indication as a general nerve block. We expect either a literature-based filing or a small clinical trial as
the principal means of proving safety and efficacy. We believe the existing literature shows safety and efficacy in 10
published studies involving more than 850 patients. Reported side effects included mild hypotension, diarrhea, and nausea. We
expect an NDA for DS-100 to be submitted in 2019. An injectable version of DS-100&rsquo;s active ingredient was previously
FDA-approved for a different indication but is not currently being sold in the market. As of the date of this prospectus, we
are not aware of any drug companies that have publicly disclosed their development of a product based on DS-100&rsquo;s
active ingredient. </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.95pt; color: #231F20"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20"><B>Early-Stage Products</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20">At any
time, we typically have various products and product ideas in early-stage development. These may include products where we have
not yet met with the FDA, or products for which we have met with the FDA and received agreement upon our clinical pathway, but
we have yet to complete significant development activities. These early-stage products include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20"><B>ET-101.
</B>ET-101 is an innovative oral liquid product for the treatment of epilepsy. The active ingredient in ET-101 is FDA-approved
in an oral solid dosage form, and there are several approved products in the market in oral solid dosage form but is not approved
in oral liquid form. The exact mechanism of action of the active ingredient is unknown. Negative side effects or adverse events
associated with the API in the currently marketed products include vision impairment, depression, and confusion. Based on a Pre-IND
meeting with the FDA, we expect to conduct a bioequivalence trial for ET-101 as the principal means of proving safety and efficacy.
We anticipate submitting a patent application on our unique formulation and expect to file the NDA for ET-101 in 2020. The market
for seizure related treatments is highly competitive with numerous treatment options available to patients, however as of the
date of this prospectus, we are not aware of any drug companies that have publicly disclosed their development of a product based
on ET-101&rsquo;s active ingredient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20"><B>ET-102.
</B>ET-102 is an innovative oral liquid product for use as a muscle relaxant in the treatment of muscle contractions due to multiple
sclerosis. The active ingredient in ET-102 is FDA-approved in an oral solid dosage form, and there are several approved products
in the market in oral solid dosage form but is not approved in an oral liquid form. The precise mechanism of action of ET-102
is not fully known but it is believed to be capable of inhibiting both monosynaptic and polysynaptic reflexes at the spinal level.
We are not aware of any major negative side effects or adverse events associated with the API in the currently marketed products,
and minor side effects include drowsiness and dizziness. Based on a Pre-IND meeting with the FDA, we expect to conduct a bioequivalence
trial for ET-102 as the principal means of proving safety and efficacy. We expect to file the NDA for ET-102 in 2020. The market
for muscle relaxant related treatments is highly competitive with numerous treatment options available to patients, however, as
of the date of this prospectus, we are not aware of any drug companies that have publicly disclosed their development of a product
based on ET-102&rsquo;s active ingredient.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Research and Development </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Set forth below is
our research and development spending for our current product candidates. We currently have four employees that support our overall
product development and we also have facility and operating costs for a laboratory that will support product development. We do
not track internal costs by product for our employees and laboratory expenses and they are listed as indirect expenses in the
table below (amounts are in thousands).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Product</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Period&nbsp;From<BR>
    April&nbsp;27,&nbsp;2017<BR> (Inception)<BR> Through<BR> December&nbsp;31,<BR> 2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months<BR>
    Ended<BR>
    June 30,<BR> 2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%">CT-100</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">93</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">74</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>DS-100</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">750</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>DS-200</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,686</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">395</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>DS-300</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">402</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">884</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>EM-100</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">470</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">978</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other products</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">132</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">135</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Indirect expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">397</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">515</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-left: 9pt; padding-bottom: 2.5pt">TOTAL</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 2.5pt double">3,930</TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 2.5pt double">2,981</TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sales and Marketing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to establish
an internal sales infrastructure in 2018. We are in the process of registering for licenses to distribute pharmaceuticals in all
required states and territories of the United States. We anticipate being fully registered with all states in advance of launching
our initial product under our own label.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may selectively
out-license or seek a marketing partner on a product by product basis for products that we deem to require large dedicated sales
forces, or for any products where we find it financial or strategically advantageous. We have engaged an experienced third-party
logistics company specializing in pharmaceuticals to manage inventory, logistics, and sales reconciliation for our commercial
products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Manufacturing and Suppliers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We rely on third party
contract manufacturing organizations, or CMO, to manufacture our products. All our manufacturing partners are based in the United
States or Europe. We seek to work with CMOs that have a long history of quality and FDA compliance. All products are manufactured
in compliance with cGMP, and our internal quality system requires us to enter quality agreements with and audit all of our manufacturers.
Our choice to rely on external manufacturers significantly reduces the amount of capital invested in our business and allows us
the flexibility to pursue a broad range of opportunities beyond the specific capabilities of a single facility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Licensing Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We source certain
products externally through the licensing or acquisition of existing development or commercial products. Among our current pipeline
of product candidates, we have entered into licensing and profit sharing arrangements for six of those products, namely EM-103,
ET-103, CT-100, DS-300, DS-200 and DS-100.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EM-100</B>.
We acquired the exclusive rights to develop, manufacture and sell the EM-100 product in the U.S. pursuant to a Sales and Marketing
Agreement dated August 11, 2017 between us and Eyemax LLC, an entity affiliated with our Chief Executive Officer. We also hold
a right of first refusal to obtain the exclusive license rights for geographic areas outside of the U.S. Pursuant to the agreement,
we are responsible for all costs of testing and FDA approval of the product, other than the FDA filing fee which will be paid
by the licensor. We are also responsible for commercializing the product in the U.S. at our expense. The licensor shall own of
all product registration and regulatory filings, all of which shall be subject to our exclusive license. We paid the licensor
$250,000 upon execution of the agreement and will pay the licensor $250,000 upon FDA approval and $500,000 upon the first commercial
sale of the product. We will also pay the licensor a royalty of 10% on the net sales of all products. The license agreement is
for an initial term of ten years from the date of the agreement, subject to successive two year renewals unless we elect to terminate
the agreement. The licensor may terminate the agreement if, in any full calendar year following the first commercial sale of the
product, the licensor fails to receive royalties of at least $100,000. The agreement also contains customary representations,
warranties, covenants and indemnities by the parties.</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: justify; text-indent: 34pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: justify; text-indent: 34pt"><B>ET-103</B>.
We acquired the exclusive license to develop, manufacture and sell ET-103 in the U.S. pursuant to an Exclusive License and Supply
Agreement dated August 3, 2018 between us and Liqmeds Worldwide Limited, an unaffiliated entity. Pursuant to the agreement, we
will be responsible for, and shall own, all regulatory filings and approvals at our expense, provided that we shall have the right
to recoup 35% of any regulatory filing fees from the initial profits from the sale of ET-103 and, provided further, the licensor
shall be responsible for any bioequivalence study and shall be responsible for 60% of the costs of such study. An affiliate of
the licensor shall manufacture the ET-103 and sell it to us at its cost. We paid the licensor $350,000 upon execution of the agreement
and will pay the licensor $1,500,000 upon the FDA&rsquo;s acceptance of an NDA for review, $1,000,000 upon FDA approval, $1,500,000
upon issuance of patent covering ET-103 listed in the FDA&rsquo;s Orange Book and $500,000 in the event of product sales in excess
of $10,000,000 in any calendar year. In addition, we are required to pay the licensor 35% of the net profit from product sales,
payable on a quarterly calendar basis; provided however, that if during any calendar quarter the net profits are negative then
a negative balance will accrue and will be offset against future milestone or profit share payments owed to the licensor. The
license agreement is for an initial term of ten years from the date of the first commercial sale of the product, subject to two
year renewals unless either party elects to terminate no less than 12 months prior to the then current term. The agreement also
contains customary representations, warranties, covenants and indemnities by the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>CT-100</B>. We
acquired from Imprimis all of its rights to the CT-100 product and all related intellectual property and know-how and trade secrets
specific to the product pursuant to an Asset Purchase and License Agreement dated May 9, 2017. Pursuant to the agreement, we also
obtained from Imprimis a non-exclusive license to certain know-how and trade secrets related, but not specific, to the CT-100
product. In addition, we licensed back to Imprimis a non-exclusive, perpetual, non-transferable and royalty free license to use,
manufacture and sell any product incorporating the intellectual property acquired from Imprimis, other than products incorporating
the synthetic corticotropin. The agreement requires us to pay Imprimis a $50,000 milestone fee upon our initial patent issuance
for the product and a six percent royalty fee on net sales of the product distributed and marketed by us or our licensees at such
times as the product is covered by an issued patent, and a three percent royalty at all other times. The agreement also contains
customary representations, warranties, covenants and indemnities by the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.95pt; text-align: justify; text-indent: 34.05pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.95pt; text-align: justify; text-indent: 34.05pt"><B>DS-300</B>.
We acquired the exclusive rights to develop, manufacture and sell the DS-300 product in the U.S. pursuant to a Sales and Marketing
Agreement dated November 17, 2017, as amended on August 29, 2018, with an unaffiliated third party. Pursuant to the agreement,
the licensor is responsible for obtaining FDA approval, at its expense, and we are responsible for commercializing the product
in the U.S., at our expense. We are entitled to 100% of the first $500,000 of net profit from the sale of the DS-300, generally
defined as gross profit less certain fees and costs incurred by us, and will pay the licensor 100% of the next $1 million of net
profit. Thereafter, we will pay 50% of the net profit to the licensor and its designees for the term of the agreement. The agreement
has a term of ten years from the date of the first commercial sale of the DS-300, subject to one five year extension at our option.
The licensor may terminate the agreement if we choose not to launch the DS-300, for commercial reasons only, within three months
after FDA approval or if during the first calendar year following the first commercial sale of the DS-300 net sales of the product
do not exceed $1 million. The agreement also contains customary representations, warranties, covenants and indemnities by the
parties.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.95pt; text-align: justify; text-indent: 34.05pt"><B>DS-200.
</B>We acquired the DS-200 product and all related intellectual property and government approvals pursuant to an Asset Purchase
Agreement dated June 23, 2017 between us and Selenix LLC, an entity affiliated with our Chief Executive Officer. Pursuant to the
agreement, we paid the seller $1.5 million and have agreed to pay $1.5 million upon submission of the NDA and $1 million upon
FDA approval. We have also agreed to pay the seller 50% of the net profit from the sale of the product for the first ten years
following the date of the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.95pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.95pt; text-align: justify; text-indent: 34.05pt"><B>DS-100</B>.
We acquired the exclusive rights to develop, manufacture and sell the DS-100 product in the U.S. pursuant to an Exclusive Development
and Supply Agreement dated July 9, 2017 between us and Andersen Pharma, LLC, an entity affiliated with our Chief Executive Officer.
We also hold an option to purchase the DS-100 product and all related intellectual property and government approvals. Pursuant
to the agreement, the licensor is responsible for obtaining FDA approval at its expense and manufacturing the product for sale
to us at its cost, however we are responsible for the advancement of the FDA submission fees, which we have the right to recoup
from the initial profits from product sales prior to any profit split. We are responsible for commercializing the product in the
U.S. at our expense. We paid the licensor $750,000 upon execution of the agreement and will pay the licensor $750,000 upon successful
completion of a registration batch of product, $750,000 upon submission of an NDA and $750,000 upon FDA approval. We will also
pay the licensor 50% of the net profit from the sale of the product. The license agreement is for an initial term of five years
from the first commercial sale of the product, subject to successive two year renewals unless either party elects to terminate
the agreement. The agreement also contains customary representations, warranties, covenants and indemnities by the parties.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our policy is to seek
to protect our proprietary position by, among other methods, filing U.S. and foreign patent applications related to our proprietary
technology, inventions and improvements that are important to the development of our business. We also rely on our trade secrets,
know-how and continuing technological innovation to develop and maintain our proprietary position. We vigorously defend our intellectual
property to preserve our rights and gain the benefit of our technological investments. Our business is not dependent, however,
upon any single patent, trademark or contract.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We own one patent
application related to our CT-100 (Synthetic Corticotropin) product candidate. The patent application was submitted on June 13,
2017 and relates to a drug to treat multiple sclerosis, autoimmune diseases, and rheumatic disorders including infantile spasms,
Addison&rsquo;s disease, Nelson&rsquo;s, Cushing&rsquo;s and West syndromes. If granted, this application would have an approximate
expiration of May 2037, in all jurisdictions where the cases are pending. The claimed subject matter in the patent application
includes claims to compositions themselves and treatment methods using known compounds and formulations and dosage types.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also hold the exclusive
rights to a provisional patent filed in the U.S. with regard to our DS-300 product candidate. The provisional patent application
was submitted on January 26, 2018 and will expire on January 25, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to seek
patent protection on our internally developed products as circumstances warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have applied for
trademark registration of the marks &ldquo;Eton&rdquo; and &ldquo;Eton Pharmaceuticals&rdquo; with the US Patent and Trademark
Office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Government Regulations and Funding</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pharmaceutical companies
are subject to extensive regulation by foreign, federal, state and local agencies, such as the U.S. FDA, and various European
regulatory authorities. The manufacture, distribution, marketing and sale of pharmaceutical products are subject to government
regulation in the U.S. and various foreign countries. Additionally, in the U.S., we must follow rules and regulations established
by the FDA requiring the presentation of data indicating that our products are safe and efficacious and are manufactured in accordance
with cGMP regulations. If we do not comply with applicable requirements, we may be fined, the government may refuse to approve
our marketing applications or allow us to manufacture or market our products, and we may be criminally prosecuted. We, our manufacturers
and clinical research organizations may also be subject to regulations under other foreign, federal, state and local laws, including,
but not limited to, the U.S. Occupational Safety and Health Act, the Resource Conservation and Recovery Act, the Clean Air Act
and import, export and customs regulations as well as the laws and regulations of other countries. The U.S. government has increased
its enforcement activity regarding illegal marketing practices domestically and internationally. As a result, pharmaceutical companies
must ensure their compliance with the Foreign Corrupt Practices Act and federal healthcare fraud and abuse laws, including the
False Claims Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These regulatory requirements
impact our operations and differ from one country to another, so that securing the applicable regulatory approvals of one country
does not imply the approval of another country. The approval procedures involve high costs and are manpower intensive, usually
extend over many years and require highly skilled and professional resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>FDA Market Approval
Process</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The steps usually
required to be taken before a new drug may be marketed in the U.S. generally include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">completion
                                         of pre-clinical laboratory and animal testing;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">completion
                                         of required chemistry, manufacturing and controls testing;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">the
                                         submission to the FDA of an investigational new drug, or IND, the application for which
                                         must be evaluated and found acceptable by the FDA before human clinical trials may commence;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">performance
                                         of adequate and well-controlled human clinical trials to establish the safety, pharmacokinetics
                                         and efficacy of the proposed drug for its intended use;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">submission
                                         and approval of an NDA; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">agreement
                                         with FDA of the language on the package insert.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical studies are
conducted under protocols detailing, among other things, the objectives of the study, what types of patients may enter the study,
schedules of tests and procedures, drugs, dosages, and length of study, as well as the parameters to be used in monitoring safety,
and the efficacy criteria to be evaluated. A protocol for each clinical study and any subsequent protocol amendments must be submitted
to the FDA as part of the IND process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials are
usually conducted in three phases. Phase 1 clinical trials are normally conducted in small groups of healthy volunteers to assess
safety of various dosing regimens and pharmacokinetics. After a safe dose has been established, in Phase 2 clinical trials the
drug is administered to small populations of sick patients to look for initial signs of efficacy in treating the targeted disease
or condition and to continue to assess safety. In the case of vaccines, the participants are healthy and the signs of efficacy
can be obtained in early Phase 1, therefore this Phase is defined as Phase 1/2. Phase 3 clinical trials are usually multi-center,
double-blind controlled trials in hundreds or even thousands of subjects at various sites to assess as fully as possible both
the safety and effectiveness of the drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials must
be conducted in accordance with the FDA&rsquo;s good clinical practices, or GCP, requirements. The FDA may order the temporary
or permanent discontinuation of a clinical study at any time or impose other sanctions if it believes that the clinical study
is not being conducted in accordance with FDA requirements or that the participants are being exposed to an unacceptable health
risk. An institutional review board, or IRB, generally must approve the clinical trial design and patient informed consent at
study sites that the IRB oversees and also may halt a study, either temporarily or permanently, for failure to comply with the
IRB&rsquo;s requirements, or may impose other conditions. Additionally, some clinical studies are overseen by an independent group
of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board or committee. This group
recommends whether or not a trial may move forward at designated check points based on access to certain data from the study.
The clinical study sponsor may also suspend or terminate a clinical trial based on evolving business objectives and/or competitive
climate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a product candidate
moves through the clinical testing phases, manufacturing processes are further defined, refined, controlled and validated. The
level of control and validation required by the FDA increases as clinical studies progress. We and the third-party manufacturers
on which we rely for the manufacture of our product candidates and their respective components (including the API) are subject
to requirements that drugs be manufactured, packaged and labeled in conformity with cGMP. To comply with cGMP requirements, manufacturers
must continue to spend time, money and effort to meet requirements relating to personnel, facilities, equipment, production and
process, labeling and packaging, quality control, recordkeeping and other requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">Assuming completion
of all required testing in accordance with all applicable regulatory requirements, detailed information on the product candidate
is submitted to the FDA in the form of an NDA, requesting approval to market the product for one or more indications, together
with payment of a user fee, unless waived. An NDA includes all relevant data available from pertinent nonclinical and clinical
studies, including negative or ambiguous results as well as positive findings, together with detailed information on the chemistry,
manufacture, controls and proposed labeling, among other things. To support marketing approval, the data submitted must be sufficient
in quality and quantity to establish the safety and efficacy of the product candidate for its intended use to the satisfaction
of the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an NDA submission
is accepted for filing, the FDA begins an in-depth review of the NDA. Under the Prescription Drug User Fee Act, or PDUFA, the
FDA&rsquo;s goal is to complete its initial review and respond to the applicant within ten months of submission, unless the application
relates to an unmet medical need, or is for a serious or life-threatening indication, in which case the goal may be within six
months of NDA submission. However, PDUFA goal dates are not legal mandates and the FDA response often occurs several months beyond
the original PDUFA goal date. Further, the review process and the target response date under PDUFA may be extended if the FDA
requests or the NDA sponsor otherwise provides additional information or clarification regarding information already provided
in the NDA. The NDA review process can, accordingly, be very lengthy. During its review of an NDA, the FDA may refer the application
to an advisory committee for review, evaluation and recommendation as to whether the application should be approved. The FDA is
not bound by the recommendation of an advisory committee, but it typically follows such recommendations. Data from clinical studies
are not always conclusive and the FDA and/or any advisory committee it appoints may interpret data differently than the applicant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After the FDA evaluates
the NDA and inspects manufacturing facilities where the drug product and/or its API will be produced, it will either approve commercial
marketing of the drug product with prescribing information for specific indications or issue a complete response letter indicating
that the application is not ready for approval and stating the conditions that must be met in order to secure approval of the
NDA. If the complete response letter requires additional data and the applicant subsequently submits that data, the FDA nevertheless
may ultimately decide that the NDA does not satisfy its criteria for approval. The FDA could also approve the NDA with a Risk
Evaluation and Mitigation Strategies, or REMS, plan to mitigate risks, which could include medication guides, physician communication
plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization
tools. The FDA also may condition approval on, among other things, changes to proposed labeling, development of adequate controls
and specifications, or a commitment to conduct post-marketing testing. Such post-marketing testing may include Phase 4 clinical
trials and surveillance to further assess and monitor the product&rsquo;s safety and efficacy after approval. Regulatory approval
of products for serious or life-threatening indications may require that participants in clinical studies be followed for long
periods to determine the overall survival benefit of the drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the FDA approves
one of our product candidates, we will be required to comply with a number of post-approval regulatory requirements. We would
be required to report, among other things, certain adverse reactions and production problems to the FDA, provide updated safety
and efficacy information and comply with requirements concerning advertising and promotional labeling for any of our products.
Also, quality control and manufacturing procedures must continue to conform to cGMP after approval, and the FDA periodically inspects
manufacturing facilities to assess compliance with cGMP, which imposes extensive procedural, substantive and record keeping requirements.
If we seek to make certain changes to an approved product, such as certain manufacturing changes, we will need FDA review and
approval before the change can be implemented. For example, if we change the manufacturer of a product or our API, the FDA may
require stability or other data from the new manufacturer, and such data will take time and are costly to generate, and the delay
associated with generating these data may cause interruptions in our ability to meet commercial demand, if any. While physicians
may use products for indications that have not been approved by the FDA, we may not label or promote the product for an indication
that has not been approved. Securing FDA approval for new indications is similar to the process for approval of the original indication
and requires, among other things, submitting data from adequate and well-controlled studies that demonstrate the product&rsquo;s
safety and efficacy in the new indication. Even if such studies are conducted, the FDA may not approve any change in a timely
fashion, or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA may also require
post-marketing testing, or Phase 4 testing, as well as risk minimization action plans and surveillance to monitor the effects
of an approved product or place conditions or an approval that could otherwise restrict the distribution or use of the product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;505(b)(2)
New Drug Applications</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to submit
applications for product candidates via the 505(b)(2) regulatory pathway. As an alternate path for FDA approval of new indications
or new formulations of previously-approved products, a company may file a Section&nbsp;505(b)(2) NDA, instead of a &ldquo;stand-alone&rdquo;
or &ldquo;full&rdquo; NDA. Section&nbsp;505(b)(2) of the FDCA, was enacted as part of the Drug Price Competition and Patent Term
Restoration Act of 1984, otherwise known as the Hatch-Waxman Amendments. Section&nbsp;505(b)(2) permits the submission of an NDA
where at least some of the information required for approval comes from studies not conducted by or for the applicant and for
which the applicant has not obtained a right of reference. Some examples of products that may be allowed to follow a 505(b)(2)
path to approval are drugs that have a new dosage form, strength, route of administration, formulation or indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Hatch-Waxman Amendments
permit the applicant to rely upon certain published nonclinical or clinical studies conducted for an approved product or the FDA&rsquo;s
conclusions from prior review of such studies. The FDA may require companies to perform additional studies or measurements to
support any changes from the approved product. The FDA may then approve the new product for all or some of the labeled indications
for which the reference product has been approved, as well as for any new indication supported by the Section 505(b)(2) application.
While references to nonclinical and clinical data not generated by the applicant or for which the applicant does not have a right
of reference are allowed, all development, process, stability, qualification and validation data related to the manufacturing
and quality of the new product must be included in an NDA submitted under Section&nbsp;505(b)(2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent that
the Section&nbsp;505(b)(2) applicant is relying on the FDA&rsquo;s conclusions regarding studies conducted for an already approved
product, the applicant is required to certify to the FDA concerning any patents listed for the approved product in the FDA&rsquo;s&nbsp;Approved
Drug Products with Therapeutic Equivalence Evaluations, or Orange Book. Specifically, the applicant must certify that: (i)&nbsp;the
required patent information has not been filed; (ii)&nbsp;the listed patent has expired; (iii)&nbsp;the listed patent has not
expired, but will expire on a particular date and approval is sought after patent expiration; or (iv)&nbsp;the listed patent is
invalid or will not be infringed by the new product. The Section&nbsp;505(b)(2) application also will not be approved until any
non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical entity, listed in the Orange Book for the
reference product has expired. If the Orange Book certifications outlined above are not accomplished, the Section&nbsp;505(b)(2)
applicant may invest a significant amount of time and expense in the development of its products only to be subject to significant
delay and patent litigation before its products may be commercialized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 505(j)
Abbreviated New Drug Applications</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 505(j) pathway
is used for product candidates that are therapeutically equivalent to an approved product. The underlying premise of the 505(j)
pathway is that a product candidate classified as therapeutically equivalent can be substituted for the approved product with
the full expectation that the substituted product will produce the same clinical effect and safety profile as the approved product
when administered under the same conditions. A product candidate utilizing the 505(j) pathway requires an abbreviated new drug
application, or ANDA, which relies on the FDA&rsquo;s finding that the previously approved drug candidate is safe and effective.
An ANDA generally must contain information to show that the product candidate is the same as the approved product with respect
to API, conditions of use, route of administration, dosage form, strength and labeling, with certain permissible differences,
and is the bioequivalent of the approved drug. The 505(j) pathway typically requires no clinical testing other than a bioequivalence
trial. While the 505(j) pathway is typically shorter and less expensive than the 505(b)(2) pathway, the 505(b)(2) pathway allows
greater flexibility as to the characteristics of the product candidate.</P>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><B>DESI
Program</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon its enactment
in 1938, the FDCA required new drugs to demonstrate that they were safe before they could be marketed. In 1962, the FDCA was amended
to require that new drugs demonstrate that they were effective as well as safe. Following the 1962 amendments to the FDCA, the
FDA adopted a program called the Drug Efficacy Study Implementation, or DESI, to review the efficacy of drugs approved between
1938 and 1962, and the drugs approved between 1938 and 1962 are commonly referred to as DESI drugs. DESI drugs were allowed to
remain on the market until they were re-reviewed as long as they weren&rsquo;t substantially changed. The DESI program removed
many products that were deemed to not be effective, but there was no comprehensive list of drugs approved and marketed at the
time and not all drugs were re-reviewed. As a result, many DESI products remained marketed without a formal approval for effectiveness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Continuing Regulation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After a drug is approved
for marketing and enters the marketplace, numerous regulatory requirements continue to apply. These include, but are not limited
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">the
                                         FDA&rsquo;s cGMP regulations require manufacturers, including third party manufacturers,
                                         to follow stringent requirements for the methods, facilities and controls used in manufacturing,
                                         processing and packing of a drug product;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">labeling
                                         regulations and the FDA prohibitions against the promotion of drugs for unapproved uses
                                         (known as off-label uses), as well as requirements to provide adequate information on
                                         both risks and benefits during promotion of the drug;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">approval
                                         of product modifications or use of a drug for an indication other than approved in an
                                         NDA;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">adverse
                                         drug experience regulations, which require us to report information on adverse events
                                         during pre-market testing;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">post-market
                                         testing and surveillance requirements, including Phase 4 trials, when necessary to protect
                                         the public health or to provide additional safety and effectiveness data for the drug;
                                         and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">the
                                         FDA&rsquo;s recall authority, whereby it can ask, or under certain conditions order,
                                         drug manufacturers to recall from the market a product that is in violation of governing
                                         laws and regulation. After a drug receives approval, any modification in conditions of
                                         use, active ingredient(s), route of administration, dosage form, strength or bioavailability,
                                         will require a new approval, for which it may be possible to submit a 505(b)(2), accompanied
                                         by additional clinical data necessary to demonstrate the safety and effectiveness of
                                         the product with the proposed changes. Additional clinical studies may be required for
                                         proposed changes.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Other U.S. Healthcare
Laws and Compliance Requirements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For products distributed
in the United States, we will also be subject to additional healthcare regulation and enforcement by the federal government and
the states in which we conduct our business. Applicable federal and state healthcare laws and regulations include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">The
                                         federal healthcare anti-kickback statute prohibits, among other things, persons from
                                         knowingly and willfully soliciting, offering, receiving, or providing remuneration, directly
                                         or indirectly, in cash or in kind, to induce or reward either the referral of an individual
                                         for, or the purchase, order, or recommendation of, any good or service, for which payment
                                         may be made under federal healthcare programs such as Medicare and Medicaid;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">The
                                         Ethics in Patient Referrals Act, commonly referred to as the Stark Law, and its corresponding
                                         regulations, prohibit physicians from referring patients for designated health services
                                         (including outpatient drugs) reimbursed under the Medicare or Medicaid programs to entities
                                         with which the physicians or their immediate family members have a financial relationship
                                         or an ownership interest, subject to narrow regulatory exceptions, and prohibits those
                                         entities from submitting claims to Medicare or Medicaid for payment of items or services
                                         provided to a referred beneficiary;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">The
                                         federal False Claims Act imposes criminal and civil penalties, including civil whistleblower
                                         or qui tam actions, against individuals or entities for knowingly presenting, or causing
                                         to be presented, to the federal government claims for payment that are false or fraudulent
                                         or making a false statement to avoid, decrease, or conceal an obligation to pay money
                                         to the federal government;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">Health
                                         Insurance Portability and Accountability Act of 1996, imposes criminal and civil liability
                                         for executing a scheme to defraud any healthcare benefit program and also imposes obligations,
                                         including mandatory contractual terms, with respect to safeguarding the privacy, security
                                         and transmission of individually identifiable health information. This statute also prohibits
                                         knowingly and willfully falsifying, concealing or covering up a material fact or making
                                         any materially false statement in connection with the delivery of or payment for healthcare
                                         benefits, items, or services; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">Analogous
                                         state laws and regulations, such as state anti-kickback and false claims laws, may apply
                                         to sales or marketing arrangements and claims involving healthcare items or services
                                         reimbursed by non-governmental third-party payors, including private insurers, and some
                                         state laws require pharmaceutical companies to comply with the pharmaceutical industry&rsquo;s
                                         voluntary compliance guidelines and the relevant compliance guidance promulgated by the
                                         federal government.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Reimbursement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales of our products
in the United States may depend, in part, on the extent to which the costs of the products will be covered by third-party payers,
such as government health programs, commercial insurance and managed health care organizations. These third-party payers are increasingly
challenging the prices charged for medical products and services. Additionally, the containment of health care costs has become
a priority of federal and state governments, and the prices of drugs have been a focus in this effort. The United States government,
state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including
price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls
and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures,
could further limit our net revenue and results. If these third-party payers do not consider our products to be cost-effective
compared to other available therapies, they may not cover our products after approval as a benefit under their plans or, if they
do, the level of payment may not be sufficient to allow us to sell our products on a profitable basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Medicare Prescription
Drug, Improvement, and Modernization Act of 2003, (the &ldquo;MMA&rdquo;), imposed new requirements for the distribution and pricing
of prescription drugs for Medicare beneficiaries and included a major expansion of the prescription drug benefit under Medicare
Part D. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities which will provide
coverage of outpatient prescription drugs. Part D plans include both stand-alone prescription drug benefit plans and prescription
drug coverage as a supplement to Medicare Advantage plans. Unlike Medicare Parts A and B, Part D coverage is not standardized.
Part&nbsp;D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop
its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription drug
formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily all
the drugs in each category or class. Any formulary used by a Part D prescription drug plan must be developed and reviewed by a
pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may increase demand for products
for which we receive marketing approval. However, any negotiated prices for our products covered by a Part D prescription drug
plan will likely be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for
Medicare beneficiaries, private payers often follow Medicare coverage policy and payment limitations in setting their own payment
rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments from non-governmental
payers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 17, 2009,
the American Recovery and Reinvestment Act of 2009 was signed into law. This law provides funding for the federal government to
compare the effectiveness of different treatments for the same illness. A plan for the research will be developed by the Department
of Health and Human Services, the Agency for Healthcare Research and Quality and the National Institutes of Health, and periodic
reports on the status of the research and related expenditures will be made to Congress. Although the results of the comparative
effectiveness studies are not intended to mandate coverage policies for public or private payers, it is not clear how such a result
could be avoided and what if any effect the research will have on the sales of our product candidates, if any such product or
the condition that it is intended to treat is the subject of a study. It is also possible that comparative effectiveness research
demonstrating benefits in a competitor&rsquo;s product could adversely affect the sales of our product candidates. Decreases in
third-party reimbursement for our products or a decision by a third-party payer to not cover our products could reduce physician
usage of the products and have a material adverse effect on our sales, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have
ten full-time employees, five of whom are engaged in research and development activities and five are engaged in general corporate
and strategy roles. We periodically utilize outside consultants on an as-needed basis, including medical consultants. We anticipate
hiring additional employees in 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our executive office
is a 5,507 square foot space located in Deer Park, Illinois. The office is occupied pursuant to a lease expiring in March 2021
at a monthly lease rate of $6,654, subject to a 3.4% rate increase in April 2019 and a 3.3% rate increase in April 2020. We lease
a 2,782 square foot laboratory space in Lake Zurich, Illinois. The laboratory is occupied pursuant to a 36 month lease expiring
in February 2021 at a monthly lease rate of $4,600.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Litigation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no pending
legal proceedings to which we or our properties are subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_005"></A>MANAGEMENT&rsquo;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION<BR>
AND RESULTS OF OPERATIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were formed in
April 2017 as a specialty pharmaceutical company focused on developing and commercializing innovative pharmaceutical products
utilizing the FDA&rsquo;s 505(b)(2) regulatory pathway. Our business model is to develop proprietary innovative products that
fulfill an unmet patient need. Since our formation, we have focused our efforts on the development and testing of our initial
product candidates, the submission of an NDA for our initial product candidate and preliminary discussions with the FDA concerning
the regulatory pathway for certain additional product candidates. We have not commenced revenue-producing operations and, under
our current plan of business, do not expect to until we have received marketing approval from the FDA for one of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, we have capitalized
our operations primarily from the June 2017 <FONT STYLE="font-family: Times New Roman, Times, Serif">private placement of approximately
$20.1 million of Series A preferred stock, par value $0.001, or the Series A preferred stock. The Series A preferred stock accumulates
dividends at the rate of 6% per annum. The shares of Series A preferred stock plus all accrued but unpaid dividends on the Series
A preferred stock will automatically convert into shares of our common stock concurrent with the completion of this offering,
at the conversion price of 50% of the initial public offering price, provided, however, in no event shall the conversion price
be greater than $3.00 nor less than $2.25 per share. Assuming that this offering was completed on June 30, 2018 at a price of
$6.00 per share, and based on dividends accrued through such date in the amount of $1,242,875, the Series A preferred stock would
have converted into 7,099,374 shares of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Plan of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
plan of operations for the 12-month period following the completion of this offering is to obtain FDA approval of our EM-100 and
DS-300 product candidates. An ANDA has been submitted for EM-100 and in April 2018 we ran a bioequivalence trial on the product
candidate. DS-300&rsquo;s NDA was filed with the FDA in January 2018. DS-300 has been granted Fast Track Designation by the FDA
and is being reviewed by the FDA as a rolling review. Our plan of operations also includes the further development, testing and
pursuit of regulatory approval of our other product candidates. We currently have numerous other product candidates in various
stages of development, and we are in active discussions with the FDA on additional products that may be added to our pipeline
if we elect to proceed with the opportunity after the outcome of our pre-IND meetings with the FDA. We also intend to develop
our own laboratory in Lake Zurich, Illinois at which we will be able to conduct our own research, formulation and testing of product
candidates. Finally, our 12 month plan of operations includes the establishment of an internal sales infrastructure. We are in
the process of registering for licenses to distribute pharmaceuticals in all required states and territories of the United States.
We anticipate being fully registered with all states in advance of launching DS-300 under our own label.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were formed on
April 27, 2017 and have not commenced revenue-producing operations. To date, our operations have consisted of the development
and testing of our initial product candidates, the submission of an NDA for our initial product candidate and preliminary discussions
with the FDA concerning the regulatory pathway for certain additional product candidates. From inception on April 27, 2017 through
December 31, 2017, we incurred $3.9 million of product development expenses and $3.2 million of administrative expenses.&nbsp;
We incurred a net loss of $7.2 million for the period from April 27, 2017 (inception) through December 31, 2017. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the six months ended June 30, 2018, we incurred $3.0 million of product development expenses and $2.7 million of administrative
expenses. We incurred a net loss of $6.1 million for the six months ended June 30, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Financial Condition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of June 30, 2018,
we had total assets of $9.6 million and working capital of $8.0 million. We believe that we require a minimum of $10 million of
additional capital in order to fund our current business plan <FONT STYLE="font-family: Times New Roman, Times, Serif">over, at
least, the 12 months following the date of this prospectus</FONT>, including the securing of regulatory approval and commencement
commercial sales of at least one product candidate. We further believe that the net proceeds of this offering, along with our
cash on hand, will allow us to fund our business plan over the 24 months following the date of this prospectus without the need
for internally or externally generated capital. We have undertaken this initial public offering of our common shares to acquire
the necessary capital. However, we may require additional capital, the receipt of which there can be no assurance. In the event
we require additional capital, we will endeavor to seek additional funds through various financing sources, including the sale
of our equity and debt securities, licensing fees for our technology and joint ventures with industry partners. In addition, we
will consider alternatives to our current business plan that may enable to us to achieve revenue producing operations and meaningful
commercial success with a smaller amount of capital. However, there can be no guarantees that such funds will be available on
commercially reasonable terms, if at all. If such financing is not available on satisfactory terms, we may be unable to further
pursue our business plan and we may be unable to continue operations, in which case you may lose your entire investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Off Balance Sheet Transactions</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have any
off-balance sheet transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Critical Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify">Our financial statements
are prepared in accordance with accounting principles generally accepted in the United States. The preparation of our financial
statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities,
costs and expenses in our financial statements. We base our estimates on historical experience, known trends and events and various
other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments
about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates
and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify">While our significant
accounting policies are described in more detail in Note&nbsp;2 to our financial statements appearing elsewhere in this prospectus,
we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation
of our financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 7.6pt; text-align: justify"><I><U>Research and Development Expenses</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 7.6pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 7.6pt; text-align: justify">Research and development (&ldquo;R&amp;D&rdquo;)
expenses include both internal R&amp;D activities and external contracted services. Internal R&amp;D activity expenses include
salaries, benefits, and stock-based compensation and other costs to support our R&amp;D operations. External contracted services
include product development efforts including certain product licensor milestone payments, clinical trial activities, manufacturing
and control-related activities and regulatory costs. R&amp;D expenses are charged to operations as incurred. We review and accrue
R&amp;D expenses based on services performed and rely upon estimates of those costs applicable to the stage of completion of each
project. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period.
Actual results could differ from our estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 7.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 7.6pt; text-align: justify">Upfront payments and milestone payments
made for the licensing of technology are expensed as research and development in the period in which they are incurred. Nonrefundable
advance payments for goods or services to be received in the future for use in research and development activities are recorded
as prepaid expenses and are expensed as the related goods are delivered or the services are performed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 7.55pt; text-align: justify"><I><U>Stock-Based Compensation</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 7.55pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 7.55pt; text-align: justify">We account for stock-based compensation
under the provisions of the Financial Accounting Standards Board (the &ldquo;FASB&rdquo;) Accounting Standards Codification (&ldquo;ASC&rdquo;)
- 718 Compensation &ndash; Stock Compensation. The guidance under ASC 718 requires companies to estimate the fair value of the
stock-based compensation awards on the date of grant for employees and directors and record expense over the related service periods,
which are generally the vesting period of the equity awards. Awards for consultants are accounted for under ASC 505-50 - Equity
Based Payments to Non-Employees. Compensation expense is recognized over the period during which services are rendered by such
consultants and non-employees until completed. At the end of each financial reporting period prior to completion of the service,
the fair value of these awards is remeasured using the then-current fair value of our common stock and updated assumption inputs
in the Black-Scholes option-pricing model (&ldquo;BSM&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 7.55pt; text-align: justify">We estimate the fair value of stock-based
option awards to our employees and directors using the BSM. The BSM requires the input of subjective assumptions, including the
expected stock price volatility, the calculation of expected term, forfeitures and the fair value of the underlying common stock
on the date of grant, among other inputs. The risk-free interest rate was determined from the implied yields for zero-coupon U.S.
government issues with a remaining term approximating the expected life of the options or warrants. Dividends on common stock
are assumed to be zero for the BSM valuation of the stock options. The expected term of stock options granted is based on vesting
periods and the contractual life of the options. Expected volatilities are based on comparable companies&rsquo; historical volatility,
which management believes represents the most accurate basis for estimating expected future volatility under the current conditions.
We account for forfeitures as they occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 7.55pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.55; text-align: justify"><I>Determination of the Fair
Value of Common Stock</I> &nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.55; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.55; text-align: justify">As there has been no public market
for our common stock to date, the estimated fair value of our common stock has been determined by our board of directors as of
the date of each grant, with input from management, considering third-party valuations of our common stock as well as our board
of directors&rsquo; assessment of additional objective and subjective factors that it believed were relevant and which may have
changed from the date of the most recent third-party valuation through the date of the grant. These third-party valuations were
performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&rsquo; Accounting
and Valuation Guide, <I>Valuation of Privately- Held-Company Equity Securities Issued as Compensation.</I> Our common stock valuations
were prepared using either the option-pricing method (&ldquo;OPM&rdquo;) or a hybrid method, both of which used market approaches
to estimate our enterprise value. The OPM treats common stock and preferred stock as call options on the total equity value of
a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company&rsquo;s
securities changes. Under this method, the common stock has value only if the funds available for distribution to stockholders
exceeded the value of the preferred stock liquidation preferences at the time of the liquidity event, such as a strategic sale
or merger. A discount for lack of marketability of the common stock is then applied to arrive at an indication of value for the
common stock. The hybrid method is a probability-weighted expected return method (&ldquo;PWERM&rdquo;) where the equity value
in one or more scenarios is calculated using an OPM. The PWERM is a scenario-based methodology that estimates the fair value of
common stock based upon an analysis of future values for the company, assuming various outcomes. The common stock value is based
on the probability-weighted present value of expected future investment returns considering each of the possible outcomes available
as well as the rights of each class of stock. The future value of the common stock under each outcome is discounted back to the
valuation date at an appropriate risk-adjusted discount rate and probability weighted to arrive at an indication of value for
the common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 7.55; text-indent: 0.5in; text-align: justify">These
third-party valuations were performed at various dates, which resulted in valuations of our common stock of $0.21 per share as
of April 30, 2017, $1.38 per share as of July 31, 2017, $1.37 per share as of September 30, 2017, $1.37 per share as of December&nbsp;31,
2017, $1.56 per share as of March&nbsp;31, 2018, $2.23 as of June 30, 2018 and $3.12 as of August 4, 2018. Our board of directors
considered various objective and subjective factors to determine the fair value of our common stock as of each grant date, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 96%; margin-left: 7.55pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         price at which we sold preferred stock and the superior rights and preferences of the
                                         preferred stock relative to our common stock at the time of each grant;</FONT></TD>
</TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 96%; margin-left: 7.55pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         progress of our research and development programs, including the status of preclinical
                                         studies and planned clinical trials for our product candidates;</FONT></TD>
</TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 96%; margin-left: 7.55pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         stage of development and our business strategy;</FONT></TD>
</TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 96%; margin-left: 7.55pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">external
                                         market conditions affecting the pharmaceutical industry, and trends within the pharmaceutical
                                         industry;</FONT></TD>
</TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 96%; margin-left: 7.55pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         financial position, including cash on hand, and our historical and forecasted performance
                                         and operating results;</FONT></TD>
</TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 96%; margin-left: 7.55pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         lack of an active public market for our common stock and our preferred stock;</FONT></TD>
</TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 96%; margin-left: 7.55pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         likelihood of achieving a liquidity event, such as an initial public offering (&ldquo;IPO&rdquo;)
                                         or a sale of our company in light of prevailing market conditions; and</FONT></TD>
</TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 96%; margin-left: 7.55pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         analysis of IPOs and the market performance of similar companies in the biopharmaceutical
                                         industry.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 7.55; text-indent: 0.5in; text-align: justify">The
assumptions underlying these valuations represent management&rsquo;s best estimates, which involve inherent uncertainties and
the application of management judgment. As a result, if factors or expected outcomes change and we use significantly different
assumptions or estimates, our stock-based compensation expense could be materially different.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.55; text-indent: 23pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 7.55; text-indent: 0.5in; text-align: justify">Following
the closing of this offering, the fair value of our common stock will be determined based on the quoted market price of our common
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.55; text-indent: 23pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.55; text-indent: 0"><B><I>Options Granted.</I></B> &nbsp;&nbsp;&nbsp;&nbsp;The
following table sets forth by grant date the number of shares subject to options granted from May&nbsp;1, 2017 through August
31, 2018, the per share exercise price of the options, the fair value of our common stock per share on each grant date, and the
per share estimated fair value of the options:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 7.55pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><B>Grant
                                         Date</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></TD><TD STYLE="padding-bottom: 1pt; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Number
                                         of</B><BR> <B>Shares&nbsp;Subject</B><BR> <B>to Options</B><BR> <B>Granted</B></P></TD><TD STYLE="padding-bottom: 1pt; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Per
                                         Share Exercise Price of Options</B></P></TD><TD STYLE="padding-bottom: 1pt; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Fair
                                         Value per Common Share on Grant Date</B></P></TD><TD STYLE="padding-bottom: 1pt; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Per
                                         Share Estimated Fair Value of Options</B></P></TD><TD STYLE="padding-bottom: 1pt; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%">May 2017</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">130,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">0.21</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">0.21</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">0.18</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>July 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">360,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.38</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.38</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.01</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>August 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.38</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.38</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.01</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>November 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.37</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.37</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.99</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>May 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.56</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.56</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.15</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>August 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">125,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.12</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.12</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.30</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.55; text-indent: 0"><B><I>RSA&rsquo;s and RSU&rsquo;s
Granted.</I></B> &nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth by grant date the number of shares subject to RSA&rsquo;s
and RSU&rsquo;s granted from May&nbsp;1, 2017 through August 31, 2018, the fair value of our common stock per share on each grant
date, and the per share estimated fair value of the RSA&rsquo;s or RSU&rsquo;s:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 7.55pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><B>Grant
                                         Date</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></TD><TD STYLE="padding-bottom: 1pt; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Number
                                         of</B><BR> <B>Shares</B><BR> <B>Granted</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P></TD><TD STYLE="padding-bottom: 1pt; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>Type
                                         of Award</B></P></TD><TD STYLE="padding-bottom: 1pt; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair Value per Common Share
    on Grant Date</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Per Share Estimated Fair Value</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%">May 2017</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2,500,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RSA</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">0.21</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">0.21</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>July 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RSU</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.38</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.38</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>September 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RSU</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.38</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.38</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>January 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">218,980</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RSA</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.37</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.37</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 7.55pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 7.55pt; text-align: justify"><I><U>Warrant Liability</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 7.55pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 7.55pt; text-align: justify">We estimate the fair value of certain
warrants at each reporting period using Level 3 inputs. The estimates in valuation models are based, in part, on subjective assumptions,
including but not limited to stock price volatility, the expected life of the warrants, the risk-free interest rate and the exercise
price of the warrants, and could differ materially in the future. Changes in the fair value of the warrant liability during the
period are recorded as a component of other income (expense). We will continue to adjust the fair value of the warrant liability
at the end of each reporting period for changes in fair value until the earlier of the exercise or expiration of the applicable
warrants.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contractual Obligations and Commitments </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">The following table summarizes our contractual
obligations as of June 30, 2018 and the effects that such obligations are expected to have on our liquidity and cash flows in
future periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; border-top: Black 1pt solid">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid; border-top: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Total</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P></TD><TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid">&nbsp;</TD><TD STYLE="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1pt solid">Less
    than 1 Year</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1pt solid">&nbsp;</TD><TD STYLE="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1pt solid">1
    to 3 Years</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1pt solid">&nbsp;</TD><TD STYLE="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1pt solid">4
    to 5 Years</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1pt solid">&nbsp;</TD><TD STYLE="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1pt solid">More
    than 5 Years</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; border-right: Black 1pt solid; border-top: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Operating
    lease commitments </FONT></TD><TD STYLE="width: 1%; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; text-align: right">375</TD><TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; text-align: right">136</TD><TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; text-align: right">239</TD><TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left; border-right: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amounts in the table reflect minimum payments due for our leases
of office and laboratory space under operating leases that expire in February and March of 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_006"></A>MANAGEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Set forth below are
our directors and executive officers:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 0.75pt solid"><B>Age</B></P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 58%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 0.75pt solid"><B>Position</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Sean E. Brynjelsen</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">47</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">President, Chief Executive Officer and Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">W. Wilson Troutman</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">63</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer, Treasurer and Secretary</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Norbert G. Riedel, Ph.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">60</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Chairman of the Board</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Mark L. Baum</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">46</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Charles J. Casamento</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">73</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Paul V. Maier</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">70</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Sean E. Brynjelsen
</I>has served as our President, Chief Executive Officer and a member of our board of directors since June 2017. Prior to joining
Eton, Mr. Brynjelsen served as Executive Vice President, Business Development, at Sagent Pharmaceuticals, Inc., which was acquired
by Nichi-Iko Pharmaceuticals Co., Ltd. for $736 million, where he made a number of successful transactions. Prior to his tenure
at Sagent, he was Senior Vice President, Global Business Development for Akorn where he completed over 100 transactions including
the acquisition of a number of products. Mr. Brynjelsen earned an MBA degree from the University of Notre Dame and holds a Master
of Science in Chemistry and a Bachelor of Science in Biochemistry from the University of Illinois.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that Mr.
Brynjelsen&rsquo;s valuable perspective and experience as our President and Chief Executive Officer, considerable experience in
the pharmaceuticals industry and extensive leadership skills qualify him to serve on our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>W. Wilson Troutman
</I>has served as our Chief Financial Officer, Treasurer and Secretary since July 2017. Mr. Troutman brings over thirty years
of business experience in financial management roles. Prior to joining Eton, Mr. Troutman served in the corporate financial and
SEC reporting role for Century Aluminum Company, a NASDAQ reporting company, beginning in 2015. From 2012 until joining Century
Aluminum, he served as Vice President and Chief Financial Officer for Omeda Communications, and prior to that he was the Corporate
Controller and Treasurer for Akorn, Inc., a manufacturer and distributor of generic pharmaceutical products from 2004 to 2012.
Mr. Troutman received an MBA from the University of Chicago in 1987 and a BS from the University of Illinois-Urbana in 1976. He
became a Certified Public Accountant in 1977 and is a member of the AICPA, the Illinois CPA Society and Financial Executives International.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Norbert G. Riedel,
Ph.D.</I> has served as a member of our board of directors since September 2017 and as Chairman of the Board since September 2018.
Dr. Riedel has served as the President and Chief Executive Officer and a director of Aptinyx Inc., a biopharmaceutical company
discovering and developing innovative therapies for challenging disorders of the brain and nervous system, since August 2015.
From January 2014 to August 2015, Dr. Riedel served as the President and Chief Executive Officer of Naurex Inc., the predecessor
company acquired by Allergan and from which Aptinyx and its technology were spun out. Prior to that time, he was Corporate Vice
President and Chief Science and Innovation Officer of Baxter International Inc., a diversified healthcare company from March 2001
until January 2013. From 1998 to 2001, Dr. Riedel served as President and General Manager of the recombinant therapeutic proteins
business unit and Vice President of Research and Development at Baxter&rsquo;s bioscience business. Prior to joining Baxter, from
1996 to 1998, he was head of worldwide biotechnology and worldwide core research functions at Hoechst-Marion Roussel, now Sanofi,
a global pharmaceutical company. Previously, he held a series of scientific management positions at Hoechst-Marion Roussel and
Hoechst AG. Dr. Riedel is a member of the board of directors of Jazz Pharmaceuticals, Zytoprotec GmbH, and the Illinois Biotechnology
Industry Organization. He also serves on the Advisory Board of Northwestern University&rsquo;s Innovation and New Ventures Office.
From 1999 to 2010, Dr. Riedel was a member of the board of directors of Oscient Pharmaceuticals Corporation, a biopharmaceutical
company, and its predecessor company, Genome Therapeutics Corporation, a genomics company. Dr. Riedel was a member of the Supervisory
Board of MediGene AG, a biotechnology company from 2003 to 2013. Dr. Riedel was a postdoctoral fellow at Harvard University from
1984 to 1987 and an Assistant Professor and Associate Professor of medicine and biochemistry at Boston University School of Medicine
from 1987 to 1991. Dr. Riedel was also a was a visiting professor at Massachusetts Institute of Technology in 1992, and in 2009,
Dr. Riedel was elected as member of the Austrian Academy of Sciences. Dr. Riedel is currently an adjunct professor at Boston University
School of Medicine, and an adjunct professor of Medicine at Northwestern University&rsquo;s Feinberg School of Medicine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Riedel&rsquo;s
extensive experience in the pharmaceutical field and his scientific and commercial expertise make him a valued member of our board
of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Mark L. Baum </I>has
served as a member of our board of directors since our inception in April 2017. Mr. Baum is a founder, member of the board of
directors and Chief Executive Officer of Imprimis, is the founder and a member of the board of directors of Surface Pharmaceuticals,
Inc., and is a founder and member of the board of directors of Melt Pharmaceuticals, Inc. Prior to Mr. Baum&rsquo;s involvement
with Imprimis, from 2001 to 2011, he was the founder and managing director of TBLF, LLC, a consulting firm and fund manager, where
he managed a series of three funds and acted as a principal investor in financing publicly traded companies or bridge-to-public
equity transactions. Before his fund management experience, Mr. Baum founded and served as the president of YesRx, and practiced
as a U.S. securities lawyer focused on public company reporting requirements and finance-related matters. Mr. Baum also served
on the board of directors for Ideal Power, Inc. until December 31, 2017, where he was chairman of the audit committee. In 2017,
Mr. Baum was named Entrepreneur of the Year&trade; for the San Diego region life sciences category by Ernst &amp; Young LLP.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that Mr.
Baum&rsquo;s years of public company executive experience, including knowledge of securities laws, reporting requirements and
public company finance-related issues, make him a valued member of our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Charles J. Casamento
</I>has served as a member of our board of directors since June 2017. Mr.&nbsp;Casamento is currently Executive Director and Principal
of The Sage Group, a healthcare advisory group specializing in mergers, acquisitions, and partnerships between biotechnology companies
and pharmaceutical companies, since 2007. He was the president and CEO of Osteologix, Inc., a public biopharmaceutical company
developing products for treating osteoporosis, from 2004 through 2007. Mr. Casamento was founder of, and from 1999 through 2004,
served as chairman of the board, president and CEO, of Questcor Pharmaceuticals, Inc. which was subsequently acquired by Mallinckrodt.
Mr.&nbsp;Casamento formerly served as RiboGene, Inc.&rsquo;s president, CEO and chairman of the board from 1993 through 1999 until
it merged with Cypros to form Questcor. He was co-founder, president and CEO of Interneuron Pharmaceuticals, Inc. (Indevus), a
biopharmaceutical company, from 1989 until 1993. Indevus was eventually acquired by Endo. Mr.&nbsp;Casamento has also held senior
management positions at Genzyme Corporation, where he was senior vice president, pharmaceuticals and biochemicals; American Hospital
Supply, where he was vice president of business development and strategic planning for the Critical Care Division; Johnson&nbsp;&amp;
Johnson, Hoffmann-LaRoche, Inc. and Sandoz Inc. Mr.&nbsp;Casamento also serves on the Board of Directors of Relmada Therapeutics,
AzurRx BioPharma and International Stem Cell Corp. He is Chairman of the Board at Relmada. During his career he has sat on the
boards of twelve public companies and has also been a Director and Vice Chairman of The Catholic Medical Missions Board, a large
not for profit organization providing health care services to third world countries. He has served as a guest lecturer at Fordham
University and is on the Science Council of Fordham University. He holds a bachelor&rsquo;s degree in Pharmacy from Fordham University
and an M.B.A. from Iona College and was originally licensed to practice pharmacy in the states of New York and New Jersey.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that Mr.
Casamento&rsquo;s significant experience as chief executive officer in various life sciences companies and his service on several
other boards bring valuable knowledge and insights to the board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 32.05pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 32.05pt"><I>Paul V. Maier
</I>has served as a member of our board of directors since September 2017. Mr. Maier has over 25 years of experience as a senior
executive in biotechnology and pharmaceutical companies and nearly 15 years of experience as a Director of multiple life science
public and private company Boards. In addition to his Board positions, Mr. Maier also currently serves as an advisor to the life
science industry. In June 2014, Mr. Maier retired after serving since November 2009 as Chief Financial Officer of Sequenom, Inc.,
a publicly held company serving the discovery, clinical research, and molecular diagnostics market. From February 2007 until November
2009, Mr. Maier served as an independent financial consultant. Previously, Mr. Maier was Senior Vice President and Chief Financial
Officer of Ligand Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, a position he held from 1992 to 2007. From
1990 to 1992, Mr. Maier served as Vice President, Finance of DFW West, a division of DFS Group, LP a private multinational retailer.
From 1984 to 1990, Mr. Maier was employed by ICN Pharmaceuticals, a pharmaceutical and biotechnology research products company,
where he held various executive positions in finance and general management in ICN as well as SPI Pharmaceuticals, a publicly
held subsidiary. Mr. Maier currently serves on the Board of Directors of Apricus Biosciences, International Stem Cell Corporation,
Biological Dynamics, and Ritter Pharmaceuticals. Mr. Maier received an MBA from Harvard Business School and a BS from Pennsylvania
State University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 32.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 32.05pt">Mr. Maier&rsquo;s service on other boards
of life sciences companies and his extensive financial management experience qualifies him to serve on our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Board Composition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors
may establish the authorized number of directors from time to time by resolution. Our board of directors currently consists of
five members, three of whom qualify as independent under the NASDAQ Stock Market rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Generally, under the
listing requirements and rules of the NASDAQ Stock Market, independent directors must comprise a majority of a listed company&rsquo;s
board of directors within one year of the completion of this offering. Our board of directors has determined that none of Messrs.
Casamento, Maier or Riedel has a relationship that would interfere with the exercise of independent judgment in carrying out the
responsibilities of a director and that each is &ldquo;independent&rdquo; as that term is defined under the applicable rules and
regulations of the SEC and the listing requirements and rules of the NASDAQ Stock Market. In making this determination, our board
of directors considered the current and prior relationships Messrs. Casamento, Maier and Riedel have with our company and all
other facts and circumstances our board of directors deemed relevant in determining their independence, including their beneficial
ownership of our capital stock. We believe that Mr. Baum is not independent due to the materiality of the transactions between
us and Imprimis Pharmaceuticals, Inc., for which Mr. Baum currently serves as Chief Executive Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with
our amended and restated certificate of incorporation to be filed upon the completion of this offering, our board of directors
will be divided into three classes with staggered three-year terms. At each annual general meeting of stockholders, the successors
to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual
meeting following election. Our directors will be divided among the three classes as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD>the
                                         Class&nbsp;I director will be Paul Maier, and his term will expire at the annual meeting
                                         of stockholders to be held in 2019;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD>the
                                         Class&nbsp;II directors will be Mark Baum and Charles Casamento, and their terms will
                                         expire at the annual meeting of stockholders to be held in 2020; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD>the
                                         Class&nbsp;III directors will be Norbert Riedel and Sean Brynjelsen, and their terms
                                         will expire at the annual meeting of stockholders to be held in 2021.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that any
additional directorships resulting from an increase in the number of directors will be distributed among the three classes so
that, as nearly as possible, each class will consist of one third of the directors. The division of our board of directors into
three classes with staggered three-year terms may delay or prevent a change of our management or a change in control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Role of the Board in Risk Oversight</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">One of the key functions
of our board of directors is informed oversight of our risk management process. Our board of directors does not have a standing
risk management committee, but rather administers this oversight function directly through the board of directors as a whole,
as well as through various standing committees of our board of directors that address risks inherent in their respective areas
of oversight. In particular, our board of directors is responsible for monitoring and assessing strategic risk exposure and our
audit committee has the responsibility to consider and discuss our major financial risk exposures and the steps our management
has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment
and management is undertaken. The audit committee also monitors compliance with legal and regulatory requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Board Committees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors
has established an audit committee, a compensation committee and a nominating and corporate governance committee, each of which
operate pursuant to a committee charter. Our board of directors may establish other committees to facilitate the management of
our business. The composition and functions of each committee are described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Audit Committee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee
consists of Paul Maier, Charles Casamento and Norbert Riedel, with Mr. Maier serving as chair of the audit committee. Our board
of directors has determined that each of these individuals meets the independence requirements of the Sarbanes-Oxley Act of 2002,
as amended, or the Sarbanes-Oxley Act, Rule 10A-3 under the Securities Exchange Act of 1934, or the Exchange Act, and the applicable
listing standards of NASDAQ. Each member of our audit committee can read and understand fundamental financial statements in accordance
with NASDAQ audit committee requirements. In arriving at this determination, the board has examined each audit committee member&rsquo;s
scope of experience and the nature of their prior and/or current employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors
has determined that Mr. Maier qualifies as an audit committee financial expert within the meaning of SEC regulations and meets
the financial sophistication requirements of the NASDAQ Listing Rules. In making this determination, our board has considered
Mr. Maier&rsquo;s formal education and previous and current experience in financial and accounting roles. Both our independent
registered public accounting firm and management periodically meet privately with our audit committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The functions of this
committee include, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">select
                                         a qualified firm to serve as the independent registered public accounting firm to audit
                                         our financial statements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">discuss
                                         the scope and results of the audit with the independent registered public accounting
                                         firm, and review, with management and the independent registered public accounting firm,
                                         our interim and year-end operating results;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">reviewing
                                         and approving the engagement of our independent auditors to perform audit services and
                                         any permissible non-audit services;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">develop
                                         procedures for employees to submit concerns anonymously about questionable accounting
                                         or audit matters;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">review
                                         our policies on risk assessment and risk management;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">review
                                         related-party transactions; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">reviewing
                                         and evaluating on an annual basis the performance of the audit committee and the audit
                                         committee charter.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that the
composition and functioning of our audit committee complies with all applicable requirements of the Sarbanes-Oxley Act, and all
applicable SEC and NASDAQ rules and regulations. We intend to comply with future requirements to the extent they become applicable
to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Compensation Committee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compensation committee
consists of Charles Casamento, Paul Maier and Norbert Riedel, with Mr. Casamento serving as chair of the compensation committee.
These individuals are non-employee directors, as defined in Rule 16b-3 promulgated under the Exchange Act, and are &ldquo;outside
directors,&rdquo; as defined pursuant to Section 162(m) of the Code. Our board of directors has determined that all of these individuals
are &ldquo;independent&rdquo; as defined under the applicable listing standards of NASDAQ, including the standards specific to
members of a compensation committee. The functions of this committee include, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">reviewing,
                                         modifying and approving (or if it deems appropriate, making recommendations to the full
                                         board of directors regarding) our overall compensation strategy and policies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">making
                                         recommendations to the full board of directors regarding the compensation and other terms
                                         of employment of our executive officers;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">reviewing
                                         and approving (or if it deems it appropriate, making recommendations to the full board
                                         of directors regarding) the equity incentive plans, compensation plans and similar programs
                                         advisable for us, as well as modifying, amending or terminating existing plans and programs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">administering
                                         our equity incentive plans;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">establishing
                                         policies with respect to equity compensation arrangements; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">reviewing
                                         and evaluating on an annual basis the performance of the compensation committee and the
                                         compensation committee charter.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that the
composition and functioning of our compensation committee complies with all applicable requirements of the Sarbanes-Oxley Act,
and all applicable SEC and NASDAQ rules and regulations. We intend to comply with future requirements to the extent they become
applicable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Nominating and Corporate Governance Committee </B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our nominating and
corporate governance committee consists of Norbert Riedel, Charles Casamento and Paul Maier, with Dr. Riedel serving as Chairperson.
The composition of our nominating and corporate governance committee meets the requirements for independence under Nasdaq Stock
Market listing standards and SEC rules and regulations. Our nominating and corporate governance committee will, among other things:
&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">identify,
                                         evaluate and make recommendations to our board of directors regarding nominees for election
                                         to our board of directors and its committees;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">evaluate
                                         the performance of our board of directors and of individual directors;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">consider
                                         and make recommendations to our board of directors regarding the composition of our board
                                         of directors and its committees;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">review
                                         developments in corporate governance practices;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">evaluate
                                         the adequacy of our corporate governance practices and reporting; and</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">develop
                                         and make recommendations to our board of directors regarding corporate governance guidelines
                                         and matters.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The nominating and
corporate governance committee operates under a written charter that satisfies the applicable listing requirements and rules of
the Nasdaq Stock Market.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Compensation Committee Interlocks and Insider Participation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of our independent
directors is currently or has been at any time one of our officers or employees. None of our executive officers currently serves,
or has served during the last year, as a member of the board of directors or compensation committee of any entity that has one
or more executive officers serving as a member of our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Code of Business Conduct and Ethics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective upon the
closing of this offering, we will adopt a Code of Business Conduct and Ethics, or the Code of Conduct, applicable to all of our
employees, executive officers and directors. Following the closing of this offering, the Code of Conduct will be available on
our website at www.etonpharma.com. The audit committee of our board of directors will be responsible for overseeing the Code of
Conduct and must approve any waivers of the Code of Conduct for employees, executive officers and directors. In addition, we intend
to post on our website all disclosures that are required by law or the listing standards of the applicable stock exchange concerning
any amendments to, or waivers from, any provision of the Code of Conduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Non-Employee Director Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2017, we granted
each of Mr. Baum and Mr. Casamento a restricted stock award for 25,000 shares of our common stock as compensation for their service
on our board of directors. In September 2017, we granted each of Mr. Riedel and Mr. Maier a restricted stock award for 25,000
shares of our common stock as compensation for their service on our board of directors. All of these restricted stock awards are
subject to quarterly vesting over one year and are 100% vested at June 30, 2018. In January 2018, we granted to each of our nonemployee
directors 54,745 shares of restricted common stock, for a total of 218,980 shares. These shares are subject to vesting at the
rate of 25% per quarter at each quarter-end in 2018 and will be 100% vested at December 31, 2018. In addition, beginning in June
2017, we began paying each of our non-employee directors a cash retainer of $12,500 per quarter as compensation for their service
on our board of directors. Our non-employee directors also received reimbursement of their actual out-of-pocket costs and expenses
incurred in connection with attending board meetings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to adopt
a non-employee director compensation policy, pursuant to which our non-employee directors will be eligible to receive compensation
for service on our board of directors and committees of our board of directors, following the completion of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Executive Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B>Summary Compensation Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
sets forth the compensation awarded to, earned by or paid to, our chief executive officer and our other executive officer for
the period from April 27, 2017 (inception) to December&nbsp;31, 2017. When reviewing the table, please note that Mr. Brynjelsen
and Mr. Troutman commenced their employment with us in June 2017 and July 2017, respectively, and that the compensation paid is
for less than a full year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Name and Principal<BR> Position</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Salary<BR> ($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Bonus<BR> ($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Stock
    Awards<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>(1)</SUP></FONT></B></FONT><BR> <FONT STYLE="font-size: 10pt"><B>($)</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Option
    </B></FONT><BR> <FONT STYLE="font-size: 10pt"><B>Awards<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>(1)</SUP></FONT></B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>($)</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">All Other<BR> Compensation<BR>
    ($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total<BR> ($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 30%; text-align: left; text-indent: -10pt; padding-left: 10pt">Sean E. Brynjelsen,<BR>
    President and Chief Executive Officer</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">2017</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">172,083</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">77,366</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">32,813</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">13,541</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">295,803</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">W. Wilson Troutman,<BR>
    Chief Financial Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2017</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">92,821</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,800</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,791</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150,412</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Amounts shown in this
                                         column do not reflect dollar amounts actually received by our named executive officers.
                                         Instead, these amounts reflect the aggregate grant date fair value of each award computed
                                         in accordance with the provisions of FASB ASC Topic 718. Assumptions used in the calculation
                                         of these amounts are included in Note 9 of our financial statements for the period ended
                                         December 31, 2017.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B>Narrative Disclosure to Summary Compensation
Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Brynjelsen Employment
Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We entered into an
employment agreement with Mr. Brynjelsen, our president and chief executive officer, in May 2017. Pursuant to the terms of his
employment agreement, Mr. Brynjelsen&rsquo;s employment is at-will and may be terminated at any time by us or Mr. Brynjelsen.
Under the terms of the employment agreement, Mr. Brynjelsen was initially entitled to receive an annual base salary of $325,000,
which was increased to $334,750 effective April 1, 2018. Mr. Brynjelsen is also entitled to receive an annual bonus of up to 45%
of his annual base salary based upon our board of directors&rsquo; assessment of Mr. Brynjelsen&rsquo;s performance and his and
our attainment of targeted goals as set by the board of directors (or the compensation committee thereof) in their sole discretion.
In accordance with the employment agreement, Mr. Brynjelsen was also granted a restricted stock award of 1,000,000 shares of our
common stock on May 17, 2017 under our 2017 Plan. One-fourth of the shares subject to the restricted stock award vest on May 17,
2018 (the first anniversary of the grant date of the restricted stock award) and the remaining shares vest in 12 equal monthly
installments thereafter, subject to Mr. Brynjelsen&rsquo;s continued service and subject to full acceleration in the event that
Mr. Brynjelsen&rsquo;s employment is terminated without cause or he resigns for good reason within one month prior to or 12 months
following a change in control. Pursuant to his employment agreement, Mr. Brynjelsen also entered into a proprietary information,
inventions, nonsolicitation and non-competition agreement with us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Troutman Employment
Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We entered into an
employment agreement with Mr. Troutman, our chief financial officer, treasurer and secretary, in June 2017. Pursuant to the terms
of his employment agreement, Mr. Troutman&rsquo;s employment is at-will and may be terminated at any time by us or Mr. Troutman.
Under the terms of the employment agreement, Mr. Troutman was initially entitled to receive an annual base salary of $200,000,
which was increased to $206,000 effective April 1, 2018. Mr. Troutman is also entitled to receive an annual bonus of up to 40%
of his annual base salary based upon our board of directors&rsquo; assessment of Mr. Troutman&rsquo;s performance and his and
our attainment of targeted goals as set by the board of directors (or the compensation committee thereof) in their sole discretion.
In accordance with the employment agreement, Mr. Troutman was also granted an option to purchase 150,000 shares of our common
stock on July 17, 2017 under our 2017 Plan. One-fourth of the shares subject to the option grant vest on July 17, 2018 (the first
anniversary of Mr. Troutman&rsquo;s commencement of employment) and the remaining shares vest in three equal yearly installments
thereafter, subject to Mr. Troutman&rsquo;s continued service and subject to full acceleration in the event that Mr. Troutman&rsquo;s
employment is terminated without cause or he resigns for good reason within one month prior to or 12 months following a change
in control. Pursuant to his employment agreement, Mr. Troutman also entered into a confidential information and inventions agreement
with us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0.22in 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B>Potential Payments Upon Termination and Change
in Control</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The definitions of
&ldquo;cause,&rdquo; &ldquo;good reason&rdquo; and &ldquo;change in control&rdquo; referenced below are defined in the individual
employment agreements between us and each of the named executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Mr. Brynjelsen</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to his employment
agreement, Mr. Brynjelsen is entitled to severance benefits if, after the six-month anniversary of his employment start date,
his employment is terminated without cause or if he resigns for good reason, subject to his execution of a release and his continued
compliance with his proprietary information, inventions, non-solicitation and non-competition agreement. If, after such six-month
anniversary of his employment start date, Mr. Brynjelsen is terminated without cause or resigns for good reason, he is eligible
to receive 12 months of continued base salary and premiums for continued health coverage. If Mr. Brynjelsen is terminated without
cause or resigns for good reason within one month prior to or 12 months following a change of control, and subject to his execution
of a release, then all unvested shares of common stock pursuant to his restricted stock award will vest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Mr. Troutman</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to his employment
agreement, Mr. Troutman is entitled to severance benefits if, after the six-month anniversary of his employment start date, his
employment is terminated without cause or if he resigns for good reason, subject to his execution of a release and his continued
compliance with his confidential information and inventions agreement and the surviving terms of his employment agreement. If,
after such six-month anniversary of his employment start date, Mr. Troutman is terminated without cause or resigns for good reason,
he is eligible to receive six months of continued base salary and premiums for continued health coverage. If Mr. Troutman is terminated
without cause or resigns for good reason within one month prior to or 12 months following a change of control, and subject to
his execution of a release, then all remaining shares of common stock underlying his outstanding options will vest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0in"><B>Equity Incentive
Plans </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The principal features
of our equity incentive plans are summarized below. These summaries are qualified in their entirety by reference to the actual
text of the plans, which are filed as exhibits to the registration statement of which this prospectus is a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2017 Equity Incentive
Plan </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors
adopted and our stockholders subsequently approved our 2017 Plan in May 2017. Our 2017 Plan provides for the grant of incentive
stock options, or ISOs, within the meaning of Section&nbsp;422 of the Code, to our employees, and for the grant of nonstatutory
stock options, or NSOs, stock appreciation rights, or SARs, restricted stock awards and restricted stock unit awards, or RSUs,
to our employees, directors, and consultants. After the closing of this offering, no further grants will be made under our 2017
Plan, and the 2017 Plan will terminate. Outstanding awards granted under the 2017 Plan will remain subject to its terms and applicable
award agreements until such awards are exercised or otherwise terminate or are forfeited by their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Authorized Shares.</I>&nbsp;As
of the date of this prospectus, the maximum number of shares of our common stock that could be issued under our 2017 Plan was
2,181,020, which includes (i)&nbsp;1,225,000 shares of our common stock issuable upon the exercise of outstanding stock options,
and (ii)&nbsp;956,020 shares of our common stock reserved for future issuance under the 2017 Plan. Shares issuable under our 2017
Plan include any authorized but unissued or reacquired shares of our common stock. Shares subject to stock awards granted under
our 2017 Plan that expire or terminate without being exercised in full or settled in cash will again be available for issuance
under our 2017 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Plan Administration.</I>&nbsp;Our
board of directors, or a duly authorized committee of our board of directors, administers our 2017 Plan. Any reference to the
board of directors in our 2017 Plan will also mean any committee or subcommittee of our board of directors to whom our board of
directors has assigned a particular administrative function. Subject to the terms of our 2017 Plan, the board of directors has
the authority to determine the terms of the awards, including recipients, the exercise or purchase price of the awards, if any,
the number of shares subject to each stock award, the fair market value of our common stock, the vesting schedule applicable to
the awards, the forms of consideration, if any, payable upon exercise or settlement of the award, and the placement of any transfer
restrictions or rights of repurchase, if any. The board of directors has full authority and discretion to take any actions it
deems necessary or advisable for the administration of the 2017 Plan. All determinations, interpretations, and constructions made
by the board of directors in good faith will be final, binding, and conclusive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Corporate Transactions.
</I>Our 2017 Plan provides that in the event of a corporate transaction, as defined under our 2017 Plan, any surviving or acquiring
corporation (or, in either case, its parent company) may assume or continue any part or all of the stock awards outstanding under
the 2017 Plan, or may substitute similar stock awards; and any reacquisition or repurchase rights held by us may be assigned to
our successor (or the successor&rsquo;s parent company). In connection with a corporate transaction, in general, the vesting of
stock awards not assumed in connection with a corporate transaction shall not be accelerated and shall terminate if not exercised
(if applicable) prior to the effective time of the corporate transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Change in Control.</I>&nbsp;Our
2017 Plan provides that in the event of a change in control, as defined under our 2017 Plan, stock awards may be subject to additional
acceleration of vesting and exercisability as may be provided in the stock award agreement covering the options or any other written
agreement with us, but in the absence of such provision, no such acceleration shall occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Plan Amendment
or Termination.</I>&nbsp;Our board of directors has the authority to suspend or terminate our 2017 Plan, provided that such action
does not materially impair the existing rights of any participant without such participant&rsquo;s written consent. Our board
of directors may amend the 2017 Plan in any respect it deems necessary or advisable, but it must seek stockholder approval to
the extent required by applicable law.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-align: justify"><B>2018 Equity Incentive Plan
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">In September 2018,
our board of directors adopted, and our stockholders have approved, our 2018 Plan in connection with this offering. The 2018 Plan
will become effective at the time of execution of the underwriting agreement for this offering. The 2018 Plan will be the successor
to our 2017 Plan, which is described above. Once the 2018 Plan becomes effective, no further grants will be made under the 2017
Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><I>Stock Awards.</I>&nbsp;Our
2018 Plan provides for the grant of ISOs to our employees and for the grant of NSOs, SARs, restricted stock awards, RSUs, performance-based
stock awards, performance-based cash awards and other forms of equity compensation to our employees, directors, and consultants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><I>Authorized Shares.</I>&nbsp;The
aggregate number of shares of our common stock that may be issued pursuant to stock awards under the 2018 Plan will not exceed
2,735,765 shares, which is the number of shares remaining available for issuance under our 2017 Plan at the time the 2018 Plan
becomes effective, or 956,020 shares, and any shares subject to outstanding stock options or other stock awards that would have
otherwise returned to our 2017 Plan (such as upon the expiration or termination of a stock option under such plan prior to its
exercise), or 1,779,745 shares. Additionally, the number of shares of our common stock reserved for issuance under our 2018 Plan
will automatically increase on January 1 of each year, beginning on January&nbsp;1, 2019 and ending on and including April&nbsp;1,
2029, by 4% of the total number of shares of our capital stock outstanding on December&nbsp;31 of the preceding fiscal year, or
a lesser number of shares determined by our board of directors. The maximum number of shares that may be issued upon the exercise
of ISOs under our 2018 Plan is 1,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Shares issued under
our 2018 Plan include authorized but unissued or reacquired shares of our common stock. Shares subject to stock awards granted
under our 2018 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares,
do not reduce the number of shares available for issuance under our 2018 Plan. Additionally, shares issued pursuant to stock awards
under our 2018 Plan that we repurchase or that are forfeited, as well as shares used to pay the exercise price of a stock award
or to satisfy the tax withholding obligations related to a stock award, become available for future grant under our 2018 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><I>Plan Administration.</I>&nbsp;Our
board of directors, or a duly authorized committee of our board of directors, will administer our 2018 Plan. Our board of directors
may also delegate to one or more of our officers the authority to (i)&nbsp;designate employees (other than officers) to receive
specified stock awards, and (ii)&nbsp;determine the number of shares of our common stock to be subject to such stock awards. Subject
to the terms of our 2018 Plan, the board of directors has the authority to determine the terms of awards, including recipients,
the exercise, purchase, or strike price of stock awards, if any, the number of shares subject to each stock award, the fair market
value of a share of our common stock, the vesting schedule applicable to the awards, together with any vesting acceleration, and
the form of consideration, if any, payable upon exercise or settlement of the award, and the terms of the award agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The board of directors
has the power to modify outstanding awards under our 2018 Plan. The board of directors has the authority to reprice any outstanding
option or SAR, cancel any outstanding stock award in exchange for new stock awards, cash or other consideration, or take any other
action that is treated as a repricing under generally accepted accounting principles, with the consent of any adversely affected
participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><I>Non-employee Director
Limits.</I>&nbsp;Stock awards granted during a single fiscal year to any non-employee director, shall not exceed $500,000, or
$800,000 with respect to the calendar year in which the non-employee director is first appointed or elected to the board, in value
(calculating the value of any such stock awards based on the grant date fair value of such stock awards for financial reporting
purposes and excluding, for this purpose, the value of any dividend equivalent payments paid pursuant to any stock award granted
in a previous fiscal year).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><I>Performance Awards.</I>&nbsp;Our
2018 Plan permits the grant of performance-based stock and cash awards intended to qualify as performance-based compensation.
Our compensation committee may establish performance goals by selecting from one or more performance criteria set forth in the
2018 Plan, including, but not limited to: earnings before interest, taxes, depreciation and amortization; total stockholder return;
return on equity or average stockholders&rsquo; equity; return on assets, investment, or capital employed; stock price margin
(including gross margin); income (before or after taxes); operating income (before or after taxes); pre-tax profit; operating
cash flow; sales or revenue targets; increases in revenue; expenses and cost reduction goals; improvement in or attainment of
working capital levels; economic value added; market share; cash flow (including cash flow per share); share price performance;
debt reduction; strategic partnerships and transactions; stockholders&rsquo; equity; capital expenditures; operating profit or
net operating profit; growth of net income or operating income; budget management;&nbsp;and other measures of performance selected
by our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><I>Corporate Transactions;
Change in Control.</I>&nbsp;Our 2018 Plan provides that in the event of certain corporate transactions, as defined in the 2018
Plan, the following provisions will apply to outstanding stock awards, unless otherwise provided in a stock award agreement or
any other written agreement between us and a participant, or unless otherwise expressly provided by our board of directors at
the time of grant of a stock award:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    surviving or acquiring corporation (or its parent) may assume, continue, or substitute similar stock awards for outstanding
    stock awards under the 2018 Plan and any reacquisition or repurchase rights held by us may be assigned to the surviving or
    acquiring corporation (or its parent); </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    the extent that outstanding stock awards are not so assumed, continued, or substituted, the vesting and, if applicable, exercisability
    of any such stock awards will not be accelerated and such stock awards will terminate if not exercised (if applicable) at
    or prior to the effective time of such corporation transaction, except that any reacquisition or repurchase rights held by
    us will not terminate and may continue to be exercised notwithstanding the corporate transaction; or </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    the extent a stock award will terminate if not exercised prior to the effective time of a corporate transaction, our board
    of directors may provide that the holder of the stock award may not exercise the stock award, but instead will receive a payment,
    in such form as may be determined by our board of directors, equal in value to the excess, if any, of the value of the property
    the participant would have received upon exercise of the stock award over any exercise price payable by such holder in connection
    with such exercise. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">A stock award may
be subject to additional acceleration of vesting and exercisability upon or after a change in control, as defined in the 2018
Plan, as may be provided in the stock award agreement for such stock award or in any other written agreement between us and a
participant, but in the absence of such a provision, no such acceleration will occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><I>Plan Amendment
or Termination</I>. Our board of directors has the authority to amend, suspend, or terminate our 2018 Plan, provided that such
action does not materially impair the existing rights of any participant without such participant&rsquo;s written consent. No
ISOs may be granted after the tenth anniversary of the date our board of directors adopted our 2018 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-align: justify"><B>2018 Employee Stock Purchase
Plan </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">In September 2018,
our board of directors adopted, and our stockholders have approved, our 2018 ESPP in connection with this offering. The 2018 ESPP
will become effective on the date the registration statement of which this prospectus forms a part is declared effective by the
SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The maximum aggregate
number of shares of our common stock that may be issued under our 2018 ESPP is 1,000,000 shares (subject to adjustment to reflect
any split of our common stock). Additionally, the number of shares of our common stock reserved for issuance under our 2018 ESPP
will increase automatically each year, beginning on January&nbsp;1, 2019 and continuing through and including January&nbsp;1,
2028, by the lesser of (i)&nbsp;1% of the total number of shares of our common stock outstanding on December&nbsp;31 of the preceding
fiscal year; and (ii)&nbsp;150,000 shares of common stock (subject to adjustment to reflect any split of our common stock). Our
board of directors may act prior to the first day of any fiscal year to provide that there will be no April&nbsp;1 increase or
that the increase will be for a lesser number of shares than would otherwise occur. Shares subject to purchase rights granted
under our 2018 ESPP that terminate without having been exercised in full will not reduce the number of shares available for issuance
under our 2018 ESPP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Our board of directors
will administer our 2018 ESPP. Our board of directors may delegate authority to administer our 2018 ESPP to our compensation committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Our employees, including
executive officers, may have to satisfy one or more of the following service requirements before participating in our 2018 ESPP,
as determined by the administrator: (i)&nbsp;customary employment for more than 20 hours per week and more than five months per
fiscal year, or (ii)&nbsp;continuous employment for a minimum period of time, not to exceed two years. An employee may not be
granted rights to purchase stock under our 2018 ESPP if such employee (i)&nbsp;immediately after the grant would own stock possessing
5% or more of the total combined voting power or value of our common stock, or (ii)&nbsp;holds rights to purchase stock under
our 2018 ESPP that would accrue at a rate that exceeds $25,000 worth of our stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">The administrator
may approve offerings with a duration of not more than 12 months, and may specify one or more shorter purchase periods within
each offering. Each offering will have one or more purchase dates on which shares of our common stock will be purchased for the
employees who are participating in the offering. The administrator, in its discretion, will determine the terms of offerings under
our 2018 ESPP. No offerings have been approved at this time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Our 2018 ESPP permits
participants to purchase shares of our common stock through payroll deductions with up to 15% of their earnings. The purchase
price of the shares will be not less than 85% of the lower of the fair market value of our common stock on the first day of an
offering or on the date of purchase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">A participant may
not transfer purchase rights under our 2018 ESPP other than by will, the laws of descent and distribution, or as otherwise provided
under our 2018 ESPP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">In the event of a
specified corporate transaction, such as a merger or sale of all or substantially all of our assets, a successor corporation may
assume, continue, or substitute each outstanding purchase right. If the successor corporation does not assume, continue, or substitute
for the outstanding purchase rights, the offering in progress will be shortened and the participants&rsquo; accumulated contributions
will be used to purchase shares within 10 business days prior to the effective date of the corporate transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Our 2018 ESPP will
remain in effect until terminated by the administrator in accordance with the terms of the 2018 ESPP. Our board of directors has
the authority to amend, suspend, or terminate our 2018 ESPP, at any time and for any reason.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Related Party Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following includes
a summary of transactions since April 27, 2017 (inception) to which we have been a party, in which the amount involved in the
transaction exceeded $120,000, and in which any of our directors, executive officers or, to our knowledge, beneficial owners of
more than 5% of our voting securities or any member of the immediate family of any of the foregoing persons had or will have a
direct or indirect material interest. Other than described below, there have not been, nor are there currently any proposed, transactions
or series of similar transactions to which we have been or will be a party other than compensation arrangements, which include
equity and other compensation, termination, change in control and other arrangements, which are described under &ldquo;Executive
compensation.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Chief Executive
Officer, Sean Brynjelsen, has a material ownership interest in several companies from which we have licensed or acquired product
development and marketing rights. Set forth below is a tabular presentation of these arrangements, and the products and transactional
agreements are more fully described in &ldquo;<I>Our Business-Products</I>&rdquo;:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 27%; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><B>Licensor/Seller</B></TD>
    <TD STYLE="width: 2%; text-align: center; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 26%; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><B>Product</B></TD>
    <TD STYLE="width: 2%; text-align: center; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 43%; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><B>Mr. Brynjelsen&rsquo;s
    % Ownership</B><BR>
    <B>&nbsp;Interest in Licensor/Seller</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Andersen Pharma, LLC</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">DS-100</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">27%</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Eyemax LLC</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">EM-100</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">33%</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Selenix LLC</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">DS-200</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">50%</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are required to
pay to the above parties licensing fees, milestone payments and royalty payments. We believe the terms of the transactional agreements,
including the licensing fees, milestone payments and royalty payments, approximate the terms and payments we could have obtained
in an arms&rsquo; length transaction with an unaffiliated party.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2017, in connection
with our corporate formation, we issued to Imprimis, our former parent and an entity affiliated with Mark L. Baum, a member of
our board of directors, 3,500,000 shares of our common stock in consideration of Imprimis&rsquo; payment of $3,500 to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2017, we entered
into a consulting agreement with Mr. Baum. Pursuant to the terms of his consulting agreement, Mr. Baum agreed to provide senior
management advisory services to us through this offering. In consideration of his services, we granted a restricted stock award
to Mr. Baum for 730,000 shares of our common stock under the 2017 Plan, all of which vested on April 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2017, we entered
into consulting agreements with three other executives of Imprimis pursuant to which the executives agreed to provide management
advisory services to us through this offering in consideration of our grant of restricted stock awards to the executives for a
total of 770,000 shares of our common stock under the 2017 Plan, all of which vested on April 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Limitation of Liability of Directors and Indemnification
of Directors and Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Delaware General
Corporation Law provides that corporations may include a provision in their certificate of incorporation relieving directors of
monetary liability for breach of their fiduciary duty as directors, provided that such provision shall not eliminate or limit
the liability of a director (i) for any breach of the director&rsquo;s duty of loyalty to the corporation or its stockholders,
(ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) for
unlawful payment of a dividend or unlawful stock purchase or redemption, or (iv) for any transaction from which the director derived
an improper personal benefit. Our amended and restated certificate of incorporation which will become effective upon the close
of this offering provides that directors are not liable to us or our stockholders for monetary damages for breach of their fiduciary
duty as directors to the fullest extent permitted by Delaware law. In addition to the foregoing, our amended and restated bylaws
which will become effective upon the close of this offering provides that we may indemnify directors and officers to the fullest
extent permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The above provisions
in our charter documents may have the effect of reducing the likelihood of derivative litigation against directors and may discourage
or deter stockholders or management from bringing a lawsuit against directors for breach of their fiduciary duty, even though
such an action, if successful, might otherwise have benefited us and our stockholders. However, we believe that the foregoing
provisions are necessary to attract and retain qualified persons as directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Insofar as indemnification
for liabilities arising under the Securities Act of 1933 may be permitted to our directors, officers and controlling persons pursuant
to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC, such indemnification is against
public policy as expressed in the Securities Act and is, therefore, unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0.25in"><A NAME="a_007"></A>PRINCIPAL
STOCKHOLDERS</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
sets forth certain information regarding the beneficial ownership of our common stock as of the date of this prospectus by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD>each
                                         person who is known by us to be the beneficial owner of more than five percent (5%) of
                                         our issued and outstanding shares of common stock;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD>each
                                         of our directors and executive officers; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD>all
                                         directors and executive officers as a group.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41pt; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The beneficial ownership
of each person was calculated based on 13,318,354 shares of common stock issued and outstanding prior to the offering, including
6,218,980 shares issued and outstanding as of the date of this prospectus, and 7,099,374 shares issuable upon the conversion of
our outstanding Series A Preferred stock outstanding as of June 30, 2018. The SEC has defined &ldquo;beneficial ownership&rdquo;
to mean more than ownership in the usual sense. For example, a person has beneficial ownership of a share not only if he owns
it, but also if he has the power (solely or shared) to vote, sell or otherwise dispose of the share. Beneficial ownership also
includes the number of shares that a person has the right to acquire within 60 days of the date of this prospectus, pursuant to
the exercise of options or warrants or the conversion of notes, debentures or other indebtedness. Two or more persons might count
as beneficial owners of the same share. Unless otherwise indicated, the address for each reporting person is c/o Eton Pharmaceuticals,
Inc. 21925 W. Field Parkway, Suite 235, Deer Park, Illinois 60010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Name of Director or Executive Officer</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<BR> Shares</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Percentage</B><BR>
                                         <B>Owned Prior</B><BR> <B>to Offering<SUP>(1)</SUP></B></P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Percentage</B><BR>
                                         <B>Owned After</B><BR> <B>Offering<SUP>(2)</SUP></B></P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left; text-indent: -10pt; padding-left: 10pt">Sean E. Brynjelsen<FONT STYLE="font-size: 10pt"><SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,024,422</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">7.7</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">6.3</TD><TD STYLE="width: 1%; text-align: left">%&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">W. Wilson Troutman<FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Mark L. Baum <FONT STYLE="font-size: 10pt"><SUP>(3)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">784,745</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.9</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.8</TD><TD STYLE="text-align: left">%&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Charles J. Casamento<FONT STYLE="font-size: 10pt"><SUP>(4)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">63,240</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Paul V. Maier<FONT STYLE="font-size: 10pt"><SUP>(3)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">54,745</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Norbert G. Riedel, Ph.D.<FONT STYLE="font-size: 10pt"><SUP>(3)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">54,745</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Directors and executive officers as a group</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,019,397</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.2</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.4</TD><TD STYLE="text-align: left">%&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">*&nbsp;
Less than 1%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Name and Address of 5% + Holders</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<BR> Shares</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage<BR> Owned Prior<BR>
    to Offering</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage<BR> Owned After<BR>
    Offering</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left; text-indent: -10pt; padding-left: 10pt">Imprimis Pharmaceuticals, Inc.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3,500,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">26.3</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">21.4</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">12264 El Camino Real, Suite 350</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">San Diego, CA 92130</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-size: 10pt">Peter Appel <SUP>(5)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,061,809</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.5</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">3505 Main Lodge Dr.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Coconut Grove, FL 33133</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Includes (i) 1,000,000 shares
                                         issued pursuant to a restricted stock purchase agreement, of which 375,000 shares remain
                                         subject to forfeiture as of the date of this prospectus, and (ii) 24,422 common shares
                                         issuable upon conversion of 23,000 shares of Series A preferred stock. Does not include
                                         200,000 shares issuable upon exercise of an unvested stock option.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">Includes 37,500 shares issuable
                                         upon exercise vested stock options and excludes 212,500 shares issuable upon exercise
                                         of unvested stock options.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">Includes 54,745 shares issued
                                         pursuant to a restricted stock purchase agreement, of which 13,686 shares remain subject
                                         to forfeiture as of the date of this prospectus. Excludes 25,000 shares issuable upon
                                         settlement of a restricted stock unit award.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(4)</TD><TD STYLE="text-align: justify">Includes 54,745 shares issued
                                         pursuant to a restricted stock purchase agreement, of which 13,686 shares remain subject
                                         to forfeiture as of the date of this prospectus. Also, includes 8,495 common shares issuable
                                         upon conversion of 8,000 shares of Series A preferred stock. Excludes 25,000 shares issuable
                                         upon settlement of a restricted stock unit award.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(5)</TD><TD STYLE="text-align: justify">Represents
                                         shares of our common stock issuable upon the conversion of 1,000,000 shares of Series
                                         A Preferred stock held by Mr. Appel.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_008"></A><FONT STYLE="text-transform: none">ESTIMATED
USE OF PROCEEDS</FONT></P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We estimate that
the net proceeds from our issuance and sale of 3,000,000 shares of our common stock in this offering will be approximately $15.8
million (or $18.3 million if the underwriters exercise in full their option to purchase additional shares), based on an initial
public offering price of $6.00&nbsp;per share, and after deducting the estimated underwriting discounts and commissions and estimated
offering expenses payable by us. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of June 30, 2018,
we had cash and cash equivalents of $8.9&nbsp;million. We intend to use the net proceeds from this offering, together with our
existing cash and cash equivalents, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.15pt"></TD><TD STYLE="width: 17.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD>approximately
                                         $10.7 million to fund clinical trials, product licensing opportunities and product development;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.15pt"></TD><TD STYLE="width: 17.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD>approximately
                                         $5.2 million to fund FDA filing fees;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.15pt"></TD><TD STYLE="width: 17.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD>approximately
                                         $2.0 million to fund laboratory expansion; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.15pt"></TD><TD STYLE="width: 17.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD>the
                                         balance for other general corporate purposes, including general and administrative expenses
                                         and working capital.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41pt; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41pt; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20">The following
table sets forth our estimates, as of the date of this prospectus, of the total dollar amount required to fund product development
through FDA approval, including development activities, licensing payments, milestone payments, clinical trial or bioequivalence
costs, and NDA filing fees, for each of our product candidates, other than CT-100, and the amount to be allocated to each of our
current product candidates, other than CT-100, from our cash on hand and the net proceeds of this offering:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.95pt">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; font-style: italic; border-bottom: Black 1pt solid">(in 000&rsquo;s)</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Allocation of Cash <BR>
    and Net Offering <BR> Proceeds</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total Estimated Expenditures
    Through <BR> Regulatory Approval</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%">ET-103</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3.2</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">5.5</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>DS-200</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.5</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>EM-100</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.2</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>DS-100</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.6</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.3</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>ET-101</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.8</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.8</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>ET-102</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.2</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">DS-300</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1.4</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1.4</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">Total</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid">15.9</TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid">18.9</TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20">As noted
in &ldquo;Our Business-Products-Innovative Products-CT-100&rdquo;, we are currently working with a clinical research organization
to analyze the cost and protocol for CT-100&rsquo;s clinical program. The product may be cost prohibitive for us, in which case
we may seek to partner or license the product to a larger and more well-capitalized company. For this reason, as of the date of
this prospectus, we are unable to estimate the amount required to fund CT-100 through regulatory approval and we do not intend
to allocate a meaningful amount of our cash on hand or net proceeds of this offering towards CT-100. In addition, the above table
reflects that we will require an additional $3.0 million of capital to fund our other product candidates through FDA approval,
and we may require funds in excess of $3.0 million in order to do so. To the extent we require additional funds to develop CT-100
or complete the development of our other product candidates through regulatory approval, we will endeavor to do so through cash
flow from operations, of which there can be no assurance. In the event we are unable to fund further development internally, we
will endeavor to seek additional funds through various financing sources, including the sale of our equity and debt securities,
licensing fees for our technology and joint ventures with industry partners. However, there can be no guarantees that such funds
will be available on commercially reasonable terms, if at all. If such financing is not available on satisfactory terms, we may
be unable to further pursue our product candidates.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41pt; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41pt; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our expected use of
net proceeds from this offering represents our current intentions based upon our present plans and business condition. As of the
date of this prospectus, we cannot predict with complete certainty all of the particular uses for the net proceeds to be received
upon the completion of this offering or the actual amounts that we will spend on the uses set forth above. We believe opportunities
may exist from time to time to expand our current business through the acquisition or in- license of complementary product candidates.
While we have no current agreements for any specific acquisitions or in-licenses at this time, we may use a portion of the net
proceeds for these purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amounts and timing
of our actual expenditures will depend on numerous factors, including the progress of our clinical trials and other development
and commercialization efforts for our initial product candidates, as well as the amount of cash used in our operations. Based
on our current operational plans and assumptions, we expect our cash and cash equivalents, together with the net proceeds from
this offering, will be sufficient to fund our planned operations over, at least, the 24 months following the close of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, we cannot
estimate with certainty the amount of net proceeds to be used for the purposes described above. We may find it necessary or advisable
to use the net proceeds for other purposes, and we will have broad discretion in the application of the net proceeds. Pending
the uses described above, we plan to invest the net proceeds from this offering in short- and intermediate-term, interest-bearing
obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the government.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_009"></A>CAPITALIZATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table sets forth our capitalization
as of June 30, 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">on
                                         an actual basis;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">on
                                         a pro forma basis to give effect to (i) the automatic conversion of all outstanding shares
                                         of our preferred stock into an aggregate of&nbsp;7,099,374 shares of common stock, which
                                         will occur upon the closing of this offering, resulting in the accretion of $866 of unaccreted
                                         issuance costs and the recognition of a beneficial conversion feature of $21,298; (ii)
                                         the exercise price of a certain outstanding warrant to purchase shares of our common
                                         stock becoming fixed upon the conversion of the preferred stock resulting in the reclassification
                                         of the warrant liability to equity upon the closing of this offering; and (iii) the filing
                                         and effectiveness of our amended and restated certificate of incorporation, which will
                                         occur immediately prior to the closing of this offering; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">on
                                         a pro forma as adjusted basis to reflect, in addition, our sale of 3,000,000 shares of
                                         common stock in this offering at the initial public offering price of $6.00 per share,
                                         after deducting underwriting discounts and commissions and estimated offering expenses
                                         payable by us.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">You should read the
information in this table together with our financial statements and related notes and &ldquo;Management&rsquo;s Discussion and
Analysis of Financial Condition and Results of Operations&rdquo; appearing elsewhere in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt"> &nbsp; </TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="10" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> As of June 30, 2018 </TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt"> &nbsp; </TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> Actual<BR>
    (unaudited) </TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> Pro Forma<BR>
    (unaudited) </TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> Pro Forma<BR>
    As <BR>
    Adjusted<BR>
    (unaudited) </TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left; padding-bottom: 2.5pt"> Cash and cash equivalents </TD><TD STYLE="width: 1%; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 2.5pt double"> $ </TD><TD STYLE="width: 10%; text-align: right; border-bottom: Black 2.5pt double"> 8,946 </TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 2.5pt"> &nbsp; </TD><TD STYLE="width: 1%; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 2.5pt double"> $ </TD><TD STYLE="width: 10%; text-align: right; border-bottom: Black 2.5pt double"> 8,946&nbsp; </TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 2.5pt"> &nbsp; </TD><TD STYLE="width: 1%; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 2.5pt double"> $&nbsp; </TD><TD STYLE="width: 10%; text-align: right; border-bottom: Black 2.5pt double"> 24,952 </TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 2.5pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"> Warrant liability </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 1,016 </TD><TD STYLE="text-align: left; padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> &mdash;&nbsp; </TD><TD STYLE="text-align: left; padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> &mdash;&nbsp; </TD><TD STYLE="text-align: left; padding-bottom: 1pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1pt"> Total redeemable convertible
    preferred stock &ndash; Series A; $0.001 par value, 10,000,000 shares authorized, 6,685,082 shares issued and outstanding,
    actual; no shares issued and outstanding, pro forma and pro forma as adjusted </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"> &nbsp; </TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"> 20,432 </TD><TD STYLE="text-align: left; padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"> &nbsp; </TD><TD STYLE="text-align: right; padding-bottom: 1pt; border-bottom: Black 1pt solid"> &mdash;&nbsp; </TD><TD STYLE="text-align: left; padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"> &nbsp; </TD><TD STYLE="text-align: right; padding-bottom: 1pt; border-bottom: Black 1pt solid"> &mdash;&nbsp; </TD><TD STYLE="text-align: left; padding-bottom: 1pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Stockholders&rsquo; (deficit) equity: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -0.125in"> Common stock, $0.001 par value, 50,000,000 shares
    authorized, 6,218,980 shares issued and outstanding, actual; 13,318,354&nbsp;shares issued and outstanding, pro forma; 16,318,354
    shares issued and outstanding, pro forma as adjusted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 6 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 13 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 16 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in"> Additional paid-in capital </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 3,225 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 46,830 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 62,631 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-bottom: 1pt"> Accumulated deficit </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"> &nbsp; </TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"> (16,167 </TD><TD STYLE="text-align: left; padding-bottom: 1pt"> ) </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"> &nbsp; </TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"> (38,331 </TD><TD STYLE="text-align: left; padding-bottom: 1pt"> )&nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"> &nbsp; </TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"> (38,331 </TD><TD STYLE="text-align: left; padding-bottom: 1pt"> )&nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-bottom: 1pt"> Total stockholders&rsquo; (deficit) equity </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"> &nbsp; </TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"> (12,936 </TD><TD STYLE="text-align: left; padding-bottom: 1pt"> ) </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"> &nbsp; </TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"> 8,512 </TD><TD STYLE="text-align: left; padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"> &nbsp; </TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"> 24,316 </TD><TD STYLE="text-align: left; padding-bottom: 1pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in; padding-bottom: 2.5pt"> Total capitalization </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double"> $ </TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double"> 8,512 </TD><TD STYLE="text-align: left; padding-bottom: 2.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double"> $ </TD><TD STYLE="text-align: right; padding-bottom: 2.5pt; border-bottom: Black 2.5pt double"> 8,512 </TD><TD STYLE="text-align: left; padding-bottom: 2.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double"> $&nbsp; </TD><TD STYLE="text-align: right; padding-bottom: 2.5pt; border-bottom: Black 2.5pt double"> 24,316 </TD><TD STYLE="text-align: left; padding-bottom: 2.5pt"> &nbsp; </TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The number of shares
of our common stock to be outstanding after this offering is based on 6,218,980 shares of our common stock outstanding as of the
date of this prospectus, plus 7,099,374 shares common stock issuable upon conversion of our Series A preferred stock as of June
30, 2018, and excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,225,000
                                         shares of our common stock issuable upon exercise of outstanding options, with an average
                                         weighted exercise price of $1.43 per share, granted pursuant to our 2017 Plan;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">100,000
                                         shares of common stock issuable upon the settlement of outstanding restricted stock units
                                         pursuant to the 2017 Plan;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">approximately
                                         1,289,548 shares of our common stock issuable upon exercise of outstanding warrants,
                                         with an average weighted exercise price of $1.61 per share as of June 30, 2018, which
                                         includes an estimated 689,548 shares of our common stock issuable upon exercise of a
                                         warrant issued to the underwriter as placement agent compensation in connection with
                                         the offering of our Series A preferred stock;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">up
                                         to 450,000 shares issuable pursuant to the underwriter&rsquo;s over-allotment option;
                                         </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">300,000
    shares issuable upon exercise of a warrant to be issued to the underwriter as part of its compensation in connection with
    this offering (up to 345,000 shares if the overallotment option is exercised) at an exercise price of $7.50 per share;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">956,020
                                         shares of our common stock to be reserved for future issuance under our 2018 Plan; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">150,000
                                         shares of common stock reserved for issuance under our 2018 ESPP.</FONT></TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_010"></A>DILUTION</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you invest in our
common stock, your interest will be diluted to the extent of the difference between the amount per share paid by purchasers of
shares of common stock in this offering and the pro forma as adjusted net tangible book value per share of common stock immediately
after the completion of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our historical net
tangible net book value (deficit) as of June 30, 2018 was $(12.9) million or $(2.08) per share of common stock based on our 6,218,980
common shares outstanding at June 30, 2018. Our historical net tangible book value (deficit) is the amount of our tangible net
assets less our total liabilities and the carrying value of our preferred stock, which is not included within shareholders&rsquo;
equity (deficit).</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of June 30, 2018,
our pro forma net tangible book value was approximately $8.5 million, or $0.64 per share of common stock. Our pro forma net tangible
book value per share represents the amount of our total tangible assets reduced by the amount of our total liabilities and divided
by the total number of shares of our common stock outstanding as of June 30, 2018, after giving effect to the automatic conversion
of all outstanding shares of our preferred stock into common stock immediately prior to the closing of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> After giving effect
to our sale in this offering of 3,000,000 shares of our common stock, at the initial public offering price of $6.00 per share,
after deducting underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted
net tangible book value as of June 30, 2018 would have been approximately $24.3 million, or $1.49 per share of our common stock.
This represents an immediate increase in pro forma as adjusted net tangible book value of $0.85 per share to our existing stockholders
and an immediate dilution of $4.51 per share to investors purchasing shares in this offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table illustrates this dilution:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%"> Initial public offering price per share </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 10%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 10%; text-align: right"> 6.00 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -0.125in"> Pro forma net tangible book value per share as
    of June 30, 2018, before giving effect to this offering </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.64 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -0.125in; padding-bottom: 1pt"> Increase in pro forma net
    tangible book value per share attributable to new investors purchasing shares in this offering </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"> &nbsp; </TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"> 0.85 </TD><TD STYLE="text-align: left; padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="text-align: right; padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="text-align: left; padding-bottom: 1pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Pro forma as adjusted net tangible book value per share, after giving effect to this offering </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"> &nbsp; </TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"> 1.49 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Dilution per share to new investors purchasing shares in this offering </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"> $ </TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"> 4.51 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> If the underwriters
exercise their option to purchase additional shares of our common stock in full, the pro forma as adjusted net tangible book value
after this offering would be $1.60 per share, the increase in pro forma net tangible book value per share would be $0.96 and the
dilution per share to new investors would be $4.40 per share, in each case assuming an initial public offering price of $6.00&nbsp;per
share. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
summarizes, on a pro forma as adjusted basis as described above, the difference between existing stockholders and new investors
with respect to the number of shares of common stock purchased from us, the total consideration paid to us and the average price
per share paid, before deducting underwriting discounts and commissions and estimated offering expenses:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shares
    Purchased</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Consideration</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Average
    Price</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Percent</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amount</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Percent</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Per
    Share</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; text-align: left; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Existing
    stockholders</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right">13,318,354</TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right">81.6</TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,055,246&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right">52.7</TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 10%; text-align: right">2.82</TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">New
    public investors</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">3,000,000</TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">18.4</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">18,000,000&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">47.3</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>6.00</TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">16,318,354</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">100.0</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">38,055,246<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">100.0</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent that
our outstanding warrants are exercised, investors will experience further dilution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise
indicated, the above discussion and tables assume no exercise of the underwriter&rsquo;s over-allotment option. If the underwriter
exercises its over-allotment option in full, our existing stockholders would own 79.4% and our new investors would own 20.6% of
the total number of shares of our common stock outstanding upon the completion of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing tables
and calculations are based on the number of shares of our common stock outstanding as of June 30, 2018, after giving effect to
the automatic conversion of all outstanding shares of our preferred stock into common stock immediately prior to the closing of
this offering, and excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,225,000
                                         shares of our common stock issuable upon exercise of outstanding options, with an average
                                         weighted exercise price of $1.43 per share, granted pursuant to our 2017 Plan;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">100,000
                                         shares of common stock issuable upon the settlement of outstanding restricted stock units
                                         pursuant to the 2017 Plan;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">approximately
                                         1,289,548 shares of our common stock issuable upon exercise of outstanding warrants,
                                         with an average weighted exercise price of $1.60 per share, which includes an estimated
                                         689,548 shares of our common stock issuable upon exercise of a warrant issued to the
                                         underwriter as placement agent compensation in connection with the offering of our Series
                                         A preferred stock;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">up
                                         to 450,000 shares issuable pursuant to the underwriter&rsquo;s over-allotment option;
                                         </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 0.5in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 0.25in">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">300,000
    shares issuable upon exercise of a warrant to be issued to the underwriter as part of its compensation in connection with
    this offering (up to 345,000 shares if the overallotment option is exercised) at an exercise price of $7.50 per share;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">956,020
                                         shares of our common stock to be reserved for future issuance under our 2018 Plan; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">150,000
                                         shares of common stock reserved for issuance under our 2018 ESPP.</FONT></TD></TR></TABLE>



<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_011"></A>DESCRIPTION
OF SECURITIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the completion
of this offering, our amended and restated certificate of incorporation will authorize us to issue up to 50,000,000 shares of
common stock, $0.001 par value per share, and 10,000,000 shares of preferred stock, $0.001 par value per share, all of which shares
of preferred stock will be undesignated. Our board of directors may establish the rights and preferences of the preferred stock
from time to time. As of June 30, 2018, we had 6,218,980 shares outstanding of common stock, held by nine stockholders of record.
As of June 30, 2018, after giving effect to the conversion of all of the outstanding shares of our Series A preferred stock into
7,099,374 shares of common stock, there would have been 13,318,354 shares of common stock issued and outstanding, held by 241
stockholders of record.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of shares
of common stock are entitled to one vote per share on all matters to be voted upon by the stockholders generally. Stockholders
are entitled to receive such dividends as may be declared from time to time by the board of directors out of funds legally available
therefore, and in the event of liquidation, dissolution or winding up of the company to share ratably in all assets remaining
after payment of liabilities. The holders of shares of common stock have no preemptive, conversion, subscription rights or cumulative
voting rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of June 30, 2018,
there were 6,685,082 shares of Series A preferred stock outstanding. All currently outstanding shares of preferred stock will
convert automatically into 7,099,374 shares of common stock immediately prior to the closing of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the completion
of this offering, our amended and restated certificate of incorporation will authorize us to issue up to 10,000,000 shares of
preferred stock, $0.001 par value, all of which shall be undesignated. Our board of directors may, without further action by our
stockholders, fix the rights, preferences, privileges, and restrictions of the preferred stock in one or more series and authorize
their issuance. These rights, preferences, and privileges could include dividend rights, conversion rights, voting rights, terms
of redemption, liquidation preferences, sinking fund terms, and the number of shares constituting any series or the designation
of such series, any or all of which may be greater than the rights of our common stock. The issuance of our preferred stock could
adversely affect the voting power of holders of our common stock and the likelihood that such holders will receive dividend payments
and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring, or preventing
a change of control or other corporate action. Upon the completion of this offering, and after giving effect to the conversion
of our Series A preferred stock, no shares of preferred stock will be outstanding, and we have no present plan to issue any shares
of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dividends</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not anticipate
the payment of cash dividends on our common stock in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the completion
of this offering, we will have outstanding the following warrants to purchase shares of our common stock:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">warrant
                                         to purchase 600,000 shares of our common stock exercisable at $0.01 per share. The warrants
                                         were issued on May 4, 2017 to Liquid Patent Advisors, LLC as consideration for consulting
                                         services; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">warrant
                                         issued to National Securities Corporation on June 26, 2017, as placement agent compensation
                                         in connection with our June 2017 placement of Series A preferred stock, to purchase shares
                                         of our common stock in an amount equal to 10% of the shares of common stock issuable
                                         upon conversion of 6,494,082 shares of our Series A preferred stock, at an exercise price
                                         equal to 50% of the initial public offering price. Assuming the conversion of all of
                                         our Series A preferred stock as of June 30, 2018, the placement agent warrant would entitle
                                         its holder to purchase 689,548 shares of our common stock.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The warrants contain
provisions for the adjustment of the exercise price and the number of shares issuable upon the exercise of the warrants in the
event of certain stock dividends, stock splits, reorganizations, reclassifications and consolidations. The holders of the shares
issuable upon exercise of the warrants issued to Liquid Patent Advisors, LLC and National Securities Corporation are entitled
to registration rights with respect to such shares as described in greater detail under the heading &ldquo;&mdash; Registration
Rights&rdquo; below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Registration Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the completion
of this offering, certain holders of an aggregate of 3,000,000 shares of our common stock, or their permitted transferees, are
entitled to rights with respect to the registration under the Securities Act of their shares of common stock, including demand
registration rights and piggyback registration rights. These rights are provided under the terms of a registration rights agreement
between us and the investors. In any registration made pursuant to this agreement, all fees, costs and expenses of the registrations
will be borne by us, and all selling expenses, including estimated underwriting discounts and selling commissions, will be borne
by the holders of the shares being registered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
our June 2017 Series A preferred stock financing, we entered into the registration rights agreement, pursuant to which we will
be required, upon the written request at any time more than 180 days after the completion of this offering by the holders of at
least 50% of the shares that are entitled to registration rights under the registration rights agreement, to register, as soon
as practicable, all or a portion of these shares for public resale. We are required to effect only one registration pursuant to
this provision of the registration rights agreement. These demand registration rights terminate as to each investor when their
shares subject to the registration rights agreement may be sold by the investor pursuant to Rule 144 under the Securities Act
without regard to both the volume limitations for sales as provided in Rule 144.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
our issuance to Liquid Patent Advisors, LLC and National Securities Corporation of warrants to purchase shares of our common stock,
we entered into a registration rights agreement with Liquid Patent Advisors, LLC and National Securities Corporation pursuant
to which we will be required, upon the written request at any time more than 180 days after the completion of this offering by
the holders of at least 50% of the shares that are entitled to registration rights under that agreement and the registration rights
agreement we entered into with the Series A preferred stock investors, as a group, to register, as soon as practicable, all or
a portion of these shares for public resale. We are required to effect only one registration pursuant to this provision of the
registration rights agreement. These demand registration rights terminate as to each stockholder when their shares subject to
the registration rights agreement may be sold by the investor pursuant to Rule 144 under the Securities Act without regard to
both the volume limitations for sales as provided in Rule 144.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the registration
rights agreement contains piggyback registration rights with respect our capital stock held by these investors. These piggyback
registration rights terminate with respect to each stockholder when their shares subject to the registration rights agreement
may be sold by the stockholder pursuant to Rule 144 under the Securities Act without regard to both the volume limitations for
sales as provided in Rule 144.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we register any
of our securities for our own account, after the completion of this offering, the holders of these shares are entitled to include
their shares in the registration. Both we and the underwriters of any underwritten offering have the right to limit the number
of shares registered by these holders for marketing reasons, subject to limitations set forth in the RRA with these investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Anti-Takeover Effects of Certain
Provisions of Delaware Law and Our Charter Documents</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a
summary of certain provisions of Delaware law, our amended and restated certificate of incorporation and amended and restated
bylaws to be effective at the close this offering. This summary does not purport to be complete and is qualified in its entirety
by reference to the corporate law of Delaware and our amended and restated certificate of incorporation and amended and restated
bylaws to be effective at the close this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Effect of Delaware
Anti-Takeover Statute.</I> We are subject to Section 203 of the Delaware General Corporation Law, an anti-takeover law. In general,
Section 203 prohibits a Delaware corporation from engaging in any business combination (as defined below) with any interested
stockholder (as defined below) for a period of three years following the date that the stockholder became an interested stockholder,
unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">prior
                                         to that date, the board of directors of the corporation approved either the business
                                         combination or the transaction that resulted in the stockholder becoming an interested
                                         stockholder;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">upon
                                         consummation of the transaction that resulted in the stockholder becoming an interested
                                         stockholder, the interested stockholder owned at least 85% of the voting stock of the
                                         corporation outstanding at the time the transaction commenced, excluding for purposes
                                         of determining the number of shares of voting stock outstanding (but not the voting stock
                                         owned by the interested stockholder) those shares owned by persons who are directors
                                         and officers and by excluding employee stock plans in which employee participants do
                                         not have the right to determine whether shares held subject to the plan will be tendered
                                         in a tender or exchange offer; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">on
                                         or subsequent to that date, the business combination is approved by the board of directors
                                         of the corporation and authorized at an annual or special meeting of stockholders, and
                                         not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding
                                         voting stock that is not owned by the interested stockholder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 203 defines
&ldquo;business combination&rdquo; to include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">any
                                         merger or consolidation involving the corporation and the interested stockholder;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">any
                                         sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation
                                         involving the interested stockholder;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">subject
                                         to certain exceptions, any transaction that results in the issuance or transfer by the
                                         corporation of any stock of the corporation to the interested stockholder;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">subject
                                         to limited exceptions, any transaction involving the corporation that has the effect
                                         of increasing the proportionate share of the stock of any class or series of the corporation
                                         beneficially owned by the interested stockholder; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">the
                                         receipt by the interested stockholder of the benefit of any loans, advances, guarantees,
                                         pledges or other financial benefits provided by or through the corporation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, Section
203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock
of the corporation, or who beneficially owns 15% or more of the outstanding voting stock of the corporation at any time within
a three-year period immediately prior to the date of determining whether such person is an interested stockholder, and any entity
or person affiliated with or controlling or controlled by any of these entities or persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Our Charter Documents.
</I>Our charter documents include provisions that may have the effect of discouraging, delaying or preventing a change in control
or an unsolicited acquisition proposal that a stockholder might consider favorable, including a proposal that might result in
the payment of a premium over the market price for the shares held by our stockholders. Certain of these provisions are summarized
in the following paragraphs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Effects of authorized
but unissued blank check preferred stock</I>. Our board of directors is authorized, without stockholder approval, to issue preferred
stock in series and to fix and state the voting rights and powers, designation, preferences and relative, participating, optional
or other special rights of the shares of each such series and the qualifications, limitations and restrictions thereof. Preferred
stock may rank prior to our common stock with respect to dividends rights, liquidation preferences, or both, and may have full
or limited voting rights. If issued, such preferred stock would increase the number of outstanding shares of our capital stock,
adversely affect the voting power of holders of our common stock, and could have the effect of deterring or delaying an attempt
to obtain control of us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><I>Classified Board</I>.
As described in &ldquo;Management&mdash;Board Composition,&rdquo; in accordance with our amended and restated certificate of incorporation
effective upon the completion of this offering, our board of directors will be divided into three classes with staggered three-year
terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><I>Board Composition</I>.
In addition, our amended and restated certificate of incorporation and amended and restated bylaws will provide that the number
of directors constituting our board of directors will be permitted to be set only by a resolution adopted by a majority vote of
our entire board of directors, and that our directors may be removed only for cause. Our amended and restated certificate of incorporation
and amended and restated bylaws will also provide that vacancies occurring on our board of directors and newly created directorships
resulting from an increase in the authorized number of directors may be filled only by vote of a majority of the remaining members
of our board of directors, even though less than a quorum. Our amended and restated certificate of incorporation and amended and
restated bylaws will provide that our board of directors is expressly authorized to adopt, amend, or repeal our bylaws, and require
a supermajority stockholder vote to amend our bylaws and certain provisions of our certificate of incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><I>Advance Notice
Provisions</I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Our amended and restated bylaws will
provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders or to nominate
candidates for election as directors at our annual meeting of stockholders. Our amended and restated bylaws will also specify
certain requirements regarding the form and content of a stockholder&rsquo;s notice. These provisions might preclude our stockholders
from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting
of stockholders if the proper procedures are not followed. We expect that these provisions may also discourage or deter a potential
acquirer from conducting a solicitation of proxies to elect the acquirer&rsquo;s own slate of directors or otherwise attempting
to obtain control of our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Cumulative Voting.
</I>Our Certificate of Incorporation does not provide for cumulative voting in the election of directors, which would allow holders
of less than a majority of the stock to elect some directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Special Meeting
of Stockholders and Stockholder Action by Written Consent.</I> A special meeting of stockholders may only be called by our president,
board of directors or such officers or other persons as our board may designate at any time and for any purpose or purposes as
shall be stated in the notice of the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"> <I>Exclusive Forum</I><B>.
</B>Unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall
be the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf; (ii) any action asserting a
claim of breach of a fiduciary duty owed to us or our stockholders by any of our directors, officers or other employees; (iii)
any action asserting a claim against us or any of our directors, officers or other employees arising pursuant to any provision
of Delaware law or our charter documents; or (iv) any action asserting a claim against us or any of our directors, officers or
other employees governed by the internal affairs doctrine, but excluding actions to enforce a duty or liability created by the
Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. In addition, unless we consent in writing
to the selection of an alternative forum, the Federal district courts of the United States of America shall be the exclusive forum
for the resolution of any complaint asserting a cause of action arising under the Securities Act. A court may determine that these
choice of forum provisions are unenforceable, and to the extent they are enforceable, they may limit a stockholder&rsquo;s ability
to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees,
which may discourage such lawsuits against us and our directors, officers and other employees, although our stockholders will
not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the closing of
this offering, the transfer agent and registrar for our common stock will be Computershare Trust Company, N.A. located at 250
Royall Street, Canton, MA 02021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_012"></A>SHARES
ELIGIBLE FOR FUTURE SALE</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to this offering,
there has been no public market for shares of our common stock. Future sales of substantial amounts of shares of common stock,
including shares issued upon the exercise of outstanding warrants and options, in the public market after this offering, or the
possibility of these sales occurring, could adversely affect the prevailing market price for our common stock or impair our ability
to raise equity capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the completion
of this offering, a total of 13,318,354 shares of common stock will be outstanding, assuming the automatic conversion of all outstanding
Series A preferred stock into shares of common stock in connection with the completion of this offering. All 3,000,000 shares
of common stock sold in this offering by us, plus any shares sold upon exercise of the underwriter&rsquo;s over-allotment option,
will be freely tradable in the public market without restriction or further registration under the Securities Act, unless these
shares are held by &ldquo;affiliates,&rdquo; as that term is defined in Rule&nbsp;144 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The remaining shares
13,318,354 of common stock will be &ldquo;restricted securities,&rdquo; as that term is defined in Rule&nbsp;144 under the Securities
Act. These restricted securities are eligible for public sale only if they are registered under the Securities Act or if they
qualify for an exemption from registration under Rules&nbsp;144 or 701 under the Securities Act, which are summarized below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the lock-up
agreements described below and the provisions of Rules&nbsp;144 and 701 under the Securities Act, these restricted securities
will be available for sale in the public market beginning more than 180&nbsp;days after the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Rule&nbsp;144</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, under
Rule&nbsp;144 as currently in effect, once we have been subject to public company reporting requirements for at least 90&nbsp;days,
a person who is not deemed to have been one of our affiliates for purposes of the Securities Act at any time during the 90&nbsp;days
preceding a sale and who has beneficially owned the shares proposed to be sold for at least six months, including the holding
period of any prior owner other than our affiliates, is entitled to sell such shares without complying with the manner of sale,
volume limitation, or notice provisions of Rule&nbsp;144, subject to compliance with the public information requirements of Rule&nbsp;144.
If such a person has beneficially owned the shares proposed to be sold for at least one year, including the holding period of
any prior owner other than our affiliates, then such person is entitled to sell such shares without complying with any of the
requirements of Rule&nbsp;144.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, under
Rule&nbsp;144, as currently in effect, our affiliates or persons selling shares on behalf of our affiliates are entitled to sell
upon expiration of the lock-up agreements described below, within any three-month period beginning 90&nbsp;days after the date
of this prospectus, a number of shares that does not exceed the greater of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">1%
                                         of the number of shares of common stock then outstanding; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         average weekly trading volume of the common stock during the four calendar weeks preceding
                                         the filing of a notice on Form&nbsp;144 with respect to such sale.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales under Rule&nbsp;144
by our affiliates or persons selling shares on behalf of our affiliates are also subject to certain manner of sale provisions
and notice requirements and to the availability of current public information about us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Rule&nbsp;701</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Rule&nbsp;701 generally
allows a stockholder who purchased shares of our common stock pursuant to a written compensatory plan or contract and who is not
deemed to have been one of our affiliates during the immediately preceding 90&nbsp;days to sell these shares in reliance upon
Rule&nbsp;144, but without being required to comply with the public information, holding period, volume limitation, or notice
provisions of Rule&nbsp;144. Rule&nbsp;701 also permits our affiliates to sell their Rule&nbsp;701 shares under Rule&nbsp;144
without complying with the holding period requirements of Rule&nbsp;144. However, all holders of Rule&nbsp;701 shares are required
to wait until 90&nbsp;days after the date of this prospectus before selling such shares pursuant to Rule&nbsp;701.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Lock-Up Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">We, our executive
officers and directors and the holders of our common stock outstanding on the date of this prospectus have entered into lock-up
agreements or otherwise agreed that we and they will not, subject to limited exceptions, (i) offer, pledge, announce the intention
to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option,
right or warrant to purchase or otherwise dispose of, directly or indirectly, or file with the SEC a registration statement under
the Securities Act relating to, any shares of our common stock outstanding as of the date of this prospectus, or publicly disclose
the intention to make any offer, sale, pledge, disposition or filing, or (ii) enter into any swap or other arrangement that transfers
all or a portion of the economic consequences associated with the ownership of any shares of common stock (regardless of whether
any of these transactions are to be settled by the delivery of shares of common stock, in cash or otherwise), in each case without
the prior written consent of the underwriter for a period of (i) 12 months after the date of this prospectus, with respect to
all shares held by our officers and directors, except for 218,980 shares issued pursuant to restricted stock agreements and (ii)
six months after the date of this prospectus with respect to the aforementioned 218,980 shares held by our officers and directors
and all shares issuable upon conversion of our Series A preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Registration Statements on Form&nbsp;S-8</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We intend to file a registration statement
on Form&nbsp;S-8 under the Securities Act to register all of the shares of common stock to be issued or reserved for issuance
under our 2007 Stock Incentive plan. Shares covered by this registration statement will be eligible for sale in the public market,
upon the expiration or release from the terms of the lock-up agreements and subject to vesting of such shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_013"></A>UNDERWRITING</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are offering the shares of common stock
described in this prospectus through the underwriter, National Securities Corporation, which is acting as lead managing underwriter
of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have agreed to enter into an underwriting
agreement with the underwriter prior to the closing of this offering. Subject to the terms and conditions of the underwriting
agreement, we will agree to sell to the underwriter, and the underwriter will agree to purchase, at the public offering price
less the underwriting discounts and commissions set forth on the cover page of this prospectus, as it may be supplemented, shares
of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriter is committed to purchase
all of the common shares offered by us, other than those covered by the option to purchase additional shares described below,
if they purchase any shares. The underwriting agreement provides that the underwriter&rsquo;s obligations to purchase shares of
our common stock are subject to conditions contained in the underwriting agreement. A copy of the underwriting agreement has been
filed as an exhibit to the registration statement of which this prospectus forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have been advised by the underwriter
that the underwriter proposes to offer shares of our common stock directly to the public at the public offering price set forth
on the cover page of this prospectus and to certain dealers that are members of the Financial Industry Regulatory Authority, or
FINRA. Any securities sold by the underwriter to such securities dealers will be sold at the public offering price less a selling
concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. After the public offering
of the shares, the offering price and other selling terms may be changed by the underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None of our securities included in this
offering may be offered or sold, directly or indirectly, nor may this prospectus and any other offering material or advertisements
in connection with the offer and sales of any of our common stock, be distributed or published in any jurisdiction, except under
circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons who receive
this prospectus are advised to inform themselves about and to observe any restrictions relating to this offering of our common
stock and the distribution of this prospectus. This prospectus is neither an offer to sell nor a solicitation of any offer to
buy any of our common stock included in this offering in any jurisdiction where that would not be permitted or legal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriter has advised us that it
does not intend to confirm sales to any accounts over which they exercise discretionary authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Underwriting Discount and Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the underwriting
discount and commission to be paid to the underwriter by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP> &nbsp; </TD>
    <TD NOWRAP> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="padding-left: 3pt; text-align: center"> <B>Without </B><BR>
    <B>Over-</B><BR>
    <B>Allotment </B> </TD>
    <TD NOWRAP> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="padding-left: 3pt; text-align: center; vertical-align: bottom"> <B>With Over-</B><BR>
    <B>Allotment </B> </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 71%; padding-left: 10pt; text-indent: -10pt"> Public offering price </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD>
    <TD STYLE="width: 12%; text-align: right"> 18,000,000 </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD>
    <TD STYLE="width: 12%; text-align: right"> 20,700,000 </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"> Underwriting discount to be paid to the underwriter </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD>
    <TD STYLE="text-align: right"> 1,476,000 </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD>
    <TD STYLE="text-align: right"> 1,697,400 </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"> Net proceeds, before other expenses </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD>
    <TD STYLE="text-align: right"> 16,524,000 </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD>
    <TD STYLE="text-align: right"> 19,002,600 </TD>
    <TD> &nbsp; </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the discount set forth
in the above table, we have agreed to issue to the underwriter and its designees a warrant to purchase up to 10% of the shares
of common stock sold in this offering and to pay $150,000 for their counsel&rsquo;s fees as well as $50,000 for certain of their
accountable expenses. The terms of the underwriter&rsquo;s warrant are more fully described in this section under the caption,
&ldquo;Underwriter Warrants.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Over-Allotment Option</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> In addition to the discount set forth
in the above table, we have granted to the underwriter an option, exercisable not later than 45 days after the date of this prospectus,
to purchase up to an additional&nbsp;450,000<B>&nbsp;</B>shares of our common stock (up to 15<B>% </B>of the shares firmly committed
in this offering) at the public offering price, less the underwriting discount, set forth on the cover page of this prospectus.
The underwriter may exercise the option solely to cover over-allotments, if any, made in connection with this offering. If any
additional shares of our common stock are purchased pursuant to the over-allotment option, the underwriter will offer these additional
shares of our common stock on the same terms as those on which the other shares of common stock are being offered hereby. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Determination of Offering Price Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> We have applied to list our common
stock on The NASDAQ Global Market under the symbol &ldquo;ETON&rdquo;. In order to meet the requirements for listing on that exchange,
the underwriters have undertaken to sell a minimum number of shares to a minimum number of beneficial owners as required by that
exchange. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before this offering, there has been no
public market for our common stock. There is no current market for our common stock. Our underwriter, National Securities Corporation,
is not obligated to make a market in our securities, and even if it chooses to make a market, can discontinue at any time without
notice. Neither we nor the underwriter can provide any assurance that an active and liquid trading market in our securities will
develop or, if developed, that the market will continue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The public offering price of the shares
offered by this prospectus has been determined by negotiation between us and the underwriter. Among the factors considered in
determining the public offering price of the shares were:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
our history and our prospects;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
the industry in which we operate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
our past and present operating results;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
the previous experience of our executive officers; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
the general condition of the securities markets at the time of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The offering price stated on the cover
page of this prospectus should not be considered an indication of the actual value of the shares. Upon the commencement of trading,
the price of our shares will be subject to change as a result of market conditions and other factors, and we cannot assure you
that the shares can be resold at or above the public offering price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Underwriter Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with this offering, we have
agreed to issue to National Securities Corporation and its designees a warrant to purchase shares of our common stock equal to
10% of the shares of common stock sold in this offering. This warrant is exercisable at $7.50 per share (125% of the price of
the common stock sold in this offering), expiring five years from the date of this prospectus. The warrant and the shares of common
stock underlying the warrant have been deemed compensation by FINRA and are therefore subject to a six month lock-up pursuant
to Rule 5110(g)(1) of FINRA. Additionally, National Securities Corporation has contractually agreed that it (or its permitted
assignees under the Rule) will not sell, transfer, assign, pledge, or hypothecate this warrant or the securities underlying this
warrant, nor will it engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective
economic disposition of this warrant or the underlying securities for a period of twelve months from the effective date of the
offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with its role as placement
agent in our offering of our Series A preferred stock, we issued to National Securities Corporation and its designees a warrant
to purchase shares of our common stock in an amount equal to 10% of the shares of common stock issuable upon conversion of 6,494,082
shares of our Series A preferred stock. This warrant is exercisable at $3.00 per share (50% of the price of the common stock sold
in this offering), expiring five years from June 26, 2017, the date the warrant was originally issued. In addition to the lock-up
provisions summarized below, the warrant and the shares of common stock underlying the warrant have been deemed compensation by
FINRA and are therefore subject to a six month lock-up pursuant to Rule 5110(g)(1) of FINRA. National Securities Corporation (or
permitted assignees under the Rule) will not sell, transfer, assign, pledge, or hypothecate this warrant or the securities underlying
this warrant, nor will it engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective
economic disposition of this warrant or the underlying securities for a period of six months from the effective date of the offering.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to our engagement agreement with
Liquid Patent Advisors, LLC, on May 4, 2017, we issued to Liquid Patent Advisors, LLC warrants to purchase up to 600,000 shares
of our common stock, exercisable at $0.01 per share, expiring after a term of five years. The warrants were issued in consideration
of Liquid Patent Advisors&rsquo; provision of consulting services. The warrants provide its holders with certain registration
and piggyback registration rights. The warrants also contain provisions for the adjustment of the exercise price and the number
of shares issuable upon the exercise of the warrants in the event of certain stock dividends, stock splits, reorganizations, reclassifications,
and consolidations. The principals of Liquid Patent Advisors hold investment banking positions with National Securities Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Lock-Up Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with our issuance of warrants
to purchase shares of our common stock to Liquid Patent Advisors, LLC and National Securities Corporation, including the underwriter
warrant to be issued to National Securities upon the completion of this offering, Liquid Patent Advisors and National Securities
have agreed not to sell, transfer or pledge, or offering to do any of the same, directly or indirectly, the shares of common stock
issuable upon exercise of such warrants for a period of 12 months following the close of this offering. We, all of our directors
and officers and our former parent, Imprimis Pharmaceuticals, have agreed in connection with the present offering, that, without
the prior written consent of National Securities Corporation, not to sell, transfer or pledge, or offer to do any of the same,
directly or indirectly, any of our outstanding shares of common stock, for a period of 12 months following the close of this offering,
except for 218,980 shares for which the lock-up period is 180 days. The holders of substantially all of our other common stock
or securities exercisable for or convertible into our common stock outstanding immediately prior to this offering have agreed
in connection with the present offering, that, without the prior written consent of National Securities Corporation, not to sell,
transfer or pledge, or offer to do any of the same, directly or indirectly, any of our securities for a period 180 days following
the close of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of shares of common stock outstanding
upon the completion of this offering subject to the 180-day lock-up totals&nbsp;218,980 shares, and the number of shares underlying
options, warrants and restricted stock units subject to the 180-day lock-up totals&nbsp;227,500 shares.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other than in respect of the warrants
issued or to be issued to Liquid Patent Advisors, LLC and National Securities Corporation, the underwriter may consent to an early
release from the lock-up period if, in its opinion, the market for the common stock would not be adversely impacted by sales and
in cases of a financial emergency of an officer, director or other stockholder. We are unaware of any security holder who intends
to ask for consent to dispose of any of our equity securities during the relevant lock-up periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Indemnification</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have agreed to indemnify the several
underwriters against certain liabilities, including liabilities under the Securities Act relating to losses or claims resulting
from material misstatements in or omissions from this prospectus, the registration statement of which this prospectus is a part,
certain free writing prospectuses that may be used in the offering and in any marketing materials used in connection with this
offering and to contribute to payments the underwriters may be required to make in respect of those liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Short Positions and Penalty Bids</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriter may engage in over-allotment,
syndicate covering transactions, and penalty bids or purchases for the purpose of pegging, fixing or maintaining the price of
the common stock, in accordance with Regulation M under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Over-allotment
involves sales by the underwriter of shares in excess of the number of shares the underwriter is obligated to purchase, which
creates a syndicate short position. The short position may be either a covered short position or a naked short position. In a
covered short position, the number of shares over-allotted by an underwriter is not greater than the number of shares that it
may purchase in the over-allotment option. In a naked short position, the number of shares involved is greater than the number
of shares in the over-allotment option. The underwriter may close out any short position by either exercising its over-allotment
option and/or purchasing shares in the open market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Syndicate
covering transactions involve purchases of the common stock in the open market after the distribution has been completed in order
to cover syndicate short positions. In determining the source of shares to close out the short position, the underwriter will
consider, among other things, the price of shares available for purchase in the open market as compared to the price at which
it may purchase shares through the over-allotment option. If an underwriter sells more shares than could be covered by the over-allotment
option, a naked short position, the position can only be closed out by buying shares in the open market. A naked short position
is more likely to be created if an underwriter is concerned that there could be downward pressure on the price of the shares in
the open market after pricing that could adversely affect investors who purchase in the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Penalty
bids permit an underwriter to reclaim a selling concession from a syndicate member when the shares originally sold by the syndicate
member are purchased in a stabilizing or syndicate covering transaction to cover syndicate short positions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> These syndicate covering transactions
and penalty bids may have the effect of raising or maintaining the market price of our common stock or preventing or retarding
a decline in the market price of the common stock. As a result, the price of the common stock may be higher than the price that
might otherwise exist in the open market. These transactions may be effected on the NASDAQ Global Market, and if commenced, they
may be discontinued at any time. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither we nor the underwriter make any
representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on
the price of the common stock. In addition, neither we nor the underwriter make any representation that the underwriter will engage
in these transactions or that any transaction, once commenced, will not be discontinued without notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Electronic Distribution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A prospectus in electronic format may
be made available on the Internet sites or through other online services maintained by the underwriter, or by its affiliates.
In those cases, prospective investors may view offering terms online and, depending upon the underwriter, prospective investors
may be allowed to place orders online. The underwriter may agree with us to allocate a specific number of shares for sale to online
brokerage account holders. Any such allocation for online distributions will be made by the underwriter on the same basis as other
allocations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other than the prospectus in electronic
format, the information on the underwriter&rsquo;s website and any information contained in any other website maintained by the
underwriter is not part of the prospectus or the registration statement of which this prospectus forms a part, has not been approved
and/or endorsed by us or the underwriter in its capacity as underwriter and should not be relied upon by investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriter&rsquo;s compensation in
connection with this offering is limited to the fees and expenses described above under &ldquo;Underwriting Discount and Expenses.&rdquo;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_014"></A>LEGAL
MATTERS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Greenberg Traurig,
LLP, Irvine, California, will pass upon the validity of the shares of common stock offered by this prospectus. Certain legal matters
will be passed upon for the underwriters by Jenner &amp; Block, LLP, New York, New York.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_015"></A>EXPERTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The financial statements
as of December&nbsp;31, 2017 and for the period from April 27, 2017 (inception) through December&nbsp;31, 2017 included in this
prospectus have been so included in reliance on the report (which contains an explanatory paragraph relating to the Company&rsquo;s
ability to continue as a going concern as described in Note 2 to the financial statements) of KMJ Corbin &amp; Company LLP, an
independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_016"></A>WHERE
YOU CAN FIND MORE INFORMATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have filed with
the SEC a registration statement on Form S-1 under the Securities Act that registers the shares of our common stock to be sold
in this offering. Our SEC filings are and will become available to the public over the Internet at the SEC&rsquo;s website at
www.sec.gov. You may also read and copy any document we file with the SEC at its public reference facilities at 100 F Street N.E.,
Washington, D.C. 20549. You can also obtain copies of the documents upon the payment of a duplicating fee to the SEC. Please call
the SEC at 1-800-SEC-0330 for further information on the operation of the public reference facilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus does
not contain all of the information set forth in the registration statement and the exhibits and schedules thereto. Some items
are omitted in accordance with the rules and regulations of the SEC. You should review the information and exhibits included in
the registration statement for further information about us and the securities we are offering. Statements in this prospectus
concerning any document we filed as an exhibit to the registration statement or that we otherwise filed with the SEC are not intended
to be comprehensive and are qualified by reference to these filings. You should review the complete document to evaluate these
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_017"></A>ETON PHARMACEUTICALS,
INC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">INDEX
TO FINANCIAL STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="width: 95%"><A HREF="#a001_v1">Report of Independent Registered Public Accounting Firm</A></TD>
    <TD STYLE="width: 5%; text-align: right"><A HREF="#a001_v1">F-1</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#a002_v1"><FONT STYLE="font-size: 10pt">Balance Sheets</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a002_v1"><FONT STYLE="font-size: 10pt">F-2</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD></TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#a003_v1"><FONT STYLE="font-size: 10pt">Statements of Operations</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a003_v1"><FONT STYLE="font-size: 10pt">F-3</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#a004_v1"><FONT STYLE="font-size: 10pt">Statements of Redeemable Convertible Preferred Stock and Shareholders&rsquo;
    Deficit</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a004_v1"><FONT STYLE="font-size: 10pt">F-4</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#a005_v1"><FONT STYLE="font-size: 10pt">Statements of Cash Flows</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a005_v1"><FONT STYLE="font-size: 10pt">F-5</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#a006_v1"><FONT STYLE="font-size: 10pt">Notes to Financial Statements</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a006_v1"><FONT STYLE="font-size: 10pt">F-6</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a001_v1"></A><B>REPORT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Board of Directors and Shareholders of<BR>
Eton Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Opinion on the Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying balance
sheet of Eton Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) as of December&nbsp;31, 2017, the related statements of operations,
redeemable convertible preferred stock and shareholders&rsquo; deficit and cash flows for the period from April 27, 2017 (inception)
through December 31, 2017, and the related notes (collectively referred to as the &ldquo;financial statements&rdquo;). In our
opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31,
2017, and the results of its operations and its cash flows for the period from April 27, 2017 (inception) through December 31,
2017, in conformity with accounting principles generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Going Concern</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements
have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements,
the Company has an accumulated deficit of $8,639 as of December 31, 2017, has negative operating cash flows during the period
ended December 31, 2017 of $4,718, and the Company&rsquo;s redeemable convertible preferred stockholders can present a demand
for payment of $20,055, plus all accrued but unpaid dividends, if the Company does not complete an initial public offering or
alternative financing by December 31, 2018. These factors raise substantial doubt about the Company&rsquo;s ability to continue
as a going concern. Management&rsquo;s plans in regard to these factors are also described in Note 2. The accompanying financial
statements do not include any adjustments that might result from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Basis for Opinion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These financial statements are the responsibility
of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s financial statements based
on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&ldquo;PCAOB&rdquo;)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audit in accordance with
the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether
the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have,
nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required
to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the
effectiveness of the Company&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audit included performing procedures
to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures
in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made
by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides
a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 2in; margin-bottom: 0pt; text-align: left">/s/
KMJ Corbin &amp; Company LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&rsquo;s auditor since 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Costa Mesa, California<BR>
May 18, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 258.75pt"></P>


<!-- Field: Page; Sequence: 76; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Eton Pharmaceuticals, Inc.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a002_v1"></A><B>Balance Sheets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>(in thousands,
except share and per share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; text-decoration: none; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31, </FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">2017</FONT></TD><TD STYLE="font-weight: bold; text-decoration: none; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-decoration: none; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; text-decoration: none; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">June
    30,</FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">2018 </FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">(unaudited)</FONT></TD><TD STYLE="font-weight: bold; text-decoration: none; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-decoration: none; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; text-decoration: none; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-decoration: none"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Pro
                                         Forma</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-decoration: none"></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-decoration: none"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>June
                                         30,</B></FONT><BR>
                                         <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2018</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-decoration: none"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;<B>(unaudited)&nbsp;</B></FONT></P></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Assets</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current assets</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">13,156</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,946</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;8,946</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prepaid expenses</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">136</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">216</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">216</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total current assets</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">13,292</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,162</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,162</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other long-term assets, net</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">32</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">251</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">251</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Property and equipment, net</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">119</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">233</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">233</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total assets</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">13,443</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,646</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>$</B></FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,646</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Liabilities, redeemable
    convertible preferred stock and shareholders&rsquo; equity (deficit)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounts payable</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">539</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">868</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">868</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accrued liabilities</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">254</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">266</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">266</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total current liabilities</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">793</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,134</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,134</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrant liability</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">520</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,016</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total liabilities</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,313</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,150</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,134</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Commitments and contingencies
    (Note 14)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Redeemable convertible
    preferred stock &ndash; Series A</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">$0.001 par value, 10,000,000 shares authorized as of December
    31, 2017 and June 30, 2018 (unaudited); 6,685,082 shares issued and outstanding as of December 31, 2017 and June 30, 2018
    (unaudited); aggregate liquidation preference of $20,698 and $21,298 as of December 31, 2017 and June 30, 2018 (unaudited),
    respectively; no shares issued and outstanding, pro forma as of June 30, 2018 (unaudited)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>19,004</B></FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>20,432</B></FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shareholders&rsquo;
    equity (deficit)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Common stock $0.001 par value, 50,000,000 shares authorized as
    of December 31, 2017 and June 30, 2018 (unaudited); 6,000,000 shares issued and outstanding as of December 31, 2017; 6,218,980
    shares issued and outstanding as of June 30, 2018 (unaudited); 13,318,354 shares issued and outstanding, pro forma as of June
    30, 2018 (unaudited)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">13</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additional paid-in-capital</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,759</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,225</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">46,830</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated deficit</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(8,639</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(16,167</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(38,331</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shareholders&rsquo;
    equity (deficit)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(6,874</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(12,936</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,512</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total liabilities,
    redeemable convertible preferred stock and shareholders&rsquo; equity (deficit)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">13,443</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,646</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,646</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See notes to financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 77; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Eton Pharmaceuticals, Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<A NAME="a003_v1"></A><B>Statements
of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(in thousands, except per share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Period
                                         From</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>April
                                         27, 2017</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Inception)</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Through</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>December
                                         31,</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2017</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Period
                                         From</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>April
                                         27, 2017</B><BR>
                                         <B>(Inception)</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>to
                                         June 30, 2017</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(unaudited)</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Six</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Months</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>June
                                         30, 2018</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(unaudited)</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating
    expenses:</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;Research
    and development expenses</FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3,930</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,503</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2,981</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;General
    and administrative expenses</FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,220</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">681</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,680</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total
    operating expenses</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">7,150</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,184</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">5,661</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 5.4pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss
    from operations</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid">(7,150</TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid">(2,184</TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid">(5,661</TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
    income (expense):</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;Interest
    and other income, net</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">57</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;Change
    in fair value of warrant liability</FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(41</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(496</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss
    before income tax expense</FONT></TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(7,156</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(2,184</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(6,100</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Income
    tax expense</FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    loss</FONT></TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(7,156</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(2,184</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(6,100</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accrued dividends
    on redeemable convertible preferred stock</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(643</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(40</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(600</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deemed
    dividends for accretion of redeemable convertible preferred stock issuance costs</FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(840</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(51</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(828</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    loss attributable to common shareholders</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(8,639</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(2,275</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(7,528</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    loss per share attributable to common shareholders &ndash; basic and diluted</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(2.50</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.69</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(1.80</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted
    average common shares outstanding &ndash; basic and diluted</FONT></TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,453</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,285</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,172</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pro
    forma net loss per share attributable to common shareholders &ndash; basic and diluted (unaudited)</FONT></TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.82</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.51</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pro
    forma weighted average common shares outstanding &ndash; basic and diluted (unaudited)</FONT></TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,679</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">11,071</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See notes to financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Eton Pharmaceuticals, Inc.<BR>
<A NAME="a004_v1"></A><B>Statements of Redeemable Convertible Preferred Stock and Shareholders&rsquo; Deficit</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(in thousands, except share amounts)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD COLSPAN="5" STYLE="border-bottom: Black 1pt solid; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Redeemable
                                         Convertible</B></P>
                                                                                                                                                      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Preferred
                                         Stock</B></P>

</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; border-left: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common
                                         Stock</B>&nbsp;</P>

</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Additional
                                         Paid-in-</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Capital</B>&nbsp;</P>

</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Accumulated
                                         Deficit</B>&nbsp;</P>

</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Total</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Shareholders&rsquo; Deficit&nbsp;</B></P>

</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares</B></TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><B>&nbsp;&nbsp;&nbsp;&nbsp;Amount</B></TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><B>&nbsp;&nbsp;&nbsp;Shares</B></TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><B>&nbsp;&nbsp;&nbsp;Amount</B></TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in">Balances at April 27, 2017 (Inception)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 23%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Common stock issued to founder</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">3,500,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">4</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">4</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,759</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,761</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Issuance of Series A redeemable convertible preferred
    stock, net of issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,685,082</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,521</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Accrued dividends on redeemable convertible preferred
    stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">643</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(643</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(643</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Deemed dividends for accretion of redeemable convertible
    stock issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">840</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(840</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(840</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,156</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,156</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in">Balances at December 31, 2017</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">6,685,082</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left"></TD><TD STYLE="font-weight: bold; text-align: right">19,004</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">6,000,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left"></TD><TD STYLE="font-weight: bold; text-align: right">6</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left"></TD><TD STYLE="font-weight: bold; text-align: right">1,759</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left"></TD><TD STYLE="font-weight: bold; text-align: right">(8,639</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left"></TD><TD STYLE="font-weight: bold; text-align: right">(6,874</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">218,980</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,466</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,466</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Accrued dividends on redeemable convertible preferred
    stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">600</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(600</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(600</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Deemed dividends for accretion of redeemable convertible
    stock issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">828</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(828</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(828</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,100</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,100</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in">Balances at June 30, 2018 (unaudited)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">6,685,082</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">20,432</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">6,218,980</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">6</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">3,225</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(16,167</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(12,936</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See notes to financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>Eton Pharmaceuticals,
Inc.</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><A NAME="a005_v1"></A><B>Statements
of Cash Flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>(in thousands)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Period
                                         From</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>April
                                         27, 2017</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Inception)</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Through</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>December
                                         31,</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2017</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Period
                                         From</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>April
                                         27, 2017</B><BR>
                                         <B>(Inception)</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>to</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>June
                                         30, 2017</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Six</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Months
                                         Ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>June
                                         30, 2018</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(unaudited)</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash flows from operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-left: 0.125in">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(7,156</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(2,184</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(6,100</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Stock-based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,761</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">501</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,466</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Change in fair value of warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">496</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Prepaid expenses and other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(170</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(304</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">539</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">230</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">329</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Accrued liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">254</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">14</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Net cash used in operating activities</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(4,718</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(1,443</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(4,078</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Cash used in investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in"><B>Purchases of property and equipment</B></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(130</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(8</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(132</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash flows from financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Proceeds from issuance of common stock</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Net cash provided by financing
    activities</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">18,004</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">18,004</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Change in cash and cash equivalents</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">13,156</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">16,553</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(4,210</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Cash and cash equivalents &ndash; beginning of period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">13,156</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents &ndash; end of period</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">13,156</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">16,553</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">8,946</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Supplemental disclosure of cash flow information</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cash paid for interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash paid for income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Supplemental disclosures of non-cash financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued dividends on redeemable convertible preferred stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(643</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(40</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(600</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Deemed dividends for accretion of redeemable convertible preferred stock issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(840</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(51</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(828</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Common stock warrant liability issued with redeemable convertible preferred stock financing</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(479</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(479</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See notes to financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 258.75pt"></P>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Eton Pharmaceuticals, Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a006_v1"></A>Notes to Financial
Statements&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(in thousands, except share and per
share amounts) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Note 1 &mdash; Company Overview</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Eton Pharmaceuticals, Inc. (&ldquo;Eton&rdquo;
or the &ldquo;Company&rdquo;) was incorporated as a Delaware &ldquo;C&rdquo; corporation on April 27, 2017 and was initially set
up as a wholly-owned subsidiary of Imprimis Pharmaceuticals, Inc. (&ldquo;Imprimis&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Eton raised $20.1 million in start-up
capital through the sale of its Series A redeemable convertible preferred stock (&ldquo;Series A Preferred&rdquo;) in June 2017
(see Note 6) and a separate management team was then established for Eton with its corporate offices located in Deer Park, Illinois.
Eton is a specialty pharmaceutical company focused on developing and commercializing prescription drug products utilizing the
U.S. Food and Drug Administration&rsquo;s (the &ldquo;FDA&rdquo;) 505(b)(2) regulatory pathway. The Company&rsquo;s business model
is to develop proprietary innovative product candidates that offer commercial and/or functional advantages to currently available
alternatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is subject to risks and uncertainties
common to early-stage companies in the pharmaceuticals industry, including, but not limited to, development by competitors of
new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations
and the ability to secure additional capital to fund operations. Product candidates currently under development may require significant
additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior
to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and
extensive compliance-reporting capabilities. Even if the Company&rsquo;s drug development efforts are successful, it is uncertain
when, if ever, the Company will realize significant revenue from product sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Note 2 &mdash; Liquidity Considerations
and Going Concern</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements
have been prepared assuming that the Company will continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2017 and June 30, 2018
(unaudited), the Company had an accumulated deficit of $8,639 and $16,167, respectively. In addition, for the period from April
27, 2017 (inception) to December 31, 2017 and for the six months ended June 30, 2018 (unaudited), the Company had net cash used
in operating activities of $4,718 and $4,078, respectively. Per the terms of its Series A Preferred offering, the Company is obligated
to pursue an initial public offering (&ldquo;IPO&rdquo;) or another alternate financing approved by the Series A Preferred shareholders
that must be completed by December 31, 2018. If the IPO or alternate financing is not completed by December 31, 2018, the Series
A Preferred shareholders can present a demand for payment of the $20,055 of initial proceeds from the Series A Preferred capital
raise plus accrued dividends, which are cumulative and accrue at an annual rate of 6.00%. The Company cannot guarantee a successful
completion of its IPO or alternate financing at this time, which raises substantial doubt about the Company&rsquo;s ability to
continue as a going concern. The future of the Company is dependent upon additional financing and revenue to fund its research
and development activities, seek regulatory approvals for its product candidates and fund required ongoing general and administrative
expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event the Company does not complete
an IPO, the Company expects to seek additional funding through private equity financings, debt financings, or other financial
arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the terms of any financing may
adversely affect the holdings or the rights of the Company&rsquo;s stockholders. If the Company is unable to obtain funding, the
Company could be forced to delay, reduce or eliminate some or all of its product research and development programs or commercialization
efforts, which could adversely affect its business prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial statements do not include
any adjustments to reflect the possible effects on the recoverability and classification of recorded assets and liabilities that
may be necessary in the event the Company cannot continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Note 3 &mdash; Summary of Significant Accounting Policies</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>Basis of Presentation</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has prepared the accompanying
financial statements in accordance with accounting principles generally accepted in the United States of America (&ldquo;U.S.
GAAP&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>Unaudited Interim Financial Information </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying balance sheet as of June
30, 2018, the statements of operations and cash flows for the periods ended June 30, 2017 and 2018, and the statement of redeemable
convertible preferred stock and shareholders&rsquo; deficit for the six months ended June 30, 2018 are unaudited. The unaudited
interim financial statements have been prepared on the same basis as the audited financial statements and, in the opinion of management,
reflect all adjustments necessary for the fair presentation of the Company&rsquo;s financial position as of June 30, 2018 and
the results of its operations and its cash flows for the periods ended June 30, 2017 and 2018. The financial data and other information
disclosed in these notes related to the periods ended June 30, 2017 and 2018 are also unaudited. The results for the periods ended
June 30, 2018 are not necessarily indicative of results to be expected for the year ending December&nbsp;31, 2018, any other interim
periods, or any future year or period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 258.75pt"></P>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Eton Pharmaceuticals, Inc. <BR>
Notes to Financial Statements&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(in thousands, except share and per
share amounts) </B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Note 3 &mdash; Summary of Significant Accounting Policies
(cont.)</U></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>Unaudited Pro Forma Information </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited pro forma balance
sheet as of June&nbsp;30, 2018 has been prepared to give effect, upon the closing of a qualified IPO, to the automatic conversion
of all outstanding shares of the Series A Preferred into shares of the Company&rsquo;s common stock as if the Company&rsquo;s
proposed IPO had occurred on June 30, 2018. In addition, the exercise price of the warrant that has been recorded as a liability
has been assumed to be fixed as if the proposed IPO had occurred on June 30, 2018, resulting in the reclassification of the warrant
liability to shareholders&rsquo; equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the accompanying statements of operations,
the unaudited pro forma basic and diluted net loss per share attributable to common shareholders for the period ended December&nbsp;31,
2017 and the period ended June &nbsp;30, 2018 have been prepared to give effect, upon the closing of a qualified IPO, to the automatic
conversion of all outstanding shares of the Series A Preferred into shares of the Company&rsquo;s common stock as if the proposed
IPO had occurred on the issuance date of the Series A Preferred for 2017 and January 1, 2018 for 2018. In addition, the exercise
price of the warrant that has been recorded as a liability has been assumed to be fixed as if the proposed IPO had occurred on
the issuance date of the Series A Preferred for 2017 and January 1, 2018 for 2018, resulting in the reclassification of the warrant
liability to shareholders&rsquo; equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>Use of Estimates </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements
in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported
amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these financial
statements include, but are not limited to, the accrual of research and development expenses and the valuation of common stock,
stock options, warrants and derivative instruments. Estimates are periodically reviewed in light of changes in circumstances,
facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ
from those estimates or assumptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>Segment Information</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company operates the business on the
basis of a single reportable segment, which is the business of developing and commercializing prescription drug products. The
Company&rsquo;s chief operating decision-maker is the Chief Executive Officer, who evaluates the Company as a single operating
segment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Cash and Cash Equivalents</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid
investments with an original maturity of three months or less to be cash equivalents. All cash and cash equivalents are held in
United States financial institutions. Cash equivalents consist of an interest-bearing checking account. From time to time, amounts
deposited exceed federally insured limits. The Company believes the associated credit risk to be minimal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Property and Equipment</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment are stated at cost.
Depreciation of property and equipment is computed utilizing the straight-line method based on the following estimated useful
lives. Computer software and hardware is depreciated over three years. Furniture and fixtures is depreciated over five years.
Leasehold improvements are amortized over their estimated useful lives or the remaining lease term, whichever is shorter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Maintenance and repairs are charged to
expense as incurred, while renewals and improvements are capitalized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Deferred Offering Costs </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company capitalizes certain legal,
professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred
offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in
shareholders&rsquo; equity (deficit) as a reduction of proceeds generated as a result of the offering. Should the planned equity
financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements
of operations. The Company recorded deferred offering costs of $0 and $202 as of December&nbsp;31, 2017 and June 30, 2018 (unaudited),
respectively, which is included in other long-term assets on the accompanying balance sheet.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Impairment of Long-Lived Assets</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Long-lived assets are reviewed for impairment
whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability
of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future
cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows,
an impairment charge is recognized in the Company&rsquo;s statement of operations for the amount by which the carrying amount
of the asset exceeds the fair value of the asset. To date, the Company has not recorded any impairment of its long-lived assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Classification and Accretion of
Redeemable Convertible Preferred Stock</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has classified the Series
A Preferred outside of shareholders&rsquo; equity (deficit) because the shares contain certain redemption features that are not
solely within the control of the Company. The carrying value of the Series A Preferred is accreted to its redemption value from
the date of issuance through the earliest date of redemption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Eton Pharmaceuticals, Inc. <BR>
Notes to Financial Statements&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(in thousands, except share and per
share amounts) </B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Note 3 &mdash; Summary of Significant Accounting Policies
(cont.)</U></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Leases</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Leases are categorized as either operating
or capital leases at inception. Operating lease costs are recognized on a straight-line basis over the term of the lease. An asset
and a corresponding liability for the capital lease obligation are established for the cost of capital leases. The capital lease
obligation is amortized over the life of the lease. The Company has not had any capital leases since its inception.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Patent Costs</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All patent-related costs incurred in connection
with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure.
Amounts incurred are classified as general and administrative expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Significant Suppliers</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is dependent on third-party
vendors for its product candidates. In particular, the Company relies, and expects to continue to rely, on a small number of vendors
to manufacture key chemicals and process its product candidates for its development programs. These programs could be adversely
affected by a significant interruption in the manufacturing process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Research and Development Expenses</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development (&ldquo;R&amp;D&rdquo;)
expenses include both internal R&amp;D activities and external contracted services. Internal R&amp;D activity expenses include
salaries, benefits, and stock-based compensation and other costs to support the Company&rsquo;s R&amp;D operations. External contracted
services include product development efforts including certain product licensor milestone payments, clinical trial activities,
manufacturing and control-related activities and regulatory costs. R&amp;D expenses are charged to operations as incurred. The
Company reviews and accrues R&amp;D expenses based on services performed and relies upon estimates of those costs applicable to
the stage of completion of each project. Significant judgments and estimates are made in determining the accrued balances at the
end of any reporting period. Actual results could differ from the Company&rsquo;s estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upfront payments and milestone payments
made for the licensing of technology are expensed as research and development in the period in which they are incurred. Nonrefundable
advance payments for goods or services to be received in the future for use in research and development activities are recorded
as prepaid expenses and are expensed as the related goods are delivered or the services are performed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>Earnings (Loss) Per Share</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net loss per common share is computed
by dividing net loss attributable to common shareholders for the period by the weighted average number of common shares outstanding
during the period. Diluted net loss per share is computed by dividing the net loss attributable to common shareholders for the
period by the weighted average number of common and common equivalent shares, such as Series A Preferred, stock options and warrants,
outstanding during the period. Common stock equivalents are excluded from the computation where their inclusion would be anti-dilutive.
No such adjustments were made for 2017 or 2018 as the Company reported a net loss for the period ended December 31, 2017 and for
the periods ended June 30, 2017 and 2018 (unaudited) as including the effects of common stock equivalents in the diluted EPS calculation
would have been antidilutive (See Note 10).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Warrant Liability</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company estimates the fair value of
certain warrants at each reporting period using Level 3 inputs. The estimates in valuation models are based, in part, on subjective
assumptions, including but not limited to stock price volatility, the expected life of the warrants, the risk-free interest rate
and the exercise price of the warrants, and could differ materially in the future. Changes in the fair value of the warrant liability
during the period are recorded as a component of other income (expense). The Company will continue to adjust the fair value of
the warrant liability at the end of each reporting period for changes in fair value until the earlier of the exercise or expiration
of the applicable warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Eton Pharmaceuticals, Inc. <BR>
Notes to Financial Statements&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(in thousands, except share and per
share amounts) </B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Note 3 &mdash; Summary of Significant Accounting Policies
(cont.)</U></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Stock-Based Compensation</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for stock-based compensation
under the provisions of the Financial Accounting Standards Board (the &ldquo;FASB&rdquo;) Accounting Standards Codification (&ldquo;ASC&rdquo;)
&mdash; 718 Compensation &mdash; Stock Compensation. The guidance under ASC 718 requires companies to estimate the fair value
of the stock-based compensation awards on the date of grant for employees and directors and record expense over the related service
periods, which are generally the vesting period of the equity awards. Awards for consultants are accounted for under ASC 505-50
&mdash; Equity Based Payments to Non-Employees. Compensation expense is recognized over the period during which services are rendered
by such consultants and non-employees until completed. At the end of each financial reporting period prior to completion of the
service, the fair value of these awards is remeasured using the then-current fair value of the Company&rsquo;s common stock and
updated assumption inputs in the Black-Scholes option-pricing model (&ldquo;BSM&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company estimates the fair value of
stock-based option awards to its employees and directors using the BSM. The BSM requires the input of subjective assumptions,
including the expected stock price volatility, the calculation of expected term, forfeitures and the fair value of the underlying
common stock on the date of grant, among other inputs. The risk-free interest rate was determined from the implied yields for
zero-coupon U.S. government issues with a remaining term approximating the expected life of the options or warrants. Dividends
on common stock are assumed to be zero for the BSM valuation of the stock options. The expected term of stock options granted
is based on vesting periods and the contractual life of the options. Expected volatilities are based on comparable companies&rsquo;
historical volatility, which management believes represents the most accurate basis for estimating expected future volatility
under the current conditions. The Company accounts for forfeitures as they occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Income Taxes</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of the process of preparing the
Company&rsquo;s financial statements, the Company must estimate the actual current tax liabilities and assess temporary differences
resulting from differing treatment of items for tax and accounting purposes. These differences result in deferred tax assets and
liabilities, which are included within the balance sheet. The Company must assess the likelihood that the deferred tax assets
will be recovered from future taxable income and, to the extent the Company believes that recovery is not likely, a valuation
allowance must be established. To the extent the Company establishes a valuation allowance or increase or decrease to this allowance
in a period, the impact will be included in income tax expense in the statement of operations. As of December 31, 2017 and June
30, 2018 (unaudited) the Company had established a 100% valuation reserve against its deferred tax assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes
under the provisions of FASB ASC 740 &mdash; Income Taxes. As of December 31, 2017, there was no unrecognized tax benefits included
in the balance sheet that would, if recognized, affect the effective tax rate. The Company&rsquo;s practice is to recognize interest
and penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties in its
balance sheet at December 31, 2017 or June 30, 2018 (unaudited) and has not recognized interest and penalties in the statements
of operations for the period ended December 31, 2017 or for the six months ended June 30, 2018 (unaudited). As of June 30, 2018
(unaudited), the Company is subject to taxation in the United States and Illinois. The Company&rsquo;s tax losses from 2017 and
2018 (unaudited) are subject to examination by the federal and state tax authorities due to the carryforward of unutilized net
operating losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The recently enacted Tax Cuts and Jobs
Act (the &ldquo;Tax Act&rdquo;) significantly revised U.S. corporate income tax law by, among other things, reducing the corporate
income tax rate to 21% and implementing a modified territorial tax system. In response to the Tax Act, the SEC issued Staff Accounting
Bulletin (&ldquo;SAB&rdquo;) 118 which allows issuers to recognize provisional estimates of the impact of the Tax Act in their
financial statements and adjust in the period in which the estimate becomes finalized, or in circumstances where estimates cannot
be made, to disclose and recognize within a one-year measurement period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Implementation of the Tax Act resulted
in an approximate $733 charge for the revaluation of the Company&rsquo;s net deferred tax assets offset by a corresponding $733
reduction in the valuation reserve for income taxes during the period ended December 31, 2017. No impact of the Tax Act has been
recorded in 2018 (unaudited). In reaching these estimates, the Company utilized all available guidance and notices issued by the
U.S. Department of the Treasury. These amounts are to be considered provisional and are not currently able to be finalized given
the complexity of the underlying calculations. The Company will update and conclude its accounting as additional information is
obtained, which is contingent on the timing of issuance of regulatory guidance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Current accounting standards include guidance
on the accounting for uncertainty in income taxes recognized in the financial statements. Such standards also prescribe a recognition
threshold and measurement model for the financial statement recognition of a tax position taken, or expected to be taken, and
provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.
The Company believes that the ultimate deductibility of all tax positions is highly certain, although there is uncertainty about
the timing of such deductibility. As a result, no liability for uncertain tax positions was recorded as of December 31, 2017 or
June 30, 2018 (unaudited).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Eton Pharmaceuticals, Inc. <BR>
Notes to Financial Statements&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(in thousands, except share and per
share amounts) </B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Note 3 &mdash; Summary of Significant Accounting Policies
(cont.)</U></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Fair Value Measurements</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We measure certain of our assets and liabilities
at fair value. Fair value represents the price that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date. Fair value accounting requires characterization of the inputs
used to measure fair value into a three-level fair value hierarchy as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Level 1 &mdash; </I></B>Inputs based
on quoted prices in active markets for identical assets or liabilities. An active market is a market in which transactions occur
with sufficient frequency and volume to provide pricing information on an ongoing basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Level 2</I></B> &mdash; Observable
inputs that reflect the assumptions market participants would use in pricing the asset or liability developed based on market
data obtained from sources independent from the entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Level 3</I></B> &mdash; Unobservable
inputs that reflect the entity&rsquo;s own assumptions about the assumptions market participants would use in pricing the asset
or liability developed based on the best information available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fair value measurements are classified
based on the lowest level of input that is significant to the measurement. The Company&rsquo;s assessment of the significance
of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities
and their placement within the fair value hierarchy levels. The determination of the fair values stated below takes into account
the market for the Company&rsquo;s financials, assets and liabilities, the associated credit risk and other factors as required.
The Company considers active markets as those in which transactions for the assets or liabilities occur in sufficient frequency
and volume to provide pricing information on an ongoing basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying amounts of cash and cash
equivalents, accounts payable and accrued liabilities approximate their fair values due to the short-term maturities of these
instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair values of the Company&rsquo;s
warrant liability at inception and for subsequent mark-to-market fair value measurements are based on management&rsquo;s valuation
model and expectations with respect to the method and timing of settlement. The Company has determined that the warrant liability
fair values are classified as Level 3 measurements within the fair value hierarchy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Impact of New Accounting Pronouncements</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2017, FASB issued ASU No. 2017-11
&mdash; Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815),
and was issued in two parts, Part I, Accounting for Certain Financial Instruments with Down Round Features and Part II, Replacement
of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily
Redeemable Noncontrolling Interests with a Scope Exception. Part I of ASU No. 2017-11 addresses the classification analysis of
certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain
financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity
classification when assessing whether the instrument is indexed to an entity&rsquo;s own stock. The amendments also clarify existing
disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or
embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence
of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present
earnings per share in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect
is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in Part II
of ASU 2017-11 recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content
in the codification, to a scope exception. Part II amendments do not have an accounting effect. ASU 2017-11 is effective for annual
and interim periods beginning after December 15, 2018, with early adoption permitted. The Company has early adopted this standard
and all instruments with down round provisions are classified within equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2016, the FASB issued ASU 2016-09
&mdash; Compensation - Stock Compensation, which simplifies the accounting for the tax effects related to stock-based compensation,
including adjustments to how excess tax benefits and a company&rsquo;s payments for tax withholdings should be classified, amongst
other items. ASU 2016-09 is effective for financial statements issued for fiscal years beginning after December 15, 2016, and
interim periods within those fiscal years with early adoption permitted. ASU 2016-09 was adopted by the Company for the period
beginning April 27, 2017 and did not have an impact on the results of operations or cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Eton Pharmaceuticals, Inc. <BR>
Notes to Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(in thousands, except share and
per share amounts) </B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Note 3 &mdash; Summary of Significant Accounting Policies
(cont.)</U></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2016, the FASB issued ASU
2016-02 (Topic 842) &ndash; Leases, which requires the lease rights and obligations arising from lease contracts, including existing
and new arrangements, with terms more than 12 months to be recognized as assets and liabilities on the balance sheet. Recognition,
measurement and presentation of expenses will depend on classification as a finance or operating lease. The amendments also require
certain quantitative and qualitative disclosures about leasing arrangements. ASU 2016-02 is effective for reporting periods beginning
after December 15, 2018 with early adoption permitted. While the Company is still evaluating ASU 2016-02, the Company expects
the adoption of ASU 2016-02 will not have a material effect on the Company&rsquo;s financial condition from the recognition of
the lease rights and obligations as assets and liabilities. The Company is currently evaluating ASU 2016-02 to determine the effect
on the Company&rsquo;s results of operations and cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2014, the FASB issued ASU No.&nbsp;2014-09,
Revenue from Contracts with Customers (Topic 606), which supersedes existing revenue recognition guidance under GAAP. The standard&rsquo;s
core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount
that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The standard
defines a five-step process to achieve this principle and will require companies to use more judgment and make more estimates
than under the current guidance. The Company expects that these judgments and estimates will include identifying performance obligations
in the customer contract, estimating the amount of variable consideration to include in the transaction price and allocating the
transaction price to each separate performance obligation. ASU 2014-09 also requires additional disclosure about the nature, amount,
timing and uncertainty of revenue and cash flows arising from customer contracts. In August 2015, the FASB issued ASU 2015-14,
Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delays the effective date of ASU 2014-09
such that the standard is effective for public entities for annual periods beginning after December&nbsp;15, 2017, including interim
periods within those fiscal years. Early adoption of the standard is permitted for annual periods beginning after December&nbsp;15,
2016, including interim periods within those fiscal years. In March 2016, the FASB issued ASU No.&nbsp;2016-08, Revenue from Contracts
with Customers (Topic 606): Principal versus Agent Considerations, which further clarifies the implementation guidance on principal
versus agent considerations in ASU 2014-09. In April 2016, the FASB issued ASU No.&nbsp;2016-10, Revenue from Contracts with Customers
(Topic 606): Identifying Performance Obligations and Licensing, clarifying the implementation guidance on identifying performance
obligations and licensing. Specifically, the amendments in this update reduce the cost and complexity of identifying promised
goods or services and improve the guidance for determining whether promises are separately identifiable. The amendments in this
update also provide implementation guidance on determining whether an entity&rsquo;s promise to grant a license provides a customer
with either a right to use the entity&rsquo;s intellectual property (which is satisfied at a point in time) or a right to access
the entity&rsquo;s intellectual property (which is satisfied over time). In May 2016, the FASB issued ASU No.&nbsp;2016-12, Revenue
from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which clarifies the objective of
the collectability criterion, presentation of taxes collected from customers, non-cash consideration, contract modifications at
transition, completed contracts at transition and how guidance in ASU 2014-09 is retrospectively applied. In December 2016, the
FASB issued ASU No.&nbsp;2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers,
which amends narrow aspects of the guidance in ASU 2014-09. ASU 2016-08, ASU 2016-10, ASU 2016-12 and ASU 2016-20 have the same
effective dates and transition requirements as ASU 2014-09. In September 2017, the FASB issued ASU No. 2017-13,&nbsp;Revenue Recognition
(Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842), which provides additional
clarification and implementation guidance related to ASU&nbsp;2014-09 and has the same effective date and transition requirements
as ASU 2014-09. The adoption of these standards did not have an impact on the Company&rsquo;s financial position, results of operations
or cash flows as the Company does not currently have any revenue-generating arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2018, the FASB issued ASU 2018-07, Compensation &ndash; Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based
Payment Accounting, which simplifies the accounting for nonemployee share-based payment transactions. The amendments specify that
Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed
in a grantor&rsquo;s own operations by issuing share-based payment awards. ASU 2018-07 will be effective for financial statements
issued for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years with early adoption permitted
(but no sooner than the adoption of Topic 606). The Company is currently evaluating ASU 2018-07 to determine the effect on the
Company&rsquo;s financial statements.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Eton Pharmaceuticals, Inc. <BR>
Notes to Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(in thousands, except share and
per share amounts) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Note 4 &mdash; Fair Value of Financial Assets and Liabilities</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents information
about the Company&rsquo;s financial assets and liabilities measured at fair value on a recurring basis and indicates the level
of the fair value hierarchy utilized to determine such fair values (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><B>Fair Value Measurements</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><B>as
    of December 31, 2017 Using:</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Level
    1</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Level
    2</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Level
    3</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Liabilities:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48%; text-align: left; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif">Warrant liability</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">&mdash;</TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">&mdash;</TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">520</TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">520</TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>



<P STYLE="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><B>Fair
    Value Measurements </B><BR> <B>as of June 30, 2018 (unaudited) Using:</B></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Level
    1</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Level
    2</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Level
    3</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Liabilities:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48%; text-align: left; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif">Warrant liability</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">&mdash;</TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">&mdash;</TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">1,016</TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">1,016</TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>



<P STYLE="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the periods ended December&nbsp;31,
2017 and June 30, 2018 (unaudited), there were no transfers between Level 1, Level 2 and Level 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Valuation of Warrant Liability </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrant liability in the table above
is composed of the fair value of a warrant to purchase shares of common stock that were issued to the Company&rsquo;s placement
agent in connection with the Series A Preferred offering (see Note&nbsp;6). The fair value of the warrant liability was determined
based on significant inputs not observable in the market, which represents a Level&nbsp;3 measurement within the fair value hierarchy.
The Company used the BSM, which incorporates assumptions and estimates, to value the warrant. Estimates and assumptions impacting
the fair value measurement include the fair value per share of the underlying shares of common stock, the remaining contractual
term of the warrant, risk-free interest rate, expected dividend yield and expected volatility of the price of the underlying common
stock. The Company determined the fair value per share of the underlying common stock by taking into consideration the most recent
sales of its preferred stock, results obtained from third-party valuations and additional factors that are deemed relevant. The
Company historically has been a private company and lacks company-specific historical and implied volatility information of its
common stock. Therefore, it estimates its expected stock volatility based on the historical volatility of publicly traded peer
companies for a term equal to the remaining contractual term of the warrant. The risk-free interest rate is determined by reference
to the U.S. Treasury yield curve for time periods approximately equal to the remaining contractual term of the warrant. The Company
estimated a 0% expected dividend yield based on the fact that the Company has never paid or declared dividends and does not intend
to do so in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table
provides a roll forward of the aggregate fair values of the Company&rsquo;s warrant liability, for which fair value is determined
using Level 3 inputs:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Period
    From April 27, 2017 (Inception) Through December 31, 2017</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><B>Six</B><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Months</B><BR>
                                         <B>Ended</B><BR>
                                         <B>June 30, 2018</B><BR>
                                         <B>(unaudited)</B></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 70%; font: bold 10pt Times New Roman, Times, Serif">Balance as of the beginning of the period</TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: bold 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: bold 10pt Times New Roman, Times, Serif; text-align: right">520</TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif">Initial fair value of warrant liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">479</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&mdash;</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif">Change in
    fair value</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">41</TD><TD STYLE="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">496</TD><TD STYLE="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance as of the end of the period</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">520</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,016</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 258.75pt"></P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Eton Pharmaceuticals, Inc. <BR>
Notes to Financial Statements<BR>
<B>(in thousands, except share and per share amounts)</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B><U>Note
5 &mdash; Property and Equipment</U></B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Property and equipment consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>December
                                         31, </B><BR>
                                         <B>2017</B>&nbsp;</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">June
    30, <BR>
    2018 <BR>
    (unaudited)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 70%; text-align: left; font: 10pt Times New Roman, Times, Serif">Computer hardware and software</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</TD><TD STYLE="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">46</TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</TD><TD STYLE="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">51</TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">Furniture and fixtures</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">42</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">66</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">Equipment</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&mdash;</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">80</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">Leasehold improvements</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">42</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">42</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">Construction in progress</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">23</TD><TD STYLE="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">130</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">262</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">Less: accumulated depreciation</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(11</TD><TD STYLE="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(29</TD><TD STYLE="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Property and equipment,
    net</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">119</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">233</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expense for the period ended
December 31, 2017 and for the periods ended June 30, 2017 and 2018 (unaudited) was $11, $0 and $18, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Note 6 &mdash; Redeemable Convertible
Preferred Stock &mdash; Series A</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has 10,000,000 authorized
shares of $0.001 par value preferred stock as per its Certificate of Incorporation. In June 2017, the Company issued 6,685,082
Series A Preferred at a price of $3.00 per share and all shares remain outstanding as of December 31, 2017. The gross proceeds
were $20,055 from the Series A Preferred stock offering. The Series A Preferred have the same voting rights as the Company&rsquo;s
common shares and bear a cumulative non-compounding dividend at a rate of 6.00% per annum on the original $3.00 per share issue
price. The Series A Preferred shareholders or their permitted transferees, are entitled to rights with respect to the registration
under the Securities Act of their shares that are converted to common stock, including demand registration rights and piggyback
registration rights. These rights are provided under the terms of a registration rights agreement between the Company and the
investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that an IPO is not completed
or alternative financing is not raised by December 31, 2018, the Company would be obligated to redeem the Series A Preferred,
in cash, subject to extension upon the consent of the holders of a majority of the outstanding Series A Preferred. Upon any liquidation,
dissolution, or winding-up of the Company, the holders of shares of Series A Preferred are entitled to receive a preferential
distribution out of the assets available for distribution, including any accrued and unpaid dividends, before any distribution
is made to shareholders of the Company&rsquo;s common stock. The Series A Preferred shareholders do not participate in sharing
earnings or losses of the Company. As of December 31, 2017, the liquidation value of the mezzanine Series A Preferred was $20,698
which consists of the issuance amount of $20,055 plus accrued dividends of $643. As of June 30, 2018 (unaudited), the liquidation
value of the mezzanine Series A Preferred was $21,298 which consists of the issuance amount of $20,055 plus accrued dividends
of $1,243.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series A Preferred will automatically
convert to common shares if the Company raises additional equity capital financing via an IPO or possible alternate financings
that are approved by a majority of the Series A Preferred shareholders. The conversion share calculation is based on the $3.00
initial issue price for the Series A Preferred plus any accrued but unpaid dividends and will automatically convert into shares
of the Company&rsquo;s common stock using a stated divisor conversion price equal to 50% of the IPO price to the public, or 50%
of the share price for the approved alternate financing, as applicable, provided that the divisor conversion price shall not be
less than $2.25 per share or greater than $3.00 per share. In addition, the Series A Preferred plus any accrued and unpaid dividends
are also convertible into shares of Company&rsquo;s common stock at the option of the preferred shareholders at a divisor conversion
rate of $3.00 per share at any point up until ten days prior to a capital financing transaction by the Company. In accordance
with relevant accounting literature, since the terms of the conversion option do not permit the Company to compute the additional
number of shares that it would need to issue upon conversion of the Series A Preferred if the contingent event occurs, the Company
will record the beneficial conversion amount as a deemed dividend only if the contingent event occurs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the Series A Preferred
having a possible cash redemption feature in the event that an IPO or alternate financing is not available by December 31, 2018,
the Series A Preferred is classified as temporary equity and not included as part of Company&rsquo;s shareholders&rsquo; equity
(deficit). In accordance with that classification, the $2,534 of issuance costs associated with the Series A Preferred offering
are being ratably accreted as a deemed dividend using the effective interest method over its expected term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 258.75pt"></P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Eton Pharmaceuticals, Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(in thousands, except share and
per share amounts) </B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Note 6 &mdash; Redeemable Convertible
Preferred Stock &mdash; Series A (cont.)</U></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a reconciliation of the
carrying value of the Series A Preferred:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>December
                                         31, </B><BR>
                                         <B>2017</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>June
                                         30,</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2018
                                         </B><BR>
                                         <B>(unaudited)</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 70%; text-align: left; font: 10pt Times New Roman, Times, Serif">Gross proceeds from Series A Preferred
    offering</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</TD><TD STYLE="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">20,055</TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</TD><TD STYLE="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">20,055</TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">Issuance costs - cash</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">(2,055</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">(2,055</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">Issuance costs &ndash; common stock warrants</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">(479</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">(479</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">Accrued dividends on Series A Preferred</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">643</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">1,243</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">Deemed dividends for accretion
    of Series A Preferred issuance costs</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">840</TD><TD STYLE="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,668</TD><TD STYLE="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance as of the end of the period</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">19,004</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">20,432</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Note 7 &mdash; Common Stock</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has 50,000,000 authorized
shares of $0.001 par value common stock as per its Certificate of Incorporation. In May 2017, the Company issued 3,500,000 shares
of its common stock to Imprimis, 1,500,000 shares of restricted stock to certain executives of Imprimis and 1,000,000 shares of
restricted stock to the Chief Executive Officer of the Company. On January 1, 2018 (unaudited), the Company issued 54,745 restricted
shares of its common stock to each of its four outside directors (218,980 total shares) as part of their compensation for board
service to the Company in 2018. The restricted shares for the Imprimis executives vest over a 12-month period, the restricted
shares to the Company&rsquo;s Chief Executive Officer vest over a 24-month period and the restricted shares to the outside directors
vest 25% at each quarter-end in 2018 and are 100% vested as of December 31, 2018. The Company accounted for the restricted stock
awards in accordance with ASC 718 or ASC 505-50 and for the period April 27, 2017 (inception) through December 31, 2017 and for
the periods ended June 30, 2017 and 2018 (unaudited) the Company recorded $1,403, $352 and $1,159, respectively, in stock-based
compensation expense for these restricted stock awards (see Note 9).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Note 8 &mdash; Common Stock Warrants</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2017, the Company issued a warrant
to purchase 600,000 shares of its common stock to consultants for business strategy and intellectual property advisory services.
The warrant vested at issuance in May 2017 and has a $0.01 exercise price per warrant share and expires five years from the date
of issuance. The Company used the BSM to value the warrant and the fair value at the date of issuance was $121 based on an expected
term of five years, volatility of 85%, a risk-free interest rate of 1.8% and a 0% rate on expected dividends. The $121 amount
for the consulting warrants was expensed as a component of the Company&rsquo;s general and administrative expenses for the period
ended December 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In conjunction with the closing of the
Series A Preferred offering in June 2017 (See Note 6), the Company issued a warrant to purchase 649,409 shares of its common stock
to the placement agent at an exercise price of $3.00 per share, provided, however, upon the conversion of the Series A Preferred
the warrant shall adjust to entitle the holder to purchase shares of common stock equal to 10% of the shares of common stock issuable
upon conversion of the Series A Preferred and the exercise price shall adjust to the conversion price of the Series A Preferred.
This warrant vested at issuance in June 2017. The Company used the BSM to value the warrant and the fair value at the date of
issuance was $479. The number of common shares issuable upon the conversion of this warrant is not fixed as it can vary by a factor
of 1.000 to 1.333 common shares per warrant share in accordance with the IPO price, and the Company has therefore considered the
warrant to be a derivative instrument. The $479 amount was recorded as a component of the issuance costs for the Series A Preferred.
As of December 31, 2017, the fair value of the warrants was $520 and the $41 increase in value was recorded as a component of
other income and expense. As of June 30, 2018 (unaudited), the fair value of the warrants was $1,016 and the $496 increase in
value was recorded as a component of other income and expense. The fair value assumptions included an expected term of five years,
expected volatility of 85%, a risk-free interest rate of 1.9% and estimate of the conversion rate. These warrants are classified
as warrant liability on the Company&rsquo;s balance sheets. The weighted average exercise price of the outstanding warrants as
of both December 31, 2017 and June 30, 2018 (unaudited) was $1.56 per share.</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The holders of these warrants or their
permitted transferees, are entitled with rights with respect to the registration under the Securities Act of their shares that
are converted to common stock, including demand registration rights and piggyback registration rights. These rights are provided
under the terms of a registration rights agreement between the Company and the investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Eton Pharmaceuticals, Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(in thousands, except share and
per share amounts) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Note 9 &mdash; Share-Based Payment
Awards</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s Board of Directors
approved the Eton Pharmaceuticals, Inc. 2017 Equity Incentive Plan in May 2017 (the &ldquo;Plan&rdquo;) which authorizes the issuance
of up to 5,000,000 shares of its common stock. The Company has granted under the Plan restricted stock awards, stock options and
restricted stock units for its common stock as detailed in the tables below. The number of shares available for future issuance
under the Plan as of December 31, 2017 and June 30, 2018 (unaudited) was 1,310,000 and 1,081,020, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shares that are expired, terminated, surrendered
or canceled without having been fully exercised will be available for future awards under the Plan. The exercise price for stock
options granted is not less than the fair value of common shares as determined by the board of directors as of the date of grant.
The Company&rsquo;s board of directors values the Company&rsquo;s common stock, taking into consideration its most recently available
valuation of common stock performed by third parties as well as additional factors which may have changed since the date of the
most recent contemporaneous valuation through the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2017, the Company issued 1,500,000
shares of restricted stock to certain executives of Imprimis and 1,000,000 shares of restricted stock to the Chief Executive Officer
of the Company. On January 1, 2018 (unaudited), the Company issued 54,745 restricted shares of its common stock to each of its
four outside directors (218,980 total shares). The restricted shares for the Imprimis executives vest over a 12-month period,
the restricted shares to the Company&rsquo;s Chief Executive Officer vest over a 24-month period and the restricted shares to
the outside directors vest 25% at each quarter-end in 2018 and are 100% vested at December 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, all stock options issued have
been non-qualified stock options (&ldquo;NQSO&rsquo;s&rdquo;) and the exercise prices were set at the fair value for the shares
at the dates of grant. Options typically have a ten-year life except for 50,000 of options awards to product consultants that
expire within five years if the Company is not able to file certain product submissions to the FDA prior to the five-year expiration
period. Furthermore, these option awards to the product consultants do not vest unless certain product submissions are made to
the FDA, and accordingly, the Company has not recorded any expense for these contingently vesting option awards to the product
consultants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the period ended December 31, 2017,
the Company&rsquo;s total stock-based compensation expense was $1,761. Of this amount, $1,735 was recorded in general and administrative
expenses and $26 was recorded in research and development expenses. For the periods ended June 30, 2017 and 2018 (unaudited),
the Company&rsquo;s total stock-based compensation expense was $501 and $1,466, respectively. Of these amounts, $501 and $1,434
was recorded in general and administrative expenses and $0 and $32 was recorded in research and development expenses, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of stock option activity is
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted <BR> Average
    Exercise<BR> Price <BR> Per Share</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted <BR> Average
    <BR> Remaining <BR> Contractual <BR> Term (years)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Aggregate <BR> Intrinsic
    <BR> Value</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Balance at April 27, 2017 (Inception)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%">Issued</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1,090,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1.24</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Forfeited/Cancelled</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Options outstanding as of December 31, 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,090,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.24</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.7</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">151</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Issued</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.56</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Forfeited/Cancelled</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Options outstanding as of June 30, 2018 (unaudited)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,100,000</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1.24</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">9.2</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">1,023</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Options exercisable at December 31, 2017</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Options vested and expected to vest at December 31, 2017</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,040,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.23</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.7</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">151</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Options exercisable at June 30, 2018 (unaudited)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">130,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.21</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.8</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">255</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in">Options vested and expected
    to vest at June 30, 2018 (unaudited)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,050,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.23</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.2</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">984</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate intrinsic value of stock
options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&rsquo;s
common stock for those stock options that had strike prices lower than the fair value of the Company&rsquo;s common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Eton Pharmaceuticals, Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Financial Statements<BR>
<B>(in thousands, except share and per share amounts) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><U>Note 9 &mdash; Share-Based Payment
Awards (cont.)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The assumptions used to calculate the fair value of options
granted during the periods ended December 31, 2017 and June 30, 2018 under the BSM were as follows:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: justify"><B>&nbsp;</B></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><B>December 31, </B><BR>
    <B>2017</B></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><B>June 30,</B><BR>
    <B>2018</B></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Expected dividends</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: justify">Expected volatility</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">85</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">85</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Risk-free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.7%
                                         &ndash; 2.3 %</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.8</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Expected term</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8
                                         - 10 years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.3 years</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Weighted average fair value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.91</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.15</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Expected Term &mdash; The Company has
opted to use the &ldquo;simplified method&rdquo; for estimating the expected term of options granted to employees and directors,
whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option (generally
10 years). The expected term of options granted to non-employees equals the contractual life of the options.</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Expected Volatility &mdash; Due to the
Company&rsquo;s limited operating history and a lack of Company specific historical and implied volatility data, the Company has
based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded.
The historical volatility data was computed using the daily closing prices for the selected companies&rsquo; shares during the
equivalent period of the calculated expected term of the stock-based awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Risk-Free Interest Rate &mdash; The risk-free
rate assumption is based on the U.S. Treasury instruments with maturities similar to the expected term of the Company&rsquo;s
stock options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Expected Dividend &mdash; The Company
has not issued any dividends in its history and does not expect to issue dividends over the life of the options and therefore
has estimated the dividend yield to be zero.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fair value of Common Stock &mdash; The
fair value of the shares of common stock underlying the stock-based awards was determined by the board of directors, with input
from management. Because there has been no public market for the Company&rsquo;s common stock, the board of directors has determined
the fair value of the common stock on the grant-date of the stock-based award by considering a number of objective and subjective
factors, including enterprise valuations of the Company&rsquo;s common stock performed by an unrelated third-party specialist,
valuations of comparable companies, sales of the Company&rsquo;s convertible preferred stock to unrelated third parties, operating
and financial performance, the lack of liquidity of the Company&rsquo;s capital stock, and general and industry-specific economic
outlook. The board of directors intended all options granted to be exercisable at a price per share not less than the estimated
per share fair value of common stock underlying those options on the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A summary of activity for restricted stock awards and restricted
stock units is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; border-bottom: Black 1pt solid">Restricted
    Stock Awards (&ldquo;RSA&rsquo;s&rdquo;)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">RSA
    Shares</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">As of April 27, 2017 (Inception)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 47%; text-align: justify; font: 10pt Times New Roman, Times, Serif">Issued</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">2,500,000</TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">Vested</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&mdash;</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">Forfeited/Cancelled</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">Unvested as of December 31, 2017</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">2,500,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">Issued</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">218,980</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">Vested</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">(1,921,990</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">Forfeited/Cancelled</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><B>Unvested as of June 30, 2018 (unaudited)</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><B>&nbsp;</B></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><B>796,990</B></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The weighted average grant date fair value of the restricted
stock awards issued was $0.21 and $1.37 during the period ended December 31, 2017 and the six months ended June 30, 2018 (unaudited),
respectively. The fair value of the restricted stock awards vested during the periods ended December 31, 2017 and June 30, 2018
(unaudited) was $0 and $2,556, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 256.5pt"></P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Eton Pharmaceuticals, Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(in thousands, except share and
per share amounts) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><U>Note 9 &mdash; Share-Based Payment
Awards (cont.)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; border-bottom: Black 1pt solid">Restricted
    Stock Units (&ldquo;RSU&rsquo;s&rdquo;)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">RSU
    Shares</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">As of April 27, 2017 (Inception)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&mdash;</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 47%; text-align: justify; font: 10pt Times New Roman, Times, Serif">Issued</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">100,000</TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">Vested</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">(50,000</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">Forfeited/Cancelled</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">Unvested as of December 31, 2017</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><B>50,000</B></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">Issued</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&mdash;</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">Vested</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">(50,000</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">Forfeited/Cancelled</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">Unvested as of June 30, 2018 (unaudited)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><B>&mdash;</B></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The weighted average grant date fair value of the restricted
stock units issued during the period ended December 31, 2017 was $1.38. The fair value of the restricted stock units vested during
the periods ended December 31, 2017 and June 30, 2018 (unaudited) was $69 and $69, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December&nbsp;31, 2017, there was
a total of $926, $862 and $88 of unrecognized compensation costs related to non-vested stock option awards, restricted stock awards
and restricted stock units, respectively. As of June 30, 2018 (unaudited), there was a total of $706, $288 and $0 of unrecognized
compensation costs related to non-vested stock option awards, restricted stock awards and restricted stock units, respectively.
There were no exercises of stock options during the periods ended December 31, 2017 and June 30, 2018 (unaudited).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Note 10 &mdash; Basic and Diluted Net Loss per Common
Share and Unaudited Pro Forma Net Loss per Common Share</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic and diluted net loss per share is
computed using the weighted average number of shares of common stock outstanding during the period. Common stock equivalents (using
the treasury stock and &ldquo;if converted&rdquo; method) from stock options, unvested RSAs and RSUs, warrants and convertible
preferred stock at December 31, 2017 and June 30, 2018 (unaudited) were 6,977,547 and 9,164,685, respectively, and are excluded
from the calculation of diluted net loss per share because the effect is anti-dilutive. Included in the basic and diluted net
loss per share calculation were RSUs awarded to directors that had vested, but the issuance and delivery of the shares are deferred
until the director retires from service as a director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table shows the computation
of basic and diluted net loss per common share:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Period
    From<BR>
    April 27, 2017 <BR>
    (Inception)<BR>
    Through <BR>
    December 31, <BR>
    2017</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Six
                                         Months</B><BR>
                                         <B>Ended June 30,</B></P>
                                                                                                                         <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2018</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(unaudited)</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 74%; text-align: justify; font: 10pt Times New Roman, Times, Serif">Net loss</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">(7,156</TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">)</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">(6,100</TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">Series A Preferred &ndash;
    dividends (accrued and deemed)</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,483</TD><TD STYLE="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,428</TD><TD STYLE="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
    loss attributable to common shareholders</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(8,639</TD><TD STYLE="padding-bottom: 2pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(7,528</TD><TD STYLE="padding-bottom: 2pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;Weighted
    average common shares outstanding (basic and diluted)</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,453,213</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,171,775</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">&nbsp;&nbsp;&nbsp;&nbsp;Net
    loss per common share (basic and diluted)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(2.50</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(1.80</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 256.5pt"></P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Eton Pharmaceuticals, Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Financial Statements<BR>
<B>(in thousands, except share and per share amounts) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><U>Note 10 &mdash; Basic and Diluted Net
Loss per Common Share and Unaudited Pro Forma Net Loss per Common Share (cont.)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>Unaudited Pro Forma Net Loss per Share Attributable to
Common Shareholders </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited pro forma basic and diluted
net loss per share attributable to common shareholders for the period ended December&nbsp;31, 2017 and the six months ended June
30, 2018 have been prepared to give effect to adjustments arising upon the closing of a qualified IPO. The unaudited pro forma
net loss attributable to common shareholders used in the calculation of unaudited pro forma basic and diluted net loss per share
attributable to common shareholders does not include the effects of the accretion of Series A Preferred to redemption value or
the change in fair value of the warrant liability because the calculation gives effect to the automatic conversion of shares of
Series A Preferred outstanding as of June &nbsp;30, 2018 into the Company&rsquo;s common stock as if the proposed IPO had occurred
on the issuance date of the Series A Preferred for 2017 and January 1, 2018 for 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited pro forma basic and diluted
weighted average common shares outstanding used in the calculation of unaudited pro forma basic and diluted net loss per share
attributable to common shareholders for the period ended December&nbsp;31, 2017 and the six months ended June&nbsp;30, 2018 have
been prepared to give effect, upon a qualified IPO, to the automatic conversion of all outstanding shares of Series A Preferred
into shares of the Company&rsquo;s common stock as if the proposed IPO had occurred on the issuance date of the Series A Preferred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unaudited pro forma basic and diluted
net loss per share attributable to common shareholders was calculated as follows (in thousands, except share and per share amounts):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Period
    From<BR> April 27, 2017<BR> (Inception) <BR> Through <BR> December 31, 2017 <B>(unaudited)</B></TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><B>Six</B><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Months
                                         </B><BR>
                                         <B>Ended </B><BR>
                                         <B>June 30,</B><BR>
                                         <B>2018</B><BR>
                                         <B>(unaudited)</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt">Numerator</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 74%; text-align: justify; padding-bottom: 1pt; padding-left: 20pt; font: 10pt Times New Roman, Times, Serif">Net
    loss attributable to common shareholders</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">(8,639</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">(7,528</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 20pt">Accretion of Series A Preferred
    to redemption value</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">1,483</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">1,428</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; padding-left: 20pt; font: 10pt Times New Roman, Times, Serif">Change
    in fair value of warrant liability</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">41</TD><TD STYLE="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">496</TD><TD STYLE="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; padding-left: 20pt; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">Pro forma
    net loss attributable to common shareholders</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif">(7,115</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">)</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif">(5,604</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 10pt">Denominator</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; padding-left: 20pt; font: 10pt Times New Roman, Times, Serif">Weighted
    average common shares outstanding (basic and diluted)</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">3,453,213</TD><TD STYLE="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">4,171,775</TD><TD STYLE="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; padding-left: 20pt; font: 10pt Times New Roman, Times, Serif">Pro forma
    adjustment to reflect assumed automatic conversion of Series A Preferred into common stock upon the closing of the proposed
    initial public offering</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">5,225,867</TD><TD STYLE="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">6,899,371</TD><TD STYLE="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; padding-left: 20pt; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">Pro forma
    weighted average common shares outstanding &ndash; basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif">8,679,080</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif">11,071,146</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; padding-left: 20pt; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">Pro forma
    net loss per share attributable to common stockholders &ndash; basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif">(0.82</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">)</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif">(0.51</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Note 11 &mdash; Related Party Transactions</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>Imprimis</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Imprimis was issued 3,500,000 shares of
the Company&rsquo;s common stock at the formation of the Company at the $0.001 par value per share price as the paid-in-capital
contribution from Imprimis. The Company and Imprimis have signed licensing agreements for two products developed by Imprimis whereby
Imprimis has assigned the product rights to the Company. The Company will pay Imprimis a $50 milestone payment upon patent approval
for each product and a royalty fee at a rate of six percent on the net sales of those two products. On December 26, 2017, one
of the products had its patent approved and a $50 milestone fee was recognized as R&amp;D expense by the Company in 2017 and paid
to Imprimis in January 2018 (unaudited).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of the early start-up for the
Company&rsquo;s pharmaceutical business, key executives at Imprimis received 1,500,000 shares of restricted common stock in the
Company for consulting services and certain Imprimis managers also received 130,000 common stock options from the Company. The
restricted stock and stock options vest 100% after one year on April 30, 2018. The Company recorded stock-based compensation expense
of $1,370 and $112 for the Imprimis restricted common stock and stock options, respectively, for the period ended December 31,
2017 as a component of its general and administrative expenses. The Company recorded stock-based compensation expense of $345
and $970 for the Imprimis restricted common stock and $28 and $80 for Imprimis stock options, respectively, for the periods ended
June 30, 2017 and 2018 (unaudited) as a component of its general and administrative expenses.</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Eton Pharmaceuticals, Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(in thousands, except share and
per share amounts) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><U>Note 11 &mdash; Related Party Transactions
(cont.)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of the early start-up for the
Company&rsquo;s business operations, Imprimis provided ongoing financial and administrative services under a Management Services
Agreement (&ldquo;MSA&rdquo;) at the rate of $10 per month. Notice was given in late August 2017 to terminate that MSA and the
services were terminated as of September 30, 2017. For the period May through September 2017, the Company paid Imprimis $50 for
the MSA- related services which was reflected as a component of the Company&rsquo;s general and administrative expenses in 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, the President and Chief
Executive Officer of Imprimis is a member of the Company&rsquo;s board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Chief Executive Officer</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s Chief Executive Officer
(&ldquo;CEO&rdquo;) has a partial interest in several companies that the Company is working on for product development and potential
marketing if the products are approved by the FDA:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company acquired the exclusive rights
to sell the EM-100 product in the U.S. pursuant to a Sales and Marketing Agreement dated August 11, 2017 between the Company and
Eyemax LLC, an entity affiliated with our Chief Executive Officer. The Company also holds a right of first refusal to obtain the
exclusive license rights for geographic areas outside of the U.S. Pursuant to the agreement, the Company is responsible for all
costs of testing and FDA approval of the product, other than the FDA filing fee which will be paid by the licensor. The Company
is also responsible for commercializing the product in the U.S. at its expense. The Company paid the licensor $250 upon execution
of the agreement which was recorded as a component of research and development expense and will pay the licensor $250 upon FDA
approval and $500 upon the first commercial sale of the product. The Company will also pay the licensor a royalty of 10% on the
net sales of all products. The license agreement is for an initial term of ten years from the date of the agreement, subject to
successive two-year renewals unless the Company elect to terminate the agreement. There were no amounts due under the terms of
this agreement as of December 31, 2017 or June 30, 2018 (unaudited).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company acquired the exclusive rights
to sell the DS-100 product in the U.S. pursuant to an Exclusive Development and Supply Agreement dated July 9, 2017 between the
Company and Andersen Pharma, LLC, an entity affiliated with our Chief Executive Officer. The Company also holds an option to purchase
the DS-100 product and all related intellectual property and government approvals at a price of one dollar. Pursuant to the agreement,
the licensor is responsible for obtaining FDA approval at its expense and manufacturing the product for sale to the Company at
its cost. The Company is responsible for commercializing the product in the U.S. at its expense. The Company paid the licensor
$750 upon execution of the agreement which was recorded as a component of research and development expense and will pay the licensor
$750 upon successful completion of a registration batch of product, $750 upon submission of an NDA and $750 upon FDA approval.
The Company will also pay the licensor 50% of the net profit from the sale of the product. The license agreement is for an initial
term of five years from the first commercial sale of the product, subject to successive two-year renewals unless either party
elects to terminate the agreement. There were no amounts due under the terms of this agreement as of December 31, 2017 or June
30, 2018 (unaudited). The aforementioned option to purchase the product and all related intellectual property and government approvals
was considered to represent variable interest in the affiliated entity. The affiliated entity was not considered to be a variable
interest entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company acquired the DS-200 product
and all related intellectual property and government approvals pursuant to an Asset Purchase Agreement dated June 23, 2017 between
the Company and Selenix LLC, an entity affiliated with our Chief Executive Officer. Pursuant to the agreement, the Company paid
the seller $1,500 which was recorded as a component of research and development expense and have agreed to pay $1,500 upon submission
of the NDA and $1,000 upon FDA approval. The Company has also agreed to pay the seller 50% of the net profit from the sale of
the product for the first ten years following the date of the agreement. There were no amounts due under the terms of this agreement
as of December 31, 2017 or June 30, 2018 (unaudited).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s CEO owns 23,000 shares
of the Company&rsquo;s Series A Preferred through a family limited partnership as of December 31, 2017 and June 30, 2018 (unaudited).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 256.5pt"></P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Eton Pharmaceuticals, Inc. <BR>
Notes to Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(in thousands, except share and
per share amounts) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Note 12 &mdash; Income Taxes</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred income taxes reflect the net
tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and
the amounts used for income tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The significant components of the Company&rsquo;s deferred
tax assets as of December 31, 2017 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 37%; text-align: left; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Net operating losses</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">1,610</TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Stock-based expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">102</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Accruals
    and other</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">64</TD><TD STYLE="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Total deferred tax assets</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,776</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Valuation
    allowance</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,776</TD><TD STYLE="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">&nbsp;&nbsp;&nbsp;Net
    deferred tax assets</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on the uncertainty of future taxable income at this time
management believes a 100% valuation reserve for the $1,776 deferred tax asset is appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A reconciliation of the statutory federal tax rate to effective
tax rate is shown below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 37%; text-align: left; font: 10pt Times New Roman, Times, Serif">Benefit at statutory rate</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">(34.0</TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">Permanent items (primarily stock compensation)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">4.2</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">State tax benefit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">(5.5</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">Federal rate change</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">10.2</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">Other items</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">0.2</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">Establishment of valuation allowance</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">24.9</TD><TD STYLE="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Income
    tax expense</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><B>&mdash;</B></TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has a federal and state NOL
carryforward of $5,648 as of December 31, 2017 which will expire in 2037 and 2039, respectively. The recently enacted Tax Act
significantly revised U.S. corporate income tax law by, among other things, reducing the corporate income tax rate from 34% to
21% and implementing a modified territorial tax system. In response to the Tax Act, the SEC issued SAB 118 which allows issuers
to recognize provisional estimates of the impact of the Tax Act in their financial statements and adjust in the period in which
the estimate becomes finalized, or in circumstances where estimates cannot be made, to disclose and recognize within a one-year
measurement period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Implementation of the Tax Act resulted
in an approximate $733 charge for the revaluation of the Company&rsquo;s net deferred tax assets offset by a corresponding $733
reduction in the valuation reserve for income taxes during the period ended December 31, 2017. In reaching these estimates, the
Company utilized all available guidance and notices issued by the U.S. Department of the Treasury. These amounts are to be considered
provisional and are not currently able to be finalized given the complexity of the underlying calculations. The Company will update
and conclude its accounting as additional information is obtained, which is contingent on the timing of issuance of regulatory
guidance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Note 13 &mdash; Employee Savings Plan</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company established an employee savings
plan pursuant to Section 401(k) of the Internal Revenue Code, effective January 1, 2018. The plan allows participating employees
to deposit into tax deferred investment accounts up to 100% of their salary, subject to annual limits. The Company makes certain
matching contributions to the plan in amounts up to 4% of the participants&rsquo; annual cash compensation, subject to annual
limits. There were no Company contributions for the period ended December 31, 2017. Company contributions for the six months ended
June 30, 2018 (unaudited) were $37.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 256.5pt"></P>

<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 256.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 256.5pt"></P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Eton Pharmaceuticals, Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(in thousands, except share and
per share amounts) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Note 14 &mdash; Commitments and
Contingencies</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Legal</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is subject to legal proceedings
and claims that may arise in the ordinary course of business. The Company is not aware of any pending or threatened litigation
matters at this time that may have a material impact on the operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal"><I><U>Leases</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 12, 2018 (unaudited), the Company
signed an amended lease agreement to lease additional office space adjacent to its current corporate office space in Deer Park,
Illinois. The amended lease runs through the end of March 2021 with $248 in total lease payments for the 2018-2021 period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 7, 2018 (unaudited), the Company
entered into a lease for laboratory space at a complex in Lake Zurich, Illinois. The lease commences on March 7, 2018 and runs
through the end of February 2021 with $166 in total lease payments for the 2018-2021 period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal"><I><U>License and product
development agreements</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has entered into various agreements
in addition to those discussed above which are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company entered into a contract for
development and production of its CT-100 product with an unaffiliated third party on November 7, 2017. Pursuant to the agreement,
the third party is responsible for development and production of the product and for obtaining FDA approval and the Company is
responsible for commercializing the product in the United States. The Company will pay the third party 30% of the net profits
from the sale of the product. The initial term is for the first ten years following the first commercial sale of the product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company acquired the exclusive rights
to sell the DS-300 product in the U.S. pursuant to a Sales and Marketing Agreement dated November 17, 2017 with an unaffiliated
third party. Pursuant to the agreement, the licensor is responsible for obtaining FDA approval, at its expense, and the Company
is responsible for commercializing the product in the U.S. at its expense. The Company will pay the third party 50% of the net
profit from the sale of the product. The initial term is for the first ten years following the first commercial sale of the product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company entered into a contract with
a clinical research organization (&ldquo;CRO&rdquo;) for clinical studies on its EM-100 product candidate and those studies are
anticipated to be completed in 2018. The Company will pay milestones at each phase of completion and may provide a notice of termination
at any point during the clinical study project. There were no milestones paid under this agreement in 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has entered into a contract
for technical validation and engineering/registration batches for its DS-300 product which are projected to be completed in 2018.
The Company may provide a notice of termination at any point during the project. There were no payments under this agreement in
2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has entered into a contract
for technical transfer, batch testing and stability studies for its DS-200 product projected to be completed in 2018. The Company
may provide a notice of termination at any point during the project. There were no payments under this agreement in 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal"><I><U>Indemnifications </U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As permitted under Delaware law and in
accordance with the Company&rsquo;s bylaws, the Company is required to indemnify its officers and directors for certain events
or occurrences while the officer or director is or was serving in such capacity. The Company is also party to indemnification
agreements with its directors and officers. The Company believes the fair value of the indemnification rights and agreements is
minimal. Accordingly, the Company has not recorded any liabilities for these indemnification rights and agreements as of December&nbsp;31,
2017 or June 30, 2018 (unaudited).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Note 15 &mdash; Subsequent Events</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the financial statements as of December
31, 2017 and for the period then ended, the Company evaluated subsequent events through May 18, 2018, which was the date the financial
statements were issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 1, 2018, the Company awarded
54,745 shares of restricted stock to each of its four outside Board of Director members for a total of 218,980 restricted stock
shares. These shares vest 25% at each quarter-end in 2018 and are 100% vested by December 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 12, 2018, the Company signed
an amended lease agreement to lease additional office space adjacent to its current corporate office space in Deer Park, Illinois.
The new lease commences on April 1, 2018 and runs through the end of March 2021 with $248 in total lease payments over the three-year
period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 7, 2018, the Company entered
into a lease for laboratory space at a complex in Lake Zurich, Illinois. The lease commences on March 7, 2018 and runs through
the end of February 2021 with $166 in total lease payments over the three-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Eton Pharmaceuticals, Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(in thousands, except share and
per share amounts) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Note 16 &mdash; Subsequent Events
(Unaudited)</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For its interim financial statements as
of June 30, 2018 and for the six months then ended, the Company evaluated subsequent events through September 25, 2018, the date
on which those financial statements were issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>







<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">3,000,000 Shares of Common Stock</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Eton Pharmaceuticals, Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PROSPECTUS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>National Securities
Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Through and including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2018 (the 25th day after the date of this prospectus), all dealers effecting transactions in these securities, whether or not
participating in this offering, may be required to deliver a prospectus. This is in addition to a dealer&rsquo;s obligation to
deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 98 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">PART
II</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">INFORMATION
NOT REQUIRED IN PROSPECTUS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">ITEM 13. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
sets forth the various expenses to be incurred in connection with the sale and distribution of our common stock being registered
hereby, all of which will be borne by us (except any underwriting discounts and commissions and expenses incurred for brokerage,
accounting, tax or legal services or any other expenses incurred in disposing of the shares). All amounts shown are estimates
except the SEC registration fee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 85%; text-align: left; font: 10pt Times New Roman, Times, Serif"> SEC Filing Fee </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"> $ </TD><TD STYLE="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"> 2,899.30 </TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"> FINRA Fee </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"> 3,993.14 </TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"> Underwriter&rsquo;s Legal Fees and Expenses. </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"> 200,000.00 </TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"> Nasdaq Fee </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"> $ </TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"> 125,000.00 </TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"> Printing Expenses </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"> 7,000.00 </TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"> Accounting Fees and Expenses </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"> 50,000.00 </TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"> Legal Fees and Expenses </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"> $ </TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"> 285,000.00 </TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"> Transfer Agent and Registrar Expenses </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"> 10,000.00 </TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> Miscellaneous </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"> 36,107.56 </TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> Total </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"> $ </TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"> 720,000.00 </TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">ITEM 14. INDEMNIFICATION OF DIRECTORS AND OFFICERS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following summary
is qualified in its entirety by reference to the complete text of any statutes referred to below and our amended and restated
certificate of incorporation and amended and restated bylaws which will become effective upon the close of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 145 of the
General Corporation Law of the State of Delaware (the &ldquo;DGCL&rdquo;) permits a Delaware corporation to indemnify any person
who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding,
whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason
of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request
of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other
enterprise, against expenses (including attorneys&rsquo; fees), judgments, fines and amounts paid in settlement actually and reasonably
incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the
person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal
action or proceeding, had no reasonable cause to believe the person&rsquo;s conduct was unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the case of an
action by or in the right of the corporation, Section 145 of the DGCL permits a Delaware corporation to indemnify any person who
was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by reason of the
fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request
of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other
enterprise, against expenses (including attorneys&rsquo; fees) actually and reasonably incurred by the person in connection with
such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not
opposed to the best interests of the corporation and except that no indemnification shall be made in respect of any claim, issue
or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that
the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the
adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity
for such expenses that the Court of Chancery or such other court shall deem proper.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 99; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 145 of the
DGCL also permits a Delaware corporation to purchase and maintain insurance on behalf of any person who is or was a director,
officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer,
employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted
against such person and incurred by such person in any such capacity, or arising out of such person&rsquo;s status as such, whether
or not the corporation would have the power to indemnify such person against such liability under Section 145 of the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Article VI of our
amended and restated certificate of incorporation states that to the fullest extent permitted by the DGCL our directors shall
not be personally liable to us or to our stockholders for monetary damages for breach of fiduciary duty as a director. If the
DGCL is amended after the date hereof to authorize corporate action further eliminating or limiting the personal liability of
directors, then the liability of our directors shall be eliminated or limited to the fullest extent permitted by the DGCL, as
so amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Article XI of our
amended and restated bylaws requires us, to the fullest extent permitted by applicable law, to provide indemnification of (and
advancement of expenses to) our directors and officers, and authorizes us, to the fullest extent permitted by applicable law,
to provide indemnification of (and advancement of expenses to) to other employees and agents (and any other persons to which the
DGCL permits us to provide indemnification) through bylaw provisions, agreements with such directors, officers, employees, agents
or other persons, vote of stockholders or disinterested directors or otherwise, subject only to limits created by the DGCL with
respect to actions for breach of duty to our corporation, our stockholders and others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the closing
of this offering we plan to enter into an underwriting agreement, which will provide that the underwriters are obligated, under
some circumstances, to indemnify our directors, officers and controlling persons against specified liabilities.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">ITEM 15. RECENT SALES OF UNREGISTERED SECURITIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Issuances of capital stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The following list
sets forth information regarding all unregistered securities sold by us since April 27, 2017 (inception) through the date of the
prospectus that forms a part of this registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 1, 2017, we
issued 3,500,000 shares of our common stock for aggregate consideration of $3,500.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2017, we issued
a warrant to purchase an aggregate of 600,000 shares of our common stock to Liquid Patent Advisors, LLC at an exercise price of
$0.01 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2017, we issued
an aggregate of 6,685,082 shares of our Series A preferred stock to 234 accredited investors at a purchase price of $3.00 per
share for aggregate consideration of approximately $20.1 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2017, we issued
a warrant <FONT STYLE="font-family: Times New Roman, Times, Serif">to National Securities Corporation, as placement agent compensation
in connection with our June 2017 placement of Series A preferred stock, to purchase shares of our common stock </FONT>equal to
10% of our common stock issuable upon conversion of out Series A preferred stock sold in the placement by National Securities
Corporation, <FONT STYLE="font-family: Times New Roman, Times, Serif">at an exercise price equal to 50% of the initial public
offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe the offers,
sales and issuances of the above securities by us were exempt from registration under the Securities Act by virtue of Section&nbsp;4(a)(2)
of the Securities Act as transactions not involving a public offering. The recipients of the securities in each of these transactions
represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with
any distribution thereof, and appropriate legends were placed upon the stock certificates, notes and warrants issued in these
transactions. All recipients had adequate access, through their relationships with us, to information about our Company. The sales
of these securities were made without any general solicitation or advertising.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The offers, sales
and issuances of the securities described in the paragraphs above were exempt from registration under Section 4(a)(2) of the Securities
Act and Regulation D promulgated under the Securities Act. Each of the purchasers represented to us that they acquired the securities
for investment only and not with a view to or for sale in connection with any distribution thereof and appropriate legends were
affixed to the securities issued in these transactions. The purchasers also represented to us that they were accredited investors
as defined in Rule 501 promulgated under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Stock Option Grants and our Common Stock Issuances to Employees,
Directors and Consultants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following list
sets forth information regarding all unregistered securities granted by us pursuant to our 2017 Plan since April 27, 2017 (inception)
through the date of the prospectus that forms a part of this registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From April 27, 2017
(inception) through the date of the prospectus that is a part of this registration statement, we have granted options under the
2017 Plan to purchase (i) an aggregate of 130,000 shares of our common stock to consultants, at an exercise price of $0.21 per
share, (ii) an aggregate of 400,000 shares of our common stock to employees at an exercise price of $1.37 per share and (iii)
an aggregate of 560,000 shares of our common stock to employees and consultants at an exercise price of $1.38 per share, 10,000
shares of our common stock to employees at an exercise price of $1.56 per share and 125,000 shares of our common stock to employees
at an exercise price of $3.12 per share. Of these, no options have been cancelled without being exercised and no shares have been
issued upon the exercise of stock options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From May 2017 through
the date of the prospectus that is part of this registration statement, we granted restricted stock awards under our 2017 Plan
for an aggregate of 2,718,980 shares of our common stock to certain individuals as consideration for services provided to the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July and September
2017, we granted restricted stock unit awards under our 2017 Plan for an aggregate of 100,000 shares of our common stock to four
of our directors as consideration for services provided to the Company.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 85.5pt; font: 10pt Times New Roman, Times, Serif">ITEM
                                         16.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">EXHIBITS</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 18%; text-align: center; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; border-bottom: Black 0.5pt solid; margin-bottom: 0pt; text-align: center">Exhibit
                                         No.</P></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"></TD>
    <TD STYLE="width: 80%; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; border-bottom: Black 0.5pt solid">Description
                                         of Document</P></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><A HREF="s113558_ex1-1.htm" STYLE="-sec-extract: exhibit"> 1.1 </A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="s113558_ex1-1.htm" STYLE="-sec-extract: exhibit"> Form of Underwriting Agreement </A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418007833/s111872_ex3-1.htm" STYLE="-sec-extract: exhibit">3.1**</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418007833/s111872_ex3-1.htm" STYLE="-sec-extract: exhibit">Amended
    and Restated Certificate of Incorporation of the Registrant, as currently in effect</A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418011027/s113298_ex3-2.htm"> 3.2** </A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418011027/s113298_ex3-2.htm"> Form of
    Amended and Restated Certificate of Incorporation of the Registrant effective immediately prior to the closing of this offering.
    </A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418007833/s111872_ex3-2.htm" STYLE="-sec-extract: exhibit">3.3**</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418007833/s111872_ex3-2.htm" STYLE="-sec-extract: exhibit">Bylaws
    of the Registrant, as currently in effect.</A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><A HREF="s113558_ex3-4.htm" STYLE="-sec-extract: exhibit"> 3.4 </A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="s113558_ex3-4.htm" STYLE="-sec-extract: exhibit"> Form of
    Amended and Restated Bylaws of the Registrant effective immediately prior to the closing of this offering. </A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><A HREF="s113558_ex4-1.htm" STYLE="-sec-extract: exhibit"> 4.1 </A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="s113558_ex4-1.htm" STYLE="-sec-extract: exhibit"> Specimen Certificate representing shares of common stock of Registrant </A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418007833/s111872_ex4-2.htm" STYLE="-sec-extract: exhibit">4.2**</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418007833/s111872_ex4-2.htm" STYLE="-sec-extract: exhibit">Warrant
    dated May 4, 2017 issued to Liquid Patent Advisors, LLC</A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418007833/s111872_ex4-3.htm" STYLE="-sec-extract: exhibit">4.3**</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418007833/s111872_ex4-3.htm" STYLE="-sec-extract: exhibit">Warrant
    dated June 26, 2017 issued to National Securities Corporation</A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><A HREF="s113558_ex4-4.htm" STYLE="-sec-extract: exhibit"> 4.4 </A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="s113558_ex4-4.htm" STYLE="-sec-extract: exhibit"> Form of Underwriter&rsquo;s Warrant </A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><A HREF="s113558_ex5-1.htm" STYLE="-sec-extract: exhibit"> 5.1 </A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="s113558_ex5-1.htm" STYLE="-sec-extract: exhibit"> Opinion of Greenberg Traurig, LLP regarding the validity of the common
    stock being registered </A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418007833/s111872_ex10-1.htm" STYLE="-sec-extract: exhibit">10.1**</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418007833/s111872_ex10-1.htm" STYLE="-sec-extract: exhibit">Securities
    Purchase Agreement dated June 19, 2017 by and among the Registrant and the Buyers named therein</A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418007833/s111872_ex10-2.htm" STYLE="-sec-extract: exhibit">10.2**</A></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418007833/s111872_ex10-2.htm" STYLE="-sec-extract: exhibit">Registration
    Rights Agreement dated June 19, 2017 by and among the Registrant and certain of its stockholders</A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418007833/s111872_ex10-3.htm" STYLE="-sec-extract: exhibit">10.3**</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418007833/s111872_ex10-3.htm" STYLE="-sec-extract: exhibit">Asset
    Purchase and License Agreement (CT-100) dated May 9, 2017 between Imprimis Pharmaceuticals, Inc. and the Registrant</A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418007833/s111872_ex10-4.htm" STYLE="-sec-extract: exhibit">10.4**</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418007833/s111872_ex10-4.htm" STYLE="-sec-extract: exhibit">Asset
    Purchase and License Agreement (CT-200) dated May 9, 2017 between Imprimis Pharmaceuticals, Inc. and the Registrant</A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418007833/s111872_ex10-5.htm" STYLE="-sec-extract: exhibit">10.5&dagger;**</A></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418007833/s111872_ex10-5.htm" STYLE="-sec-extract: exhibit">Asset
    Purchase Agreement (DS-200) dated June 23, 2017 between Selenix, LLC and the Registrant</A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418007833/s111872_ex10-6.htm" STYLE="-sec-extract: exhibit">10.6&dagger;**</A></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418007833/s111872_ex10-6.htm" STYLE="-sec-extract: exhibit">Exclusive
    Development and Supply Agreement (DS-100) dated July 9, 2017 between Andersen Pharma, LLC and the Registrant</A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418011027/s113298_ex10-7.htm" STYLE="-sec-extract: exhibit"> 10.7** </A></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418011027/s113298_ex10-7.htm" STYLE="-sec-extract: exhibit"> Exclusive
    Sales and Marketing Agreement (EM-100) dated August 11, 2017 between Eyemax, LLC and the Registrant </A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418011027/s113298_ex10-8.htm" STYLE="-sec-extract: exhibit"> 10.8&dagger;** </A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418011027/s113298_ex10-8.htm" STYLE="-sec-extract: exhibit"> Development,
    Supply and Commercialization Agreement (CT-100) dated November 7, 2017 between Amphastar Pharmaceuticals, Inc. and the Registrant </A></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 18%; text-align: center; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418007833/s111872_ex10-9.htm" STYLE="-sec-extract: exhibit">10.9&dagger;**</A></TD>
    <TD STYLE="width: 2%; text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 80%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418007833/s111872_ex10-9.htm" STYLE="-sec-extract: exhibit">Sales/Marketing
    Agreement (DS-300) dated November 17, 2017 by and among AL Pharma, Inc., SCS National, LLC, Dry Creek Project, LLC and the
    Registrant</A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418007833/s111872_ex10-10.htm" STYLE="-sec-extract: exhibit">10.10+**</A></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418007833/s111872_ex10-10.htm" STYLE="-sec-extract: exhibit">Eton
    Pharmaceuticals, Inc. 2017 Stock Incentive Plan</A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418007833/s111872_ex10-11.htm" STYLE="-sec-extract: exhibit">10.11+**</A></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418007833/s111872_ex10-11.htm" STYLE="-sec-extract: exhibit">Consulting
    Agreement by and between the Registrant and Mark L. Baum, dated as of May 1, 2017</A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418007833/s111872_ex10-12.htm" STYLE="-sec-extract: exhibit">10.12+**</A></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418007833/s111872_ex10-12.htm" STYLE="-sec-extract: exhibit">Offer
    Letter Agreement by and between the Registrant and Sean E. Brynjelsen, dated as of May 17, 2017</A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418007833/s111872_ex10-13.htm" STYLE="-sec-extract: exhibit">10.13+**</A></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418007833/s111872_ex10-13.htm" STYLE="-sec-extract: exhibit">Offer
    Letter Agreement by and between the Registrant and W. Wilson Troutman, dated as of June 27, 2017</A></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center; width: 18%"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418011027/s113298_ex10-14.htm" STYLE="-sec-extract: exhibit"> <FONT STYLE="font-size: 10pt">10.14**</FONT> </A></TD>
    <TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: justify; width: 80%"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418011027/s113298_ex10-14.htm" STYLE="-sec-extract: exhibit"> <FONT STYLE="font-size: 10pt">Exclusive
    License and Supply Agreement (ET-103) dated August 3, 2018 between the Registrant, Liqmeds Worldwide Limited and LM Manufacturing,
    Ltd. </FONT> </A></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418011027/s113298_ex10-15.htm" STYLE="-sec-extract: exhibit"> 10.15+** </A></TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418011027/s113298_ex10-15.htm" STYLE="-sec-extract: exhibit"> 2017 Equity
    Incentive Plan </A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418011027/s113298_ex10-16.htm" STYLE="-sec-extract: exhibit"> 10.16+** </A></TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418011027/s113298_ex10-16.htm" STYLE="-sec-extract: exhibit"> 2018 Equity
    Incentive Plan </A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418011027/s113298_ex10-17.htm" STYLE="-sec-extract: exhibit"> 10.17+** </A></TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418011027/s113298_ex10-17.htm" STYLE="-sec-extract: exhibit"> 2018 Employee
    Stock Purchase Plan </A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418011027/s113298_ex10-18.htm" STYLE="-sec-extract: exhibit"> 10.18** </A></TD>
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418011027/s113298_ex10-18.htm" STYLE="-sec-extract: exhibit"> Amendment
    No. 1 dated August 29, 2018 to Sales/Marketing Agreement (DS-300) dated November 17, 2017 between AL Pharma, Inc. and the
    Registrant </A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 18%"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418007833/s111872_ex21-1.htm" STYLE="-sec-extract: exhibit">21.1**</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%"><A HREF="http://www.sec.gov/Archives/edgar/data/1710340/000161577418007833/s111872_ex21-1.htm" STYLE="-sec-extract: exhibit">List
    of Subsidiaries</A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><A HREF="s113558_ex23-1.htm" STYLE="-sec-extract: exhibit">23.1</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="s113558_ex23-1.htm" STYLE="-sec-extract: exhibit">Consent of
    KMJ Corbin &amp; Company LLP, Independent Registered Public Accounting Firm</A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><A HREF="s113558_ex5-1.htm" STYLE="-sec-extract: exhibit"> &nbsp;23.2 </A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="s113558_ex5-1.htm" STYLE="-sec-extract: exhibit"> Consent of Greenberg Traurig, LLP (included in Exhibit 5.1) </A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><A HREF="#b_007" STYLE="-sec-extract: exhibit">&nbsp;24.1**</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#b_007" STYLE="-sec-extract: exhibit">Power of Attorney</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30pt">* To be submitted by amendment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30pt">&dagger; Portions of this exhibit (indicated by asterisks)
have been omitted pursuant to a request for confidential treatment and have been separately filed with the Securities and Exchange
Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30pt">+ Indicates management compensatory plan, contract
or arrangement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30pt">** Previously filed</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 1in; font: 10pt Times New Roman, Times, Serif">ITEM
                                         17.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">UNDERTAKINGS</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned registrant
hereby undertakes to provide to the underwriter at the closing specified in the underwriting agreements, certificates in such
denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Insofar as indemnification
for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the
registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities
and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding)
is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant
will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will
be governed by the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned registrant
undertakes that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus as filed as
part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant
to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the
time it was declared effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus
shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Pursuant to the requirements of the
Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of Deer Park, Illinois on this 31<SUP>st</SUP> day of October 2018. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><B>ETON PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/s/ Sean E. Brynjelsen</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Sean E. Brynjelsen</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer and Director</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Executive Officer)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><A NAME="b_007"></A>Pursuant
to the requirements of the Securities Act of 1933, this registration statement on Form S-1 has been signed by the following persons
in the capacities and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 42%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in; border-bottom: Black 1pt solid"> <B>&nbsp;Signature</B> </P></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="width: 35%; text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> <B>Title</B> </TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="width: 21%; text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> <B>Date</B> </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> /s/ Sean E. Brynjelsen </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> President, </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> October 31, 2018 </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> Sean E. Brynjelsen </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> Chief Executive Officer </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> and Director </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> <I>&nbsp;(Principal Executive Officer)</I> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> /s/ W. Wilson Troutman </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> Chief Financial Officer, </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> October 31, 2018 </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> W. Wilson Troutman </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> Treasurer and Secretary </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> <I>(Principal Financial and </I> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> <I>Accounting Officer)</I> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> * </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> Mark L. Baum </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> Director </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> October 31, 2018 </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> * </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> Charles J. Casamento </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> Director </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> October 31, 2018 </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> * </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> Paul V. Maier </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> Director </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> October 31, 2018 </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> * </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> Norbert G. Riedel, Ph.D. </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> Director </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"> October 31, 2018 </TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="width: 5%">* By:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; width: 37%">/s/ Sean E. Brynjelsen</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 37%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 19%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Sean E. Brynjelsen</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">As Attorney-in-fact</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 103; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>s113558_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 1.1</B></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ETON PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDERWRITING AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">New York, New York</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">November __, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">National Securities Corporation,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As Representative of the Several Underwriters</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">200 Vesey Street, 25th Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10281</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned, Eton Pharmaceuticals, Inc. (together with its
affiliates, subsidiaries, predecessors, and successors, the &ldquo;<B>Company</B>&rdquo;), a company formed under the laws of Delaware,
hereby confirms its agreement with National Securities Corporation (hereinafter referred to as the &ldquo;<B>Representative</B>&rdquo;),
a Washington corporation, and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as
representative (the Representative and such other underwriters being collectively called the &ldquo;<B>Underwriters</B>&rdquo;
or, individually, an &ldquo;<B>Underwriter</B>&rdquo;) as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchase
and Sale of Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Firm
Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nature
and Purchase of Firm Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(i) On the basis of the representations and
warranties herein contained, but subject to the terms and conditions herein set forth, the Company agrees to issue and sell, severally
and not jointly, to the several Underwriters, an aggregate of 3,000,000 shares (&ldquo;<B>Firm Shares</B>&rdquo;) of the Company&rsquo;s
common stock, par value $0.001 per share (the &ldquo;<B>Common Stock</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(ii) The Underwriters, severally and not jointly,
agree to purchase from the Company the number of Firm Shares set forth opposite their respective names on Schedule 1 attached hereto
and made a part hereof at a purchase price (net of discounts and commissions) of [___] per Share [91.5% of the per Share offering
price]. The Firm Shares are to be offered initially to the public (the &ldquo;<B>Offering</B>&rdquo;) at the offering price set
forth on the cover page of the Prospectus (as defined in Section 2.1.1 hereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Shares
Payment and Delivery</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(i) Delivery and payment for the Firm Shares
shall be made at 10:00 a.m., Eastern time, on the third (3rd) Business Day following the effective date (the &ldquo;<B>Effective
Date</B>&rdquo;) of the Registration Statement (as defined in Section 2.1.1 below) (or the fourth (4th) Business Day following
the Effective Date, if the Registration Statement is declared effective on or after 4:30 p.m.) or at such earlier time as shall
be agreed upon in writing by the Representative and the Company at the offices of Jenner &amp; Block LLP, counsel to the Underwriters
(&ldquo;<B>J&amp;B</B>&rdquo;), or at such other place (or remotely by facsimile or other electronic transmission) as shall be
agreed upon in writing by the Representative and the Company. The hour and date of delivery and payment for the Firm Shares is
called the &ldquo;<B>Closing Date</B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(ii) Payment for the Firm Shares shall be
made on the Closing Date by wire transfer in Federal (same day) funds, payable to the order of the Company upon delivery of the
certificates (in form and substance satisfactory to the Underwriters) representing the Firm Shares (or through the facilities of
the Depository Trust Company (the &ldquo;<B>DTC</B>&rdquo;)) for the account of the Underwriters. The Firm Shares shall be registered
in such name or names and in such authorized denominations as the Representative may request in writing at least two (2) full Business
Days prior to the Closing Date. The Company shall not be obligated to sell or deliver the Firm Shares except upon tender of payment
by the Representative for all the Firm Shares. The term &ldquo;<B>Business Day</B>&rdquo; means any day other than a Saturday,
a Sunday or a legal holiday or a day on which banking institutions are authorized or obligated by law to close in New York City.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Over-allotment
Option</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Option
Shares</U>. For the sole purpose of covering any over-allotments in connection with the distribution and sale of the Firm Shares,
the Underwriters are hereby granted an option to purchase up to 450,000 shares of Common Stock representing up to fifteen percent
(15%) of the Firm Shares sold in the offering from the Company (the &ldquo;<B>Over-allotment Option</B>&rdquo;). Such additional
Over-allotment Option shares of Common Stock, the net proceeds of which will be deposited with the Company&rsquo;s account, are
hereinafter referred to as &ldquo;<B>Option Shares</B>.&rdquo; The purchase price to be paid for the Option Shares will be the
public offering price, less the underwriting discount, as set forth in Section 1.1.1 hereof. The Firm Shares and the Option Shares
are hereinafter referred to collectively as the &ldquo;<B>Public Securities</B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise
of Option</U>. The Over-allotment Option granted pursuant to Section 1.2.1 hereof may be exercised by the Representative as to
all (at any time) or any part (from time to time) of the Option Shares within 45 days after the Effective Date. The Underwriters
will not be under any obligation to purchase any Option Shares prior to the exercise of the Over-allotment Option. The Over-allotment
Option granted hereby may be exercised by the giving of oral notice to the Company from the Representative, which must be confirmed
in writing by overnight mail or facsimile or other electronic transmission setting forth the number of Option Shares to be purchased
and the date and time for delivery of and payment for the Option Shares (the &ldquo;<B>Option Closing Date</B>&rdquo;), which will
not be later than five (5) full Business Days after the date of the notice or such other time as shall be agreed upon in writing
by the Company and the Representative, at the offices of J&amp;B or at such other place (including remotely by facsimile or other
electronic transmission) as shall be agreed upon in writing by the Company and the Representative. If such delivery and payment
for the Option Shares does not occur on the Closing Date, the Option Closing Date will be as set forth in the notice. Upon exercise
of the Over-allotment Option, the Company will become obligated to convey to the Underwriters, and, subject to the terms and conditions
set forth herein, the Underwriters will become obligated to purchase, the number of Option Shares specified in such notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment
and Delivery</U>. Payment for the Option Shares will be made on the Option Closing Date by wire transfer in Federal (same day)
funds as follows: [___] per Option Share, [91.5% of the per Share offering price], payable to the order of the Company upon delivery
of certificates (in form and substance satisfactory to the Underwriters) representing the Option Shares (or through the facilities
of DTC) for the account of the Underwriters. The Option Shares shall be registered in such name or names and in such authorized
denominations as the Representative may request in writing at least two (2) full Business Days prior to the Option Closing Date.
The Company shall not be obligated to sell or deliver the Option Shares except upon tender of payment by the Representative for
applicable Option Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Underwriters&rsquo;
Warrants</U>. The Company hereby agrees to issue and sell to the Representative on the Closing Date and Option Closing Date warrants
to purchase that number of shares of Common Stock equal to an aggregate of 10% of the shares of Common Stock sold in the Offering
(the &ldquo;<B>Underwriters&rsquo; Warrants</B>&rdquo;). The Underwriters&rsquo; Warrants shall be exercisable, in whole or in
part, commencing twelve (12) months after the Effective Date and expiring five (5) years after the Effective Date at an initial
exercise price per share of [___] [125% of the per Share offering price]. The Underwriters&rsquo; Warrants and the shares of Common
Stock issuable upon exercise thereof (&ldquo;<B>Warrant Shares</B>&rdquo;) are sometimes referred to herein collectively as the
&ldquo;<B>Warrant Securities</B>.&rdquo; The Representative understands and agrees that there are significant restrictions pursuant
to FINRA Rule 5110 against transferring the Warrant Securities and by its acceptance thereof shall agree that it will not sell,
transfer, assign, pledge or hypothecate the Warrant Securities, or any portion thereof, or be the subject of any hedging, short
sale, derivative, put or call transaction that would result in the effective economic disposition of such securities other than
in accordance with FINRA Rule 5110. Notwithstanding anything in this Agreement to the contrary, the Warrant Securities may not
be sold, transferred, assigned, pledged, or hypothecated prior to the date that is three hundred sixty-five (365) days immediately
following the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
and Warranties of the Company</U>. The Company represents and warrants to the Underwriters as of the Applicable Time (as defined
below) and as of the Closing Date and as of the Option Closing Date, if any, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Filing
of Registration Statem</U>ent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">2.1.1. <U>Pursuant to the Act</U>. The Company
has filed with the Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;) a registration statement and an amendment
or amendments thereto, on Form S-1 (File No. 333-226774), including any related preliminary prospectus or prospectuses, including
those that omitted information pursuant to Rule 430A, for the registration of the Public Securities under the Securities Act of
1933, as amended (the &ldquo;Act&rdquo;), which registration statement and amendment or amendments have been prepared by the Company
in all material respects in conformity with the requirements of the Act and the rules and regulations of the Commission under the
Act (the &ldquo;<B>Regulations</B>&rdquo;). Except as the context may otherwise require, such registration statement on file with
the Commission at the time the registration statement becomes effective (including the prospectus, financial statements, schedules,
exhibits and all other documents filed as a part thereof or incorporated therein by reference pursuant to Item 12 of Form S-1 and
all information deemed to be a part thereof as of the Effective Date pursuant to paragraph (b) of Rule 430A of the Regulations
and any registration statement filed pursuant to Rule 462(b)) is referred to herein as the &ldquo;<B>Registration Statement</B>.&rdquo;
As used herein, the term &ldquo;<B>Preliminary Prospectus</B>&rdquo; shall mean the preliminary prospectus dated [_________], 2018
made part of the Registration Statement. The final prospectus in the form first furnished to the Underwriters for use in the Offering
is hereinafter called the &ldquo;<B>Prospectus</B>.&rdquo; The Registration Statement has been declared effective by the Commission
on the date hereof. &ldquo;<B>Applicable Time</B>&rdquo; means 5:00 p.m. on the Effective Date or such other time as agreed to
in writing by the Company and the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">2.1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Pursuant
to the Exchange Act</U>. The Company has filed with the Commission a Form 8-A (File Number) providing for the registration under
the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;), of the Firm Shares, and the Option Shares.
The registration of the Firm Shares and the Option Shares under the Exchange Act has been declared effective by the Commission
on the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Stop Orders, etc.<FONT STYLE="font-size: 10pt">&nbsp;</FONT>Neither the Commission nor, to the Company&rsquo;s knowledge, any
state regulatory authority has issued any order preventing or suspending the use of the Preliminary Prospectus, the Prospectus
or the Registration Statement or has instituted or, to the Company&rsquo;s knowledge, threatened to institute any proceedings
with respect to such an order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclosures
in Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>10b-5
Representation</U>. At the respective times of use of the Preliminary Prospectus and Prospectus and the effectiveness of the Registration
Statement and any post-effective amendments thereto (and at the Closing Date and the Option Closing Date, if any):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(i) The Preliminary Prospectus, Prospectus,
Registration Statement and any post-effective amendments thereto did and will contain all material statements that are required
to be stated therein in accordance with the Act and the Regulations, and will in all material respects conform to the requirements
of the Act and the Regulations;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(ii) Neither the Preliminary Prospectus, the
Prospectus nor the Registration Statement, nor any amendment or supplement thereto, on such dates, do or will contain any untrue
statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements
therein, in light of the circumstances under which they were made, not misleading. The representation and warranty made in this
Section 2.3.1(ii) does not apply to statements made or statements omitted in reliance upon and in conformity with written information
furnished to the Company with respect to the Underwriters by the Representative expressly for use in the Preliminary Prospectus,
the Prospectus or the Registration Statement or any amendment thereof or supplement thereto. The parties acknowledge and agree
that such information provided by or on behalf of any Underwriter consists solely of the names of the Underwriters appearing in
the &ldquo;Underwriting&rdquo; section of the Prospectus and the following additional disclosure contained in the &ldquo;Underwriting&rdquo;
section of the Prospectus: (i) the [<B>fourth and sixth</B>] paragraphs under &ldquo;Underwriting,&rdquo; (ii) the statements in
&ldquo;Underwriting - Determination of Offering Price Listing,&rdquo; and (iii) the [<B>first</B>] paragraph under &ldquo;Underwriting
- Short Positions and Penalty Bids&rdquo; (the &ldquo;<B>Underwriters&rsquo; Information</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclosure
of Agreements</U>. The agreements and documents described in the Preliminary Prospectus, the Prospectus and the Registration Statement
conform to the descriptions thereof contained therein and there are no agreements or other documents required by the Act and the
Regulations to be described therein or to be filed with the Commission as exhibits to the Registration Statement, that have not
been so described or filed. Each agreement or other instrument (however characterized or described) to which the Company is a party
or by which it is or may be bound or affected and (i) that is referred to in the Preliminary Prospectus or the Prospectus, or (ii)
is material to the Company&rsquo;s business, has been duly authorized and validly executed by the Company, is in full force and
effect in all material respects and is enforceable against the Company and, to the Company&rsquo;s knowledge, the other parties
thereto, in accordance with its terms, except (x) as such enforceability may be limited by bankruptcy, insolvency, reorganization
or similar laws affecting creditors&rsquo; rights generally, (y) as enforceability of any indemnification or contribution provision
may be limited under the federal or state securities laws, and (z) that the remedy of specific performance and injunctive and other
forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding
therefore may be brought. None of such agreements or instruments has been assigned by the Company, and neither the Company nor,
to the Company&rsquo;s knowledge, any other party is in default thereunder and, to the Company&rsquo;s knowledge, no event has
occurred that, with the lapse of time or the giving of notice, or both, would constitute a default thereunder. To the Company&rsquo;s
knowledge, performance by the Company of the material provisions of such agreements or instruments will not result in a violation
of any existing applicable law, rule, regulation, judgment, order or decree of any governmental agency or court, domestic or foreign,
having jurisdiction over the Company or any of its assets or businesses, including, without limitation, those relating to environmental
laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Prior
Securities Transactions</U>. No securities of the Company that are required to be &ldquo;integrated&rdquo; pursuant to the Act
or the regulations thereunder with the offer and sale of the shares of Common Stock pursuant to the Registration Statement have
been offered or sold, either prior to the initial filing of the Registration Statement or the Effective Date, by the Company or,
to the Company&rsquo;s knowledge, any of its affiliates or by or on behalf of, or for the benefit of, any person or persons controlling,
controlled by, or under common control with the Company, except as disclosed in the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes
After Dates in Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Material Adverse Change</U>. Since the respective dates as of which information is given in the Registration Statement and the
Prospectus, except as otherwise specifically stated therein: (i) there has been no material adverse change in the condition, financial
or otherwise, of the Company taken as a whole; (ii) there have been no material transactions entered into by the Company required
to be disclosed in the Prospectus or the Registration Statement, other than as contemplated pursuant to this Agreement; and (iii)
no officer or director of the Company has resigned from any position with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Recent
Securities Transactions, etc</U>. Subsequent to the respective dates as of which information is given in the Registration Statement
and the Prospectus, and except as may otherwise be indicated or contemplated herein or disclosed in the Registration Statement
and the Prospectus, the Company has not: (i) issued any securities or incurred any liability or obligation, direct or contingent,
for borrowed money; or (ii) declared or paid any dividend or made any other distribution on or in respect to its capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Independent
Accountants.<FONT STYLE="font-size: 10pt">&nbsp;</FONT>To the knowledge of the Company, KMJ Corbin &amp; Company LLP (&ldquo;<B>KMJ</B>&rdquo;),
whose report is filed with the Commission as part of the Registration Statement, are independent registered public accountants
as required by the Act and the Regulations. KMJ has not, during the periods covered by the financial statements included in the
Prospectus, provided to the Company any non-audit services, as such term is used in Section 10A(g) of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial
Statements<FONT STYLE="font-size: 10pt"></FONT>. <FONT STYLE="font-size: 10pt">The financial statements, including the notes
thereto and supporting schedules, if any, included in the Preliminary Prospectus, the Prospectus and the Registration Statement
fairly present the financial position and the results of operations of the Company at the dates and for the periods to which they
apply; and such financial statements have been prepared in conformity with generally accepted accounting principles (&ldquo;<B>GAAP</B>&rdquo;),
consistently applied throughout the periods involved; and the supporting schedules included in the Registration Statement, if
any, present fairly the information required to be stated therein. The Preliminary Prospectus, the Prospectus and the Registration
Statement disclose all material off-balance sheet transactions, arrangements, obligations (including contingent obligations),
and other relationships of the Company with unconsolidated entities or other persons required to be disclosed under Item 303(a)(4)
of Regulation S-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Authorized
Capital; Options, etc<FONT STYLE="font-size: 10pt"></FONT>. <FONT STYLE="font-size: 10pt">The Company had, at the date or
dates indicated in the Preliminary Prospectus, the Prospectus and the Registration Statement, the duly authorized, issued and
outstanding capitalization as set forth therein. Based on the assumptions stated in the Preliminary Prospectus, the Prospectus
and the Registration Statement, the Company will have on the Closing Date the adjusted stock capitalization set forth therein
(as such adjusted stock capitalization may be further adjusted for the final determination of the shares of Common Stock to be
issued upon conversion of the Company&rsquo;s preferred stock. Except as set forth in, or contemplated by, the Registration Statement
and the Prospectus, on the Effective Date and on the Closing Date, there will be no options, warrants, or other rights to purchase
or otherwise acquire any authorized, but unissued shares of Common Stock of the Company or any security convertible into shares
of Common Stock of the Company, or any contracts or commitments on the part of the Company to issue or sell shares of Common Stock
or any such options, warrants, rights or convertible securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Valid
Issuance of Securities, etc.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Outstanding
Securities<FONT STYLE="font-size: 10pt">. All issued and outstanding securities of the Company issued prior to the transactions
contemplated by this Agreement have been duly authorized and validly issued and are fully paid and non-assessable; the holders
thereof have no rights of rescission with respect thereto, and are not subject to personal liability by reason of being such holders;
and none of such securities were issued in violation of the preemptive rights of any holders of any security of the Company or
similar contractual rights granted by the Company. The authorized Common Stock of the Company conforms in all material respects
to all statements relating thereto contained in the Preliminary Prospectus, the Prospectus and the Registration Statement. The
offers and sales of the outstanding shares of Common Stock were at all relevant times either registered under the Act and the
applicable state securities or Blue Sky laws or, based in part on the representations and warranties of the purchasers of such
shares of Common Stock, exempt from such registration requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Securities
Sold Pursuant to this Agreement<FONT STYLE="font-size: 10pt">. The Public Securities have been duly authorized for issuance and
sale and, when issued and paid for, will be validly issued, fully paid and non-assessable; the holders thereof are not and will
not be subject to personal liability by reason of being such holders; the Public Securities are not and will not be subject to
the preemptive rights of any holders of any security of the Company or similar contractual rights granted by the Company; and
all corporate action required to be taken for the authorization, issuance and sale of the Public Securities has been duly and
validly taken. The Public Securities conform in all material respects to all statements with respect thereto contained in the
Preliminary Prospectus, the Prospectus and the Registration Statement. The Warrant Shares issuable upon exercise of the Underwriters&rsquo;
Warrants have been reserved for issuance upon the exercise thereof and, when issued in accordance with the terms of such securities
will be validly issued, fully paid and non-assessable; the holders thereof are not and will not be subject to personal liability
by reason of being such holders; and all corporate action required to be taken for the authorization, issuance and sale of the
Warrant Securities has been duly and validly taken. The Warrant Securities conform in all material respects to all statements
with respect thereto contained in the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration
Rights of Third Parties</U>. Except as set forth in the Preliminary Prospectus, the Prospectus and the Registration Statement,
no holders of any securities of the Company or any rights exercisable for or convertible or exchangeable into securities of the
Company have the right to require the Company to register any such securities of the Company under the Act or to include any such
securities in a registration statement to be filed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Validity
and Binding Effect of Agreements</U>. This Agreement has been duly and validly authorized by the Company, and, when executed and
delivered, will constitute a valid and binding obligation of the Company, enforceable against the Company in accordance with its
respective terms, except: (i) as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting
creditors&rsquo; rights generally; (ii) as enforceability of any indemnification or contribution provision may be limited under
the federal or state securities laws; and (iii) that the remedy of specific performance and injunctive and other forms of equitable
relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding therefor may be
brought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Conflicts, etc</U>. The execution, delivery, and performance by the Company of this Agreement and all ancillary documents, the
consummation by the Company of the transactions herein and therein contemplated and the compliance by the Company with the terms
hereof and thereof do not and will not, with or without the giving of notice or the lapse of time or both: (i) result in a material
breach of, or conflict with any of the terms and provisions of, or constitute a material default under, any agreement or instrument
to which the Company is a party; (ii) result in any violation of the provisions of the Certificate of Incorporation of the Company
(as the same may be amended from time to time, the &ldquo;<B>Certificate of Incorporation</B>&rdquo;); or (iii) result in the Company&rsquo;s
violation of any existing applicable law, rule, regulation, judgment, order or decree of any governmental agency or court, domestic
or foreign, having jurisdiction over the Company or any of its properties or business constituted as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Defaults; Violations</U>. No material default exists in the due performance and observance of any term, covenant or condition
of any material license, contract, indenture, mortgage, deed of trust, note, loan or credit agreement, or any other agreement or
instrument evidencing an obligation for borrowed money, or any other material agreement or instrument to which the Company is a
party or by which the Company may be bound or to which any of the properties or assets of the Company is subject. The Company is
not in violation of any term or provision of its Certificate of Incorporation, or in violation of any franchise, license, permit,
applicable law, rule, regulation, judgment or decree of any governmental agency or court, domestic or foreign, having jurisdiction
over the Company or any of its properties or businesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Corporate
Power; Licenses; Consents</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.13.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Conduct
of Business</U>. Except as described in the Preliminary Prospectus, the Prospectus and the Registration Statement, the Company
has all requisite corporate power and authority, and has all necessary authorizations, approvals, orders, licenses, certificates
and permits of and from all governmental regulatory officials and bodies that it needs as of the date hereof to conduct its business
purpose as described in the Preliminary Prospectus and the Prospectus. The disclosures in the Preliminary Prospectus, the Prospectus
and the Registration Statement concerning the effects of Federal, state, local and foreign regulation on this Offering and the
Company&rsquo;s business purpose as currently contemplated are correct in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.13.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Transactions
Contemplated Herein</U>. The Company has all corporate power and authority to enter into this Agreement and to carry out the provisions
and conditions hereof, and all consents, authorizations, approvals and orders required in connection therewith have been obtained.
No consent, authorization or order of, and no filing with, any court, government agency or other body is required for the valid
issuance, sale and delivery of the securities and the consummation of the transactions and agreements contemplated by this Agreement
and as contemplated by the disclosures in the Preliminary Prospectus and the Prospectus, except with respect to applicable Federal
and state securities laws and regulations and the rules and regulations of the Financial Industry Regulatory Authority, Inc. (&ldquo;<B>FINRA</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>D&amp;O
Questionnaires</U>. To the Company&rsquo;s knowledge, all information contained in the questionnaires (the &ldquo;<B>Questionnaires</B>&rdquo;)
completed by each of the Company&rsquo;s officers and directors immediately prior to the Offering, as well as in the Lock-Up Agreement
provided to the Underwriters, is true and correct in all material respects and the Company has not become aware of any information
which would cause the information disclosed in the Questionnaires completed by each such officer or director to become inaccurate
and incorrect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Litigation;
Governmental Proceedings</U>. There is no action, suit, proceeding, inquiry, arbitration, investigation, litigation or governmental
proceeding pending or, to the Company&rsquo;s knowledge, threatened against, or involving the Company or, to the Company&rsquo;s
knowledge, any executive officer or director that is required to be disclosed in the Preliminary Prospectus, the Prospectus and
the Registration Statement which has not been disclosed therein or in connection with the Company&rsquo;s listing application for
the listing of the shares of Common Stock on the Nasdaq Capital Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Good
Standing</U>. The Company has been duly organized and is validly existing as a corporation and is in good standing under the laws
of Delaware as of the date hereof, and is duly qualified to do business and is in good standing in each jurisdiction in which its
ownership or lease of property or the conduct of business requires such qualification, except where the failure to qualify would
not have a Material Adverse Effect (as defined in Section 2.20).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transactions
Affecting Disclosure to FINRA</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.17.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Finder&rsquo;s
Fees</U>. Except as described in the Preliminary Prospectus, the Prospectus and the Registration Statement, there are no claims,
payments, arrangements, agreements or understandings relating to the payment of a finder&rsquo;s, consulting or origination fee
by the Company or any of its officers or directors with respect to the sale of the securities hereunder or any other arrangements,
agreements or understandings of the Company or, to the Company&rsquo;s knowledge, any of its shareholders that may affect the Underwriters&rsquo;
compensation, as determined by FINRA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.17.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Payments
Within Twelve Months</U>. Except as described in the Preliminary Prospectus, the Prospectus and the Registration Statement, the
Company has not made any direct or indirect payments (in cash, securities or otherwise) to: (i) any person, as a finder&rsquo;s
fee, consulting fee or otherwise, in consideration of such person raising capital for the Company or introducing to the Company
persons who raised or provided capital to the Company; (ii) to any FINRA member; or (iii) to the Company&rsquo;s knowledge, to
any person or entity that has any direct or indirect affiliation or association with any FINRA member, within the twelve months
prior to the Effective Date, other than payments to the Underwriters as provided hereunder in connection with the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.17.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Use
of Proceeds</U>. None of the net proceeds of the Offering will be paid by the Company to any participating FINRA member or its
affiliates, except as specifically authorized herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.17.4&nbsp;&nbsp;&nbsp;&nbsp;<U>FINRA
Affiliation</U>. To the Company&rsquo;s knowledge, no officer, director or any beneficial owner of the Company&rsquo;s unregistered
securities has any direct or indirect affiliation or association with any FINRA member (as determined in accordance with the rules
and regulations of FINRA) except as set forth in the Registration Statement. The Company will advise the Representative if it learns
that any officer, director or owner of at least 5% of the Company&rsquo;s outstanding shares of Common Stock (or securities convertible
into shares of Common Stock) is or becomes an affiliate or associated person of a FINRA member participating in the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Foreign
Corrupt Practices Act</U>. Neither the Company nor any of the directors, employees or officers of the Company or, to its knowledge,
any other person acting on behalf of the Company has, directly or indirectly, given or agreed to give any money, gift or similar
benefit (other than legal price concessions to customers in the ordinary course of business) to any customer, supplier, employee
or agent of a customer or supplier, or official or employee of any governmental agency or instrumentality of any government (domestic
or foreign) or any political party or candidate for office (domestic or foreign) or other person who was, is, or may be in a position
to help or hinder the business of the Company (or assist it in connection with any actual or proposed transaction) that (i) might
subject the Company to any damage or penalty in any civil, criminal or governmental litigation or proceeding, (ii) if not given
in the past, might have had a Material Adverse Effect as reflected in any of the financial statements contained in the Preliminary
Prospectus, the Prospectus or (iii) if not continued in the future, might have a Material Adverse Effect. The Company has taken
reasonable steps to ensure that its accounting controls and procedures are sufficient to cause the Company to comply in all material
respects with the Foreign Corrupt Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Officers&rsquo;
Certificate</U>. Any certificate pursuant to this Agreement signed by any duly authorized officer of the Company and delivered
to the Representative shall be deemed a representation and warranty by the Company to the Underwriters as to the matters covered
thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Possession
of Licenses and Permits</U>. The Company (A) possesses the licenses, permits, certificates, authorizations, consents and approvals
(collectively, &ldquo;<B>Governmental Licenses</B>&rdquo;) issued by the appropriate governmental entities necessary to conduct
its business as currently conducted as described in the Preliminary Prospectus, the Prospectus and the Registration Statement,
and (B) has obtained all necessary Governmental Licenses from other persons necessary to conduct its business, except, in each
case of clauses (A) and (B), (i) as described in the Preliminary Prospectus, the Prospectus and the Registration Statement or (ii)
to the extent that any failure to possess any Governmental Licenses, provide any notice, make any filing, or obtain any Governmental
Licenses would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the assets, business
or operations of the Company or its subsidiaries taken as a whole (&ldquo;<B>Material Adverse Effect</B>&rdquo;); none of the Company
and subsidiaries is in violation of, or in default under, any Governmental License, as except as would not reasonably be expected
to have a Material Adverse Effect. All of the Governmental Licenses are valid and in full force and effect, except when the invalidity
of such Governmental Licenses or the failure of such Governmental Licenses to be in full force and effect would not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Company has not received any notice of proceedings
relating to the revocation or modification of any Governmental Licenses which, individually or in the aggregate, if the subject
of an unfavorable decision, ruling or finding, would have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Title
to Property</U>. The Company has legal and valid title to all assets and properties described as owned by it in the Preliminary
Prospectus, the Prospectus and the Registration Statement (whether through fee ownership, mineral estates or similar rights of
ownership), in each case free and clear of all liens, except as would not reasonably be expected, individually or in the aggregate,
to have a Material Adverse Effect, and any real property or personal property held under lease by the Company is held under a lease
that is valid, existing and enforceable by the Company with such exceptions as would not reasonably be expected, individually or
in the aggregate, to have a Material Adverse Effect, and the Company has not received any written notice of any material claim
that is adverse to the rights of the Company under any lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Possession
of Intellectual Property</U>. The Company owns or possesses all licenses or other rights to use all patents, trademarks, service
marks, trade names, copyrights, software and design licenses, trade secrets, manufacturing processes, other intangible property
rights and know-how as are necessary for the conduct of its business as described in the Preliminary Prospectus, the Prospectus
and the Registration Statement (collectively, &ldquo;<B>Intellectual Property</B>&rdquo;), except where the failure to own or possess
such Intellectual Property would not reasonably be expected to have a Material Adverse Effect. The Company has not received written
notice of any infringement of or conflict with (and the Company does not know of any such infringement of or conflict with) any
asserted rights of others with respect to any Intellectual Property that would reasonably be expected to have a Material Adverse
Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Company
IT Systems</U>. The Company owns or has a valid right to access and use all computer systems, networks, hardware, software, databases,
websites and equipment used to process, store, maintain and operate data, information and functions necessary for the conduct of
its business (the &ldquo;<B>Company IT Systems</B>&rdquo;), except where the failure to own or have the right to access the Company
IT Systems would not reasonably be expected to have a Material Adverse Effect. The Company IT Systems are adequate for, and operate
and perform in all material respects as required in connection with, the operation of the business of the Company as currently
conducted, except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Environmental
Laws</U>. Except as described in the Preliminary Prospectus, the Prospectus and the Registration Statement, (A) the Company is
not in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or rule of common
law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or
judgment, relating to pollution or protection of human health, the environment (including, without limitation, ambient air, surface
water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating
to the release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum
or petroleum products, asbestos-containing materials or mold (collectively, &ldquo;<B>Hazardous Materials</B>&rdquo;) or to the
manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively,
&ldquo;<B>Environmental Laws</B>&rdquo;), except for those violations that would not reasonably be expected, individually or in
the aggregate, to have a Material Adverse Effect, (B) the Company has all permits, authorizations and approvals required under
any applicable Environmental Laws and is in compliance in all material respects with their requirements, (C) there are no pending
or, to the Company&rsquo;s knowledge, threatened administrative, regulatory or judicial actions, suits, demands, demand letters,
claims, liens, notices of noncompliance or violation, investigations or proceedings relating to any Environmental Law against the
Company, and (D) to the Company&rsquo;s knowledge, there are no events or circumstances that would reasonably be expected to form
the basis of an order for clean-up or remediation, or an action, suit or proceeding by any private party or governmental body or
agency, against or affecting the Company relating to Hazardous Materials or any Environmental Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment
of Taxes</U>. Except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect or
where such matters are the result of a pending bona fide dispute with taxing authorities, (A) the Company has accurately prepared
and timely filed all federal, state, foreign and other tax returns or other statements that are or were required to be filed by
it, if any, and has paid or made provision for the payment of all taxes, assessments, governmental or other similar charges, including
without limitation, all sales and use taxes and all taxes which it is obligated to withhold from amounts owing to employees, creditors
and third parties, with respect to the periods covered by such tax returns (whether or not such amounts are shown as due on any
tax return), (B) no deficiency assessment with respect to a proposed adjustment of the Company&rsquo;s federal, state, local or
foreign taxes is pending or, to the Company&rsquo;s knowledge, threatened, (C) since the date of the most recent audited financial
statements, the Company has not incurred any liability for taxes other than in the ordinary course of its business, and (D) there
is no tax lien, whether imposed by any federal, state, foreign or other taxing authority, outstanding against the assets, properties
or business of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Insurance</U>.
The Company carries, or is covered by, insurance (issued by insurers of recognized financial responsibility) in such amounts and
covering such risks as is appropriate for the conduct of its entire business and the value of its assets, all of which insurance
is in full force and effect in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Investment
Company Act</U>. The Company is not, nor upon the sale of the Public Securities as contemplated herein and the application of the
net proceeds therefrom as described in the Preliminary Prospectus, the Prospectus and the Registration Statement under the caption
&ldquo;Estimated Use of Proceeds&rdquo;, will the Company be, an &ldquo;investment company&rdquo; or an entity &ldquo;controlled&rdquo;
by an &ldquo;investment company&rdquo; (as such terms are defined in the Investment Company Act of 1940, as amended, and the rules
and regulations promulgated thereunder).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Employment
Laws Compliance</U>. The Company has not violated, or received any notice of any violation with respect to, any law, rule, regulation,
order, decree or judgment applicable to it and its business, including those relating to transactions with affiliates, environmental,
safety or similar laws, federal or state laws relating to discrimination in the hiring, promotion or pay of employees, federal
or state wages and hours law, the Employee Retirement Income Security Act of 1974, as amended, or the rules and regulations promulgated
thereunder, except for those violations that would not reasonably be expected, individually or in the aggregate, to have a Material
Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Money
Laundering Laws</U>. The Company has not, and, to the Company&rsquo;s knowledge, none of the officers, directors, employees or
agents purporting to act on behalf of the Company or a subsidiary, as applicable, has made any payment of funds of the Company
or a subsidiary or received or retained any funds in violation of any law, rule or regulation relating to the &ldquo;know your
customer&rdquo; and anti-money laundering laws of any jurisdiction (collectively, the &ldquo;<B>Money Laundering Laws</B>&rdquo;)
and no action, suit or proceeding by or before any governmental entity involving the Company with respect to the Money Laundering
Laws is pending or, to the Company&rsquo;s knowledge, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>OFAC</U>.
The Company has not, and, to the Company&rsquo;s knowledge, none of its directors, officers, agents or employees purporting to
act on behalf of the Company is currently the target of or reasonably likely to become the target of any U.S. sanctions administered
by the Office of Foreign Assets Control of the U.S. Department of the Treasury (&ldquo;<B>OFAC</B>&rdquo;); and the Company will
not directly or indirectly use the proceeds of the offering of the Public Securities hereunder, or lend, contribute or otherwise
make available such proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of financing the
activities of any person currently the target of any U.S. sanctions administered by OFAC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Lock-up
Agreements</U>. Each of the Company&rsquo;s officers and directors, and the Company&rsquo;s former parent, Imprimis Pharmaceuticals,
Inc. (the &ldquo;<B>Lock-Up Parties</B>&rdquo;), have agreed that for a period of twelve (12) months following the initial listing
on an exchange or trading medium (the &ldquo;<B>Lock-Up Period</B>&rdquo;), such persons and their affiliated parties shall not
sell, contract to sell, grant any option for the sale or otherwise dispose of any of our equity securities, or any securities convertible
into or exercisable or exchangeable for our equity securities, without the consent of the Representative, except for 281,980 shares
of our common stock held by the Lock-Up Parties for which the Lock-Up Period shall be six months following the initial listing
on an exchange or trading medium. The Representative may consent to an early release from the Lock-Up period if, in its opinion,
the market for shares of Common Stock would not be adversely impacted by sales and in cases of financial emergency of an officer,
director or other stockholder. The Company has caused each of the Lock-Up Parties to deliver to the Representative the agreements
of each Lock-Up Party to the foregoing effect prior to the date that the Company requests that the Commission declare the Registration
Statement effective under the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.32&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsidiaries</U>.
The Company has no subsidiary that is a &ldquo;significant subsidiary&rdquo; of the Company within the meaning of Rule 1.01 of
Regulation S-X under the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.33&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Related
Party Transactions</U>. Except as disclosed in the Prospectus and the Registration Statement, there are no business relationships
or related party transactions involving the Company or any other person required to be described in the Prospectus that have not
been described as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.34&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Board
of Directors</U>. The Board of Directors of the Company is comprised of the persons set forth under the heading of the Prospectus
captioned &ldquo;Management&rdquo;. The qualifications of the persons serving as board members and the overall composition of the
board comply with the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder applicable to the Company and the rules of
the Nasdaq Capital Market. At least one member of the Board of Directors of the Company qualifies as a &ldquo;financial expert&rdquo;
as such term is defined under the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder and the rules of the Nasdaq Capital
Market. In addition, at least a majority of the persons serving on the Board of Directors qualify as &ldquo;independent&rdquo;
as defined under the rules of the Nasdaq Capital Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Sarbanes-Oxley
Compliance</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.35.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclosure
Controls</U>. The Company has developed and currently maintains disclosure controls and procedures that will comply with Rule 13a-15
or 15d-15 of the Exchange Act, and such controls and procedures are effective to ensure that all material information concerning
the Company will be made known on a timely basis to the individuals responsible for the preparation of the Company&rsquo;s Exchange
Act filings and other public disclosure documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.35.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance</U>.
On the Effective Date, the Company was in material compliance with the provisions of the Sarbanes-Oxley Act of 2002 applicable
to it, and has implemented such programs and taken reasonable steps to ensure the Company&rsquo;s future compliance (not later
than the relevant statutory and regulatory deadlines therefore) with all the material provisions of the Sarbanes-Oxley Act of 2002.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Covenants
of the Company</U>. The Company covenants and agrees as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Amendments to Registration Statement</U>. The Company will deliver to the Representative, prior to filing, any amendment or
supplement to the Registration Statement or Prospectus proposed to be filed after the Effective Date, and it will not file any
such amendment or supplement to which the Representative shall reasonably object in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Federal
Securities Laws</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance</U>.
During the time when a Prospectus is required to be delivered under the Act, the Company will use its best efforts to comply with
all requirements imposed upon it by the Act, the Regulations and the Exchange Act and by the regulations under the Exchange Act,
as from time to time in force, so far as necessary to permit the continuance of sales of or dealings in the Public Securities in
accordance with the provisions hereof and the Prospectus. If at any time when a Prospectus relating to the Public Securities is
required to be delivered under the Act, any event shall have occurred as a result of which, in the opinion of counsel for the Company
or counsel for the Underwriters, the Prospectus, as then amended or supplemented, includes an untrue statement of a material fact
or omits to state any material fact required to be stated therein or necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading, or if it is necessary at any time to amend the Prospectus to comply with
the Act, the Company will notify the Representative promptly and prepare and file with the Commission, subject to Section 3.1 hereof,
an appropriate amendment or supplement in accordance with Section 10 of the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Filing of Final Prospectus</U>. The Company will file the Prospectus (in form and substance satisfactory to the Representative)
with the Commission pursuant to the requirements of Rule 424 of the Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exchange
Act Registration</U>. For a period of three years from the Effective Date, the Company will use its best efforts to maintain the
registration of the shares of Common Stock under the provisions of the Exchange Act. The Company will not deregister the shares
of Common Stock under the Exchange Act without the prior written consent of the Representative. The foregoing requirements shall
automatically terminate in the event that the Company, directly or indirectly, in one or more related transactions, (1) sells,
transfers or otherwise disposes of all or substantially all of its assets to any other person, or (2) consummates a stock or share
purchase agreement or other business combination (including, without limitation, a merger, consolidation, reorganization, recapitalization,
spin-off or scheme of arrangement) with any other person whereby such other person acquires more than 50% of the outstanding shares
of the Company&rsquo;s voting stock and the Company is not the surviving entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.2.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Free
Writing Prospectuses</U>. The Company represents and agrees that it has not made and will not make any offer relating to the Public
Securities that would constitute an issuer free writing prospectus, as defined in Rule 433 of the 1933 Act, without the prior consent
of the Representative. Any such free writing prospectus consented to by the Representative is hereinafter referred to as a &ldquo;<B>Permitted
Free Writing Prospectus</B>.&rdquo; The Company represents that it will treat each Permitted Free Writing Prospectus as an &ldquo;issuer
free writing prospectus&rdquo; as defined in Rule 433, and has complied and will comply with the applicable requirements of Rule
433 of the 1933 Act, including timely Commission filing where required, legending and record keeping.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
to Underwriters of Prospectuses</U>. The Company will deliver to each of the several Underwriters, without charge, from time to
time during the period when the Prospectus is required to be delivered under the Act or the Exchange Act such number of copies
of each Prospectus as such Underwriters may reasonably request and, as soon as the Registration Statement or any amendment or supplement
thereto becomes effective, deliver to the Representative two original executed Registration Statements, including exhibits, and
all post-effective amendments thereto and copies of all exhibits filed therewith or incorporated therein by reference and all original
executed consents of certified experts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Effectiveness
and Events Requiring Notice to the Representative</U>. The Company will notify the Representative immediately and confirm the notice
in writing: (i) of the effectiveness of the Registration Statement and any amendment thereto; (ii) of the issuance by the Commission
of any stop order or of the initiation, or the threatening, of any proceeding for that purpose; (iii) of the issuance by any state
securities commission of any proceedings for the suspension of the qualification of the Public Securities for offering or sale
in any jurisdiction or of the initiation, or the threatening, of any proceeding for that purpose; (iv) of the mailing and delivery
to the Commission for filing of any amendment or supplement to the Registration Statement or Prospectus; (v) of the receipt of
any comments or request for any additional information from the Commission; and (vi) of the happening of any event during the period
described in this Section 3.4 hereof that, in the judgment of the Company, makes any statement of a material fact made in the Registration
Statement or the Prospectus untrue or that requires the making of any changes in the Registration Statement or the Prospectus in
order to make the statements therein, in light of the circumstances under which they were made, not misleading. If the Commission
or any state securities commission shall enter a stop order or suspend such qualification at any time, the Company will make every
reasonable effort to obtain promptly the lifting of such order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Intentionally
Omitted.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reports
to the Representative</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Periodic
Reports, etc</U>. For a period of three years from the Effective Date, the Company will furnish to the Representative copies of
such financial statements and other periodic and special reports as the Company from time to time furnishes generally to holders
of any class of its securities and also promptly furnish to the Representative: (i) a copy of each periodic report the Company
shall be required to file with the Commission; (ii) a copy of every press release and every news item and article with respect
to the Company or its affairs which was released by the Company and posted to the Company&rsquo;s web site; (iii) a copy of each
Form 8-K prepared and filed by the Company; and (iv) five copies of each Registration Statement. Documents filed with the Commission
pursuant to its EDGAR system or posted to the Company&rsquo;s web site shall be deemed to have been delivered to the Representative
pursuant to this Section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transfer
Sheets</U>. For a period of three years from the Effective Date, the Company shall retain a transfer and registrar agent acceptable
to the Representative (the &ldquo;<B>Transfer Agent</B>&rdquo;) and will furnish to the Representatives at the Company&rsquo;s
sole cost and expense such transfer sheets of the Company&rsquo;s securities as the Representative may reasonably request, including
the daily and monthly consolidated transfer sheets of the Transfer Agent and DTC. Computershare Trust Company, N.A. is acceptable
to the Underwriters to act as Transfer Agent for the Company&rsquo;s shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Intentionally
Omitted</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment
of Expenses</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>General
Expenses Related to the Offering</U>. The Company hereby agrees to pay on each of the Closing Date and the Option Closing Date,
if any, to the extent not paid at the Closing Date, all expenses incident to the performance of the obligations of the Company
under this Agreement, including, but not limited to: (i) all filing fees and communication expenses relating to the registration
of the Public Securities to be sold in the Offering with the Commission; (b) all filing fees associated with the review of the
Offering by FINRA; (c) all fees and expenses relating to the listing of the shares of Common Stock on NASDAQ and such other stock
exchanges as the Company and the Underwriter together determine; (d) all fees, expenses and disbursements relating to the registration
or qualification of the Public Securities under the &ldquo;blue sky&rdquo; securities laws of such states and other jurisdictions
as the Representative may reasonably designate; (e) all fees, expenses and disbursements relating to the registration, qualification
or exemption of the Public Securities under the securities laws of such foreign jurisdictions as the Underwriters may reasonably
designate; (f) the costs of all mailing and printing of the Registration Statements, Preliminary Prospectuses, Prospectuses and
all amendments, supplements and exhibits thereto and as many preliminary and final Prospectuses as the Underwriters may reasonably
deem necessary; (g) the costs of preparing, printing and delivering certificates representing the Public Securities and fees and
expenses of the Transfer Agent for the shares of Common Stock; (h) stock transfer and/or stamp taxes, if any, payable upon the
transfer of securities from the Company to the Underwriters; (i) the fees and expenses of the Company&rsquo;s accountants; (j)
the fees and expenses of the Company&rsquo;s legal counsel and other agents and representatives; and (k) the Company&rsquo;s actual
&ldquo;road show&rdquo; expenses for the Offering. With respect to any transaction pursuant to the Offering, the Company&rsquo;s
obligation to reimburse expenses incurred by the Representative, with the exception of legal fees and expenses, will be $50,000,
subject to the Representative&rsquo;s delivery of appropriate expense reports. With respect to any transaction pursuant to the
Offering, the Company will not required to reimburse the Representative more than $150,000 in legal fees. The Representative has
the right to deduct from the net proceeds of the Offering any advance made by the Underwriters to pay for the expenses of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Application
of Net Proceeds</U>. The Company will apply the net proceeds from the Offering received by it in a manner consistent with the application
described under the caption &ldquo;Estimated Use Of Proceeds&rdquo; in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
of Earnings Statements to Security Holders</U>. The Company will make generally available to its security holders as soon as practicable,
but not later than the first day of the fifteenth full calendar month following the Effective Date, an earnings statement (which
need not be certified by independent public or independent certified public accountants unless required by the Act or the Regulations,
but which shall satisfy the provisions of Rule 158(a) under Section 11(a) of the Act) covering a period of at least twelve consecutive
months beginning after the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stabilization</U>.
Neither the Company, nor, to its knowledge, any of its employees, directors or stockholders (without the consent of the Representative)
has taken or will take, directly or indirectly, any action designed to or that has constituted or that might reasonably be expected
to cause or result in, under the Exchange Act, or otherwise, stabilization or manipulation of the price of any security of the
Company to facilitate the sale or resale of the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Internal
Controls</U>. The Company will maintain a system of internal accounting controls sufficient to provide reasonable assurances that:
(i) transactions are executed in accordance with management&rsquo;s general or specific authorization; (ii) transactions are recorded
as necessary in order to permit preparation of financial statements in accordance with GAAP and to maintain accountability for
assets; (iii) access to assets is permitted only in accordance with management&rsquo;s general or specific authorization; and (iv)
the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken
with respect to any differences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Accountants</U>. As of the Effective Date, the Company shall retain KMJ or other independent public accountants reasonably acceptable
to the Representative, and the Company shall continue to retain a nationally recognized independent certified public accounting
firm for a period of at least three years after the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Fiduciary Duties</U>. The Company acknowledges and agrees that the Underwriters&rsquo; responsibility to the Company is solely
contractual in nature and that none of the Underwriters or their affiliates or agents shall be deemed to be acting in a fiduciary
capacity, or otherwise owes any fiduciary duty to the Company or any of its affiliates in connection with the Offering and the
other transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conditions
of Underwriters&rsquo; Obligations</U>. The obligations of the several Underwriters to purchase and pay for the Public Securities,
as provided herein, shall be subject to the continuing accuracy of the representations and warranties of the Company as of the
date hereof and as of each of the Closing Date and the Option Closing Date, if any, to the accuracy of the statements of officers
of the Company made pursuant to the provisions hereof and to the performance by the Company of its obligations hereunder and to
the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulatory
Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Effectiveness
of Registration Statement</U>. The Registration Statement shall have become effective not later than 5:00 P.M., Eastern time, on
the date of this Agreement or such later date and time as shall be consented to in writing by the Representative, and, at each
of the Closing Date and the Option Closing Date, no stop order suspending the effectiveness of the Registration Statement shall
have been issued and no proceedings for that purpose shall have been instituted or shall be pending or contemplated by the Commission
and any request on the part of the Commission for additional information shall have been complied with to the reasonable satisfaction
of the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>FINRA
Clearance</U>. By the Effective Date, the Representative shall have received oral clearance from FINRA as to the amount of compensation
allowable or payable to the Underwriters as described in the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Nasdaq
Clearance</U>. On the Closing Date, the Company&rsquo;s shares of Common Stock, including the Public Securities, shall have been
approved for listing on the Nasdaq Capital Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Company
Counsel Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing
Date Opinion of Counsel</U>. On the Closing Date, the Representative shall have received the favorable opinion of Greenberg Traurig,
LLP, counsel to the Company (&ldquo;<B>GT</B>&rdquo;), dated the Closing Date, addressed to the Representative, in form and substance
reasonably satisfactory in all respects to the Representative. The opinion of GT shall include a statement to the effect that such
counsel has participated in conferences with officers and other representatives of the Company, the Underwriters and the independent
registered public accounting firm of the Company, at which conferences the contents of the Preliminary Prospectus, the Prospectus
and the Registration Statement contained therein and related matters were discussed and, although such counsel is not passing upon
and does not assume any responsibility for the accuracy, completeness or fairness of the statements contained in the Preliminary
Prospectus, the Prospectus and the Registration Statement contained therein, solely on the basis of the foregoing without independent
check and verification, no facts have come to the attention of such counsel which lead them to believe that the Registration Statement
or any amendment thereto, at the time the Registration Statement or amendment became effective, contained an untrue statement of
a material fact or omitted to state a material fact required to be stated therein or necessary to make the statements therein not
misleading or the Prospectus or any amendment or supplement thereto, at the time they were filed pursuant to Rule 424(b) or at
the date of such counsel&rsquo;s opinion, contained an untrue statement of a material fact or omitted to state a material fact
required to be stated therein or necessary to make the statement therein, in light of the circumstances under which they were made,
not misleading (except that such counsel need express no view and shall not be deemed to have rendered an opinion with respect
to the financial information and statistical data). The Registration Statement and the Prospectus and any post-effective amendments
or supplements thereto (other than the financial statements including notes and schedules, financial data and statistical data
included therein, as to which no opinion need be rendered) each as of their respective dates complied as to form in all material
respects with the requirements of the Act and Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Option
Closing Date Opinion of Counsel</U>. On the Option Closing Date, if any, the Representative shall have received the favorable opinion
of GT, counsel to the Company, dated the Option Closing Date, addressed to the Representative and in form and substance reasonably
satisfactory to the Representative, confirming as of the Option Closing Date, the statements made by such counsel in its opinion
delivered on the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reliance</U>.
In rendering its opinion, GT may rely: (i) as to matters involving the application of laws other than the laws of the United States
and jurisdictions in which they are admitted, to the extent such counsel deems proper and to the extent specified in such opinion,
if at all, upon an opinion or opinions (in form and substance reasonably satisfactory to the Representative) of other counsel reasonably
acceptable to the Representative, familiar with the applicable laws; and (ii) as to matters of fact, to the extent they deem proper,
on certificates or other written statements of officers of the Company and officers of departments of various jurisdictions having
custody of documents respecting the corporate existence or good standing of the Company, provided that copies of any such statements
or certificates shall be delivered to J&amp;B if requested. The opinion of GT and any opinion relied upon by GT shall include a
statement to the effect that it may be relied upon by counsel for the Underwriters in its opinion delivered to the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Cold
Comfort Letter</U>. At the time this Agreement is executed, and at each of the Closing Date and the Option Closing Date, if any,
the Representative shall have received a letter in form and substance satisfactory in all respects (including the non-material
nature of the changes or decreases, if any, referred to in clause (iii) below) to the Representative and to J&amp;B from KMJ dated,
respectively, as of the date of this Agreement and as of the Closing Date and the Option Closing Date, if any:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(i) Confirming that they are independent public
accountants with respect to the Company within the meaning of the Act and the applicable Regulations and that they have not, during
the periods covered by the financial statements included in the Prospectus, provided to the Company any non-audit services, as
such term is used in Section 10A(g) of the Exchange Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(ii) Stating that in their opinion the financial
statements of the Company included in the Registration Statement and Prospectus comply as to form in all material respects with
the applicable accounting requirements of the Act and the published Regulations thereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(iii) Stating that, on the basis of a limited
review which included a reading of the latest available unaudited interim financial statements of the Company (with an indication
of the date of the latest available unaudited interim financial statements), a reading of the latest available minutes of the stockholders
and board of directors and the various committees of the board of directors, consultations with officers and other employees of
the Company responsible for financial and accounting matters and other specified procedures and inquiries, nothing has come to
their attention which would lead them to believe that: (a) the unaudited financial statements of the Company included in the Registration
Statement do not comply as to form in all material respects with the applicable accounting requirements of the Act and the Regulations
or are not fairly presented in conformity with GAAP applied on a basis substantially consistent with that of the audited financial
statements of the Company included in the Registration Statement; (b) at a date not later than five days prior to the Effective
Date, Closing Date or Option Closing Date, as the case may be, there was any change in the capital stock or long-term debt of the
Company, or any decrease in the shareholders&rsquo; equity of the Company as compared with amounts shown in the June 30, 2018 balance
sheet included in the Registration Statement, other than as set forth in or contemplated by the Registration Statement, or, if
there was any decrease, setting forth the amount of such decrease, and (c) during the period from June 30, 2018 to a specified
date not later than five days prior to the Effective Date, Closing Date or Option Closing Date, as the case may be, there was any
decrease in revenues, net earnings or net earnings per share, in each case as compared with the corresponding period in the preceding
year and as compared with the corresponding period in the preceding quarter, other than as set forth in or contemplated by the
Registration Statement, or, if there was any such decrease, setting forth the amount of such decrease;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(iv) Setting forth, at a date not later than
five days prior to the Effective Date, the amount of liabilities of the Company (including a breakdown of commercial paper and
notes payable to banks and related parties);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(v) Stating that they have compared specific
dollar amounts, numbers of shares, percentages of revenues and earnings, statements and other financial information pertaining
to the Company set forth in the Prospectus in each case to the extent that such amounts, numbers, percentages, statements and information
may be derived from the general accounting records, including work sheets, of the Company and excluding any questions requiring
an interpretation by legal counsel, with the results obtained from the application of specified readings, inquiries and other appropriate
procedures (which procedures do not constitute an examination in accordance with generally accepted auditing standards) set forth
in the letter and found them to be in agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(vi) Stating that they have not since the
Company&rsquo;s formation brought to the attention of the Company&rsquo;s management any control deficiencies related to internal
structure, design or operation as defined in the Statement on Auditing Standards No. 325 &ldquo;Communications About Control Deficiencies
in an Audit of Financial Statements,&rdquo; in the Company&rsquo;s internal controls; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(vii) Statements as to such other matters
incident to the transaction contemplated hereby as you may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Officers&rsquo;
Certificates</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Officers&rsquo;
Certificate</U>. At each of the Closing Date and the Option Closing Date, if any, the Representative shall have received a certificate
of the Company signed by the Chairman of the Board and Chief Executive Officer of the Company, who can be the same person, dated
the Closing Date or the Option Closing Date, as the case may be, respectively, to the effect that the Company has performed all
covenants and complied with all conditions required by this Agreement to be performed or complied with by the Company prior to
and as of the Closing Date, or the Option Closing Date, as the case may be, and that the conditions set forth in Section 4.5 hereof
have been satisfied as of such date and that, as of the Closing Date and the Option Closing Date, as the case may be, the representations
and warranties of the Company set forth in Section 2 hereof are true and correct. In addition, the Representative will have received
such other and further certificates of officers of the Company as the Representative may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Secretary&rsquo;s
Certificate</U>. At each of the Closing Date and the Option Closing Date, if any, the Representative shall have received a certificate
of the Company signed by the Secretary or Assistant Secretary of the Company, dated the Closing Date or the Option Date, as the
case may be, respectively, certifying: (i) that the Certificate of Incorporation is true and complete, has not been modified and
is in full force and effect; (ii) that the resolutions of the Company&rsquo;s Board of Directors relating to the public offering
contemplated by this Agreement are in full force and effect and have not been modified; (iii) all correspondence between the Company
or its counsel and the Commission; and (iv) as to the incumbency of the officers of the Company. The documents referred to in such
certificate shall be attached to such certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Material Cha</U>nges. Prior to and on each of the Closing Date and the Option Closing Date, if any: (i) there shall have been no
material adverse change or development involving a prospective material adverse change in the condition or the business activities,
financial or otherwise, of the Company from the latest dates as of which such condition is set forth in the Registration Statement
and Prospectus taken as a whole; (ii) no action suit or proceeding, at law or in equity, shall have been pending or threatened
against the Company or any officers or directors before or by any court or federal or state commission, board or other administrative
agency wherein an unfavorable decision, ruling or finding may materially adversely affect the business, operations, or financial
condition or income of the Company, except as set forth in the Registration Statement and Prospectus; (iii) no stop order shall
have been issued under the Act and no proceedings therefore shall have been initiated or threatened by the Commission; and (iv)
the Registration Statement and the Prospectus and any amendments or supplements thereto shall contain all material statements which
are required to be stated therein in accordance with the Act and the Regulations and shall conform in all material respects to
the requirements of the Act and the Regulations, and neither the Registration Statement nor the Prospectus nor any amendment or
supplement thereto shall contain any untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
of Agreements</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Effective
Date Deliveries</U>. On the Effective Date, the Company shall have delivered to the Representative executed copies of this Agreement,
the Underwriters&rsquo; Warrant Agreement and the Lock-Up Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing
Date Deliveries</U>. On the Closing Date, the Company shall have delivered to the Underwriters the Firm Shares, and on the Option
Closing Date, if any, the Company shall have delivered to the Underwriters the Option Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification
of Underwriters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>General</U>.
The Company hereby agrees to indemnify, defend and hold harmless the Representative, Underwriters, their subsidiaries, parents
and affiliates, including Liquid Venture Partners, LLC (&ldquo;<B>Liquid</B>&rdquo;) and each of their directors, officers, managers,
agents, contractors, employees, members, counsel, and each other person or entity who controls the Representative or Liquid or
any of their affiliates within the meaning of Section 15 of the Securities Act (collectively, the &ldquo;<B>Indemnified Parties</B>&rdquo;)
to the fullest extent permitted by law from and against any and all losses, claims, damages, expenses, or liabilities (or actions
in respect thereof) (&ldquo;<B>Losses</B>&rdquo;), joint or several, to which they or any of them may become subject under any
statute or at common law, and to reimburse such Indemnified Parties for any reasonable legal or other expense (including but not
limited to the cost of any investigation, preparation, response to third party subpoenas) incurred by them in connection with any
litigation or administrative or regulatory action (&ldquo;<B>Proceeding</B>&rdquo;), whether pending or threatened, and whether
or not resulting in any liability, insofar as such losses, claims, liabilities, or litigation arise out of or are based upon any
untrue statement or alleged untrue statement of a material fact contained in (1) )&nbsp; the Preliminary Prospectus, the Registration
Statement or the Prospectus (as from time to time each may be amended and supplemented); (2)&nbsp;any materials or information
provided to investors by, or with the approval of, the Company in connection with the marketing of the offering of the Public Securities,
including any &ldquo;road show&rdquo; or investor presentations made to investors by the Company (whether in person or electronically);
or (3) the omission or alleged omission to state in any of the foregoing a material fact required to be stated therein or necessary
to make the statements therein, in light of the circumstances under which they were made, not misleading; provided, however, the
foregoing indemnification provisions shall not apply to (i) statements or omissions made in reliance upon and in conformity with
the Underwriters&rsquo; Information, (ii) amounts paid in settlement of any such litigation if such settlement is effected without
the prior written consent of the Company, which consent will not be unreasonably withheld, conditioned or delayed, or (iii) such
Losses resulted from the gross negligence or willful misconduct, the breach of the Underwriting Agreement or violation of applicable
law by the Representative or any Indemnified Party; and provided that the Company will not be responsible for the fees and expenses
of more than one counsel to all Indemnified Parties, in addition to appropriate local counsel, unless in the reasonable opinion
of counsel to any Indemnified Party there exists a potential conflict of interest which would make it inappropriate for one counsel
to represent all such Indemnified Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Procedure</U>.
Each Indemnified Party shall, promptly after the receipt of notice of the commencement of any claim or Proceeding against such
Indemnified Party in respect of which indemnity may be sought from the Company, notify the Company in writing of the commencement
thereof. The omission of any Indemnified Party to so notify the Company of any such action shall not relieve the Company from any
liability which it may have to such Indemnified Party (a) other than pursuant to Section 5.1.1 or (b) under Section 5.1.1 unless,
and only to the extent that, such omission results in the Company&rsquo;s forfeiture of substantive rights or defenses. In case
any such claim or Proceeding shall be brought against any Indemnified Party, and it shall notify the Company of the commencement
thereof, the Company shall be entitled to assume the defense thereof at its own expense, with counsel satisfactory to such Indemnified
Party in its reasonable judgment; provided, however, that any Indemnified Party may, at its own expense, retain separate counsel
to participate in such defense at its own expense. Notwithstanding the foregoing, in any claim or proceeding in which both the
Company, on the one hand, and an Indemnified Party, on the other hand, are, or are reasonably likely to become, a party, such Indemnified
Party shall have the right to employ separate counsel and to control its own defense of such claim if, in the reasonable opinion
of counsel to such Indemnified Party, either (x) one or more defenses are available to the Indemnified Party that are not available
to the Company or (y) a conflict or potential conflict exists between the Company, on the one hand, and such Indemnified Party,
on the other hand, that would make such separate representation advisable; provided, however, that the Company (i) shall not be
liable for the fees and expenses of more than one counsel to all Indemnified Parties and (ii) shall reimburse the Indemnified Parties
for all of such fees and expenses of such counsel incurred in any action between the Company and the Indemnified Parties or between
the Indemnified Parties and any third party, as such expenses are incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reimbursement</U>.
In the event the Company chooses not to accept the defense of the Proceeding, the Company will reimburse all Indemnified Parties
for all reasonable expenses (including, but not limited to, reasonable fees and disbursements of counsel for all Indemnified Parties)
incurred by any such Indemnified Parties in connection with investigating, preparing, and defending any such action or claim, whether
or not in connection with pending or threatened litigation in connection with the transaction to which an Indemnified Party is
a party, promptly as such expenses are incurred or paid (unless the Indemnified Parties request they be paid in advance pursuant
to Section 5.1.4 below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.1.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Advances</U>.
Notwithstanding any other provision hereof or any other agreement between the parties, in the event the Company chooses not to
accept the defense of the Proceeding, the Company shall advance, to the extent not prohibited by law, all expenses reasonably anticipated
to be incurred by or on behalf of the Indemnified Parties in connection with any Proceeding, whether pending or threatened, within
thirty (30) days of receipt of a statement or statements (&ldquo;Statement(s)&rdquo;) from the Indemnified Parties, or any of them,
requesting such advances from time to time, so long as the Company has received a written undertaking of such Indemnified Parties
to repay the Company the amount so advanced if it shall be finally determined that such Indemnified Parties were not entitled to
indemnification hereunder. This advancement obligation shall include any refundable retainers of counsel retained by Indemnified
Parties (as selected by Indemnified Parties in their sole and absolute discretion). Any Statement requesting advances shall evidence
the expenses anticipated or incurred by the Indemnified Parties with reasonable particularity and may include only those expenses
reasonably expected to be incurred within the 60-day period following each Statement. In the event some portion of the amounts
advanced pursuant to this Section 5.1.4 is unused, or in the event a court of competent jurisdiction finally determines that the
Indemnified Parties are not entitled to be indemnified against certain expenses, Indemnified Parties shall return the unused or
disallowed portion of any advances within thirty (30) days of the final disposition of any Proceeding to which such advances pertain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification
of the Company</U>. The Company agrees that no Indemnified Party shall have any liability to the Company or its respective owners,
successors, heirs, parents, affiliates, security holders or creditors for any Losses, except to the extent such Losses resulted
from the Company&rsquo;s use of the Underwriters&rsquo; Information or such Indemnified Person&rsquo;s gross negligence or willful
misconduct, breach of the Underwriting Agreement or violation of applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Contribution</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Contribution
Rights</U>. If such indemnification is for any reason not available or insufficient to hold an Indemnified Party harmless, the
Company agrees promptly to contribute to the Losses involved in such proportion as is appropriate to reflect the relative benefits
received (or anticipated to be received) by the Company, on the one hand, and by the Representative, on the other hand, with respect
to this Agreement, or, if such allocation is determined by a court or arbitral tribunal to be unavailable, in such proportion as
is appropriate to reflect other equitable considerations such as the relative fault of the Company on the one hand and of the Representative
on the other hand; provided, however, that, to the extent permitted by applicable law, the Indemnified Parties shall not be responsible
for amounts which in the aggregate are in excess of the amount of all cash fees and value of warrants or other in-kind consideration,
exclusive of costs, actually received by the Representative from the Company in connection with this Agreement. Relative benefits
to the Company, on the one hand, and to the Representative, on the other hand, with respect to this Agreement shall be deemed to
be in the same proportion as (i) the total value received or proposed to be received by the Company in connection with the Offering,
whether or not consummated, bears to (ii) all fees received or proposed to be received by the Representative in connection with
the applicable engagement (including warrants or other in-kind consideration). Relative fault shall be determined, in the case
of Losses arising out of or based on any untrue statement or any alleged untrue statement of a material fact or omission or alleged
omission to state a material fact, by reference to, among other things, whether the untrue or alleged untrue statement of a material
fact or the omission or alleged omission to state a material fact relates to information supplied by the Company to the Representative
and the parties&rsquo; relative intent, knowledge, access to information and opportunity to correct or prevent such untrue statement
or omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act of 1933,
as amended) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Contribution
Procedure</U>. Within fifteen days after receipt by any party to this Agreement (or its representative) of notice of the commencement
of any action, suit or proceeding, such party will, if a claim for contribution in respect thereof is to be made against another
party (&ldquo;<B>Contributing Party</B>&rdquo;), notify the Contributing Party of the commencement thereof, but the omission to
so notify the Contributing Party will not relieve it from any liability which it may have to any other party other than for contribution
hereunder. In case any such action, suit or proceeding is brought against any party, and such party notifies a Contributing Party
or its representative of the commencement thereof within the aforesaid fifteen days, the Contributing Party will be entitled to
participate therein with the notifying party and any other Contributing Party similarly notified. Any such Contributing Party shall
not be liable to any party seeking contribution on account of any settlement of any claim, action or proceeding affected by such
party seeking contribution without the written consent of such Contributing Party. The contribution provisions contained in this
Section are intended to supersede, to the extent permitted by law, any right to contribution under the Act, the Exchange Act or
otherwise available. Each Underwriter&rsquo;s obligations to contribute pursuant to this Section 5.3 are several and not joint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Settlement</U>.
The Company will not, without the Representative&rsquo;s prior written consent, settle, compromise, or consent to the entry of
any judgment in or otherwise seek to terminate any pending Proceeding in respect of which indemnification may be sought hereunder
(whether or not any Indemnified Party is a party therein) unless the Company has given the Representative reasonable prior written
notice thereof and such settlement, compromise, consent or termination includes an unconditional release of each Indemnified Party
from any liabilities arising out of such Proceeding. The Company will not permit any such settlement, compromise, consent or termination
to include a statement as to, or an admission of, fault, culpability or a failure to act by or on behalf of an Indemnified Party,
without such Indemnified Party's prior written consent. No Indemnified Party seeking indemnification, reimbursement or contribution
under this Agreement will, without the Company's prior written consent (which shall not be unreasonably withheld) settle, compromise,
consent to the entry of any judgment in or otherwise seek to terminate any Proceeding referred to herein or admit fault, culpability
or failure to act by or on behalf of the Company or any Indemnified Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival;
Successors</U>. The indemnity, contribution and expense reimbursement obligations set forth herein shall be in addition to any
liability the Company may have to any Indemnified Party at common law or otherwise (but not duplicative of or effective to result
in any multiplicative return of Losses or of any such liability of the Company), and shall remain operative and in full force and
effect notwithstanding the termination of this Agreement, the closing of the contemplated Offering, and any successor of the Representative
or any other Indemnified Parties shall be entitled to the benefit of the provisions hereof. Prior to entering into any agreement
or arrangement with respect to, or effecting, any merger, statutory exchange or other business combination or proposed sale or
exchange, dividend or other distribution or liquidation of all or a significant portion of its assets in one or a series of transactions
or any significant recapitalization or reclassification of its outstanding securities that does not directly or indirectly provide
for the assumption of the obligations of the Company set forth herein, the Company will promptly notify the Representative in writing
thereof and, if requested by the Representative, shall arrange in connection therewith alternative means of providing for the obligations
of the Company set forth herein, including the assumption of such obligations by another party, insurance, surety bonds or the
creation of an escrow, in each case in an amount and on terms and conditions reasonably satisfactory to the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Default
by an Underwriter</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Default
Not Exceeding 10% of Firm Shares or Option Shares</U>. If any Underwriter or Underwriters shall default in its or their obligations
to purchase the Firm Shares or the Option Shares, if the Over-allotment Option is exercised, hereunder, and if the number of the
Firm Shares or Option Shares with respect to which such default relates does not exceed in the aggregate 10% of the number of Firm
Shares or Option Shares that all Underwriters have agreed to purchase hereunder, then such Firm Shares or Option Shares to which
the default relates shall be purchased by the non-defaulting Underwriters in proportion to their respective commitments hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Default
Exceeding 10% of Firm Shares or Option Shares</U>. In the event that the default addressed in Section 6.1 relates to more than
10% of the Firm Shares or Option Shares, the Representative may, in its discretion, arrange for itself or for another party or
parties to purchase such Firm Shares or Option Shares to which such default relates on the terms contained herein. If, within one
(1) Business Day after such default relating to more than 10% of the Firm Shares or Option Shares, the Representative does not
arrange for the purchase of such Firm Shares or Option Shares, then the Company shall be entitled to a further period of one (1)
Business Day within which to procure another party or parties satisfactory to the Representative to purchase said Firm Shares or
Option Shares on such terms. In the event that neither the Representative nor the Company arrange for the purchase of the Firm
Shares or Option Shares to which a default relates as provided in this Section 6, this Agreement will automatically be terminated
by the Representative or the Company without liability on the part of the Company (except as provided in Sections 3.10 and 5 hereof)
or the several Underwriters (except as provided in Section 5 hereof); provided, however, that if such default occurs with respect
to the Option Shares, this Agreement will not terminate as to the Firm Shares; and provided further that nothing herein shall relieve
a defaulting Underwriter of its liability, if any, to the other Underwriters and to the Company for damages occasioned by its default
hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Postponement
of Closing Date</U>. In the event that the Firm Shares or Option Shares to which the default relates are to be purchased by the
non-defaulting Underwriters, or are to be purchased by another party or parties as aforesaid, the Representative or the Company
shall have the right to postpone the Closing Date or Option Closing Date for a reasonable period, but not in any event exceeding
five (5) Business Days, in order to effect whatever changes may thereby be made necessary in the Registration Statement or the
Prospectus or in any other documents and arrangements, and the Company agrees to file promptly any amendment to the Registration
Statement or the Prospectus that in the opinion of counsel for the Underwriter may thereby be made necessary. The term &ldquo;Underwriter&rdquo;
as used in this Agreement shall include any party substituted under this Section 6 with like effect as if it had originally been
a party to this Agreement with respect to such securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional
Covenants</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Board
Composition and Board Designations</U>. The Company shall ensure that: (i) the qualifications of the persons serving as board members
and the overall composition of the board comply with the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder and with
the listing requirements of the NYSE, the NYSE MKT, NASDAQ or any other national securities exchange or national securities association,
as the case may be, in the event the Company seeks to have its Public Securities listed on another exchange or quoted on an automated
quotation system, and (ii) if applicable, at least one member of the board of directors qualifies as a &ldquo;financial expert&rdquo;
as such term is defined under the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Prohibition
on Press Releases and Public Announcements</U>. The Company will not issue press releases or engage in any other publicity, without
prior notice to the Representative, for a period ending at 5:00 p.m. Eastern time on the first business day following the 25th
day following the Closing Date, other than normal and customary releases issued in the ordinary course of the Company&rsquo;s business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">7.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Blue
Sky Compliance</U>. The Company shall be responsible for the qualification or registration of the Public Securities for sale under
(or obtain exemptions from the application of) the state securities or blue sky laws of those jurisdictions in the United States
designated by the Representative, shall comply with such laws and shall continue such qualifications, registrations and exemptions
in effect so long as required for the distribution of the shares of Common Stock, if such filings are so required. The Company
shall not be required to qualify as a foreign corporation or to take any action that would subject it to general service of process
in any such jurisdiction where it is not presently qualified or where it would be subject to taxation as a foreign corporation.
The Company will advise the Representative promptly of the suspension of the qualification or registration of (or any such exemption
relating to) the Public Securities for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding
for any such purpose, and in the event of the issuance of any order suspending such qualification, registration or exemption, the
Company shall use its best efforts to obtain the withdrawal thereof at the earliest possible moment. The Company, at its expense,
will cause its counsel to provide to the Representative a Preliminary Blue Sky Memorandum no later than the date first public version
of the Registration Statement is filed with the Commission and a Final Blue Sky Memorandum at the Effective Date, in such quantities
as the Underwriter reasonably request, for its use and the use of the selling members in connection with the offer and sale of
the Public Securities. The Company will, from time to time, prepare and file such statements, reports, certificates, notices and
other forms and documents as are or may be required to continue such qualifications in effect for so long as the Representative
may request for the distribution of the Public Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">7.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Free
Writing Prospectuses</U>. Each Underwriter severally covenants with the Company not to take any action that would result in the
Company being required to file with the Commission under Rule 433(d) a free writing prospectus prepared by or on behalf of such
Underwriter that otherwise would not be required to be filed by the Company thereunder, but for the action of the Underwriter.
Any such free writing prospectus consented to by the Company is hereinafter referred to as an &ldquo;<B>Underwriter Free Writing
Prospectus</B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Effective
Date of this Agreement and Termination Thereof</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Effective
Date</U>. This Agreement shall become effective when both the Company and the Representative have executed the same and delivered
counterparts of such signatures to the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>.
The Representative shall have the right to terminate this Agreement at any time prior to any Closing Date, (i) if any domestic
or international event or act or occurrence has materially disrupted, or in the Representative&rsquo;s opinion will in the immediate
future materially disrupt, general securities markets in the United States; or (ii) if trading on the NYSE Euronext, the NASDAQ
Global Market or the NASDAQ Capital Market shall have been suspended or materially limited, or minimum or maximum prices for trading
shall have been fixed, or maximum ranges for prices for securities shall have been required by FINRA or by order of the Commission
or any other government authority having jurisdiction, or (iii) if the United States shall have become involved in a new war or
an increase in major hostilities, or (iv) if a banking moratorium has been declared by a New York State or federal authority, or
(v) if a moratorium on foreign exchange trading has been declared which materially adversely impacts the United States securities
markets, or (vi) if the Company shall have sustained a material loss by fire, flood, accident, hurricane, earthquake, theft, sabotage
or other calamity or malicious act which, whether or not such loss shall have been insured, will, in the Representative&rsquo;s
opinion, make it inadvisable to proceed with the delivery of the Firm Shares or Option Shares, or (vii) if the Company is in material
breach of any of its representations, warranties or covenants hereunder, or (viii) if the Representative shall have become aware
after the date hereof of such a material adverse change in the conditions or prospects of the Company, or such adverse material
change in general market conditions as in the Representative&rsquo;s reasonable judgment would make it impracticable to proceed
with the offering, sale and/or delivery of the securities or to enforce contracts made by the Underwriters for the sale of the
securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">8.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Expenses</U>.
Except in the case of a default by the Underwriters pursuant to Section 6.2 above, in the event that this Agreement shall not be
carried out for any reason whatsoever, within the time specified herein or any extensions thereof pursuant to the terms herein,
the Company shall promptly pay the Representative its accrued but unpaid fees and unreimbursed expenses incurred up to and as of
the date of termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">9.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
All notices, demands, and other communications to given pursuant to this Agreement shall be in writing and shall be personally
delivered, sent by overnight delivery using a nationally recognized courier service, sent by facsimile transmission, or emailed.
Notice shall be deemed received: (a) if personally delivered, upon the date of delivery to the address of the receiving party;
(b) if sent by overnight courier, the date actually received by the recipient; (c) if sent by facsimile or email, when sent. The
parties will each promptly notify the other of any changes to the following contact information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><U>Notices to the NSC shall be sent to</U>:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">National Securities Corporation<BR>
        200 Vesey Street, 25th Floor<BR>
        New York, NY 10281<BR>
        Attention: Jonathan C. Rich<BR>
        e-mail: <U>jrich@nationalsecuritiesib.com</U><BR>
        <BR>
        <U>with a copy to</U>:<BR>
        <BR>
        Liquid Venture Partners, LLC<BR>
        2121 Rosecrans Avenue, Suite 4305<BR>
        El Segundo, CA 90245<BR>
        Attention: Ankur V. Desai<BR>
        e-mail: adesai@liquidventure.com</P></TD>
    <TD STYLE="width: 50%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><U>Notices to the Company shall be sent to</U>:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Eton Pharmaceuticals, Inc.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">21925 W Field Parkway, Suite 235</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Deer Park, IL 60010</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attention: Sean Brynjelsen</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">e-mail: sbrynjelsen@etonpharma.com</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><U>with a copy (which shall not constitute
        notice) to</U>:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Greenberg Traurig, LLP<BR>
        3161 Michelson Drive, Suite 1000<BR>
        Irvine, CA 92612<BR>
        Attention: Daniel Donahue<BR>
        email: donahued@gtlaw.com</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>with a copy (which shall not constitute notice) to</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jenner &amp; Block LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">919 Third Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attention: Martin C. Glass</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">e-mail : mglass@jenner.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">9.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Section
Headings</U>. The section headings herein are for convenience of reference only, and shall not limit or otherwise affect the meaning
hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">9.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire
Agreement</U>. This Agreement sets forth the entire understanding of the parties relating to the subject matter hereof and supersedes
and cancels any prior communications, understandings and agreements, whether oral or written, between the Representative and the
Company. This Agreement may not be amended or modified except in writing. Neither party shall assign its rights or duties hereunder
without the prior written consent of the other party, which may be withheld in the other party&rsquo;s sole and absolute discretion;
provided however that nothing in this sentence shall impact the Representative&rsquo;s ability to engage in customary arrangements
in connection with the formation of a selling group for the Offering. Notwithstanding the foregoing, the Representative may assign
its rights to its Fees and Warrants per Section 1 to any affiliate of the Representative. This Agreement shall apply to, inure
to the benefit of and be binding upon and enforceable against each of the parties and their successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">9.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Third
Party Beneficiaries</U>. This Agreement is intended solely for the benefit of the parties hereto and, with the exception of the
rights and benefits conferred upon the Indemnified Parties by Section 5 of this Agreement, shall not be deemed or interpreted to
confer any rights upon any third parties. The term &ldquo;successors and assigns&rdquo; shall not include a purchaser, in its capacity
as such, of securities from any of the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">9.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law</U>. All aspects of the relationship created by this Agreement shall be governed by and construed in accordance with the laws
of the State of New York, applicable to contracts made and to be performed in New York, without regard to its conflicts of laws
provisions. All actions and proceedings which are not submitted to arbitration pursuant to Section 9.6 hereof shall be heard and
determined exclusively in the state and federal courts located in the Borough of Manhattan in the City of New York, and the Company,
Liquid and the Representative hereby submit to the jurisdiction of such courts and irrevocably waive any defense or objection to
such forum, on forum non conveniens grounds or otherwise. The parties agree to accept service of process by mail, to their principal
business address, addressed to the chief executive officer and secretary thereof. The parties hereby agree that this Section 9.5
shall survive the termination and/or expiration of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">9.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Arbitration</U>.
Any dispute, claim or controversy arising out of or relating to this Agreement or the breach, termination, enforcement, interpretation
or validity thereof, including the determination of the scope or applicability of this agreement to arbitrate, shall be determined
by arbitration in New York City (with the exception of claims to enforce the indemnity provision contained herein, which may, at
the option of the party seeking relief, be submitted either to arbitration or to any court of competent jurisdiction). The arbitration
shall be administered either by FINRA Dispute Resolution pursuant to its Code of Arbitration Procedure, or if FINRA cannot or does
not accept the arbitration, by JAMS pursuant to its Streamlined Arbitration Rules and Procedures. Judgment on the Award may be
entered in any court having jurisdiction. This clause shall not preclude parties from seeking provisional remedies in aid of arbitration
from a court of appropriate jurisdiction. The arbitrator may, in the award, allocate all or part of the costs of the arbitration,
including the fees of the arbitrator and the reasonable attorneys&rsquo; fees of the prevailing party. The parties hereby agree
that this Section 9.6 shall survive the termination and/or expiration of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">9.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Execution
in Counterparts</U>. This Agreement may be executed via facsimile transmission and may be executed in separate counterparts, each
of which shall be deemed to be an original and all of which together shall constitute a single instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">9.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>.
Should any one or more covenants, restrictions and provisions contained in this Agreement be held for any reason to be void, invalid
or unenforceable, in whole or in part, such unenforceability will not affect the validity of any other term of this Agreement,
and the invalid provision will be binding to the fullest extent permitted by law and will be deemed amended and construed so as
to meet this intent. To the extent any provision cannot be so amended or construed as a matter of law, the validity of the remaining
provisions shall be deemed unaffected and the illegal or invalid provision will be deemed stricken from this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">9.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver,
etc</U>. The failure of any of the parties hereto to at any time enforce any of the provisions of this Agreement shall not be deemed
or construed to be a waiver of any such provision, nor to in any way effect the validity of this Agreement or any provision hereof
or the right of any of the parties hereto to thereafter enforce each and every provision of this Agreement. No waiver of any breach,
non-compliance or non-fulfillment of any of the provisions of this Agreement shall be effective unless set forth in a written instrument
executed by the party or parties against whom or which enforcement of such waiver is sought; and no waiver of any such breach,
non-compliance or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance
or non-fulfillment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[SIGNATURE PAGE FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If the foregoing correctly sets forth the understanding between
the Underwriters and the Company, please so indicate in the space provided below for that purpose, whereupon this letter shall
constitute a binding agreement between us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">ETON PHARMACEUTICALS, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Sean Brynjelsen,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Accepted on the date first above written.</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">NATIONAL SECURITIES CORPORATION,</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">as Representative of the several Underwriters</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Jonathan C. Rich, </FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">EVP &ndash; Head of Investment Banking</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 74%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 0.75pt solid"><B><U STYLE="text-decoration: none">Name of Underwriter</U></B></P></TD>
    <TD NOWRAP STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: black 1pt solid; text-align: center; width: 25%"><FONT STYLE="font-size: 10pt"><B>Number
    of Firm <BR> Shares</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">National Securities Corporation</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.4
<SEQUENCE>3
<FILENAME>s113558_ex3-4.htm
<DESCRIPTION>EXHIBIT 3.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 3.4</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">AMENDED AND RESTATED</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">BYLAWS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ETON PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ARTICLE I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>OFFICES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
1.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Registered
Office.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif"> The registered office of the corporation in the State
of Delaware shall be in the City of Dover, County of Kent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other
Offices.</B> The corporation shall also have and maintain an office or principal place of business at such place as may be fixed
by the corporation&rsquo;s Board of Directors (the &ldquo;<B><I>Board of Directors</I></B>&rdquo;), and may also have offices at
such other places, both within and without the State of Delaware as the Board of Directors may from time to time determine or the
business of the corporation may require.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CORPORATE SEAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
3.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Corporate
Seal.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif"> The Board of Directors may adopt a corporate seal. The
corporate seal shall consist of a die bearing the name of the corporation and the inscription, &ldquo;Corporate Seal-Delaware.&rdquo;
Said seal may be used by causing it or a facsimile thereof to be impressed or affixed or reproduced or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE III</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>STOCKHOLDERS&rsquo; MEETINGS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
4.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Place
of Meetings.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif"> Meetings of the stockholders of the corporation
may be held at such place, either within or without the State of Delaware, as may be determined from time to time by the Board
of Directors. The Board of Directors may, in its sole discretion, determine that the meeting shall not be held at any place, but
may instead be held solely by means of remote communication as provided under the Delaware General Corporation Law (the &ldquo;<B><I>DGCL</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
5.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Annual
Meetings.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>The
annual meeting of the stockholders of the corporation, for the purpose of election of directors and for such other business as
may properly come before it, shall be held on such date and at such time as may be designated from time to time by the Board of
Directors. Nominations of persons for election to the Board of Directors of the corporation and the proposal of business to be
considered by the stockholders may be made at an annual meeting of stockholders: (i) pursuant to the corporation&rsquo;s notice
of meeting of stockholders (with respect to business other than nominations); (ii) brought specifically by or at the direction
of the Board of Directors; or (iii) by any stockholder of the corporation who was a stockholder of record at the time of giving
the stockholder&rsquo;s notice provided for in Section 5(b) of these Amended and Restated Bylaws (the &ldquo;<B><I>Bylaws</I></B>&rdquo;),
who is entitled to vote at the meeting and who complied with the notice procedures set forth in this Section 5. For the avoidance
of doubt, clause (iii) above shall be the exclusive means for a stockholder to make nominations and submit other business (other
than matters properly included in the corporation&rsquo;s notice of meeting of stockholders and proxy statement under Rule 14a-8
under the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (the &ldquo;<B><I>1934 Act</I></B>&rdquo;))
before an annual meeting of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>At
an annual meeting of the stockholders, only such business shall be conducted as is a proper matter for stockholder action under
Delaware law and as shall have been properly brought before the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>For
nominations for the election to the Board of Directors to be properly brought before an annual meeting by a stockholder pursuant
to clause (iii) of Section 5(a) of these Bylaws, the stockholder must deliver written notice to the Secretary at the principal
executive offices of the corporation on a timely basis as set forth in Section 5(b)(iii) of these Bylaws and must update and supplement
such written notice on a timely basis as set forth in Section 5(c) of these Bylaws. Such stockholder&rsquo;s notice shall set forth,
as to each nominee such stockholder proposes to nominate at the meeting: (1) the name, age, business address and residence address
of such nominee; (2) the principal occupation or employment of such nominee; (3) the class and number of shares of each class of
capital stock of the corporation which are owned of record and beneficially by such nominee; (4) the date or dates on which such
shares were acquired and the investment intent of such acquisition; (5) with respect to each nominee for election or re-election
to the Board of Directors, include a completed and signed questionnaire required by Section 5(e) of these Bylaws; and (6) such
other information concerning such nominee as would be required to be disclosed in a proxy statement soliciting proxies for the
election of such nominee as a director in an election contest (even if an election contest is not involved), or that is otherwise
required to be disclosed pursuant to Section 14 of the 1934 Act and the rules and regulations promulgated thereunder (including
such person&rsquo;s written consent to being named as a nominee and to serving as a director if elected). The corporation may require
any proposed nominee to furnish such other information as it may reasonably require to determine the eligibility of such proposed
nominee to serve as an independent director of the corporation or that could be material to a reasonable stockholder&rsquo;s understanding
of the independence, or lack thereof, of such proposed nominee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>Other
than proposals sought to be included in the corporation&rsquo;s proxy materials pursuant to Rule 14(a)-8 under the 1934 Act, for
business other than nominations for the election to the Board of Directors to be properly brought before an annual meeting by a
stockholder pursuant to clause (iii) of Section 5(a) of these Bylaws, the stockholder must deliver written notice to the Secretary
at the principal executive offices of the corporation on a timely basis as set forth in Section 5(b)(iii) of these Bylaws, and
must update and supplement such written notice on a timely basis as set forth in Section 5(c) of these Bylaws. Such stockholder&rsquo;s
notice shall set forth, as to each matter such stockholder proposes to bring before the meeting, a brief description of the business
desired to be brought before the meeting, the reasons for conducting such business at the meeting, and any material interest (including
any anticipated benefit of such business to any stockholder giving the notice and the beneficial owner, if any, on whose behalf
the nomination or proposal is made (each, a &ldquo;<B><I>Proponent</I></B>&rdquo; and collectively, the &ldquo;<B><I>Proponents</I></B>&rdquo;)
other than solely as a result of its ownership of the corporation&rsquo;s capital stock, that is material to any Proponent individually,
or to the Proponents in the aggregate) in such business of any Proponent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>To
be timely, the written notice required by Section 5(b)(i) or 5(b)(ii) of these Bylaws must be received by the Secretary at the
principal executive offices of the corporation not later than the close of business on the 90th day nor earlier than the close
of business on the 120th day prior to the first anniversary of the preceding year&rsquo;s annual meeting; <I>provided, however,</I>
that, subject to the last sentence of this Section 5(b)(iii), in the event that the date of the annual meeting is advanced more
than 30 days prior to or delayed by more than 30 days after the anniversary of the preceding year&rsquo;s annual meeting, notice
by the stockholder to be timely must be so received not earlier than the close of business on the 120th day prior to such annual
meeting and not later than the close of business on the later of the 90th day prior to such annual meeting or the 10th day following
the day on which public announcement of the date of such meeting is first made. In no event shall an adjournment or a postponement
of an annual meeting for which notice has been given, or the public announcement thereof has been made, commence a new time period
for the giving of a stockholder&rsquo;s notice as described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>A
stockholder providing written notice required by Section 5(b)(i) or (ii) of these Bylaws shall update and supplement such notice
in writing, if necessary, so that the information provided or required to be provided in such notice is true and correct in all
material respects as of (i) the record date for the meeting and (ii) the date that is five business days prior to the meeting and,
in the event of any adjournment or postponement thereof, five business days prior to such adjourned or postponed meeting. In the
case of an update and supplement pursuant to clause (i) of this Section 5(c), such update and supplement shall be received by the
Secretary at the principal executive offices of the corporation not later than five business days after the record date for the
meeting. In the case of an update and supplement pursuant to clause (ii) of this Section 5(c), such update and supplement shall
be received by the Secretary at the principal executive offices of the corporation not later than two business days prior to the
date for the meeting, and, in the event of any adjournment or postponement thereof, two business days prior to such adjourned or
postponed meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>Notwithstanding
anything in Section 5(b)(iii) of these Bylaws to the contrary, in the event that the number of directors in an Expiring Class (as
defined below) is increased and there is no public announcement of the appointment of a director to such class, or, if no appointment
was made, of the vacancy in such class, made by the corporation at least 10 days before the last day a stockholder may deliver
a notice of nomination in accordance with Section 5(b)(iii) of these Bylaws, a stockholder&rsquo;s notice required by this Section
5 and which complies with the requirements in Section 5(b)(i) of these Bylaws, other than the timing requirements in Section 5(b)(iii)
of these Bylaws, shall also be considered timely, but only with respect to nominees for any new positions in such Expiring Class
created by such increase, if it shall be received by the Secretary at the principal executive offices of the corporation not later
than the close of business on the 10th day following the day on which such public announcement is first made by the corporation.
For purposes of this Section 5, an &ldquo;<B><I>Expiring Class</I></B>&rdquo; shall mean a class of directors whose term shall
expire at the next annual meeting of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>To
be eligible to be a nominee for election or re-election as a director of the corporation pursuant to a nomination under clause
(iii) of Section 5(a) of these Bylaws, such proposed nominee or a person on such proposed nominee&rsquo;s behalf must deliver (in
accordance with the time periods prescribed for delivery of notice under Section 5(b)(iii) or 5(d) of these Bylaws, as applicable)
to the Secretary at the principal executive offices of the corporation a written questionnaire with respect to the background and
qualification of such proposed nominee and the background of any other person or entity on whose behalf the nomination is being
made (which questionnaire shall be provided by the Secretary upon written request).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>A
person shall not be eligible for election or re-election as a director unless the person is nominated either in accordance with
clause (ii) of Section 5(a) of these Bylaws, or in accordance with clause (iii) of Section 5(a) of these Bylaws. Except as otherwise
required by law, the chairman of the meeting shall have the power and duty to determine whether a nomination or any business proposed
to be brought before the meeting was made, or proposed, as the case may be, in accordance with the procedures set forth in these
Bylaws and, if any proposed nomination or business is not in compliance with these Bylaws, to declare that such proposal or nomination
shall not be presented for stockholder action at the meeting and shall be disregarded, notwithstanding that proxies in respect
of such nominations or such business may have been solicited or received.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>Notwithstanding
the foregoing provisions of this Section 5, in order to include information with respect to a stockholder proposal in the proxy
statement and form of proxy for a stockholders&rsquo; meeting, a stockholder must also comply with all applicable requirements
of the 1934 Act and the rules and regulations thereunder. Nothing in these Bylaws shall be deemed to affect any rights of stockholders
to request inclusion of proposals in the corporation&rsquo;s proxy statement pursuant to Rule 14a-8 under the 1934 Act; <I>provided,
however,</I> that any references in these Bylaws to the 1934 Act or the rules and regulations thereunder are not intended to and
shall not limit the requirements applicable to proposals and/or nominations to be considered pursuant to Section 5(a)(iii) of these
Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>For
purposes of Sections 5 and 6 of these Bylaws,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B><I>public
announcement</I></B>&rdquo; shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or
comparable national news service or in a document publicly filed by the corporation with the Securities and Exchange Commission
pursuant to Section 13, 14 or 15(d) of the 1934 Act; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B><I>affiliates</I></B>&rdquo;
and &ldquo;<B><I>associates</I></B>&rdquo; shall have the meanings set forth in Rule 405 under the Securities Act of 1933, as amended
(the &ldquo;<B><I>1933 Act</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Special
Meetings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>Special
meetings of the stockholders of the corporation may be called, for any purpose as is a proper matter for stockholder action under
Delaware law, by (i) the Chairman of the Board of Directors, (ii) the Chief Executive Officer, (iii) the Board of Directors pursuant
to a resolution adopted by a majority of the total number of authorized directors (whether or not there exist any vacancies in
previously authorized directorships at the time any such resolution is presented to the Board of Directors for adoption), or (iv)
the holders of at least 40% of the voting power of all of the then-outstanding shares of capital stock of the corporation entitled
to vote generally in the election of directors, voting together as a single class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>The
Board of Directors shall determine the time and place, if any, of such special meeting. Upon determination of the time and place,
if any, of the meeting, the Secretary shall cause a notice of meeting to be given to the stockholders entitled to vote, in accordance
with the provisions of Section 7 of these Bylaws. No business may be transacted at such special meeting otherwise than specified
in the notice of meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>Nominations
of persons for election to the Board of Directors may be made at a special meeting of stockholders at which directors are to be
elected (i) by or at the direction of the Board of Directors or (ii) by any stockholder of the corporation who is a stockholder
of record at the time of giving notice provided for in this paragraph, who shall be entitled to vote at the meeting and who delivers
written notice to the Secretary of the corporation setting forth the information required by Section 5(b)(i) of these Bylaws. In
the event the corporation calls a special meeting of stockholders for the purpose of electing one or more directors to the Board
of Directors, any such stockholder of record may nominate a person or persons (as the case may be), for election to such position(s)
as specified in the corporation&rsquo;s notice of meeting, if written notice setting forth the information required by Section
5(b)(i) of these Bylaws shall be received by the Secretary at the principal executive offices of the corporation not later than
the close of business on the later of the 90th day prior to such meeting or the 10th day following the day on which public announcement
is first made of the date of the special meeting and of the nominees proposed by the Board of Directors to be elected at such meeting.
The stockholder shall also update and supplement such information as required under Section 5(c) of these Bylaws. In no event shall
an adjournment or a postponement of a special meeting for which notice has been given, or the public announcement thereof has been
made, commence a new time period for the giving of a stockholder&rsquo;s notice as described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>Notwithstanding
the foregoing provisions of this Section 6, a stockholder must also comply with all applicable requirements of the 1934 Act and
the rules and regulations thereunder with respect to matters set forth in this Section 6. Nothing in these Bylaws shall be deemed
to affect any rights of stockholders to request inclusion of proposals in the corporation&rsquo;s proxy statement pursuant to Rule
14a-8 under the 1934 Act; <I>provided, however,</I> that any references in these Bylaws to the 1934 Act or the rules and regulations
thereunder are not intended to and shall not limit the requirements applicable to nominations for the election to the Board of
Directors to be considered pursuant to Section 6(c) of these Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notice
of Meetings.</B> Except as otherwise provided by law, notice, given in writing or by electronic transmission, of each meeting of
stockholders shall be given not less than 10 nor more than 60 days before the date of the meeting to each stockholder entitled
to vote at such meeting, such notice to specify the place, if any, date and hour, in the case of special meetings, the purpose
or purposes of the meeting, and the means of remote communications, if any, by which stockholders and proxy holders may be deemed
to be present in person and vote at any such meeting. If mailed, notice is deemed given when deposited in the United States mail,
postage prepaid, directed to the stockholder at such stockholder&rsquo;s address as it appears on the records of the corporation.
If sent via electronic transmission, notice is deemed given as of the sending time recorded at the time of transmission. Notice
of the time, place, if any, and purpose of any meeting of stockholders may be waived in writing, signed by the person entitled
to notice thereof, or by electronic transmission by such person, either before or after such meeting, and will be waived by any
stockholder by his attendance thereat in person, by remote communication, if applicable, or by proxy, except when the stockholder
attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because
the meeting is not lawfully called or convened. Any stockholder so waiving notice of such meeting shall be bound by the proceedings
of any such meeting in all respects as if due notice thereof had been given.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Quorum.</B>
At all meetings of stockholders, except where otherwise provided by statute or by the corporation&rsquo;s Amended and Restated
Certificate of Incorporation (&ldquo;<B><I>Certificate of Incorporation</I></B>&rdquo;), or by these Bylaws, the presence, in person,
by remote communication, if applicable, or by proxy duly authorized, of the holders of a majority of the outstanding shares of
stock entitled to vote shall constitute a quorum for the transaction of business. In the absence of a quorum, any meeting of stockholders
may be adjourned, from time to time, either by the chairman of the meeting or by vote of the holders of a majority of the shares
represented thereat, but no other business shall be transacted at such meeting. The stockholders present at a duly called or convened
meeting, at which a quorum is present, may continue to transact business until adjournment, notwithstanding the withdrawal of enough
stockholders to leave less than a quorum. Except as otherwise provided by statute or by applicable stock exchange rules, or by
the Certificate of Incorporation or these Bylaws, in all matters other than the election of directors, the affirmative vote of
the majority of shares present in person, by remote communication, if applicable, or represented by proxy at the meeting and entitled
to vote generally on the subject matter shall be the act of the stockholders. Except as otherwise provided by statute, the Certificate
of Incorporation or these Bylaws, directors shall be elected by a plurality of the votes of the shares present in person, by remote
communication, if applicable, or represented by proxy at the meeting and entitled to vote generally on the election of directors.
Where a separate vote by a class or classes or series is required, except where otherwise provided by the statute or by the Certificate
of Incorporation or these Bylaws, a majority of the outstanding shares of such class or classes or series, present in person, by
remote communication, if applicable, or represented by proxy duly authorized, shall constitute a quorum entitled to take action
with respect to that vote on that matter. Except where otherwise provided by statute or by the Certificate of Incorporation or
these Bylaws, the affirmative vote of the majority (plurality, in the case of the election of directors) of shares of such class
or classes or series present in person, by remote communication, if applicable, or represented by proxy at the meeting shall be
the act of such class or classes or series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
9.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Adjournment
and Notice of Adjourned Meetings.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif"> Any meeting of stockholders,
whether annual or special, may be adjourned from time to time either by the chairman of the meeting or by the vote of a majority
of the shares present in person, by remote communication, if applicable, or represented by proxy at the meeting. When a meeting
is adjourned to another time or place, if any, notice need not be given of the adjourned meeting if the time and place, if any,
thereof are announced at the meeting at which the adjournment is taken. At the adjourned meeting, the corporation may transact
any business which might have been transacted at the original meeting. If the adjournment is for more than 30 days or if after
the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each
stockholder of record entitled to vote at the meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
10.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Voting
Rights.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif"> For the purpose of determining those stockholders entitled
to vote at any meeting of the stockholders, except as otherwise provided by law, only persons in whose names shares stand on the
stock records of the corporation on the record date, as provided in Section 12 of these Bylaws, shall be entitled to vote at any
meeting of stockholders. Every person entitled to vote shall have the right to do so either in person, by remote communication,
if applicable, or by an agent or agents authorized by a proxy granted in accordance with Delaware law. An agent so appointed need
not be a stockholder. No proxy shall be voted after three years from its date of creation unless the proxy provides for a longer
period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
11.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Joint
Owners of Stock.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif"> If shares or other securities having voting
power stand of record in the names of two or more persons, whether fiduciaries, members of a partnership, joint tenants, tenants
in common, tenants by the entirety, or otherwise, or if two or more persons have the same fiduciary relationship respecting the
same shares, unless the Secretary is given written notice to the contrary and is furnished with a copy of the instrument or order
appointing them or creating the relationship wherein it is so provided, their acts with respect to voting shall have the following
effect: (a) if only one votes, his act binds all; (b) if more than one votes, the act of the majority so voting binds all; or (c)
if more than one votes, but the vote is evenly split on any particular matter, each faction may vote the securities in question
proportionally, or may apply to the Delaware Court of Chancery for relief as provided in the DGCL, Section 217(b). If the instrument
filed with the Secretary shows that any such tenancy is held in unequal interests, a majority or even-split for the purpose of
clause (c) of this Section 11 shall be a majority or even-split in interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
12.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">List
of Stockholders.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif"> The Secretary shall prepare and make, at least
10 days before every meeting of stockholders, a complete list of the stockholders entitled to vote at said meeting, arranged in
alphabetical order, showing the address of each stockholder and the number of shares registered in the name of each stockholder.
Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, (a) on a reasonably accessible
electronic network, provided that the information required to gain access to such list is provided with the notice of the meeting,
or (b) during ordinary business hours, at the principal place of business of the corporation. In the event that the corporation
determines to make the list available on an electronic network, the corporation may take reasonable steps to ensure that such information
is available only to stockholders of the corporation. The list shall be open to examination of any stockholder during the time
of the meeting as provided by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
13.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Action
Without Meeting.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif"> No action shall be taken by the stockholders
except at an annual or special meeting of stockholders called in accordance with these Bylaws, and no action shall be taken by
the stockholders by written consent or electronic transmission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
14.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Organization.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>At
every meeting of stockholders, the Chairman of the Board of Directors, or, if a Chairman has not been appointed or is absent, the
President, or, if the President is absent, a chairman of the meeting chosen by a majority in interest of the stockholders entitled
to vote, present in person or by proxy, shall act as chairman. The Secretary, or, in his or her absence, an Assistant Secretary
directed to do so by the President, shall act as secretary of the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>The
Board of Directors of the corporation shall be entitled to make such rules or regulations for the conduct of meetings of stockholders
as it shall deem necessary, appropriate or convenient. Subject to such rules and regulations of the Board of Directors, if any,
the chairman of the meeting shall have the right and authority to prescribe such rules, regulations and procedures and to do all
such acts as, in the judgment of such chairman, are necessary, appropriate or convenient for the proper conduct of the meeting,
including, without limitation, establishing an agenda or order of business for the meeting, rules and procedures for maintaining
order at the meeting and the safety of those present, limitations on participation in such meeting to stockholders of record of
the corporation and their duly authorized and constituted proxies and such other persons as the chairman shall permit, restrictions
on entry to the meeting after the time fixed for the commencement thereof, limitations on the time allotted to questions or comments
by participants and regulation of the opening and closing of the polls for balloting on matters which are to be voted on by ballot.
The date and time of the opening and closing of the polls for each matter upon which the stockholders will vote at the meeting
shall be announced at the meeting. Unless and to the extent determined by the Board of Directors or the chairman of the meeting,
meetings of stockholders shall not be required to be held in accordance with rules of parliamentary procedure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE IV</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DIRECTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
15.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Number
and Term of Office.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif"> The authorized number of directors of the
corporation shall be fixed in accordance with the Certificate of Incorporation. Directors need not be stockholders unless so required
by the Certificate of Incorporation. If for any cause, the directors shall not have been elected at an annual meeting, they may
be elected as soon thereafter as convenient at a special meeting of the stockholders called for that purpose in the manner provided
in these Bylaws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
16.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Powers.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
The business and affairs of the corporation shall be managed by or under the direction of the Board of Directors, except as may
be otherwise provided by statute or by the Certificate of Incorporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Classes
of Directors.</B> Subject to the rights of the holders of any series of Preferred Stock to elect additional directors under specified
circumstances, immediately following the closing of the initial public offering pursuant to an effective registration statement
under the 1933 Act covering the offer and sale of Common Stock to the public (the &ldquo;<B><I>Initial Public Offering</I></B>&rdquo;),
the directors shall be divided into three classes designated as Class I, Class II and Class III, respectively. The Board of Directors
is authorized to assign members of the Board of Directors already in office to such classes at the time the classification becomes
effective. At the first annual meeting of stockholders following the closing of the Initial Public Offering, the term of office
of the Class I directors shall expire and Class I directors shall be elected for a full term of three years. At the second annual
meeting of stockholders following the closing of the Initial Public Offering, the term of office of the Class II directors shall
expire and Class II directors shall be elected for a full term of three years. At the third annual meeting of stockholders following
the closing of the Initial Public Offering, the term of office of the Class III directors shall expire and Class III directors
shall be elected for a full term of three years. At each succeeding annual meeting of stockholders, directors shall be elected
for a full term of three years to succeed the directors of the class whose terms expire at such annual meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding the foregoing provisions
of this Section 17, each director shall serve until his or her successor is duly elected and qualified or until his or her earlier
death, resignation or removal. No decrease in the number of directors constituting the Board of Directors shall shorten the term
of any incumbent director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vacancies.</B>
Unless otherwise provided in the Certificate of Incorporation, and subject to the rights of the holders of any series of Preferred
Stock, any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other causes and
any newly created directorships resulting from any increase in the number of directors shall, unless the Board of Directors determines
by resolution that any such vacancies or newly created directorships shall be filled by stockholders, be filled only by the affirmative
vote of a majority of the directors then in office, even though less than a quorum of the Board of Directors, or by a sole remaining
director, and not by the stockholders, <I>provided, however</I>, that whenever the holders of any class or classes of stock or
series thereof are entitled to elect one or more directors by the provisions of the Certificate of Incorporation, vacancies and
newly created directorships of such class or classes or series shall, unless the Board of Directors determines by resolution that
any such vacancies or newly created directorships shall be filled by stockholders, be filled by a majority of the directors elected
by such class or classes or series thereof then in office, or by a sole remaining director so elected, and not by the stockholders.
Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the director
for which the vacancy was created or occurred and until such director&rsquo;s successor shall have been elected and qualified.
A vacancy in the Board of Directors shall be deemed to exist under this Bylaw in the case of the death, removal or resignation
of any director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
19.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Resignation.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
Any director may resign at any time by delivering his or her notice in writing or by electronic transmission to the Secretary,
such resignation to specify whether it will be effective at a particular time. If no such specification is made, it shall be deemed
effective at the time of delivery to the Secretary. When one or more directors shall resign from the Board of Directors, effective
at a future date, a majority of the directors then in office, including those who have so resigned, shall have power to fill such
vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become effective, and each director
so chosen shall hold office for the unexpired portion of the term of the director whose place shall be vacated and until his successor
shall have been duly elected and qualified.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
20.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Removal.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>Subject
to the rights of holder of any series of Preferred Stock to elect additional directors under specified circumstances, neither the
Board of Directors nor any individual director may be removed without cause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>Subject
to any limitation imposed by law, any individual director or directors may be removed with cause by the affirmative vote of the
holders of at least 66 2/3% of the voting power of all then outstanding shares of capital stock of the corporation entitled to
vote generally at an election of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
21.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Meetings.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regular
Meetings.</B> Unless otherwise restricted by the Certificate of Incorporation, regular meetings of the Board of Directors may be
held at any time or date and at any place within or without the State of Delaware which has been designated by the Board of Directors
and publicized among all directors, either orally or in writing, by telephone, including a voice-messaging system or other system
designed to record and communicate messages, facsimile, telegraph or telex, or by electronic mail or other electronic means. No
further notice shall be required for regular meetings of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Special
Meetings.</B> Unless otherwise restricted by the Certificate of Incorporation, special meetings of the Board of Directors may be
held at any time and place within or without the State of Delaware whenever called by the Chairman of the Board, the Chief Executive
Officer or a majority of the authorized number of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Meetings
by Electronic Communications Equipment.</B> Any member of the Board of Directors, or of any committee thereof, may participate
in a meeting by means of conference telephone or other communications equipment by means of which all persons participating in
the meeting can hear each other, and participation in a meeting by such means shall constitute presence in person at such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notice
of Special Meetings.</B> Notice of the time and place of all special meetings of the Board of Directors shall be orally or in writing,
by telephone, including a voice messaging system or other system or technology designed to record and communicate messages, facsimile,
telegraph or telex, or by electronic mail or other electronic means, during normal business hours, at least 24 hours before the
date and time of the meeting. If notice is sent by U.S. mail, it shall be sent by first class mail, charges prepaid, at least three
days before the date of the meeting. Notice of any meeting may be waived in writing, or by electronic transmission, at any time
before or after the meeting and will be waived by any director by attendance thereat, except when the director attends the meeting
for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is
not lawfully called or convened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Waiver
of Notice.</B> The transaction of all business at any meeting of the Board of Directors, or any committee thereof, however called
or noticed, or wherever held, shall be as valid as though it had been transacted at a meeting duly held after regular call and
notice, if a quorum be present and if, either before or after the meeting, each of the directors not present who did not receive
notice shall sign a written waiver of notice or shall waive notice by electronic transmission. All such waivers shall be filed
with the corporate records or made a part of the minutes of the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
22.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Quorum
and Voting.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>Unless
the Certificate of Incorporation requires a greater number, and except with respect to questions related to indemnification arising
under Section 45 of these Bylaws for which a quorum shall be one-third of the exact number of directors fixed from time to time,
a quorum of the Board of Directors shall consist of a majority of the exact number of directors fixed from time to time by the
Board of Directors in accordance with the Certificate of Incorporation; <I>provided, however,</I> at any meeting whether a quorum
be present or otherwise, a majority of the directors present may adjourn from time to time until the time fixed for the next regular
meeting of the Board of Directors, without notice other than by announcement at the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>At
each meeting of the Board of Directors at which a quorum is present, all questions and business shall be determined by the affirmative
vote of a majority of the directors present, unless a different vote be required by law, the Certificate of Incorporation or these
Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
23.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Action
Without Meeting. </FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">Unless otherwise restricted by the Certificate
of Incorporation or these Bylaws, any action required or permitted to be taken at any meeting of the Board of Directors or of any
committee thereof may be taken without a meeting, if all members of the Board of Directors or committee, as the case may be, consent
thereto in writing or by electronic transmission, and such writing or writings or transmission or transmissions are filed with
the minutes of proceedings of the Board of Directors or committee. Such filing shall be in paper form if the minutes are maintained
in paper form and shall be in electronic form if the minutes are maintained in electronic form.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
24.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Fees
and Compensation.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif"> Directors shall be entitled to such compensation
for their services as may be approved by the Board of Directors, including, if so approved, by resolution of the Board of Directors,
a fixed sum and expenses of attendance, if any, for attendance at each regular or special meeting of the Board of Directors and
at any meeting of a committee of the Board of Directors. Nothing herein contained shall be construed to preclude any director from
serving the corporation in any other capacity as an officer, agent, employee, or otherwise and receiving compensation therefor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
25.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Committees.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Executive
Committee.</B> The Board of Directors may appoint an Executive Committee to consist of one or more members of the Board of Directors.
The Executive Committee, to the extent permitted by law and provided in the resolution of the Board of Directors shall have and
may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the corporation,
and may authorize the seal of the corporation to be affixed to all papers which may require it; but no such committee shall have
the power or authority in reference to (i) approving or adopting, or recommending to the stockholders, any action or matter (other
than the election or removal of directors) expressly required by the DGCL to be submitted to stockholders for approval, or (ii)
adopting, amending or repealing any Bylaw of the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other
Committees.</B> The Board of Directors may, from time to time, appoint such other committees as may be permitted by law. Such other
committees appointed by the Board of Directors shall consist of one or more members of the Board of Directors and shall have such
powers and perform such duties as may be prescribed by the resolution or resolutions creating such committees, but in no event
shall any such committee have the powers denied to the Executive Committee in these Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Term.</B>
The Board of Directors, subject to any requirements of any outstanding series of Preferred Stock and the provisions of subsections
(a) or (b) of this Section 25, may at any time increase or decrease the number of members of a committee or terminate the existence
of a committee. The membership of a committee member shall terminate on the date of his death or voluntary resignation from the
committee or from the Board of Directors. The Board of Directors may at any time for any reason remove any individual committee
member and the Board of Directors may fill any committee vacancy created by death, resignation, removal or increase in the number
of members of the committee. The Board of Directors may designate one or more directors as alternate members of any committee,
who may replace any absent or disqualified member at any meeting of the committee, and, in addition, in the absence or disqualification
of any member of a committee, the member or members thereof present at any meeting and not disqualified from voting, whether or
not he or they constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the
place of any such absent or disqualified member.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Meetings.</B>
Unless the Board of Directors shall otherwise provide, regular meetings of the Executive Committee or any other committee appointed
pursuant to this Section 25 shall be held at such times and places as are determined by the Board of Directors, or by any such
committee, and when notice thereof has been given to each member of such committee, no further notice of such regular meetings
need be given thereafter. Special meetings of any such committee may be held at any place which has been determined from time to
time by such committee, and may be called by any director who is a member of such committee, upon notice to the members of such
committee of the time and place of such special meeting given in the manner provided for the giving of notice to members of the
Board of Directors of the time and place of special meetings of the Board of Directors. Notice of any special meeting of any committee
may be waived in writing or by electronic transmission at any time before or after the meeting and will be waived by any director
by attendance thereat, except when the director attends such special meeting for the express purpose of objecting, at the beginning
of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Unless otherwise provided
by the Board of Directors in the resolutions authorizing the creation of the committee, a majority of the authorized number of
members of any such committee shall constitute a quorum for the transaction of business, and the act of a majority of those present
at any meeting at which a quorum is present shall be the act of such committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
26.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Duties
of Chairman of the Board of Directors.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif"> The Chairman of the
Board of Directors, when present, shall preside at all meetings of the stockholders and the Board of Directors. The Chairman of
the Board of Directors shall perform other duties commonly incident to the office and shall also perform such other duties and
have such other powers, as the Board of Directors shall designate from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 27.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lead
Independent Director.</B> The Chairman of the Board of Directors, or if the Chairman is not an independent director, one of the
independent directors, may be designated by the Board of Directors as lead independent director (&ldquo;<B><I>Lead Independent
Director</I></B>&rdquo;) to serve until replaced by the Board of Directors. The Lead Independent Director will: with the Chairman
of the Board of Directors, establish the agenda for regular Board meetings and serve as chairman of Board of Directors meetings
in the absence of the Chairman of the Board of Directors; establish the agenda for meetings of the independent directors; coordinate
with the committee chairs regarding meeting agendas and informational requirements; preside over meetings of the independent directors;
preside over any portions of meetings of the Board of Directors at which the evaluation or compensation of the Chief Executive
Officer is presented or discussed; preside over any portions of meetings of the Board of Directors at which the performance of
the Board of Directors is presented or discussed; and perform such other duties as may be established or delegated by the Chairman
of the Board of Directors<B>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
28.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Organization.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
At every meeting of the directors, the Chairman of the Board of Directors, or, if a Chairman has not been appointed or is absent,
the Lead Independent Director, or if the Lead Independent Director is absent, the Chief Executive Officer (if a director), or,
if a Chief Executive Officer is absent, the President (if a director), or if the President is absent, the most senior Vice President
(if a director), or, in the absence of any such person, a chairman of the meeting chosen by a majority of the directors present,
shall preside over the meeting. The Secretary, or in his absence, any Assistant Secretary or other officer or director directed
to do so by the Chairman, shall act as secretary of the meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE V</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OFFICERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
29.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Officers
Designated.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif"> The officers of the corporation shall include,
if and when designated by the Board of Directors, the Chairman of the Board of Directors, the Chief Executive Officer, the President,
one or more Vice Presidents, the Secretary, the Chief Financial Officer and the Treasurer. The Board of Directors may also appoint
one or more Assistant Secretaries and Assistant Treasurers and such other officers and agents with such powers and duties as it
shall deem necessary. The Board of Directors may assign such additional titles to one or more of the officers as it shall deem
appropriate. Any one person may hold any number of offices of the corporation at any one time unless specifically prohibited therefrom
by law. The salaries and other compensation of the officers of the corporation shall be fixed by or in the manner designated by
the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
30.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Tenure
and Duties of Officers.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General.</B>
All officers shall hold office at the pleasure of the Board of Directors and until their successors shall have been duly elected
and qualified, unless sooner removed. Any officer elected or appointed by the Board of Directors may be removed at any time by
the Board of Directors. If the office of any officer becomes vacant for any reason, the vacancy may be filled by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Duties
of Chief Executive Officer.</B> The Chief Executive Officer shall preside at all meetings of the stockholders and at all meetings
of the Board of Directors, unless the Chairman of the Board of Directors or the Lead Independent Director has been appointed and
is present. Unless an officer has been appointed Chief Executive Officer of the corporation, the President shall be the Chief Executive
Officer of the corporation and shall, subject to the control of the Board of Directors, have general supervision, direction and
control of the business and officers of the corporation. To the extent that a Chief Executive Officer has been appointed and no
President has been appointed, all references in these Bylaws to the President shall be deemed references to the Chief Executive
Officer. The Chief Executive Officer shall perform other duties commonly incident to the office and shall also perform such other
duties and have such other powers, as the Board of Directors shall designate from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Duties
of President.</B> The President shall preside at all meetings of the stockholders and at all meetings of the Board of Directors,
unless the Chairman of the Board of Directors, the Lead Independent Director, or the Chief Executive Officer has been appointed
and is present. Unless another officer has been appointed Chief Executive Officer of the corporation, the President shall be the
Chief Executive Officer of the corporation and shall, subject to the control of the Board of Directors, have general supervision,
direction and control of the business and officers of the corporation. The President shall perform other duties commonly incident
to the office and shall also perform such other duties and have such other powers, as the Board of Directors shall designate from
time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Duties
of Vice Presidents.</B> The Vice Presidents may assume and perform the duties of the President in the absence or disability of
the President or whenever the office of President is vacant. The Vice Presidents shall perform other duties commonly incident to
their office and shall also perform such other duties and have such other powers as the Board of Directors or the Chief Executive
Officer, or, if the Chief Executive Officer has not been appointed or is absent, the President shall designate from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Duties
of Secretary.</B> The Secretary shall attend all meetings of the stockholders and of the Board of Directors and shall record all
acts and proceedings thereof in the minute book of the corporation. The Secretary shall give notice in conformity with these Bylaws
of all meetings of the stockholders and of all meetings of the Board of Directors and any committee thereof requiring notice. The
Secretary shall perform all other duties provided for in these Bylaws and other duties commonly incident to the office and shall
also perform such other duties and have such other powers, as the Board of Directors shall designate from time to time. The President
may direct any Assistant Secretary or other officer to assume and perform the duties of the Secretary in the absence or disability
of the Secretary, and each Assistant Secretary shall perform other duties commonly incident to the office and shall also perform
such other duties and have such other powers as the Board of Directors or the President shall designate from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Duties
of Chief Financial Officer.</B> The Chief Financial Officer shall keep or cause to be kept the books of account of the corporation
in a thorough and proper manner and shall render statements of the financial affairs of the corporation in such form and as often
as required by the Board of Directors or the President. The Chief Financial Officer, subject to the order of the Board of Directors,
shall have the custody of all funds and securities of the corporation. The Chief Financial Officer shall perform other duties commonly
incident to the office and shall also perform such other duties and have such other powers as the Board of Directors or the President
shall designate from time to time. To the extent that a Chief Financial Officer has been appointed and no Treasurer has been appointed,
all references in these Bylaws to the Treasurer shall be deemed references to the Chief Financial Officer. The President may direct
the Treasurer, if any, or any Assistant Treasurer, or the Controller or any Assistant Controller to assume and perform the duties
of the Chief Financial Officer in the absence or disability of the Chief Financial Officer, and each Treasurer and Assistant Treasurer
and each Controller and Assistant Controller shall perform other duties commonly incident to the office and shall also perform
such other duties and have such other powers as the Board of Directors or the President shall designate from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Duties
of Treasurer.</B> Unless another officer has been appointed Chief Financial Officer of the corporation, the Treasurer shall be
the chief financial officer of the corporation and shall keep or cause to be kept the books of account of the corporation in a
thorough and proper manner and shall render statements of the financial affairs of the corporation in such form and as often as
required by the Board of Directors or the President, and, subject to the order of the Board of Directors, shall have the custody
of all funds and securities of the corporation. The Treasurer shall perform other duties commonly incident to the office and shall
also perform such other duties and have such other powers as the Board of Directors or the President shall designate from time
to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
31.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Delegation
of Authority.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif"> The Board of Directors may from time to time
delegate the powers or duties of any officer to any other officer or agent, notwithstanding any provision hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
32.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Resignations.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
Any officer may resign at any time by giving notice in writing or by electronic transmission to the Board of Directors or to the
President or to the Secretary. Any such resignation shall be effective when received by the person or persons to whom such notice
is given, unless a later time is specified therein, in which event the resignation shall become effective at such later time. Unless
otherwise specified in such notice, the acceptance of any such resignation shall not be necessary to make it effective. Any resignation
shall be without prejudice to the rights, if any, of the corporation under any contract with the resigning officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
33.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Removal.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
Any officer may be removed from office at any time, either with or without cause, by the affirmative vote of a majority of the
directors in office at the time, or by the unanimous written consent of the directors in office at the time, or by any committee
or by the Chief Executive Officer or by other superior officers upon whom such power of removal may have been conferred by the
Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE VI</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXECUTION OF CORPORATE INSTRUMENTS AND
VOTING OF SECURITIES OWNED BY THE CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
34.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Execution
of Corporate Instruments.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif"> The Board of Directors may, in its
discretion, determine the method and designate the signatory officer or officers, or other person or persons, to execute on behalf
of the corporation any corporate instrument or document, or to sign on behalf of the corporation the corporate name without limitation,
or to enter into contracts on behalf of the corporation, except where otherwise provided by law or these Bylaws, and such execution
or signature shall be binding upon the corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All checks and drafts drawn on banks or
other depositaries on funds to the credit of the corporation or in special accounts of the corporation shall be signed by such
person or persons as the Board of Directors shall authorize so to do.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless authorized or ratified by the Board
of Directors or within the agency power of an officer, no officer, agent or employee shall have any power or authority to bind
the corporation by any contract or engagement or to pledge its credit or to render it liable for any purpose or for any amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
35.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Voting
of Securities Owned by the Corporation.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif"> All stock and other
securities of other corporations owned or held by the corporation for itself, or for other parties in any capacity, shall be voted,
and all proxies with respect thereto shall be executed, by the person authorized so to do by resolution of the Board of Directors,
or, in the absence of such authorization, by the Chairman of the Board of Directors, the Chief Executive Officer, the President,
or any Vice President.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ARTICLE VII</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SHARES OF STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
36.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Form
and Execution of Certificates.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif"> The shares of the corporation
shall be represented by certificates, or shall be uncertificated if so provided by resolution or resolutions of the Board of Directors.
Certificates for the shares of stock of the corporation, if any, shall be in such form as is consistent with the Certificate of
Incorporation and applicable law. Every holder of stock represented by certificate in the corporation shall be entitled to have
a certificate signed by or in the name of the corporation by the Chairman of the Board of Directors, the Chief Executive Officer,
or the President or any Vice President and by the Chief Financial Officer, Treasurer or Assistant Treasurer or the Secretary or
Assistant Secretary, certifying the number of shares owned by him in the corporation. Any or all of the signatures on the certificate
may be facsimiles. In case any officer, transfer agent, or registrar who has signed or whose facsimile signature has been placed
upon a certificate shall have ceased to be such officer, transfer agent, or registrar before such certificate is issued, it may
be issued with the same effect as if he were such officer, transfer agent, or registrar at the date of issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 37.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lost
Certificates.</B> A new certificate or certificates shall be issued in place of any certificate or certificates theretofore issued
by the corporation alleged to have been lost, stolen, or destroyed, upon the making of an affidavit of that fact by the person
claiming the certificate of stock to be lost, stolen, or destroyed. The corporation may require, as a condition precedent to the
issuance of a new certificate or certificates, the owner of such lost, stolen, or destroyed certificate or certificates, or the
owner&rsquo;s legal representative, to agree to indemnify the corporation in such manner as it shall require or to give the corporation
a surety bond in such form and amount as it may direct as indemnity against any claim that may be made against the corporation
with respect to the certificate alleged to have been lost, stolen, or destroyed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
38.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Transfers.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>Transfers
of record of shares of stock of the corporation shall be made only upon its books by the holders thereof, in person or by attorney
duly authorized, and, in the case of stock represented by certificate, upon the surrender of a properly endorsed certificate or
certificates for a like number of shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>The
corporation shall have power to enter into and perform any agreement with any number of stockholders of any one or more classes
of stock of the corporation to restrict the transfer of shares of stock of the corporation of any one or more classes owned by
such stockholders in any manner not prohibited by the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
39.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Fixing
Record Dates.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>In
order that the corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any
adjournment thereof, the Board of Directors may fix a record date, which record date shall not precede the date upon which the
resolution fixing the record date is adopted by the Board of Directors, and which record date shall, subject to applicable law,
not be more than 60 nor less than 10 days before the date of such meeting. If no record date is fixed by the Board of Directors,
the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close
of business on the day next preceding the day on which notice is given, or if notice is waived, at the close of business on the
day next preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of or to
vote at a meeting of stockholders shall apply to any adjournment of the meeting; <I>provided, however,</I> that the Board of Directors
may fix a new record date for the adjourned meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>In
order that the corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or
allotment of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of
stock, or for the purpose of any other lawful action, the Board of Directors may fix, in advance, a record date, which record date
shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more
than 60 days prior to such action. If no record date is fixed, the record date for determining stockholders for any such purpose
shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
40.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Registered
Stockholders.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif"> The corporation shall be entitled to recognize
the exclusive right of a person registered on its books as the owner of shares to receive dividends, and to vote as such owner,
and shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of any other
person whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE VIII</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OTHER SECURITIES OF THE CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
41.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Execution
of Other Securities.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif"> All bonds, debentures and other corporate
securities of the corporation, other than stock certificates (covered in Section 36 of these Bylaws), may be signed by the Chairman
of the Board of Directors, the Chief Executive Officer, the President or any Vice President, or such other person as may be authorized
by the Board of Directors, and the corporate seal impressed thereon or a facsimile of such seal imprinted thereon and attested
by the signature of the Secretary or an Assistant Secretary, or the Chief Financial Officer or Treasurer or an Assistant Treasurer;
<I>provided, however,</I> that where any such bond, debenture or other corporate security shall be authenticated by the manual
signature, or where permissible facsimile signature, of a trustee under an indenture pursuant to which such bond, debenture or
other corporate security shall be issued, the signatures of the persons signing and attesting the corporate seal on such bond,
debenture or other corporate security may be the imprinted facsimile of the signatures of such persons. Interest coupons appertaining
to any such bond, debenture or other corporate security, authenticated by a trustee as aforesaid, shall be signed by the Treasurer
or an Assistant Treasurer of the corporation or such other person as may be authorized by the Board of Directors, or bear imprinted
thereon the facsimile signature of such person. In case any officer who shall have signed or attested any bond, debenture or other
corporate security, or whose facsimile signature shall appear thereon or on any such interest coupon, shall have ceased to be such
officer before the bond, debenture or other corporate security so signed or attested shall have been delivered, such bond, debenture
or other corporate security nevertheless may be adopted by the corporation and issued and delivered as though the person who signed
the same or whose facsimile signature shall have been used thereon had not ceased to be such officer of the corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE IX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DIVIDENDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
42.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Declaration
of Dividends.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif"> Dividends upon the capital stock of the corporation,
subject to the provisions of the Certificate of Incorporation and applicable law, if any, may be declared by the Board of Directors
pursuant to law at any regular or special meeting. Dividends may be paid in cash, in property, or in shares of the capital stock,
subject to the provisions of the Certificate of Incorporation and applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
43.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Dividend
Reserve.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif"> Before payment of any dividend, there may be set aside
out of any funds of the corporation available for dividends such sum or sums as the Board of Directors from time to time, in their
absolute discretion, think proper as a reserve or reserves to meet contingencies, or for equalizing dividends, or for repairing
or maintaining any property of the corporation, or for such other purpose as the Board of Directors shall think conducive to the
interests of the corporation, and the Board of Directors may modify or abolish any such reserve in the manner in which it was created.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE X</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FISCAL YEAR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
44.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Fiscal
Year. </FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">The fiscal year of the corporation shall be fixed by
resolution of the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE XI</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEMNIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
45.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Indemnification
of Directors, Officers, Employees and Other Agents.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Directors
and Officers.</B> The corporation shall indemnify its directors and officers to the extent not prohibited by the DGCL or any
other applicable law; <I>provided, however,</I> that the corporation may modify the extent of such indemnification by
individual contracts with its directors and officers; and, <I>provided, further,</I> that the corporation shall not be
required to indemnify any director or officer in connection with any proceeding (or part thereof) initiated by such person
unless (i) such indemnification is expressly required to be made by law, (ii) the proceeding was authorized by the Board of
Directors of the corporation, (iii) such indemnification is provided by the corporation, in its sole discretion, pursuant to
the powers vested in the corporation under the DGCL or any other applicable law or (iv) such indemnification is required to
be made under subsection (d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employees
and Other Agents.</B> The corporation shall have power to indemnify its employees and other agents as set forth in the DGCL or
any other applicable law. The Board of Directors shall have the power to delegate the determination of whether indemnification
shall be given to any such person (except for officers) or other persons as the Board of Directors shall determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expenses.</B>
The corporation shall advance to any person who was or is a party or is threatened to be made a party to any threatened, pending
or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he
is or was a director or officer, of the corporation, or is or was serving at the request of the corporation as a director or officer
of another corporation, partnership, joint venture, trust or other enterprise, prior to the final disposition of the proceeding,
promptly following request therefor, all expenses incurred by any director or officer in connection with such proceeding provided,
however, that if the DGCL requires, an advancement of expenses incurred by a director or officer in his or her capacity as a director
or officer (and not in any other capacity in which service was or is rendered by such indemnitee, including, without limitation,
service to an employee benefit plan) shall be made only upon delivery to the corporation of an undertaking (hereinafter an &ldquo;<B><I>undertaking</I></B>&rdquo;),
by or on behalf of such indemnitee, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision
from which there is no further right to appeal (hereinafter a &ldquo;<B><I>final adjudication</I></B>&rdquo;) that such indemnitee
is not entitled to be indemnified for such expenses under this Section 45 or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding the foregoing, unless otherwise
determined pursuant to paragraph (e) of this Section 45, no advance shall be made by the corporation to an officer of the corporation
(except by reason of the fact that such officer is or was a director of the corporation in which event this paragraph shall not
apply) in any action, suit or proceeding, whether civil, criminal, administrative or investigative, if a determination is reasonably
and promptly made (i) by a majority vote of directors who were not parties to the proceeding, even if not a quorum, or (ii) by
a committee of such directors designated by a majority vote of such directors, even though less than a quorum, or (iii) if there
are no such directors, or such directors so direct, by independent legal counsel in a written opinion, that the facts known to
the decision-making party at the time such determination is made demonstrate clearly and convincingly that such person acted in
bad faith or in a manner that such person did not believe to be in or not opposed to the best interests of the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Enforcement.</B>
Without the necessity of entering into an express contract, all rights to indemnification and advances to directors and officers
under this Section 45 shall be deemed to be contractual rights and be effective to the same extent and as if provided for in a
contract between the corporation and the director or officer. Any right to indemnification or advances granted by this Section
45 to a director or officer shall be enforceable by or on behalf of the person holding such right in any court of competent jurisdiction
if (i) the claim for indemnification or advances is denied, in whole or in part, or (ii) no disposition of such claim is made within
90 days of request therefor. To the extent permitted by law, the claimant in such enforcement action, if successful in whole or
in part, shall be entitled to be paid also the expense of prosecuting the claim. In connection with any claim for indemnification,
the corporation shall be entitled to raise as a defense to any such action that the claimant has not met the standards of conduct
that make it permissible under the DGCL or any other applicable law for the corporation to indemnify the claimant for the amount
claimed. In connection with any claim by an officer of the corporation (except in any action, suit or proceeding, whether civil,
criminal, administrative or investigative, by reason of the fact that such officer is or was a director of the corporation) for
advances, the corporation shall be entitled to raise a defense as to any such action clear and convincing evidence that such person
acted in bad faith or in a manner that such person did not believe to be in or not opposed to the best interests of the corporation,
or with respect to any criminal action or proceeding that such person acted without reasonable cause to believe that his conduct
was lawful. Neither the failure of the corporation (including its Board of Directors, independent legal counsel or its stockholders)
to have made a determination prior to the commencement of such action that indemnification of the claimant is proper in the circumstances
because the director or officer has met the applicable standard of conduct set forth in the DGCL or any other applicable law, nor
an actual determination by the corporation (including its Board of Directors, independent legal counsel or its stockholders) that
the claimant has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that claimant
has not met the applicable standard of conduct. In any suit brought by a director or officer to enforce a right to indemnification
or to an advancement of expenses hereunder, the burden of proving that the director or officer is not entitled to be indemnified,
or to such advancement of expenses, under this Section 45 or otherwise shall be on the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-Exclusivity
of Rights.</B> The rights conferred on any person by this Bylaw shall not be exclusive of any other right which such person may
have or hereafter acquire under any applicable statute, provision of the Certificate of Incorporation, Bylaws, agreement, vote
of stockholders or disinterested directors or otherwise, both as to action in such person&rsquo;s official capacity and as to action
in another capacity while holding office. The corporation is specifically authorized to enter into individual contracts with any
or all of its directors, officers, employees or agents respecting indemnification and advances, to the fullest extent not prohibited
by the DGCL, or by any other applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Survival
of Rights.</B> The rights conferred on any person by this Bylaw shall continue as to a person who has ceased to be a director or
officer, or, if applicable, employee or other agent, and shall inure to the benefit of the heirs, executors and administrators
of such a person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insurance.</B>
To the fullest extent permitted by the DGCL or any other applicable law, the corporation, upon approval by the Board of Directors,
may purchase insurance on behalf of any person required or permitted to be indemnified pursuant to this Section 45.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amendments.</B>
Any repeal or modification of this Section 45 shall only be prospective and shall not affect the rights under this Bylaw in effect
at the time of the alleged occurrence of any action or omission to act that is the cause of any proceeding against any agent of
the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Saving
Clause.</B> If this Bylaw or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then
the corporation shall nevertheless indemnify each director and officer to the full extent not prohibited by any applicable portion
of this Section 45 that shall not have been invalidated, or by any other applicable law. If this Section 45 shall be invalid due
to the application of the indemnification provisions of another jurisdiction, then the corporation shall indemnify each director
and officer to the full extent under any other applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain
Definitions.</B> For the purposes of this Bylaw, the following definitions shall apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>The
term &ldquo;<B><I>proceeding</I></B>&rdquo; shall be broadly construed and shall include, without limitation, the investigation,
preparation, prosecution, defense, settlement, arbitration and appeal of, and the giving of testimony in, any threatened, pending
or completed action, suit or proceeding, whether civil, criminal, administrative or investigative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>The
term &ldquo;<B><I>expenses</I></B>&rdquo; shall be broadly construed and shall include, without limitation, court costs, attorneys&rsquo;
fees, witness fees, fines, amounts paid in settlement or judgment and any other costs and expenses of any nature or kind incurred
in connection with any proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>The
term the &ldquo;<B><I>corporation</I></B>&rdquo; shall include, in addition to the resulting corporation, any constituent corporation
(including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued,
would have had power and authority to indemnify its directors, officers, and employees or agents, so that any person who is or
was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such constituent
corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise,
shall stand in the same position under the provisions of this Section 45 with respect to the resulting or surviving corporation
as he would have with respect to such constituent corporation if its separate existence had continued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>References
to a &ldquo;<B><I>director</I></B>,&rdquo; &ldquo;<B><I>officer</I></B>,&rdquo; &ldquo;<B><I>employee</I></B>,&rdquo; or &ldquo;<B><I>agent</I></B>&rdquo;
of the corporation shall include, without limitation, situations where such person is serving at the request of the corporation
as, respectively, a director, officer, employee, trustee or agent of another corporation, partnership, joint venture, trust or
other enterprise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>References
to &ldquo;<B><I>other enterprises</I></B>&rdquo; shall include employee benefit plans; references to &ldquo;fines&rdquo; shall
include any excise taxes assessed on a person with respect to an employee benefit plan; and references to &ldquo;<B><I>serving
at the request of the corporation</I></B>&rdquo; shall include any service as a director, officer, employee or agent of the corporation
which imposes duties on, or involves services by, such director, officer, employee, or agent with respect to an employee benefit
plan, its participants, or beneficiaries; and a person who acted in good faith and in a manner such person reasonably believed
to be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner
&ldquo;<B><I>not opposed to the best interests of the corporation</I></B>&rdquo; as referred to in this Section 45.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE XII</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
46.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Notices.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notice
to Stockholders.</B> Written notice to stockholders of stockholder meetings shall be given as provided in Section 7 of these Bylaws.
Without limiting the manner by which notice may otherwise be given effectively to stockholders under any agreement or contract
with such stockholder, and except as otherwise required by law, written notice to stockholders for purposes other than stockholder
meetings may be sent by U.S. mail or nationally recognized overnight courier, or by facsimile, telegraph or telex or by electronic
mail or other electronic means.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notice
to Directors.</B> Any notice required to be given to any director may be given by the method stated in subsection (a), as otherwise
provided in these Bylaws, or by overnight delivery service, facsimile, telex or telegram, except that such notice other than one
which is delivered personally shall be sent to such address as such director shall have filed in writing with the Secretary, or,
in the absence of such filing, to the last known post office address of such director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Affidavit
of Mailing.</B> An affidavit of mailing, executed by a duly authorized and competent employee of the corporation or its transfer
agent appointed with respect to the class of stock affected, or other agent, specifying the name and address or the names and addresses
of the stockholder or stockholders, or director or directors, to whom any such notice or notices was or were given, and the time
and method of giving the same, shall in the absence of fraud, be prima facie evidence of the facts therein contained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Methods
of Notice.</B> It shall not be necessary that the same method of giving notice be employed in respect of all recipients of notice,
but one permissible method may be employed in respect of any one or more, and any other permissible method or methods may be employed
in respect of any other or others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notice
to Person With Whom Communication is Unlawful.</B> Whenever notice is required to be given, under any provision of law or of the
Certificate of Incorporation or Bylaws of the corporation, to any person with whom communication is unlawful, the giving of such
notice to such person shall not be required and there shall be no duty to apply to any governmental authority or agency for a license
or permit to give such notice to such person. Any action or meeting which shall be taken or held without notice to any such person
with whom communication is unlawful shall have the same force and effect as if such notice had been duly given. In the event that
the action taken by the corporation is such as to require the filing of a certificate under any provision of the DGCL, the certificate
shall state, if such is the fact and if notice is required, that notice was given to all persons entitled to receive notice except
such persons with whom communication is unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notice
to Stockholders Sharing an Address.</B> Except as otherwise prohibited under the DGCL, any notice given under the provisions of
the DGCL, the Certificate of Incorporation or the Bylaws shall be effective if given by a single written notice to stockholders
who share an address if consented to by the stockholders at that address to whom such notice is given. Such consent shall have
been deemed to have been given if such stockholder fails to object in writing to the corporation within 60 days of having been
given notice by the corporation of its intention to send the single notice. Any consent shall be revocable by the stockholder by
written notice to the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE XIII</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
47.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Amendments.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT STYLE="font-family: Times New Roman, Times, Serif">Subject
to the limitations set forth in Section 45(h) of these Bylaws or the provisions of the Certificate of Incorporation, the Board
of Directors is expressly empowered to adopt, amend or repeal the Bylaws of the corporation. Any adoption, amendment or repeal
of the Bylaws of the corporation by the Board of Directors shall require the approval of a majority of the authorized number of
directors. The stockholders also shall have power to adopt, amend or repeal the Bylaws of the corporation; <I>provided, however,</I>
that, in addition to any vote of the holders of any class or series of stock of the corporation required by law or by the Certificate
of Incorporation, such action by stockholders shall require the affirmative vote of the holders of at least 66 2/3% of the voting
power of all of the then- outstanding shares of the capital stock of the corporation entitled to vote generally in the election
of directors, voting together as a single class.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>4
<FILENAME>s113558_ex4-1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 4.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B><IMG SRC="s113558_ex4-1img01.jpg" ALT="">&nbsp;</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>5
<FILENAME>s113558_ex4-4.htm
<DESCRIPTION>EXHIBIT 4.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt"><B>Exhibit
4.4</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>THIS
WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE &ldquo;SECURITIES ACT&rdquo;), OR ANY OTHER SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED, PLEDGED OR
HYPOTHECATED IN THE ABSENCE OF (1) AN EFFECTIVE REGISTRATION STATEMENT COVERING SUCH SECURITIES UNDER THE SECURITIES ACT AND ANY
OTHER APPLICABLE SECURITIES LAWS, OR (2) AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS
NOT REQUIRED</B>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>IN ADDITION,
THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED, OR HYPOTHECATED,
OR BE THE SUBJECT OF ANY HEDGING, SHORT SALE, DERIVATIVE, PUT, OR CALL TRANSACTION THAT WOULD RESULT IN THE EFFECTIVE ECONOMIC
DISPOSITION OF SUCH SECURITIES BY ANY PERSON FOR A PERIOD OF ONE HUNDRED EIGHTY (180) DAYS IMMEDIATELY FOLLOWING THE DATE OF EFFECTIVENESS
OF THE PUBLIC OFFERING OF THE COMPANY&rsquo;S SECURITIES PURSUANT TO REGISTRATION STATEMENT NO.: 333-226774 AS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION, EXCEPT IN ACCORDANCE WITH FINRA RULE 5110(G)(2).</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ETON PHARMACEUTICALS,
INC.</B><BR>
<BR>
<B>UNDERWRITER WARRANT</B><BR>
<BR>
<B>300,000 shares of Common Stock</B><BR>
<BR>
<B>November [___], 2018</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">This
<B>UNDERWRITER WARRANT </B>(this &ldquo;<B>Warrant&rdquo;) </B>of Eton Pharmaceuticals, Inc., a corporation, duly organized and
validly existing under the laws of the State of Delaware (the &ldquo;<B>Company&rdquo;), </B>is being issued pursuant to that
certain Underwriting Agreement, dated November [___], 2018 (the &ldquo;<B>Underwriting Agreement&rdquo;), </B>between the Company
and National Securities Corporation (the &ldquo;<B>Underwriter&rdquo;) </B>relating to a firm commitment public offering (the
&ldquo;<B>Offering&rdquo;) </B>of 3,000,000 shares of common stock, $0.001 par value, of the Company (the &ldquo;<B>Common Stock&rdquo;)
</B>underwritten by the Underwriter.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>FOR
VALUE RECEIVED, </B>the Company hereby grants to National Securities Corporation and its permitted successors and assigns (collectively,
the &ldquo;<B>Holder&rdquo;) </B>the right to purchase from the Company up to 300,000 shares of Common Stock (such shares underlying
this Warrant, the &ldquo;<B>Warrant Shares</B>&rdquo;), at a per share purchase price equal to $7.50 (the &ldquo;<B>Exercise Price</B>&rdquo;)<B>,
</B>subject to the terms, conditions and adjustments set forth below in this Warrant.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Date
of Warrant Exercise</U>. This Warrant shall become exercisable twelve (12) months after the Base Date (the &ldquo;<B>Exercise
Date</B>&rdquo;). As used in this Warrant, the term &ldquo;<B>Base Date&rdquo; </B>shall mean November [___], 2018 (the effective
date of the registration statement). Except as permitted by applicable rules of the Financial Industry Regulatory Authority, Inc.
(&ldquo;<B>FINRA</B>&rdquo;), this Warrant and the underlying Warrant Shares shall not be sold, transferred, assigned, pledged
or hypothecated prior to the date that is one hundred eighty (180) days immediately following the Base Date pursuant to FINRA
Rule 5110(g)(1), except as permitted under FINRA Rule 5110(g)(2).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Expiration
of Warrant</U>. This Warrant shall expire on the five (5) year anniversary of the Base Date (the &ldquo;<B>Expiration Date</B>&rdquo;).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise
of Warrant</U>. This Warrant shall be exercisable pursuant to the terms of this Section 3.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 48px; font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Manner
    of Exercise</U>.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Warrant may only be exercised by the Holder hereof on or after the Exercise Date and on or prior to the Expiration Date, in accordance
with the terms and conditions hereof, in whole or in part (but not as to fractional shares) with respect to any portion of this
Warrant, during the Company&rsquo;s normal business hours on any day other than a Saturday or a Sunday or a day on which commercial
banking institutions in New York, New York are authorized by law to be closed (a &ldquo;<B>Business Day&rdquo;</B>), by surrender
of this Warrant to the Company at its office maintained pursuant to Section 10.2(a) hereof, accompanied by a written exercise
notice in the form attached as <U>Exhibit A</U> to this Warrant (or a reasonable facsimile thereof) duly executed by the Holder,
together with the payment of the aggregate Exercise Price for the number of Warrant Shares purchased upon exercise of this Warrant.
Upon surrender of this Warrant, the Company shall cancel this Warrant document and shall, in the event of partial exercise, replace
it with a new Warrant document in accordance with Section 3.3.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as provided for in Section 3.1(c) below, each exercise of this Warrant must be accompanied by payment in full of the aggregate
Exercise Price in cash by check or wire transfer in immediately available funds for the number of Warrant Shares being purchased
by the Holder upon such exercise.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
aggregate Exercise Price for the number of Warrant Shares being purchased may also, in the sole discretion of the Holder, be paid
in full or in part on a &ldquo;cashless basis&rdquo; at the election of the Holder:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 192px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 48px; font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    the form of Common Stock owned by the Holder (based on the Fair Market Value (as defined below) of such Common Stock on the
    date of exercise);</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 192px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 48px; font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    the form of Warrant Shares withheld by the Company from the Warrant Shares otherwise to be received upon exercise of this
    Warrant having an aggregate Fair Market Value on the date of exercise equal to the aggregate Exercise Price of the Warrant
    Shares being purchased by the Holder; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 192px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 48px; font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
    a combination of the foregoing, provided that the combined value of all cash and the Fair Market Value of any shares surrendered
    to the Company is at least equal to the aggregate Exercise Price for the number of Warrant Shares being purchased by the Holder.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">For
purposes of this Warrant, the term &ldquo;<B>Fair Market Value&rdquo; </B>means with respect to a particular date, the average
closing price of the Common Stock for the five (5) trading days immediately preceding the applicable exercise herein as officially
reported by the principal securities exchange on which the Common Stock is then listed or admitted to trading, or, if the Common
Stock is not listed or admitted to trading on any securities exchange as determined in good faith by resolution of the Board of
Directors of the Company, based on the best information available to it.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">To
illustrate a cashless exercise of this Warrant under Section 3.1(c)(ii) (or for a portion thereof for which cashless exercise
treatment is requested as contemplated by Section 3.1(c)(iii) hereof), the calculation of such exercise shall be as follows:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">X = Y (A-B)/A</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">where:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.4in; text-indent: -0.4in"><FONT STYLE="font-size: 10pt">X
=&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the number of Warrant Shares to be issued to the Holder (rounded to the nearest whole share).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">Y =&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
number of Warrant Shares with respect to which this Warrant is being exercised.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">A =&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Fair Market Value of the Common Stock.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">B =&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Exercise Price.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of Rule 144 and sub-section (d)(3)(ii) thereof, it is intended, understood, and acknowledged that the Common Stock issuable
upon exercise of this Warrant in a cashless exercise transaction as described in Section 3.1(c) above shall be deemed to have
been acquired at the time this Warrant was issued. Moreover, it is intended, understood, and acknowledged that the holding period
for the Common Stock issuable upon exercise of this Warrant in a cashless exercise transaction as described in Section 3.1(c)
above shall be deemed to have commenced on the date this Warrant was issued.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>When
Exercise Effective</U>. Each exercise of this Warrant shall be deemed to have been effected immediately prior to the close of
business on the Business Day on which this Warrant shall have been duly surrendered to the Company as provided in Sections 3.1
and 12 hereof, and, at such time, the Holder in whose name any certificate or certificates for Warrant Shares shall be issuable
upon exercise as provided in Section 3.3 hereof shall be deemed to have become the holder or holders of record thereof of the
number of Warrant Shares purchased upon exercise of this Warrant.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
of Common Stock Certificates and New Warrant</U>. As soon as reasonably practicable after each exercise of this Warrant, in whole
or in part, and in any event within three (3) Business Days thereafter, the Company, at its expense (including the payment by
it of any applicable issue taxes), will cause to be issued in the name of and delivered to the Holder hereof or, subject to Sections
9 and 10 hereof, as the Holder (upon payment by the Holder of any applicable transfer taxes) may direct:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
certificate or certificates (with appropriate restrictive legends, as applicable) for the number of duly authorized, validly issued,
fully paid and non-assessable Warrant Shares to which the Holder shall be entitled upon exercise; and</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in
case exercise is in part only, a new Warrant document of like tenor, dated the date hereof, for the remaining number of Warrant
Shares issuable upon exercise of this Warrant after giving effect to the partial exercise of this Warrant (including the delivery
of any Warrant Shares as payment of the Exercise Price for such partial exercise of this Warrant).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Adjustments</U>. For so long as this Warrant is outstanding:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Mergers
or Consolidations</U>. If at any time after the date hereof there shall be a capital reorganization (other than a combination
or subdivision of Common Stock otherwise provided for herein) resulting in a reclassification to or change in the terms of securities
issuable upon exercise of this Warrant (a &ldquo;<B>Reorganization&rdquo;</B>), or a merger or consolidation of the Company with
another corporation, association, partnership, organization, business, individual, government or political subdivision thereof
or a governmental agency (a &ldquo;<B>Person&rdquo; </B>or the &ldquo;<B>Persons&rdquo;</B>) (other than a merger with another
Person in which the Company is a continuing corporation and which does not result in any reclassification or change in the terms
of securities issuable upon exercise of this Warrant or a merger effected exclusively for the purpose of changing the domicile
of the Company) (a &ldquo;<B>Merger&rdquo;</B>), then, as a part of such Reorganization or Merger, lawful provision and adjustment
shall be made so that the Holder shall thereafter be entitled to receive, upon exercise of this Warrant, the number of shares
of stock or any other equity or debt securities or property receivable upon such Reorganization or Merger by a holder of the number
of shares of Common Stock which might have been purchased upon exercise of this Warrant immediately prior to such Reorganization
or Merger. In any such case, appropriate adjustment shall be made in the application of the provisions of this Warrant with respect
to the rights and interests of the Holder after the Reorganization or Merger to the end that the provisions of this Warrant (including
adjustment of the Exercise Price then in effect and the number of Warrant Shares) shall be applicable after that event, as near
as reasonably may be, in relation to any shares of stock, securities, property or other assets thereafter deliverable upon exercise
of this Warrant. The provisions of this Section 4.1 shall similarly apply to successive Reorganizations and/or Mergers.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Splits
and Subdivisions; Dividends</U>. In the event the Company should at any time or from time to time effectuate a split or subdivision
of the outstanding shares of Common Stock or pay a dividend in or make a distribution payable in additional shares of Common Stock
or other securities, or rights convertible into, or entitling the holder thereof to receive, directly or indirectly, additional
shares of Common Stock (hereinafter referred to as &ldquo;<B>Common Stock Equivalents</B>&rdquo;) without payment of any consideration
by such holder for the additional shares of Common Stock or Common Stock Equivalents (including the additional shares of Common
Stock issuable upon conversion or exercise thereof), then, as of the applicable record date (or the date of such distribution,
split or subdivision if no record date is fixed), the per share Exercise Price shall be appropriately decreased and the number
of Warrant Shares shall be appropriately increased in proportion to such increase (or potential increase) of outstanding shares;
provided, however, that no adjustment shall be made in the event the split, subdivision, dividend or distribution is not effectuated.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Combination
of Shares</U>. If the number of shares of Common Stock outstanding at any time after the date hereof is decreased by a combination
of the outstanding shares of Common Stock, the per share Exercise Price shall be appropriately increased and the number of shares
of Warrant Shares shall be appropriately decreased in proportion to such decrease in outstanding shares.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustments
for Other Distributions</U>. In the event the Company shall declare a distribution payable in securities of other Persons, evidences
of indebtedness issued by the Company or other Persons, assets (excluding cash dividends or distributions to the holders of Common
Stock paid out of current or retained earnings and declared by the Company&rsquo;s Board of Directors) or options or rights not
referred to in Sections 4.2 or 4.3 then, in each such case for the purpose of this Section 4.4, upon exercise of this Warrant,
the Holder shall be entitled to a proportionate share of any such distribution as though the Holder was the actual record holder
of the number of Warrant Shares as of the record date fixed for the determination of the holders of Common Stock of the Company
entitled to receive such distribution.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Impairment</U>. The Company will not, by amendment of its certificate of incorporation or by-laws or through any consolidation,
merger, reorganization, transfer of assets, dissolution, issue or sale of securities or any other voluntary action, avoid or seek
to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the
carrying out of all of the terms and in the taking of all actions necessary or appropriate in order to protect the rights of the
Holder against impairment.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
as to Adjustments</U>. With respect to each adjustment pursuant to Section 4 of this Warrant, the Company, at its expense, will
promptly compute the adjustment or re-adjustment in accordance with the terms of this Warrant and furnish the Holder with a certificate
certified and confirmed by the Secretary or Chief Financial Officer of the Company setting forth, in reasonable detail, the event
requiring the adjustment or re-adjustment and the amount of such adjustment or re-adjustment, the method of calculation thereof
and the facts upon which the adjustment or re-adjustment is based, and the Exercise Price and the number of Warrant Shares or
other securities purchasable hereunder after giving effect to such adjustment or re-adjustment, which report shall be mailed by
first class mail, postage prepaid to the Holder.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reservation
of Shares</U>. The Company shall, solely for the purpose of effecting the exercise of this Warrant, at all times during the term
of this Warrant, reserve and keep available out of its authorized shares of Common Stock, free from all taxes, liens and charges
with respect to the issue thereof and not subject to preemptive rights of shareholders of the Company, such number of its shares
of Common Stock as shall from time to time be sufficient to effect in full the exercise of this Warrant. If at any time the number
of authorized but unissued shares of Common Stock shall not be sufficient to effect in full the exercise of this Warrant, in addition
to such other remedies as shall be available to Holder, the Company will promptly take such corporate action as may, in the opinion
of its counsel, be necessary to increase the number of authorized but unissued shares of Common Stock to such number of shares
as shall be sufficient for such purposes, including without limitation, using its Reasonable Commercial Efforts (as defined in
Section 19 hereof) to obtain the requisite shareholder approval necessary to increase the number of authorized shares of Common
Stock. The Company hereby represents and warrants that all shares of Common Stock issuable upon proper exercise of this Warrant
shall be duly authorized and, when issued and paid for upon proper exercise, shall be validly issued, fully paid and nonassessable.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 48px; font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Registration
    and Listing</U>.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Definition
of Registrable Securities; Majority</U>. As used herein, the term &ldquo;<B>Registrable Securities</B>&rdquo; means any shares
of Common Stock issuable upon the exercise of this Warrant until the date (if any) on which such shares shall have been transferred
or exchanged and new certificates for them not bearing a legend restricting further transfer shall have been delivered by the
Company and subsequent disposition of the shares shall not require registration or qualification under the Securities Act or any
similar state law then in force. For purposes of this Warrant, the term &ldquo;<B>Majority Holders</B>&rdquo; shall mean in excess
of fifty percent (50%) of the then outstanding Warrant Shares.</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 48px; font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Demand
    Registration Rights</U>.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company, upon written demand (&ldquo;<B>Demand Notice</B>&rdquo;) of the Majority Holders, agrees to register on one occasion
all of the Registrable Securities (a &ldquo;<B>Demand Right</B>&rdquo;). On such occasion, the Company will file a registration
statement or a post-effective amendment to the registration statement covering the Registrable Securities within forty-five (45)
days after receipt of a Demand Notice and use its Reasonable Commercial Efforts to have such registration statement or post-effective
amendment declared effective as soon as possible thereafter; provided, however, that the Company shall not be required to comply
with a Demand Notice if the Company has filed a registration statement with respect to which the Holder is entitled to piggyback
registration rights pursuant to Section 8.3 hereof and either: (i) the Holder has elected to participate in the offering covered
by such registration statement or (ii) if such registration statement relates to an underwritten primary offering of securities
of the Company, until the offering covered by such registration statement has been withdrawn or until thirty (30) days after such
offering is consummated. The demand for registration may be made at any time during a period of four years beginning one (1) year
from the Base Date. The Company covenants and agrees to give written notice of its receipt of any Demand Notice to all other registered
Holders of the Warrants and/or the Registrable Securities within ten days from the date of the receipt of any such Demand Notice.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company shall bear all fees and expenses attendant to registering the Registrable Securities pursuant to Section 8.2(a), but the
Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to represent
them in connection with the sale of the Registrable Securities. The Company agrees to use its Reasonable Commercial Efforts to
qualify or register the Registrable Securities in such states as are reasonably requested by the Majority Holder(s); provided,
however, that in no event shall the Company be required to register the Registrable Securities in a state in which such registration
would cause (i) the Company to be obligated to register, license or qualify to do business in such state, submit to general service
of process in such state or would subject the Company to taxation as a foreign corporation doing business in such jurisdiction
or (ii) the principal stockholders of the Company to be obligated to escrow their shares of capital stock of the Company. The
Company shall cause any registration statement or post-effective amendment filed pursuant to the Demand Right granted under Section
8.2(a) to remain effective for a period of nine (9) consecutive months from the effective date of such registration statement
or post-effective amendment. The Holders shall only use the prospectuses provided by the Company to sell the Registrable Securities
covered by such registration statement, and will immediately cease to use any prospectus furnished by the Company if the Company
advises the Holder that such prospectus may no longer be used due to a material misstatement or omission.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 48px; font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Incidental
    Registration Rights</U>.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the Company, for a period of six (6) years commencing one (1) year after the Base Date, proposes to register any of its securities
under the Securities Act (other than in connection with a transaction contemplated by Rule 145(a) promulgated under the Securities
Act or pursuant to registration on Form S-4 or S-8 or any successor forms) whether for its own account or for the account of any
holder or holders of its shares other than Registrable Securities (any shares of such holder or holders (but not those of the
Company and not Registrable Securities) with respect to any registration are referred to herein as, &ldquo;<B>Other Shares</B>&rdquo;),
the Company shall at each such time give prompt (but not less than thirty (30) days prior to the anticipated effectiveness thereof)
written notice to the holders of Registrable Securities of its intention to do so. The holders of Registrable Securities shall
exercise the &ldquo;piggy-back&rdquo; rights provided herein by giving written notice within fifteen (15) days after the receipt
of any such notice (which request shall specify the Registrable Securities intended to be disposed of by such holder). Except
as set forth in Section 8.3(b), the Company will use its Reasonable Commercial Efforts to effect the registration under the Securities
Act of all of the Registrable Securities which the Company has been so requested to register by such holder, to the extent required
to permit the disposition of the Registrable Securities so to be registered, by inclusion of such Registrable Securities in the
registration statement which covers the securities which the Company proposes to register. The Company will pay all Registration
Expenses, as defined in Section 8.6 herein, in connection with each registration of Registrable Securities pursuant to this Section
8.3.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the Company at any time proposes to register any of its securities under the Securities Act as contemplated by this Section 8.3
and such securities are to be distributed by or through one or more underwriters, the Company will, if requested by a holder of
Registrable Securities, use its Reasonable Commercial Efforts to arrange for such underwriters to include all the Registrable
Securities to be offered and sold by such holder among the securities to be distributed by such underwriters, provided that if
the managing underwriter of such underwritten offering shall inform the Company by letter of its belief that inclusion in such
registration statement and/or distribution of all or a specified number of such securities proposed to be distributed by such
underwriters would interfere with the successful marketing of the securities being distributed by such underwriters (such letter
to state the basis of such belief and the approximate number of such Registrable Securities, such Other Shares and shares held
by the Company proposed so to be registered which may be distributed without such effect), then the Company may, upon written
notice to such holder, the other holders of Registrable Securities, and holders of such Other Shares, reduce pro rata in accordance
with the number of shares of Common Stock desired to be included in such registration statement and/or distribution (if and to
the extent stated by such managing underwriter to be necessary to eliminate such effect) the number of such Registrable Securities
and Other Shares the registration and/or distribution of which shall have been requested by each holder thereof so that the resulting
aggregate number of such Registrable Securities and Other Shares so included in such registration and/or distribution, together
with the number of securities to be included in such registration and/or distribution for the account of the Company, shall be
equal to the number of shares stated in such managing underwriter&rsquo;s letter.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">8.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration
Procedures</U>. Whenever the holders of Registrable Securities have properly requested that any Registrable Securities be registered
pursuant to the terms of this Warrant, the Company shall use its Reasonable Commercial Efforts to effect the registration for
the sale of such Registrable Securities in accordance with the intended method of disposition thereof, and pursuant thereto the
Company shall as expeditiously as possible:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;prepare
and file with the SEC a registration statement with respect to such Registrable Securities and use its Reasonable Commercial Efforts
to cause such registration statement to become effective;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;notify
such holders of the effectiveness of each registration statement filed hereunder and prepare and file with the SEC such amendments
and supplements to such registration statement and the prospectus used in connection therewith as may be necessary to (i) keep
such registration statement effective and the prospectus included therein usable for a period commencing on the date that such
registration statement is initially declared effective by the SEC and ending on the earlier of (A) the date when all Registrable
Securities covered by such registration statement have been sold pursuant to the registration statement or cease to be Registrable
Securities, or (B) nine months from the effective date of the registration statement; and (ii) comply with the provisions of the
Securities Act with respect to the disposition of all securities covered by such registration statement during such period in
accordance with the intended methods of disposition by the sellers thereof set forth in such registration statement;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;furnish
to such holders such number of copies of such registration statement, each amendment and supplement thereto, the prospectus included
in such registration statement (including each preliminary prospectus) and such other documents as such seller may reasonably
request in order to facilitate the disposition of the Registrable Securities owned by such holders;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;use
its Reasonable Commercial Efforts to register or qualify such Registrable Securities under such other securities or blue sky laws
of such jurisdictions as such holders reasonably request and do any and all other acts and things which may be reasonably necessary
or advisable to enable such holders to consummate the disposition in such jurisdictions of the Registrable Securities owned by
such holders; provided, however, that the Company shall not be required to: (i) qualify generally to do business in any jurisdiction
where it would not otherwise be required to qualify but for this subparagraph; (ii) subject itself to taxation in any such jurisdiction;
or (iii) consent to general service of process in any such jurisdiction;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;notify
such holders, at any time when a prospectus relating thereto is required to be delivered under the Securities Act, of the happening
of any event as a result of which the prospectus included in such registration statement contains an untrue statement of a material
fact or omits any material fact necessary to make the statements therein, in light of the circumstances in which they are made,
not materially misleading, and, at the reasonable request of such holders, the Company shall prepare a supplement or amendment
to such prospectus so that, as thereafter delivered to the purchasers of such Registrable Securities, such prospectus shall not
contain an untrue statement of a material fact or omit to state any material fact necessary to make the statements therein, in
light of the circumstances in which they are made, not materially misleading;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;provide
a transfer agent and registrar for all such Registrable Securities not later than the effective date of such registration statement;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;make
available for inspection by any underwriter participating in any disposition pursuant to such registration statement, and any
attorney, accountant or other agent retained by any such underwriter, all financial and other records, pertinent corporate documents
and properties of the Company, and cause the Company&rsquo;s officers, directors, managers, employees and independent accountants
to supply all information reasonably requested by any such underwriter, attorney, accountant or agent in connection with such
registration statement;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;otherwise
use its Reasonable Commercial Efforts to comply with all applicable rules and regulations of the SEC, and make available to its
security holders, as soon as reasonably practicable, an earnings statement of the Company, which earnings statement shall satisfy
the provisions of Section 11(a) of the Securities Act and, at the option of the Company, Rule 158 thereunder;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in
the event of the issuance of any stop order suspending the effectiveness of a registration statement, or of any order suspending
or preventing the use of any related prospectus or suspending the qualification of any Registrable Securities included in such
registration statement for sale in any jurisdiction, the Company shall use its Reasonable Commercial Efforts promptly to obtain
the withdrawal of such order; and</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if
the offering is underwritten, use its Reasonable Commercial Efforts to furnish on the date that Registrable Securities are delivered
to the underwriters for sale pursuant to such registration, an opinion dated such date of counsel representing the Company for
the purposes of such registration, addressed to the underwriters covering such issues as are reasonably required by such underwriters.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">8.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Listing</U>.
The Company shall secure the listing of the Common Stock underlying this Warrant upon each national securities exchange or automated
quotation system upon which shares of Common Stock are then listed or quoted (subject to official notice of issuance) and shall
maintain such listing of shares of Common Stock. The Company shall at all times comply in all material respects with the Company&rsquo;s
reporting, filing and other obligations under the by-laws or rules of the Nasdaq Capital Market (or such other national securities
exchange or market on which the Common Stock may then be listed, as applicable).&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">8.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Expenses</U>.
The Company shall pay all Registration Expenses relating to the registration and listing obligations set forth in this Section
8. For purposes of this Warrant, the term &ldquo;<B>Registration Expenses</B>&rdquo; means: (a) all registration, filing and FINRA
fees, (b) all reasonable fees and expenses of complying with securities or blue sky laws, (c) all word processing, duplicating
and printing expenses, (d) the fees and disbursements of counsel for the Company and of its independent public accountants, including
the expenses of any special audits or &ldquo;cold comfort&rdquo; letters required by or incident to such performance and compliance,
(e) premiums and other costs of policies of insurance (if any) against liabilities arising out of the public offering of the Registrable
Securities being registered if the Company desires such insurance, if any, and (f) fees and disbursements of one counsel for the
selling holders of Registrable Securities; provided however, that, in any case where Registration Expenses are not to be borne
by the Company, such expenses shall not include (and such expenses shall be borne by the Company): (i) salaries of Company personnel
or general overhead expenses of the Company, (ii) auditing fees, or (iii) other expenses for the preparation of financial statements
or other data, to the extent that any of the foregoing either is normally prepared by the Company in the ordinary course of its
business or would have been incurred by the Company had no public offering taken place. Registration Expenses shall not include
any underwriting discounts and commissions which may be incurred in the sale of any Registrable Securities and transfer taxes
of the selling holders of Registrable Securities.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">8.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Information
Provided by Holders</U>. Any holder of Registrable Securities included in any registration shall furnish to the Company such information
as the Company may reasonably request in writing, including, but not limited to, a completed and executed questionnaire requesting
information customarily sought of selling security holders, to enable the Company to comply with the provisions hereof in connection
with any registration referred to in this Warrant. The Holder agrees to suspend all sales of Registrable Securities pursuant to
a registration statement filed under Section 8.3 in the event the Company notifies Holder pursuant to Section 8.4(e) that the
prospectus relating thereto is no longer current and will not resume sales under such registration statement until advised by
the Company that the prospectus has been appropriately supplemented or amended.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">8.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>FINRA
Public Offering System Filings</U>. In the event that a registration statement covering the Registrable Securities is filed, within
one (1) Business Day of the filing of such registration statement, the Company will prepare and file the selling stockholder resale
offering described in such registration statement for review by FINRA via FINRA&rsquo;s Public Offering System filing system (&ldquo;<B>Public
Offering System Filing</B>&rdquo;) for the purpose of having the prospectus contained within such registration statement treated
as a &ldquo;base prospectus&rdquo; in connection with such resale offering. The Company will use its Reasonable Commercial Efforts
to have the Public Offering System Filing approved by FINRA within thirty (30) days of such filing date. The Company shall bear
all expenses of the Public Offering System Filing, including fees and expenses of one counsel or other advisor to the Holder.
In all circumstances, the Company shall pay for all FINRA filing fees associated with the Public Offering System Filing.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">8.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Effectiveness
Period</U>. The Company shall use its Reasonable Commercial Efforts to keep each registration statement contemplated hereunder
continuously effective under the Securities Act until the date which is the earlier date of when (i) all Registrable Securities
covered by such registration statement have been sold, (ii) all Registrable Securities covered by such registration statement
may be sold immediately without registration under the Securities Act and without volume restrictions pursuant to Rule 144 under
the Securities Act, as determined by the counsel to the Company pursuant to a written opinion letter to such effect, addressed
and reasonably acceptable to the Company&rsquo;s transfer agent and the affected holders of Registrable Securities, or (iii) nine
months from the effective date of such registration statement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">8.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Net
Cash Settlement</U>. Notwithstanding anything herein to the contrary, in no event will the Holder hereof be entitled to receive
a net-cash settlement as liquidated damages in lieu of physical settlement in shares of Common Stock, regardless of whether the
Common Stock underlying this Warrant is registered pursuant to an effective registration statement; provided, however, that the
foregoing will not preclude the Holder from seeking other remedies at law or equity for breaches by the Company of its registration
obligations hereunder.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 48px; font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Restrictions
    on Transfer</U>.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">9.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Restrictive
Legends</U>. This Warrant and each Warrant issued upon transfer or in substitution for this Warrant pursuant to Section 10 hereof,
each certificate for Common Stock issued upon the exercise of the Warrant and each certificate issued upon the transfer of any
such Common Stock shall be transferable only upon satisfaction of the conditions specified in this Section 9. Each of the foregoing
securities shall be stamped or otherwise imprinted with a legend reflecting the restrictions on transfer set forth herein and
any restrictions required under the Securities Act or other applicable securities laws.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">9.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
of Proposed Transfer</U>. Prior to any transfer of any securities which are not registered under an effective registration statement
under the Securities Act <B>(</B>&ldquo;<B>Restricted Securities&rdquo;), </B>which transfer may only occur if there is an exemption
from the registration provisions of the Securities Act and all other applicable securities laws, the Holder will give written
notice to the Company of the Holder&rsquo;s intention to effect a transfer (and shall describe the manner and circumstances of
the proposed transfer). The following provisions shall apply to any proposed transfer of Restricted Securities:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
in the opinion of counsel for the Holder reasonably satisfactory to the Company the proposed transfer may be effected without
registration of the Restricted Securities under the Securities Act (which opinion shall state in detail the basis of the legal
conclusions reached therein), the Holder shall thereupon be entitled to transfer the Restricted Securities in accordance with
the terms of the notice delivered by the Holder to the Company. Each certificate representing the Restricted Securities issued
upon or in connection with any transfer shall bear the restrictive legends required by Section 9.1 hereof.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the opinion called for in (i) above is not delivered, the Holder shall not be entitled to transfer the Restricted Securities until
either: (x) receipt by the Company of a further notice from such Holder pursuant to the foregoing provisions of this Section 9.2
and fulfillment of the provisions of clause (i) above, or (y) such Restricted Securities have been effectively registered under
the Securities Act.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">9.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Other Transfer Restrictions</U>. Notwithstanding any other provision of this Warrant: (i) prior to the Exercise Date, this Warrant
or the Restricted Securities thereunder may only be transferred or assigned to the persons permitted under FINRA Rule 5110(g),
and (ii) subject at all times to FINRA Rule 5110(g), no opinion of counsel shall be necessary for a transfer of Restricted Securities
by the holder thereof to any Person employed by or owning equity in the Holder, if the transferee agrees in writing to be subject
to the terms hereof to the same extent as if the transferee were the original purchaser hereof and such transfer is permitted
under applicable securities laws.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">9.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination
of Restrictions</U>. Except as set forth in Section 9.3 hereof and subject at all times to FINRA Rule 5110(g), the restrictions
imposed by this Section 9 upon the transferability of Restricted Securities shall cease and terminate as to any particular Restricted
Securities: (a) which shall have been effectively registered under the Securities Act, or (b) when, in the opinion of counsel
for the Company, such restrictions are no longer required in order to insure compliance with the Securities Act or Section 10
hereof. Whenever such restrictions shall cease and terminate as to any Restricted Securities, the Holder thereof shall be entitled
to receive from the Company, without expense (other than applicable transfer taxes, if any), new securities of like tenor not
bearing the applicable legends required by Section 9.1 hereof.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 48px; font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Ownership,
    Transfer, Sale and Substitution of Warrant</U>.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">10.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Ownership
of Warrant</U>. The Company may treat any Person in whose name this Warrant is registered in the Warrant Register maintained pursuant
to Section 10.2(b) hereof as the owner and holder thereof for all purposes, notwithstanding any notice to the contrary, except
that, if and when any Warrant is properly assigned in blank, the Company may (but shall not be obligated to) treat the bearer
thereof as the owner of such Warrant for all purposes, notwithstanding any notice to the contrary. Subject to Sections 9 and 10
hereof, this Warrant, if properly assigned, may be exercised by a new holder without a new Warrant first having been issued.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 48px; font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Office;
    Exchange of Warrant</U>.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company will maintain its principal office at the location identified in the prospectus relating to the Offering or at such other
offices as set forth in the Company&rsquo;s most current filing (as of the date notice is to be given) under the Securities Exchange
Act of 1934, as amended, or as the Company otherwise notifies the Holder.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company shall cause to be kept at its office maintained pursuant to Section 10.2(a) hereof a Warrant Register for the registration
and transfer of the Warrant. The name and address of the holder of the Warrant, the transfers thereof and the name and address
of the transferee of the Warrant shall be registered in such Warrant Register. The Person in whose name the Warrant shall be so
registered shall be deemed and treated as the owner and holder thereof for all purposes of this Warrant, and the Company shall
not be affected by any notice or knowledge to the contrary.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the surrender of this Warrant, properly endorsed, for registration of transfer or for exchange at the office of the Company maintained
pursuant to Section 10.2(a) hereof, the Company at its expense will (subject to compliance with Section 9 hereof, if applicable)
execute and deliver to or upon the order of the Holder thereof a new Warrant of like tenor, in the name of such holder or as such
holder (upon payment by such holder of any applicable transfer taxes) may direct, calling in the aggregate on the face thereof
for the number of shares of Common Stock called for on the face of the Warrant so surrendered (after giving effect to any previous
adjustment(s) to the number of Warrant Shares).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">10.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Replacement
of Warrant</U>. Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation
of this Warrant and, in the case of any such loss, theft or destruction of this Warrant, upon delivery of indemnity reasonably
satisfactory to the Company in form and amount or, in the case of any mutilation, upon surrender of this Warrant for cancellation
at the office of the Company maintained pursuant to Section 10.2(a) hereof, the Company will execute and deliver, in lieu thereof,
a new Warrant of like tenor and dated the date hereof.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">10.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Opinions</U>.
In connection with the sale of the Warrant Shares by Holder, the Company agrees to cooperate with the Holder, and at the Company&rsquo;s
expense, to have its counsel provide any legal opinions required to remove the restrictive legends from the Warrant Shares in
connection with a sale, transfer or legend removal request of Holder.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification</U>.
In the event of any piggyback registration of any Warrant Shares under the Securities Act, and in connection with any registration
statement or any other disclosure document pursuant to which securities of the Company are sold, the Company will, and hereby
does, jointly and severally, indemnify and hold harmless the Holder, its directors, officers, fiduciaries, and agents (each, a
&ldquo;<B>Covered Person</B>&rdquo;) against any losses, claims, damages or liabilities, joint or several, to which such Covered
Person may be or become subject under the Securities Act, any other securities or other laws of any jurisdiction, common law or
otherwise, insofar as such losses, claims, damages or liabilities (or actions or proceedings in respect thereof) arise out of
or are based upon (1) any untrue statement or alleged untrue statement of any material fact contained or incorporated by reference
in any registration statement under the Securities Act, any preliminary prospectus or final prospectus included therein, or any
amendment or supplement thereto, or any document incorporated by reference therein, or any other such disclosure document, or
(2) any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statement
therein not misleading, and will reimburse such Covered Person for any legal or any other expenses incurred in connection with
investigating or defending any such loss, claim, damage, liability, action or proceeding, provided, however, the Company shall
not be liable to any Covered Person in any such case to the extent that any such loss, claim, damage, liability, action or proceeding
is determined, by a final, non-appealable judgment by a court or arbitral tribunal of competent jurisdiction, to have arisen out
of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in such registration
statement, any such preliminary prospectus, final prospectus, amendment or supplement, any document incorporated by reference
or other such disclosure document in reliance upon and in conformity with written information furnished to the Company through
an instrument duly executed by such Covered Person specifically stating that it is for use in the preparation thereof.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Rights or Liabilities as Stockholder</U>. No Holder shall be entitled to vote or be deemed the holder of any equity securities
which may at any time be issuable on the exercise hereof, nor shall anything contained herein be construed to confer upon the
Holder, as such, any of the rights of a stockholder of the Company or any right to vote for the election of directors or upon
any matter submitted to stockholders at any meeting thereof, or to give or withhold consent to any corporate action (whether upon
any recapitalization, issuance of stock, reclassification of stock, change of par value, consolidation, merger, conveyance, or
otherwise) or to receive notice of meetings until the Warrant shall have been exercised and the shares of Common Stock purchasable
upon the exercise hereof shall have become deliverable, as provided herein.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
Any notice or other communication in connection with this Warrant shall be given in writing and directed to the parties hereto
as follows: (a) if to the Holder, at the address of the holder in the Warrant Register maintained pursuant to Section 10 hereof,
or (b) if to the Company, to the attention of its Chief Executive Officer at its office maintained pursuant to Section 10.2(a)
hereof; provided<I>, </I>that the exercise of the Warrant shall also be effected in the manner provided in Section 3 hereof. Notices
shall be deemed properly delivered and received when delivered to the notice party (i) if personally delivered, upon receipt or
refusal to accept delivery, (ii) if sent via facsimile, upon mechanical confirmation of successful transmission thereof generated
by the sending telecopy machine, (iii) if sent by a commercial overnight courier for delivery on the next Business Day, on the
first Business Day after deposit with such courier service, (iv) if sent by registered or certified mail, five (5) Business Days
after deposit thereof in the U.S. mail, or (v) if sent by email, the date of transmission if such notice or communication is delivered
via email at the email address specified in the Underwriting Agreement prior to 5:00 p.m. (prevailing Pacific time) on a Business
Day, or the next Business Day after the date of transmission if such notice or communication is delivered via email at the email
address specified in the Underwriting Agreement on a day that is not a Business Day or later than 5:00 p.m. (prevailing Pacific
time) on a Business Day.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment
of Taxes</U>. The Company will pay all documentary stamp taxes attributable to the issuance of shares of Common Stock underlying
this Warrant upon exercise of this Warrant; provided<I>, </I>however<I>, </I>that the Company shall not be required to pay any
tax which may be payable in respect of any transfer involved in the transfer or registration of this Warrant or any certificate
for shares of Common Stock underlying this Warrant in a name other than that of the Holder. The Holder is responsible for all
other tax liability that may arise as a result of holding or transferring this Warrant or receiving shares of Common Stock underlying
this Warrant upon exercise hereof.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments</U>.
This Warrant and any term hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the
party against which enforcement of the change, waiver, discharge or termination is sought.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law</U>. This Warrant shall be construed and enforced in accordance with and governed by the laws of the State of New York. Each
of the parties consents to the exclusive jurisdiction of the Federal or state courts whose districts encompass any part of the
County of New York located in the City of New York, New York in connection with any dispute arising under this Agreement and hereby
waives, to the maximum extent permitted by law, any objection, including any objection based on <I>forum non conveniens, </I>to
the bringing of any such proceeding in such jurisdictions. Each party to this Agreement irrevocably consents to the service of
process in any such proceeding by any manner permitted by law.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">17.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Section Headings</U>. The section headings in this Warrant are for purposes of convenience
only and shall not constitute a part hereof.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>.
In case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability
of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the parties will
attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor,
and upon so agreeing, shall incorporate such substitute provision in this Warrant.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">19.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reasonable Commercial Efforts</U>. When used herein, the term &ldquo;<B>Reasonable
Commercial Efforts</B>&rdquo; means, with respect to the applicable obligation of the Company, reasonable commercial efforts for
similarly situated, publicly-traded companies.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">(Signature
on Following Page)</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>IN
WITNESS WHEREOF, </B>the Company has caused this Underwriter Warrant to be duly executed as of the date first above written.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.2in; text-indent: 0.05in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ETON
    PHARMACEUTICALS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 7%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="width: 39%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>EXHIBIT
A</B><BR>
<B>FORM OF EXERCISE NOTICE</B><BR>
[To be executed only upon exercise of Warrant]</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">To ETON PHARMACEUTICALS, INC.:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">The undersigned registered holder
of the within Warrant hereby irrevocably exercises the Warrant pursuant to Section 3.1 of the Warrant with respect to [_____]
Warrant Shares, at an exercise price of $7.50 per share, and requests that the certificates for such Warrant Shares be issued,
subject to Sections 9 and 10, in the name of and delivered to:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: black 1pt solid; font-size: 11pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; font-size: 11pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; font-size: 11pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; font-size: 11pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">The undersigned is hereby making
payment for the Warrant Shares in the following manner:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">[check one]</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by cash in accordance with Section 3.1(b) of
the Warrant</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">via cashless exercise in accordance with Section
3.1(c) of the Warrant in the following manner:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: black 1pt solid; font-size: 11pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; font-size: 11pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; font-size: 11pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">The undersigned hereby represents
and warrants that it is, and has been since its acquisition of the Warrant, the record and beneficial owner of the Warrant.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">Dated:</FONT></TD>
    <TD STYLE="width: 25%; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 66%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">Print or Type Name</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 55%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Signature must conform in all respects
    to name of</FONT><FONT STYLE="font-size: 10pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">holder as specified on the face of Warrant)</FONT></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Street Address)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(City)</FONT></TD>
    <TD STYLE="width: 15%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State)</FONT></TD>
    <TD STYLE="width: 15%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</FONT></TD>
    <TD STYLE="width: 55%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>EXHIBIT
B</B><BR>
<B>FORM OF ASSIGNMENT</B><BR>
[To be executed only upon transfer of Warrant]</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">For value received, the undersigned
registered holder of the within Warrant hereby sells, assigns and transfers unto______________________ [include name and addresses]
the rights represented by the Warrant to</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">purchase________ shares of Common
Stock of ETON PHARMACEUTICALS, INC. to which the Warrant relates, and appoints________ Attorney to make such transfer on the books
of ETON PHARMACEUTICALS maintained for the purpose, with full power of substitution in the premises.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:</FONT></TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Signature must conform in all</FONT><FONT STYLE="font-size: 10pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">respects to name of holder as </FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">specified on the face of Warrant)</FONT></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Street Address)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(City) </FONT></TD>
    <TD STYLE="width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State) </FONT></TD>
    <TD STYLE="width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</FONT></TD>
    <TD STYLE="width: 15%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signed in the presence of:</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Signature of Transferee)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Street Address)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(City) </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signed in the presence of:</FONT></TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>6
<FILENAME>s113558_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>GREENBERG TRAURIG, LLP</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>3161 Michelson Drive, Suite 1000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Irvine, California 92612</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">October 31, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Eton Pharmaceuticals,
Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">21925 W. Field Parkway,
Suite 235</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Deer Park, Illinois 60010</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Re: Registration Statement on Form S-1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have acted as counsel
to Eton Pharmaceuticals, Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), in connection with the Registration Statement
on Form&nbsp;S-1 (File No.&nbsp;333-226774) (the &ldquo;<B>Registration Statement</B>&rdquo;) filed with the Securities and Exchange
Commission under the Securities Act of 1933, as amended, for the registration of (i)&nbsp;up to 3,450,000 shares (the &ldquo;<B>Common
Shares</B>&rdquo;) of the Company&rsquo;s $0.001 par value common stock (&ldquo;<B>Common Stock</B>&rdquo;); (ii)&nbsp;a warrant
to purchase up to 345,000 shares of Common Stock to be issued to the underwriter (the &ldquo;<B>Underwriter&rsquo;s Warrant</B>&rdquo;);
and (iii)&nbsp;up to 345,000 shares of Common Stock underlying the Underwriter&rsquo;s Warrant (the &ldquo;<B>Underlying Shares</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You have requested
our opinion as to the matters set forth below in connection with the Registration Statement. For purposes of rendering this opinion,
we have examined the Registration Statement, forms of the Amended and Restated Certificate of Incorporation and Amended and Restated
By-laws of the Company currently in effect, the Underwriter&rsquo;s Warrant, and the corporate action of the Company that provides
for the issuance of the Common Shares and execution of the Underwriter&rsquo;s Warrant, and we have made such other investigation
as we have deemed appropriate. We have examined and relied upon certificates of public officials and, as to certain matters of
fact that are material to our opinion, we have also relied on a certificate of an officer of the Company. We have not independently
verified the matters set forth in such certificates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We express no opinion
herein as to the laws of any state or jurisdiction other than the General Corporation Law of the State of Delaware and the federal
laws of the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based upon and subject
to the foregoing, it is our opinion that the Common Shares are duly authorized for issuance by the Company and, when issued and
paid for as described in the Registration Statement, will be validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based upon and subject
to the foregoing, it is our opinion that the Underwriter&rsquo;s Warrant has been duly authorized for issuance by the Company and,
when issued in conformity with and pursuant to the Registration Statement, will be validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based upon and subject
to the foregoing, it is our opinion that the Underlying Shares have been duly authorized for issuance by the Company and, upon
exercise and payment of the exercise price therefor in accordance with the terms of the Underwriter&rsquo;s Warrant, will be validly
issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We hereby consent to
the filing of this opinion as an exhibit to the Registration Statement and to the reference to our name under the caption &ldquo;Legal
Matters&rdquo; in the prospectus made part of the Registration Statement.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">/s/ GREENBERG TRAURIG, LLP</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>s113558_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">We
hereby consent to the use in this Amendment No. 3  to the Registration Statement on Form&nbsp;S-1&nbsp;(No. 333-226774) of
Eton Pharmaceuticals, Inc. of our report dated May 18, 2018 relating to the financial statements of Eton Pharmaceuticals,
Inc., which appears in such Registration Statement. We also consent to the reference to us under the heading
&ldquo;Experts&rdquo; in such Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">/s/ KMJ Corbin &amp; Company LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Costa Mesa, California</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">October 31, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>s113558_ex4-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 s113558_ex4-1img01.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!\@,T P$1  (1 0,1 ?_$ 04   $#!0$! 0
M       %!@<" P0("0$*"P$!  $% 0$!              $" P0%!@<("1
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M*.E*.E*.E*.E*.E*.E*.E*.E*.E*.E*.E*.E*.E*.E*.E*.E*.E*9>2&@/\
M'=]8C$2-@![2[2T&!AW7H9:;!S!OD1B(MZ*2WHY&2W^%!78?QJG*;:.FG6Z[
M;E^7[BP)_6CQ]F; WJR+NCBM*I]1UN-R);<RW%U!%Q7,]ZXXR^S>6Q#C39@E
MXS*3T(7].6?=!(/1B>S;))+[$>QVLP-C:U+5;1!M78%N5FXCBMX6+1+'NU/,
MZ8@DQ0(#-RL!2 JX; 78<VT-QBB.@=87).9.1R)"ZR%IG.]196NQ.X#6P;J!
MX UL^%B$'#8D(C>$)BQ+Z;G<R611L8V%V7X2;"Y!-J6NL*MG1TI1TI1TI1TI
M1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI
M1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI
M1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI
M1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI2%/UBM6MFG'VBO0=D8(N"
MNTF4_$Q\PT2=$(HF1RFVD6[E$C@B:IB@<"@8"F$-=!'I2HY_<SB'\P;?W38V
M\7P;77\A5?;Y/6Z:;_A/WMOT:]*FYJ8^E11TI1TI1TI1TI1TI1TI1TI1TI1T
MI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI3+R2U!]CJ_,ABY6<!Y2[2U&%@7
M/HYR8!Q!ODABX9X"2XM960W^)NIL/L6.4VT=-.MUVW+Z'<6!,)8H"F; WJ2C
M=%':53OD6XW1I\3BXNH(N*YCO: 979O+XI@R,H2<9E+Z,#;)YMT$@]*%[-ME
MDOLC;:=KD&QM:ENN)>"O0*(-73($8:+2]$^4\SYIXV*!/2O%MI/*Z;Z;%#;0
MW' 1T#K"Y%M_(3ON1[S.=RBRM=CYE&ME/4#P%;3A8_2X?$B].2+;C1#9(;NE
MD4;7-A=UZ,;"Y!-J61$  1$= #N(CV  #Z1ZPJV=> (& #%$! 0 0$!U 0'N
M @(=A 0Z4J/,L6MS1L>6>W-9NL5T]?8DD5)>X,)F5@VS=)R@#E-6*KSEK.2C
M]XB84&35H8SER\4223(H<X)FS./QURLQ,=ED?>;60@,3;35@5 '5B= H))'6
MNK['X2'N3NK#X*;&S,M<J0QB+%>*.9F*G:1).K0QHAL\LDH$<<2N[LBJ6&HS
M7D1R*+6;*]GJ)BZL6G%>*8S,62JY/REECSR43:Y7(+JH4J!6 [A&L64M/Q^J
M>5>NE)1DTF7/HT2.$VZKD>A;A^',\:PRSO!/D&&-E"FQ01AW;IN7?(-B@*Q0
M;B06 KW:?Z4_2AN8P\;B^3YK-X7F^;DXK GACQW$<N-'@KE9<PLIR,?YK.48
MT,:X\LN)'\Q(T3RI%2[%\D,F9!FIR!QS7\>Q+FL0%HO4@\R7(ST0P?UEA:Y6
MMUB$*:.*=6#EGI()TK,R:H.FT+J@ -'7F'QVI.%PL.))<QYF5W6,",*2&*!F
M;7X@-P"*+%]?,MM=9F_23L_M;CL;D^[,KE9X<S*Q\-$X^.&5TR'QHLC(FM)8
M31(9HUQ,=3')E_J7GA],;V5)<N,H-H/D#<FU5@%*[B%#+(03,*)E5VPL"V/T
MU$8M<<IM40H<F$F]*!CLV)#NU2ZI(ZJAVR4[>P6FP\9I'];),6X[X@5]2U_T
MCYQ8?O-H.ITKHL3Z%]F3<EVMV_-FY0Y7GFXSUG^<XU7@&<09!_+6/SL?IH;"
M68B)3:23R5<;<FLZSL#8I.LPV-!2JV;\;88=S-IJ>4J?\4E<CS]#K3E$*'9'
M,7=JS(41Y<B.' OB&;3#11 [,Y"B*@PW!\7%*B3-->3%EF"JT3V$:R,/U%!1
MA($L-NJ$'</"J)OH]]->-Y/$P^8R.8WYO;F?RRQ8V3QV5Z<>!!FY"GYV!9,3
M(3,3$,<?HD28LBR+.K$!0-N;LHOEZS8F3JM==N*59H*L3TTRL]:=F>N%[WAJ
M@33J*K47;I:S-BC*7>=,U1<M@53^&()N-B@N2I2W;$8X].0,C@2HS*I5A8".
M:106*!>B1W(-O,2+C;>9O].>%'V'A]\-FY<<7(X<V1#"^/D+L5<+E<V%9,B3
M%BQV_3Q,,2/'(5;YB1HMR"$NZV_([+9*%1LAO*[B<\?G..Q^KB* 1M$\UG*[
M)9/M]*KE92OAE8]TG8X>*C;VU=2[V*3:"U>HE8))+"[0=%QSPW'_ #<N&KY&
M_%:3UFVJ581([-Z>HVDF,A%:]U.\D;2M:.7Z2]C-W/R7:F/E\X,KMJ7.'*3G
M'A:&>/CL7+GR#A6=3!+))AR1XL62TOJ0L<IWC$$D)HG.3V4*#(V.%M&-X:\O
MJ3=X/&L\OC=Y)-"REKRI 5V5P<YCX^=%[\#C9^RS(5Z;2<NG!XE=XQDO*=@H
MOX)BX/!RT26"9HEEB:1?4 -EB9A."5MN*J/40@#< R6#@7JXWZ-]F=SXF)R/
M#<OD<;C<CQTW(0KGK&WIXW&SSQ\PKO#L]:2#'B^>PVCCC&2D63B;%R4B]16;
M9SS/8;M(XFKD'BUC?JZSMDQ/3=A>6H:4LTIT+BPKJ+B$F949DR\I:<BJ$,]4
M$21L<U254;+JN"I%MMQ7&PXJ\A,\YQ'*!54+ON[2V)OIHD8\O[S$@, MZPIO
MIM]/>*[=B[YY;)YJ7MC+DQHH88$QOFPV5+R6V24O>*T>-@J1"HOD3R.BS1)$
M7+A;Y^NLSBS+USK5,@)BT42\LJ76H.-L9).+L OXG'K[X@QDS_"2V55!2YKF
M9-&8HK3GI44&NQ=TF!;+<1C19^/C3R.L$L1=F*V*V,@L1KM^ 7+7"7):X4UJ
M9?I?V[Q_>O ]O\QR&5C\-R?&OEY$TD!CD@V2YR;'C'J_+@C$02RR[TP_4DEF
MW10L3#,QS%O<968X[:#J<G9U9QE6)0S.IY8*YBI5]F/&N/4R2>*7T.PR;&SK
M>N9!*_5@P(Y7,H5$[=TX:KD5'91=N8DDQW/(L&PL+M%J!#))I*"8RI:/:'T%
MKW4,"*]!P/H%VUF<Q*LV3G0\.,9\B/?D\9MDC3BN0SB8^225^/DA:?!,*YEX
MT"F1988IHV0954Y890O\0U2K5>I$=)MX')5V=6:;K^3G<98J?2+TCCZ(4K^,
M8B//E")FI>PBZ1E&;Q)5[ >B 56JXNDB$IR. P<-RT[RF/?$FU6C!5WC]0[I
M"?2("V*%3:3=H1M-['-_0_LSM?/>3E\KD9L-\KC\1<>&?CUD@RLS#.=*)^0E
M<<=+%%!Z;8TL3+#F^M9)HA"[,X8CE!?;-=:S'Q<9CV'I=\8UAE1;/(IWN>K=
MEG;=B]"YL'$?D.$BD:TT?LK.Y^'%J\VW@)J28(B]06(9=!J:S)P6)!CNTC3-
MDQ%C(HV*RJDNP@QL=Q!7S>JAD16.T@@%AJL_Z,]L</V]F96;-RN1W#QDF0^9
MCH<.'(QX<7D6Q'5\&:0Y#(^.OKGD<-\W$@F?Y:2-A'+,(]E>7&9:O6ZC-VUE
MC1BA9I_D"U>2];H.9+VTKL%@"PRE9E9.0KM14E;*LC-N(TSLSH")MHYN/C5\
MAA*<<M.WN.GFDBQS.2BX]@SPH6;(4, &>RC;>UNK'I;I7587T*^G_-<OG\=P
M4G,22X>+PC)%D9O%8;3S<W!'D1QI/E"/'!A601".[23OYDV %1(L=R>RTNK!
MP,MB2)B;/8,71N=47:5A4EZC$8P:4UJ]NK1_,,B%!]>(7(3AO#M6K8PH.V,J
MUD"J;$':*>(_!\> \L>0S0).8+;;.92Y"$ ]$:.[DG4,C);52>4R_HUV-&F3
MR>%SL\_#8O-2<,5, BRI>1;+9,1DB<^3#EP5?*DDD&^*;&FQ2NZ2"1FR_P">
ML1!VRVP<K!0KIK5<&/;X#6.GSIV&5RA7<91F9+)0DV2[19NQA#T">05:2*AS
M&]2QD$U$_P"SANO)VG)+!'+&[!I,H1ZKY1$TIA62]]6]12"OL9"#K6WQO],F
M?R7!X/)863D)-F]R)A;I(08(^.GY"3BL?-+A@SS#-A=98% 'IS8K(_ZNDI2N
M5<[5R?J&-9EEA1SD+)4\P9U67AI6UK5VNQ1*=>KC8G%HJ[H$;!(F9HT%=I$K
MH/6B4THLHH8C(&2Y#X,>!Q<T,F;$<D8<"$L&";F.]$4*P\HOZ@+@@E+ >;<"
M.+P>R?IIRW%Y_=_'R=Q)VMQ&,[Y,4L6,)YY#E8>+ N/DK>",,<U),E'BE;$5
M%4-D'(C94V5S+G&%O&,H*21P>$)8JYDV<N:\1*V&7/'J88DX1C<6L%/O9*O0
M:"DTE*F%$LD1N$*X2.@\.MXSJ=5Q\;Q<N+/*GS7J(\2I<*+^L&*%E 9O+;7;
M?>#=;7 K,POI_P#3?D.W.8Y+$;N3^8XF7Q\.(LL<$0<<M',^*TT"1SS$1&,!
MSCESEHRR0+'O5:C#$/-.Z9Y050H]7I%>D%V$^[8N9^?86Q@B:%J5"N8$D&]#
MM,DNCY8^Y':F!15!0KIN;0IA(LDGG<AVUB\4;Y4DKH"H(52I\SR)H74>*7Z'
M0^\$]EWY_IY[=^F4@E[CS>1RL598%=8(7QG/K9.;B71LW&C4V?$$@*JZF.0:
M@-&[-:<YIYEK-8HLU+UK'J\C;<#TO-B+*'JN5)6(>O\ (LLC$U#'3FS1@R$1
MC]9](K),AL$\=&*!=P50Q$TDE>K\7;/&SSRQ1O,$CRWAN6B! C%WD"FQDL+M
MZ:7:PL"216ZXW_3S]/\ F.9Y+C\',Y5<3![FR^(+RY/&QRHF#$9<K/7'DV2Y
MH2,-+\CA!LG8A4,[NE/J\\XUX&WY[I-:KU0EYW&F/9R6HK)_;%FRMFR/1F-;
M>7^IV,6[!8D/#1ZUZCFS1ZW]0HJK%S)C)[&A=V+B]KB7'Q,F9Y%BGF <A?AC
M<L(W774G8Q(-K!XM;M7-]M_Z;XN3X'MCN+E\O/@XWF.5ABS'3&##'P,Q\A<+
M)@W.#+*XPYY)8GV*JY&  ^Z<VKD.8EXLB\NSQI0FAW%?FX*%MR,C#6J]6;'T
MD-7FGMOA;-CB@":XS#ZMW1@WAW2T.1X5HDZ3?"DNW51%2%[<Q8%5\Z4V=6*6
M*HL@W*$99)/( R$N ]KD%;@@VIQ?H%VWQ$<&1WAR;B+*QIIL4QRXV'CYT?S,
M*8LV/GYO_"Q)D8COE1KE&(RM&V-OBE20*[(_-F?;?<6\5C]G@N>AYO T-FZJ
ME+(71<)H\X"S".K"-J_L+(6+R;0_#ESQJ0@T5*8[(IRF+U8?C.)Q\8R9ARDD
M3+,#:)Y=NI;;J;@?N;CJ/BK1Y7TZ^F' \ V=W3)W+B\AC]SR\1D^3$'HB&SO
MD'&\[[UA.N,,AOU5(7(*D&F++\Q\ARS?'\Y3:(UKE:R@]O:5/"WTO)5YN*S?
M&T-"IV/XM2<5,Y>9BU'EX?O8UJIHJ@5K&E=F,8'J"9<E.W,.)I8LF4O/ $W[
M'C1/U"VVSRD*;(%8]#=MO[I-=+@?0'M3!EY3C>X.3?+YCAH\(Y7RN7Q^'BAN
M0EF,'I9?)/%%($PTAR)%NKF3(,  ./*YSJSRJS%.N<FOIC';"G-,:U^2?2E4
MD*5DJ:<MIZ,P-6LJ/8.6RQ&I(8UC'C"RV T<J@<OG%-MM  76(4(GX'C8A D
M<QD:=P X>-1M,[1!A$?U""J[@>FOL%8W,?1/L#C8N&QL#EI<^?F,J-(\E,OC
MXE:&3FLCC4FBXR0MR$BOCP"=7!V;I+DF.-B6K)<WLA1\]=6R5-K;]K739\.S
MAU8'(4&I\$PG1)FR+6DF0Y1H%!M1%["TCH][#Q9SRC5.5!?0Q&J_5^/MC$>*
M,F1PS^A<WC;S3.J[?3!]1?*68.WE)2W5A6ZQ/].7:N5QG'3/R&9%-ECA0THF
MP9AZW+YD6.,8X,;?.XQ$#3SQ962!C2-C&.X::*I6RQRLMF.;C7X.+QPC<(Q=
MCAVP61**?O!LK6JWJ Y#V.\25=BTVBY)V4IT+A$KMHP 2K2A%%T4Q!;P@; X
M_@,?-QGEDF,;@S*MP-I9&QU0,;^4.TUBW1; G2]<3V1]$>#[MX#*Y'-Y9L#,
M27E8,<R(GR[9.'-P<&''/(6!ACRI>7,4LQNN.5BD8&/U"(H>_,,;*6>MUJNU
MNJSI+*XNBD;/MKW4"Q,A"Q%\R=#U28BF;RTQ]C?MYZFXL>/3>-D<5'3IN1N"
MA5$_)GKV>1"\TSR(4"74H]PS1Q%@2%*C:\H74] Q-K&W;X_^E65>'S.7Y7+S
M<9L-,020-A97JQS2X7'RY,4CKC/ C0Y?(Q0C=,+1QRM+L*-L=-OY,YRJD?D6
MS&A<5/:_3L#XZS3'QR#"\K6%X.3G]RA8F!6!J_<).5(.0J0JKBV0,L^3< DB
MFFH&XUC&X/B\AX8-\XEDRY(2;IM'I!&+=/W@]A<V6UR2*TO _1[Z;<WE<3PX
MR.;CY3/[FS^)>1GPQ G\N3%EEF&Y%*B9,K:GJ.%A9"\CLAL&[/<[9ZG8^L]D
MFJW6).6A\O*X]@CKH6_&Q++&5&FHY!RKY:1>&)[U6;/6(9B\C(Y!ZD"$O+NH
MT4C@W= ?J]%VK#D9<<,<CK&V/ZC?!)M+N8XO.AV,K$AF*FZ('OJMJVO&?Z:>
M,Y_NG#XCC\O,AP<C@1G3 '%SSCR964<'C;9>&_R>1CY$KQ9$[Q-OQ<6/+WJ9
M8"M/=SS4,WOT[4#5J!^#O\HXUJV([>-A.$/DJI6JLXSL%Q=IJG:D2B+53VF0
MT'Q&QSF1=PZQ'9#;6[T$,8=L@XB9&]_4$$CS)M\T;JTJH.NJN8RM^H<%3U6_
M.Q?Z>!+VQC<Z,S)^?BX7D,GE,7T!ZO'Y6-D<A!BJ0&)EQLIL%X3( 'BRE:!A
M>7',D?RG/*SX\ISR9RI3:Y&6HSNA.4J65TZH<O"15A&S2%I!9SDN4A*UD"&A
M82G/BQ=DK,H_CIAX42F;-")ZJY4?:D&9DB/ D=L>T@WVWABNT)I&"T99G7='
M(JL@_>8G3J,+_3-PW=7/Q\?V5R&7-P@3-4Y>U<V*:2#Y=,:R\?'-D8,LLN5"
M<G Y#&AGQ8C<2SL]DZ!XVL[RZX\HUPD6;6/D+34:[8)!@Q>M))DQ?R\0T?/&
M;.08NGS-\U;.5S$35265(H0H"!AUUZY+-@7%S)<9"2D<C*"002 2 2" 02/
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MY95:*-50^I(;7=B6I-<<\2VH]@/<ZNUN'Q^X2MS-\< !4C'DY7:]6)J*CG3
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M(Q5P@;7KZ8LE_P#DC0>P5I,KNON3-BR(,O-R)(<I<59@7)$BX48BQ _M&/&
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MJR'U3 @RLY%S+QN\.  #E!VLF<!34,4;!Y'-WM(LC@L@0V)^ $%5^Y2 1["
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M-EU"I))ND(]_).7!"@4I"K.%#% -VG5H\AF>KZJ.R$2O( #8*SV#$>RX 'W
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M$5%V;598Q%5R%,BF=,P&.'81RO\ Z!O>(?T_4P5U'65NI\"?3T)]AU]U6O\
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MK1^?8;^9?_T"?]?T^2F]WYTWK1^?8;^9?_T"?]?T^2F]WYTWK7GY^A?YI_\
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MA'0;B,<4@(!U$R,6QVRRL@9*4^(*>%-BZ++NCFM'+[F7_A/Y:$XXJ1)$'?\
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MD^@Z;71O460H%96+;2#16LH8_N</(3E2M<39F,0U.\E4X)4\I*QJ:8.A%)]
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M2'[E*0IO<,X5#N774"@&X0'L @ !<]*G[J\'P,B>XF8RBQ@*4I1WN'*P@(E
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MI$O4$%:A4YL47"A55@%:NPB J"<IA$1VB)M1'=N[CU\4<KN_G.46_P"VD/\
M]6U?8O#V_DF.!T]%/^@M/T=B0#V $TBCV#V%(F7V!]A2EZP=3]];$:"K3<HE
M1 3??6'U"H_6HL &$/L A1 H!] % .I/7[M*#I[ZI2_%65<"'W#';(!_%(F(
M N8/M57 0_S2 '0Z#;^-35IR=(R@)*G*1ND!%5]PAM64,8W@;:?>.'N"8Q0
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M X\A (8?8(E$@CV VO5!!(N+$?;V4OK[#64J42B(NT$W*??^T)$VKI#])CD
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M!BF =! 0'N @/5^K%65E12 H$+Y%U3;4$]= ,8.YCJ#^PBD'<YOH#L'<0ZD
M'KT'6G2J2E3;$476-O4-M%9;01,<1$I2(HD#7:3>.A"!](_2(B/35C8=/MK3
MIJ:I(D902K.@+J74R2 B I-R@&[><0':HN >T_L+^SI[17MHOY^VGWU243O
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MV@![P&*"YU10V%'VB45#>W40ZJN0-=!^TU'[:QE!>'-X]1DS=C>E:*N :%
M,8%%579D6QRCMT**@F*/[)>JAM&OP^\]?V?U5&I]YI//(K "IG<8]-X2ZF;Q
MB)%$"$-H&YP^BE6YA3)KJ81#:!0$=INJMH_=/Y_V&HO[:H+8HYVB<GJ1=I("
M!1:>G.=@F B >-5P=%I(K*%$-=I$S=@UVZ=^GID'06)\?'\NE-X-65;$@0/"
MU;2"RP',"3!B0%6XZ:&*)89T9-WH<!$=5@3+VW  AU/IWU-OO/7\Z;AX5E)-
M9:5T7.#)N9(3^0C)0WQA @:@D ZD(V:;@$P""(* 4>P:CWZ@E$TUL?;T_O\
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M62Q2S7M<FR"SY)S6W8S&<FLT]C7E6E<>9 K"K>2PG17<<WCV+ZFQ*,X(.I)
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MRW234(DDH4_OW>O<0[&XS&[?[>18LAX[[K [$&E]19F9KZD$7#$@DWK]S_\
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MEVPE-'#1K)H.C@+9$J:0%JG^M&+$HQ^%]2#&  ,A1/FF&FX.Y\I4L-R^4L&
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M79RD3+-$9",DFBQ+&<BS5^Q<IJIF 1 Q#@(#U4,8D7O5/S"^PUF?_.BN;_\
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MNI)S4L_I!WLS.RKC8"SQXL=4^A2B<"$*!>"R>T>_^5Y9>2Y3'>2<R*23)#8
M->P DL -; #]IKX?[E_TK?ZZ_J=]3H/J)]2^W\[/YE\W'>6:3-XS;'#'*K".
M*),P)%#&M]D42!1<D*68D\V?]VM_^2KRD_\ O>XZ_P#BCL/79_6<$8. #U]1
MO^B*^N?_ *;O_P#83V7_ /I7._\  @KZY.OG^OPKHZ4IEY)=@PQW?7PRTE
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MO6AA  44.HL;V@.TBVPA134 -IRB&OUE&VT*3I?0_;^B@ZW'6O4@U=+NV7O
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MU ![ &FGR<W)S-OS#;MM[?C;^P5Y3W#W=W!W2L YV<SG'#;"0H(#[=PN +_
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M8A51.42A[=P'>7U%[B.WB\?%:%-"[*ZH/=<R:GVA02.I%J_97Z(_ZMO]?O\
MJ#R9%^G' =KS<3 ^R;-GQ,C'PHF(OL,SY_ZD@!!,4*RRJI#% I!KG]2&'R(K
M58V\'.R//#'<>Z=)MD[5;'6.G< W*HJ*8.9 E/AK3.MFY0T,8Q&2NTHCKIH/
M779;_5/&@]:,<7,P%]J>J&_#>RK^;"OJ+N/)_P#IEO"<2W)<;%],^5RD0L<;
M&7/6=K"^U#E2XT+-U !E6YZ=:Z_-_D:?+FMN)W>5\99'S+=:R]ITO:*K9(/*
M-+F:_+ILXYVY;JHNV- %-=(CIL*:Q .4Z9RF3-M.40#ST_5#O&#D!@9L./',
M) K*T<@87(\#)[#<?GTKX-E_^F1?ZL>"[XC[)[QXGM_CN8CSXL?)QYN.RXIX
MB\BJP*OFW!*MN4V*L"&6ZD$Z??[M;_\ )5Y2?_>]QU_\4=AZZ#ZSF^%@D]3(
MW_1%>]__ $W?_P"PGLO_ /2N=_X$%?7)U\_U^%='2E,S([P(['E\D!F7U<!C
M3+0\&PQ;/XC)P(-8-\N,S'1X*)"_?1>SSHH[B^50@%U#77K<]N0_,=PX&.(8
M\DR9L"^D[;$EW2J/3=[':KWVLUCM!)MI7,]Z9(PNSN6S#DRX0BXS*?YB)/4E
M@VP.WK1QW'J216WHEQN90MQ>EJN+>HKT$X]8O(^>&BUOB#I'T[E]Y6*!_6.&
M^X_@7=;MYR:CM,80U[=8?(IZ?(3Q[%CVS.-BFZK9B-H/B%Z ^(%ZVG#2>MP^
M)-ZCS;\:(^HPVL]T4[V77:S?$1?0FU<<_GFK,&_&/""KZ.3DA#F+@A-F162D
MXA)H]64LR2,BI(19@71*Q$^_:;\-738(AN 0]B^@HD/=.>$?8/Y)EWT!OHGE
MU]M>9?6AD7MO#W"Y_FN-;K[6]E<-FJD=-WR?6ND/"3)L.9AO%DWV:9?MT+-B
MJRW5Y"3C2981;F._-$Y3+2Y8S<<T.)&KMN^<M$T6I6#8Y_8\U9L7B%&%-*GS
MG'1)=0!LR%A+)U&BR1[HV/[I522=U>/<><?*Y8?.Q*YP^1D>Q)\T#R!6&G5H
MY-KJ/$$@ ;:^QRLLU/RU6@-W.-?A=PFT,(G^&-@-J(  :ZA]G7Q:=+_?7V#U
M'NI=]";_ "?U!U1O%+5K3S.RM;^/7$3DSG.B(UUW=,182R'D2I,K:B\<U-U9
M:M77LI#(V9M'/8Y\X@SO4" Y*BNBJ*6NTY1T'H&!J5 ) KF-BCYPJK^<RI%9
MOQ6K3I7&[YU0;5263QM"S&,\R8FXAY%Y+YVHMHG+/*_#;)%OI#&KAM4)!DFD
M@\BI%D].)TCG,6JXJLQ^PTZIKYR$''*S<DRXLY1F:97XB\3\I:T\EXO8G)"X
MFIG'C(F5W2,"^?)R*RU:J?)"$%BCJ"DM(-W*!002*1R>-PJ/3\+TV(KYQAZ9
M&V>,R[A=]-W%;+.;J'AY?%UI@7T-D']WG-E?B/#L+; LW=IN&(I)FYL$"X<N
MY%HZ^,Z/56#;R @S/-Q4^G[]/[JW>XG\W4^6UWLE=J6%+_1JU3,7XEO]GN%[
MGJRR=1MGS#5VUJKN.DZ6Q6<6!>2CH@KP74F(IL!*W2,B*H.0!*"P%4E;=36]
MWHC_ %E_5U&\53:CT)O\G]0=-XI:HMR@S5VT<B2W@6->&GB6*4#"F<(*?,4=
MHZE, Z:#KJ&@]9.*P:0Z>%6Y!TMUO6*)DC-"MT$Q(X5%38D(CO1<IJ:JKKJ#
MJ(^G7 #&.(B)AT -1$ ZV6N[<?A']'LJGPTJC:461S'WJ/G!P2'3LJ9^B;4B
M211#1)%!5/<4/NE)[PB.HB+][_=']%/"K:IQ]&#Y0OD?@*9TD4^XD<('W'8-
MP-["^X<IS=M0 3#V#L'Q;1\/VUIX>^O51,FLQ<)B59X^%1N4^FJ*2"J95RF
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M4"&;J"0F[0Q1.4?=  ZKM+8L3K?7WBH%9;5Z10KE\FQ9(O$55"JE.*ZR2S9
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ML"OA.A91DA]1Z[S^J\_XF_=WZIVK>]A>IW-:US:MADF[A?44D55>_O&*0Q@
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MT<HDX--NU$SSRGP\[@Y !P0V\8$2@"OG\@"67QN("L1*=P#_ +PZCX1\.MO
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M<U@&%-L[T;*R8C)O*\#6$?+C.-(TIBC(.8GQ^H30 0%4Z8$U[];GMR#YGN'
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MHQ%"L><[KQ<H>1B.,6UJYQ;I3D%'P"LQ/0;:>?IJPKFN++N3LT"G40/YBE6
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MZB\1T\%_H_MO2YJVDU0CA/'G=M5EUC'7;D 5'!G!5!_M!E_$44B(M5!T-[P
M"9B$#4= Z@NS^;:0!4]-/&JVY(R.26:.%WKY7<44C)-T2J/TU0V$( *K&'5'
M:*6@ET*D4HCVUZDF20[E  _HITKQH:/:"N#Q-<ZP) J54[HA4BQY1$"( (MA
M,8K0X[3CVWZ@8>YM $2L!M(M]WC_ 'U TJEB=F5SM79N"MP 58I!1X)3II^Q
M3S?@Z^H(!_PRB&I$A /O;M#^I;0B_CI]O]M!UUJD5F!G1FB;14L8JH;<8'@]
MW0 856"1A0 / J("<PAV 0,F ]] FTEMQ(W_ '?M^WWT\?=5QTY8M%B^!!P!
MG8 55,'"9DFYO=2))* +<FQ O8B@:AO';I^T/4!9&%B1I]K5/2O5THY@GZM-
M1Z HCJ\WHH+*/$CGU.<VQ9(RKM-0VY,-!U[D#L(: 78V-OM_5_MJ>FM,G(>)
MZAF"LM:[<GST8M"Y8WO[).,>NHAVWF\5Y K.3J</K6Z+H#-_S15&:CU/L#A$
M#([@ 0,%#$VV[38&BD@W%.+)M :9=H-OQO:WCYY6;Q$*P<\2(ET6TF:.<+)+
M*ILG*Y')V:I_"!=P)B)2B(!H.@A;.RUB+5-R#?QIEVC"-1L-HS'<Y9M8V%DS
MEB""PC=96(E58E9M2JV?)*D2O5]K91.%LC=3*\L87VU<3#Z<=GX/O-B'X&L:
MN*= *H@<$8AK-I3ME6@'-2?AAN.P0LQ@E6K>!>X^A)(\I7D9",1:-3.YRO+.
M72;-\9454T'K@@@?> ED*RFXUJV6)%CTO21A[C+C3!4I597%CN=C%:MA3'V!
M18.K"L=C:Z9BDJ2&.)6YQSAL@WGKW48T7+%M,%.BX-'OEFRH*) W*A390/,#
M:UJJ!W&QU\:BJK\ N/=(E*]-0]<M9)NN5;&M*C)1Y9GKMPI7\49\7Y(U=LX
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M'U=C!]( /5096Z?E4&PU%8LF]!2->B[2.X5],HDBJEH5T)UB^!(IC:;7 ;U
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M=VNWQ-CI6'R?T^YWB<=\O.DPUQU]2S>N@#B-=RF/<1O]<!_04>>0QN-H(%W
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M>P>K^*;3FW^'^NK4GA2,U*8$B-)#:99SN5,J4 *#E50?*?[N@).T/9H&FH%
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M6#"ZL"U-I%]-*;V5.3?%W!TO$5[-7(;#N%YZ?8?%8.&RGD^BTB2F(OUBL?\
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M\OH"6,S7_AB1-UMPH:Y(HSX&0LKI67827P'X>+:=CU@??FI601K/I=BX^?\
M,*T2Z*SVZ^I,V4 F[8;0V)EK?=$XV[K^4Z;;;K_\FXO[+B_6D_:O<N-Z@R>.
MS8S#ZWJ;H9!L^6"'(W77R^@)8S+?^&)$+6W"AKDBCO@9"RNE9=A)? ?AXMYR
M/6]=^:E9!"L^EV+CY_S"M$.B,]NOJ3-E )N$AM);$RUONB<;=U_*=-MMU_\
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M=W\381VSS+-_$KYDR"38;70=SVY%Z_<.! 8I)P^; OI(_IO)>51Z:/==CO\
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MT4U :Q]]9+\B0O6#M0?,L<B[@K)N41*S6*44"H-D3#J '\AC%64T':40$2@
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MF _HKUWZNYW!9QY3(/:>>_-O(A/.2<CS>4DC;DO*?YGB8\LF]1Z(.2D; D$
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MYB.X^\:BMQZ#CJ@8KK+&EXSI56H%1C-WH*U3H&,KD(V.<I"JK)QT2V:M?4+
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M@4DA+NI5RQ:P0$;LTDP,Y77(!CI$*<X=OV#V/!WIRLG&OD-CF.!Y UMVXAE
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M(8T%N*>]+4%0S&<F+]G_ .VQ!C_'[Z=;'B;_ ,RAVWOO\/4__-?J?^AK7?\
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M?';UW \QC"U[:^:U?-0_@0E^0.3()YH]B[/?\SU6:<N&*3^-2JLS8IY-W89
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MOD>TJDW6)O'EG:O)%N[G6DV5)=12&*A'O"'<LEM3"!T^:[-[Q[CQPG!]YC+
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M0,H.M1UBQK',./\ SH=R97[Z 1XL1R98U-^E"NW2!<[8>]29I*R4=+>F<%2
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M;7$Z;IDS<UN:;SK"3^+0L,=?<^8K>G5;+*)&\Q5E /&%RV1CO-MGQ(V)*$-
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MUZM5JR?G=9(4K :,DT(PJ@*'<MC-0='V7>4OU)Y+BAC39V/-QF. <C&Q43'
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M@LWK/_TVK[(X39_*H/3-T])?^@M/W0/J#]0=:^MC1H'U!^H.E*STP L<Z$
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M2>E&3>BN4'JRJ)-EC9''<<1@9.;"WSTDH)7'\K1!I(HF 6ZJ/6W2W.GE6WE
M)] [;Y[L3L%XNR.X.[^)R3WGR')132P\$/0GXM)LSC.+R%7&WP0H.5]7DA)*
M&B_X?&$3?+1I(S7:VAY(9GR]F_&V*L@G9\C)/'N \<K5O(J3+X5?K%QUPW.X
M LK^3C95-T]+"LI6<=OE79P3%5=N15=-=%8!RC J<;C<7FSP[L)9)Y-T=[QK
MDS+.H!%AN(C"@:V!(!!%;V3A<?&^GG ?3KO+G.)6;L^'/YS/$_'EA)A0<]R\
M'-XT<<D15#,\6%'"L0+;4F9(FCDC-8&#>.SVW.L:XQK7'ND7>/QWB[DE'L(3
M.$S*."OXY/EU-P#>QQ[RO,GCQC)E0CD&;LCD6H*I>1R4P@(#TY3F$QQ-G39D
ML333XQ+0 :'Y16VD,0"NI(M>QLM97U)^K./PD7,=Y<MW7R7&9/+<WV_))/PT
M42['/:T,[02KD.B-'>1Y8C$)-C;82 =*G+"T/3N(O(*-KV8G:E,L,%Q4QS*5
MR7R+E=*H5UQ8H+(^=YPE:IT>>;EE5J4BI),(IK%N7+E9HV;D54 QS 8^KY.7
M)[CX<S<8!)"^?(&$<6]@K10+N8[19]&<L  22!IT\U^HG(]P?7[Z5R\K].D'
M(<3E=\\A%D1X'&'*G3'FX_A83D9,GHQ!<LK'-DR9,<<:S22,B$*"JL.NVNBI
M97SU!VG'_#5@:5Y6V19: R'#0#/D''%.M5)",CJC<F=XA5:U$NE&!/@C\C8R
M#=54!-O+OTS)H,H\?BRP3<B0N OFC+''/Q [T*-N;7SK>Y'2U=5RG"]R2=C]
ML<IP?*_4*2*#L;' GP)IWX*2PR8Y&R<1\.89$JAS\Y"9!)(JFVT[:V>^8!44
M9[%O'G%!XVAX4(X>6VXU>VYPOCN0IN.K%CZ)5>!CRZMD6<G49Y[D]L[,VCEI
M)=1!D#5VHD15VW0:N-'VED&'.S.0W2Y)LB,D,8#R+(;>HFJNHCM=@H%[J#92
M6'C?^EKN!^&[S[M[\$O*=QRB/%Q<G$X;"1,S/Q\Z4)\]B$O'E0IQS*),A,=%
M:3U($=DAEEFBQ^/RM4RGPTRM(QN$<JTR)HF';UC^J5Z\9GF[):@-2*W+M&D;
M:HR31AR5YQ,1BK:05,L@+=5D[0,V**/IR)SRWS.!W+CI+E02R39*2,R0JJ^=
M@24(W;@INHL;@@WUN2^J.3S?8W^HC@\#D>Y.#Y+,Y3G\+.R9\+B(<?&'SD\3
M-)BR1M*9UBD$F.H1_46:*03$2>JS<_%4;"[XWXHX[JXRM(PV W6#LTGGT;+&
M$BUZ)FF]8WD\0LY"9\SERL1&ZVVSI"DB8CA!O74"+)AMVAUH&..9R.6$T?J9
M0FA"[3</ D@E(70#R)$=="9#8U]6A^(Q_J]SGU63F<+^8=TIS'$+"V/(9!F\
M3A<A'RC)%957=AXO'-N>\<CY\C1M<DE^V+$%R_(^;K5)X0QQ4\4FYH9!DKUF
METSD++R>H4+!\@))HM9:U9$IMPY>,*P^=BTD91ON6C8Y49 A'1$=0Q8N1QOF
ML;'CRII.0'&QB. $+C2,<<'8R[0+L/,JG1F\EUO7)\5W]VZW<?;G X/<G+9W
M?B_3K!CP^&5TQ^W,V6;@XV&-D8YA55?(1?5@QI++/.HQ&:%I+4KV.N8]KV<9
MJ3:8T9W2V+Y^A4E<.WRSR-5YAUJU2%N@V+"4Q!E"HV!Y9;YC@K%4DI&F>QQ8
M52M'4;*OA2*7QVH9LR?BU0SF* 8A_6C4/B,H1B1-$ZA4DOY6LV\268)?K@<-
MR_=7+_3+&PFYF3C.$3M69EY7!QDR>U,C&CQ9GDBY3CLJ!,?"SRX./D"*<YB\
MBJS1XV\G?UQ>9$:VJN7Y\TXV&F)A9G?*G8W^/9BDK7-]8FC60KMY1JK5)NXL
M1YV(DG;EDL90Q3IN3;50 3' OGB89@GB1\W;'='42!]@4D-&6UV@$ ,+:$=/
M"O@G#[2?A>8XO#R.\!BX._"R<>/.BS%PU@9DR,%LEBRXZQ2QI',@6ZM&"4.B
MD\C\)R6&L1U2I/6%0PUDEM5<3Y-L:\MCN6N6*,^4[\J1<4>"@N2D!29:Q0MI
MLF0+'$Q\=$-Y#X<_0M"X>GCR"=V=/T+DDY/D<B1'ER8#)D1*!(J2P/N)NV,S
MJK*D:EF<KN4Q#S/\-_O3ZC8WU#[[YW/QLW/[BX:?-Y[CH%BSXL3D^$RCDRRB
M:;MZ?,BQYL;&P<>6>?+>'YB%^-0^KED+ KHUKPSD/"6+<]8TS=B"VU0^:.-5
MKN,')!EX;O6;[R'J16DEEY^9O7Q'X<]OE8FF2R+>4*JNDE75S)'7,*@A>@Y'
M#Y7.Q<SC<B.1<?-1&7T=C1X[W$2^;J(V5@2M@3(+@:5G\-]0NU?J+WQVKWI]
M->X,#.A[?[QQ<2:/^5?)Y&%P&7OCXJ/=/_$3!R89D=\<JC-GQ!UB&P%1)&6V
M5G^/F&;#C._K..(W*.@8\M*:^2B.G%LR'9WLD%&>,IAU*BN#.OX,9M7B*[<Q
M6R"\PL<_C4,F0]&[%6++Y.&>&V?@R2+:.VR-0/4! %KM.66QU(0 7 )&-)E\
M%B\-W7]0^%YGBEC[\[)SL_&(X\JN-@8Z1G,1H5BV[I^::6)TD!D=,6-5+(&9
M5#C9Q1M]KQ)BN_C@[%]-JE.J5RR ;)]2F9H^5\OG0AKQ#Q] L3AZA',XYC8Y
M"72^)DT=I.FS)-)$@'435+1S7<.-C<C/B?-3R9$LB1^DZKZ4-V0F1;7)*@';
MTL223H16#]7OKQV_V_\ 4#F^U#W+S?(\WR'(8F#_ "W*AA'&<4&EPY9,['"&
M1Y'QXXF^7-XFCDF>21BJNA3YF<PW>. 50IE7(U>SM:Q]QS"_O)+*\?:XB&BD
M[OB*"FY>]X[93)YV+IS%^_536:@5BI' 8@ LD G$M4</)8G=\F3/<1/-D>F!
M$4).R9E"2$;2Y !!\V[70Z5=X_BOJ+VQ_JJY#N3FV>/BLSE>X/D5CXN3%EEE
M.'RLT,6%GO$(9,MT1"DA,RY!#'TY/+?>'BS=*&#"RLZUACB7>5:>6G(MISC?
M$TFKR""'KWT?$*V1P_M5VG[$_6?-TU&+D3-%=WE$"**FT#E^?Q<IG1I\GD(O
M4WZ9)=AT!.VR(JBUP1J.G05\V?73MKN3)?"GY[N+OSBQGMEWB[@ES,A&8HDD
MH@$>-APXZ!"RS(!*MM@+(@N=MZOBU9"$M**6-U* I=WKZ.O==N64I91*5ATU
M4'R;R)D(%M.^CAY$J[Q-5--5L)441 1$FOCYZ?/'JQWG]7T@#&R1#0]+$-MN
M18&]CJ?S^?N7[R*\S@.W-OR:<9'&^%/A\=%^G(04*2ID&+?*FV)E9ED!=[BS
M?$F1N#T27,D.YHUR-3FB!)@+@PR].RD+(OB1$>Z%JTB%WK%Z^8GE7;]#53P)
MG0314$=IA232<FYQBZ31_-$[=AA4,!N(ON (!L%.E];CWG8Y_P!1<AN!;.Q>
M7XT=RN[0_)R<1CQS(GJNFXS*K*CB)('LN]@[2(!N =VI%U^8J\39&<K@6YD7
MG08FD6CC+5?DT')$Y%.9 (D)ZRJMVQUYB*2,LY31 5MVJGM4-UD-,L[HT>9$
M50FWZ+"UQMUVKX FPOIX>%;[+Y2'F<K%R,+NSBVQ\5WV,.(R(BNZ,P_JF"(,
MVV*1@D9;R6LG[JT\,?499E?X51OBV[P[:O.%WZ-CE<L(6J/A%U6KY1P#J&<O
M7KAV7U#G8U,FD30%0WF()52!C9N06PWOD1,7%MHAV$ZBUFL .FMSX?<:YONO
MN+YGM;)/^8.,R)<I%1L:+B?EI90&0*5F555?*NZ3<S?"=JF\;&1,V\<JSFBT
M42V2^0,QT.V8T2N3>IVC$=]"A32$9D=O7 M<6_60AW[>282'Y88*%(HF'C5;
M@8H@(CUS76O PP \*CP.%R1DUU"<M^=#E+PBH)E.11U@ R:A1\2B:E..5!0-
MPB'80$/9]DV((\*%O</RK#_N?BF70.6/.@A0]@!R'(4/X-*. =5E=QN2"?M[
MZI5M?A K*7X>B1)JI_>UYS#YDC#H7D.4N@D4,3WA_)1MXB  .O;JE4N3_91G
M \!5+3A^*SE)+^]KSG#>;: FY#E.74W8-2?DHNOM^OHZ6%2&\O058'B$("(?
MWM.=&H:A_P#Y$E^C_P#@CJOT]/#\JI#B_05D?W/A%KY0Y:\YQ$JQ2" <AR[O
M?(<VHF_)7L#Q^S3J@)K:XJIF'L!JP'$$?_EM.=(?IY$%_P#C(ZED%M"*I#^X
M5DN>'HI+&*/+7G,/NIG 2\ARE*(*)E.&@?DH=- -U3M]E-_N%>(</O(90O\
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MQCL92B5]BG\(O!!6Y9S9;9!5EBZ@%&955VWBA6AVQQ.RB"JE.><+)Y[CL67
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MPM_P<.GL_372ITZTE;BCI2CI2HDSPY59X>R$Z1<NV:J%<=G3=,)R_P!:>(F
MR6AV\]BR*G,B1:H?0K$-'#PO[!!#7K/XM0W(1*0""_0K&P_]&4K&?N8@5W7T
MSA3([^XJ&1(Y$;+4%7APLA#H=&AY*2'!D'^[E2I$?WF&E6./SE9YAK'[I=R\
M>++0>\[J0GLB6=ZL/K'0;W$_EJ(@<CRA] _E)9F@YT[;=@%$9Y50O(RJ   W
M@L:CH/W8BT8_YI(_&]7/JC"F/]0.4AC2.-%R;!4AP<=!Y%T6'C)9L",?[N-*
M\?C?<6 F+K7UP-'2E'2E'2E'2E'2E'2E'2E'2E'2E'2E'2E'2E'2E'2E'2E'
M2E,[(@";']Z*4M=,8:=9P*6X"4M2,(PCX +:#&$I2UT1_P!>$1  ;;^MQVZ0
M.X,$GYD#YR'_ ,O_ !_XB_P/^^_[/_?VUS?>0)[/Y4*,(L>-RO\ SFF)_ ?_
M ,U?_P#E_P#M_P#NMU+-> 0@(,!". 0AXP!"($!B0$&2&H18@(@,<'^@T_T6
MWK#Y#_YA/;U/XS_Q/XGQ'X_]_P#Q>^];+A[_ ,HQ;^C?Y:+^#_"^!?X7_=_X
M/]VU<9?GE-(UY@OC G(OU& $YM8.5:"2*7FBO'::-I%)@HQ0.34CH-2^0P[4
M?O[3F*!#>R_09I5[BY,Q*&;^19>A8+H0@)N0>GL\:\R^LIB'!\?ZI(!Y?&M8
M7UNU<$IEFI=LQ7*O>"I0[QAD3)D?"F9TZEU1P^3"?ET)>0GE08L6Z2U=;MW*
MJDBZ<F!CXA5 Y"EU#WC$V\7P6-G;I6C;&QVD9Y'<+9%(5 6)NV@"@68M;V5X
M3D^KR',Y&&1$FW(G2/8BJ3=V!+D6T74ECT )I:K=+=3ME?4K$]@Q]<8[T\FU
MO5VNT16*W38:$<Q:B\NXI"EI>C*V&1C8_'4HY,>)B'J3IPR(\(F4[1!<,7(Y
M*+'Q$SN8BR<>7?>&&(LTDC7%ED,8L+^JE]SBP)4GS$5D8_'RY&6V)Q,N/.FS
M]660*(XUMJT8<W-O38@JIN0& N :4F5MQLD[9DR9:;Q2+._-!R[*9M+RY9!Q
M_/D03095A&/RE8W4K;92+=1,:L_D6KAJK'0C%N*0KF0\&^T<#E7C$O#PP9.$
M=P*ILCF3J7+8Z@1J0S!5<$-(;7L;VOQY?'HQCY.66'+ N&?=)$UQ8 3L6D86
M&XJ00@O;H*0#*8;7%U"HY<1_,\W(C;&2K"Y,S8R;(MI&'1:P\U;E'J%?B++(
M,98[IJV=( H@5)DBH=-8$O2Y8//JRL,$G%1-I!0B<Z&[B.VYD!7S,#8G<1<#
M7&MQ$RLARQ\T[ @HUXA:UE+WLK$&X!'2P)!Z.=:W8K<R*9*/;K9D+(3E[&V%
MDCC0+36JS!RS&-A5V8OLI01X:STNN/XMX9496':K;I-LJB8Q5QUZUW\KYA$,
MO(Q0XO'H64M,4>1U9B"%@\RRR!A;:Y'E(/32LYL_B7V18<DV3G'S[8MRH"H!
M!,HL45@;DJ#Y@1UIN62MOZZE5DLGS-(BJ#-5Z%FJAD>BLH7(#QR$S&3]W>+Y
M/0C9)ODF0 '=-EF;EQ(Q3@9-RR2<++OA;$WYV!R4&29I>$3*?DH9"LD$NY-%
M=4_0##TU#;T*A&  )4! =,7-P9,=81R\D"\?*BO'-%M<C<K-:<@[S;:P8E3<
MBY+6I@Y"BD\9O9)HV6HMG,I "U/(/ZM3;M$.ZN*_JDK9$**,I1G,BN#0Q$W1
M%$U4B%,D)B""A2;+C7/,8ZF03QH'N0KNKJZ@AHV"E2""=0;CQ]E]7R"_RB;T
MU,4KE-"RHZLA.CJ2""#[>OA]WVB8T2>)8SH!'R2"+D*E7!40:D;$;-Q_+\4'
M@;D9@5N5!$0$I0+V  T]@!U\1\HRMR<VR^T2N-;WT=NM]:^R^)!_EL-[;O27
MI:WPKTMI3QT'K%K.L:-!Z4L:SB (QRP:>UTE_P#@C]6F^,5<6L'0>W8?HZK\
M*I/Q5FR0#ZPXZ#IL0[__ )NF/5$?2KC?#7K !$[C3V^D<?\ N.DF@%6P*Q%"
MB!M!#Z/\?52?#4$$&L]0!%BV'0?:Z$?UI_XNK7[_ .-7?W3]U82 ?C(Z_P Z
MG_[LO5U_AJVMP:K> ;U3C4!U\ZNO_ACT3X=*EJOH%U8O>VHZMM?Z0>J6^,56
M/AK"( [@[#_V!U4_PFK:_$*5'*2BJJ!"$$QO3-@*7Z1 4@_[6@]6!5PB^M9#
M38W\A4QWN"H.1,N7[J6B!Q J'UG WM-^KZ^AZT (%)A&JJRAA* %+J)SJ'':
M0A1'43'-]'_;$?9KU=WC;;W53M.Z],+,S3UN/%&32OHVI123CU$XAY9&U/3>
M 1^D#PQIMRX:D;[8WS^)$#@9=42$$2@83DR>-;9EAMYC&T^8+OMIIY=?&USX
M#7W5V_8&1\MW+',V6V#'Z,H,RX[93+Y/*!"JL2#)LW-:R*&;4@*VM55IC^(D
M:^NVXY2K1VHPEV29Y+.<;))*,WL9(1T@BS1?R#X[LSUM)*I)F23$A#O-YE *
M)S];V;)21'W9JE-RG2 C4$$7L!:Q Z^SI7KW*<Y#R$&2N1W?COB+/"Y$?"R1
MG>DL<D>XI&@78T:,P9KE8MH0D*M)/[I#JPRSA3 <G!O2SL.V&/7S(\DEYB-*
MS>(JHLG)I9FA",G)V;-IL.8P@=W[J "F EJ_F0$@5<M63:3?T0 #<=18[CJ3
M^'76LM^_K<D(HNZ8,C".-,P=>)6-8I"Z$-(OI,T\BAYI=P %HM9+/K(L(VF(
MJNI5-#CQ72+P5?>2T#!6^ZUF\SA5Y.1:+'BEQ=+O)E".7=O7AB'5433.9 I
M'N.F)(8WE,[9CD.X#,B,BV (OI87L!H-=;US/)S<=DY_\_RN[,PIEYJQS38F
M'D84)6.)@)?*%B+JB1 JJE@'+>RZ$T6L3:^*7:(XYF0OUE^),$E&V7Z^1RL@
MPCV*;@GPU%8T5$INH5FV\9T#"9,OCWB&XHGN%8GQOE9<V^''8_P6MJ3;7J;,
M3>_OK82+Q>;VZG;6=W=O[7PS&Y!XF?:I>1ROZA'J2;)FDW!Q8G?M!L=JFAQY
MJPBCZ.F0U>82S2,=2,,;)N11GXDJ;%():*9'CW_PA9:,7<*()KD.")@ AM4S
M:"%#<SD"_P"HSNI(#>E'M.NA-Q?6UR.O7K6%/]7>9C+B;D<G,S8)95CG_EV!
MZ$A+GTI&$B>J!(%5V5E+WW* PT+6JM68,(60NR6(ZVUOC5^C'M()EFYE+1CR
M!EV1(J=D %>;&-9.4$7CE".!3<=151$FY'0NS(GF>1UQ3DN<0@DL8""&4W4?
M#<] 6]US8^.]YSFLG*RH>WIN?S'[5D5I'G?AWBE6>)O5@CL(?4=6*1OD%;*J
MK(Q$ESNL1^/DWCMD@MQLFD5)1->1$JV>V*K=TI&,"$(LT;D?G1D%GH*F3  0
M%'5?N8B:@F"6S" 2N:I"Z?\ ES<7/B;:6Z];Z>T5?F[K>*.1X.\,8Q0$( O"
M.&7>Q-G8H"@2P8W??9-%+):LF9QZZG0?VVP\?EB6]U9%EG<8ME7U+-RXED%E
M'T_ I-I.,AJ_++2+5FBV=+ NNFJN >(1 !"F++$-H(<P''":-Z5B+=%:X)86
M)) L+#K6)QW=^-Q!BX#B.ZU;A8\,*LHXRS(L3 )!,6CDFR(Q&TK21J4C*(2'
MI>K-;D:B6R0\9@EBG(OH""G%Z_<,E1-Z?V"6CGS"/(H>(<OED8PPDDI)07A$
MVZ*RR12@!1$X%MY$J9)267+/IARH9(S&%!!/4#7HNFI )K Y_EL+FY,/D.1[
MHE.'#DS0+-B\?+A+#')&\C?JJ@9Q=(%](M(RJS'S *3B6=I)612FJO>,,:WD
M8=_+.JI&Q64JK"$9F;/H^8<)J1<-Z*,4=/DVB3Q(IS. $VT5 #4 -7"R0K(%
MSV]-E <F)FOH5&K7.ER#T]U9/#S8O%8^<D'>LIP<B.,94DG&Y,VX,DD*;9)M
M\FU"SQ,1LT)VG2X?$YA9E;IE2XRU2KL>]GTF<G+(GR#>VUF,NA#,V3UHX)".
MVT ]?LU$P:)J(;$?$@F.I0UZPX>3;'B&-%(Y120#Z<96VXD'S L >MCK<FN:
MXWZC9' \0. P,_+?"QF>.-OD<)L?:9G='!F5IU22_J%7NVYW%CUJ(V.-J]*T
M9)TZPS"JVEA/L?35M#/B<BI)Q+U9$\C*O)P9XI2NE':PMD&JAQ37$[=,VPH)
M[-D^9-'E;%R6&.R&[?+VL1>P"[>GB3X:G4WOZ!D]W<MA]PC'QNX<E.!GQGW9
M#<(8RDJ B.)(?0/EVCU9)54&,+(PW,6W.^8JAK!+(6.Q<;7YI*6:2+E,B.<X
MAFP4,NDS5<MHIM$OTO7B[=.5"$%-,4B^4?? BQ=+$>0(8S##FCTT('\ D^.I
M)&EA^.GM%:G!YN'@^-;C.-[OB&#C/&@_^#2NX*EP'D:5&VE5568LVXA1Y2\9
MIL3= D)ZN0*DW@!=L>NJIPB5;-E7>=_#DD'5C!09)M)QC9-)S9GOX'KSO#F5
M5 AD@$Y3A?AREAF?T\P'?YMWI=#8+T()T4:[;:"]]+53A]XX^!S64.-[K5TR
MU,QR/Y9I'*47'L(VCD8E<=//Z B 52P<A2IJKU.=UVR/9B&PB=E;6$4M(Q4/
M,Y;1L"CQK..XR!F(D(!*519GBD&#E^9%1V04RG(F3<4!$A(R,@3PB.3*OCEK
M$K#ML5!93NM>]PMP/>?OL\KW%!RW#Q\=R/<OJ<#+.(Y98>*: (T*2SQ2^N8B
MXE9U@#K$P8@NVTD!F<<O(2,W!*4V3XL00Q]D525^"1F1:77GCEU6GC>09M'C
MJ#0C#)N@06,Y:IE74 I=1$ #<4;$*I#-\PN>^Y/WC&[ !A8D;KZ>!T%6.%3!
MXOD1S</>^49<0$>M+@9DZJN2K1NZ+,TETW*(Y6*+K:QZ&I M&$FUABZU%OZA
M5 BJ? J,*I%?GBZ,;+%LEXYHX7A5%H=5"-?F/+LT$%W!CJ$.FB10QA$!#K$A
MY-H7>1)9/4D<%VV(5-B;&Q%QH38>TVK1<7]0YN'S,S.Q>0SOG\W*5\F;Y/#>
M"1A(X2;;*#(H$3NR* I4N5 M4+#CN"?0"\N?#D0I>EY9DT&OI9_)(E)4S*'*
M=PUGS6+;&+*2;I-L5HFJ!'#E1(VX@E2$FR.9*LXC&2PQ0I.[Y>UW]A7;KH";
MVT%^MS?T"3NOE,7FH\%.X)T[=$#R"<\'Z8;*M\+PB#]2T:M)ZS+Y(@XVL&DW
M*KVHJ2["L0+KCK)Q[-G%.#P1PSG%MRNTSO4I@$ROV+WXC-R#B0E5B"J)]ITS
MB!C;5$M+0R!'))*N:I<L+_H'32VH(LH  _$=-#6NCYV/!S<WDH>[H7RY9U]6
M_#2G;Y#%JCIZ<*+'$A L"&6X6Z25?>T22;U-R+OCVZC'$W9&,S/PI\K [G'C
MZ$8+H1TJA:E)1J:-%R^F72:(K+.ECJ#M$I163.!<M&R0!F!E5"%;TK* QU!2
MVM@H)L!8?<15E>Z<.3GXPO=:RPX^$\4$W\LVQ1I,X,D38HC;U0JPQLX5(U51
MN#,$92@.,2M@ &08*<-7\7&1B\97G6:E9%]8$2S4:W=214F,\T=^L8-%WA0=
MK*E2. )D6#74 O#D6^+YL%&8@L(;!="0-5(L3;0"XUM6R3OS)CC3);N9),.:
M>59<A>("1PWAD=([O"R['<1?IHI=3O:,Z:R4YM=M4='<(\8Z\I.3:$HH('O>
M/4Y_U*228/V[B3!@@O\ &G\8JJ= Q%EE#I%-N[E,7K 7&QPMCG/Z*V_ZN3;[
MC:_P@VOH!?[ZX_%X+M_T&B_SIF#BL?T]/DLXPA;WC98]Y!A215#715#%0.H-
M92>&F$=5)FE1-+IJ%6FCA/)UQ2YW8DY(SL5&IN(1F\?I*@D#EC+L6P"JBOX4
MA1\H%$0#JC^9O+D+DRRR_,+Y=^Q-H4GS&WL()ZBYO:L23ZC9&;SN-W#R7(\B
M>>QAZ!RAAX9@2"60K,PC(OM>)Y" T>]M^PFQ-1(GCZ!;5\LJUP]&*W!M-N45
M::EGPK^/+7'B2R9)I9^:Q@R/*!(.6[=)N)C;'*A5"J <$]-D<N<Y'IG)88Q4
M>?Y>QW"WEMMO:P))]FENM=_E=V\J>9;!G[@F7M^3%5AEG@]CF==K&$(,<OZ1
M17D:2PO&I0J5WW582H)LH%W6X3C>\8LK05I85T%<W0KI9XO$-EO UAE4W*[]
MZQ )YQY$V@))$2U, AO1ZMS9)>7UI,T%H_+_  &TN>IT !\HU-S?[C6!R//M
MFYPY?-[OCDR<)C"+<-,HC65O,TH*JBM^C'M:4LY:RD';)5^)I,C QK"1:X >
MA+BPL\&ZKK[+9IZ16@W<,1@\<L9.0E_A4:E(!,/"$$Z;H0$# 8J9ER*!2^6D
MSE'S!Z5U;<(=H# W%P!<VL/9^-B*QLSN?$Y'+EP,ONJ,\=ZN-,F0G%^@BS+,
M716CCB]60Q^E$2 T8((*EA$REMNL<P;E*478XC03%JZ@'J"0YZ;S+R4:N'+.
M+D8OU;6R UC69&(G$B9E44SG\8AL-U?^=E1E#Y)L0P_\O8 @$@VVW)O[CX]:
MW;=T\K!D1)D<\Q21)U)'"-$D3*K2QR;6QRTCE[78*[!=X.X5($4\GXVO0]49
M<7HB2%G"JO()K8,BTZS2B$*G,D5>-EI.<;.W*AE'$N<Z)RK+IB B ZB E#%=
M87F?(DSV6[ ,5C=1>VALI \-=!7+YL'%<EGYG-9/>T\#29")-)!Q^7C1&;TR
M$;TH&5=%B57NB-X]"#4D0F,E87)[Z_M8&G1DK, L:2?-)^SKV$T8X:M4Q(6*
M.4U9!05F3=-8R(%0,4@[3#NT'!FY 28(PR\I1>@*J%O<^/Q>)M?6N$Y#N]\S
MLV+M6?*Y&7#QMOIHT&,(/45F-_5'_$%;/(R!R6!(N--)]>) Z4(=+LN+=N)D
M^P%5U2*&B.@ !3E[>[[!#V?5UIQ8#6O-R"3I6.P$Z"KG4 VF:N!$A@U(<2$U
M %"=M0 ?K[AU)-P/;5=M-:MJH ND*C8- +W40$=3(@ ZB)1'03HAK[?:7MKU
M(\IN:!KZ50Y ?2L?K K@!_@4#ZNVG5<?4U0_6J& "#Q VG;RIZ#]N\G23I4K
M\-6%0_%5[?Z0_P#[H>K@Z5;/6LM,#>B6[#H#AO\ 1]95P_[75GQUJHWO6,(#
MH/;Z!_[70#6HL:R7H")R?7Z=KK^GTR74KHUZ:D53'A^.;L/^KNO_ -'4ZJD^
M&B]:PA =QM0'N(C_ (1ZE>E5/X5G' ?A[?L(@"[G3_P4.J3_ !*@ D5B)@/D
M)V_;+_VPZK;X34 :UD2 #Z]V.G87"NG_ (8]4Q_"*J;X?QK$T'JY5NQHT'ZN
MFM+&N0GSB9)[!8<Q7+-&->EEB9@A$6T?9*K!6R-\WY3R$]4!PUG64@VCS+-F
M9O$OXCA^$H4= UZ]=^B^,F7W#D0N\J*,%R3&S*WQQCJI!Z^%Z\G^KTS8O"8\
MJ*CL<M  ZJR@[7/1@1K[;7K@VRJM1CJ&XNUBNS&!AT332D4SA8!B]M5LDXN.
M?V:;9U=A"E:2PNHUK7CMPF5@091ZJI$5#B*HH&^A)L[,DY'^58N.9<AK78N=
MD09U"F3>2HW7W!1<FQ(Z7KP6/"Q5PQGSS[(@=!L&Z0A&)";=3M(L6-@- >MJ
MDE2M7J#BF4Q?(V*8UZ?_ #K625_"=E;1N27>/:]96#V7L4W0\52TG#7J1:SC
ME9HTK$[(':M3I#HBS.(&7TIR>,RIWP<!Y6R8_3D#Y*$P^JZ;5C22508E(\QE
MC2[&VK 77:C&S\.),O/"+!()$].!@)?31[EV2-CZK> BD-@/9XX+J<P7;HU)
M%EEYG$(/)B+F+,PM2YJ3;ZQX6]:7?1L1&K"JPF5(MG-MR#'Q;]422YA23$BI
M5#I9./C<]Q^0]\,RE0RH8_U8Y"-X!+VN+E2=[J 5U-] ;.1/PN7$JQY8C!(9
MP_Z;HIVG:J]#8, $1B;Z"W6K4=8<#*I2]B=YC"O5&SQK!\Z1M;YR^R7"KL4T
MW+YN>ELDIBR-U6"#<')' F(V5@_Y(VQ%1$DOC]S2F/%7 $F9&=-@'HN&N ?4
M.U6%P1MM<.""+->JEDX56DE?*:/$D4:L291;4@1B[ ^.Z]MITZ6I;B49.Y/5
M5\/)G!E$C/7N,C\]3[FFU6Q6&E1!XRU%K>.9R3D,3))PT P7=L;>#QG(+G*F
MHDZ:D32,?#88W"P*G/$K)+:-FQ ))(DD;<IDG51,-SG:\-BENH8W%9@7(Y.8
MMPZW5 9%7*.Q92BV8) S&(V47671K]"-#4?QM.KLO'3AC6=FQN57C5T+ECR1
MK4%'NV2$1!1\!8Y:GG1E)BLV:M1GA76(SB'"HQQVAW0)F22\Q=NW(Y6/D11B
M,M@2;&AF).UB7W(LI*AT=P+!W%FW 7N;5ITPH,N.2220+GIN66*PW+9=K&,
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MB4#& IA]XA!+D#FN3%B).G3RKX_A]OSK+7ZQ?4=6C=>1L8MVVT&.!=K7) B
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M3"PO4 WK.?:>H,7Z2$1(/Z2(IE']0AU2.E2.E4,BB0ZYP'[C5P/<=.QB>/\
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M4D:TH.P,+5H<1U$413,/VI*B ?\ BF#_  =6D'GJINE6(\=CM$1^[Y"@8/K
M1VCW^CL8>JI!I[ZA!:]6%RF*LH4?:0YB?^"80^K[.JD'E%JAAK6>! -'K$^E
M-1%7[/>(=,P_I$VWJR#^I^-5D:?A6"@F8PB8"B)2A[Q@ ="ZCH740#0-1]G5
MV31:H4&]9,B7<N54 _ED45!T^L4RE'Z_VBCU3%J+5+C6KL:0ZAU4M>QFZQ==
M!T)H7<!C:![ .4.HD &M2OL-"QRE3,DW$2IAH)S"&AES (=S_4F4==I>_P!?
MMZH!N;&JMHK)%(JS5HJH;:FD"J2@Z^^8=XJD33+J&IA _M]@?3TO8FHZU;2<
M#ZQOV B"9R FD77:0IA$AQ$1[F.8H]S>T>FA7WTM:K9VR;,3J." =03G\"!M
M?H$=JBP![$OJ >YOT=5@EK =*BPO>KI15=-!WB957U)1$=.X@HD( &@?=*7Q
M=@]@!U0=&TZ5)KTABM!*"(@97< J+%'4"% 0'Q(#_E!]X_M'V!H'?J"?;4VH
M5:@9PX$1 B)%3"90>X !AW%*4 T QS%'L ?P]2";5%5J'*HT.FF38DDNF8"Z
MZF,!R*%$ZIOVCF,7] >P.H]]3:O$4DVRB*BI0%;R)F(D(C^&7<'XJN@Z[M/N
ME_A'Z-5STI;V5:.@95PXW&TVJ*&554$1*0 .("81UU'330 #N/L#I<U%A5QT
M<2M&J2 G!$QU2B!OOJ&(H0=QP#737=J!?8'Z>I4"YO2KZ)/2IN=1#U(( <2Z
M 8J(>5(0 VNH"L(B Z?LZ?7[*:D5:9HZN45EC:%$RAB%]IG"A  1'OWV%,'O
M&_@#J?W34'3[JM-"JO'>]<X%2*H4O8NA0#=J1!$O;Z1]GL -1'JI@ HMUI[A
MTK(3$SMUZHXE(V;**J>/0=#B3<H*:>OWC&$-3#^C[.HM86/4U-9*)7)Q%P3:
M"SG^SM4]NI44S?BG6T]H%*4O;7VZZ_3U2;>-15B3<&23)'D$=J8!YA$=1.;[
MP;Q^DYQ'>;[1T^CJI1?6AO3=,7WA_P"SZ.L@#2K9!O7F@]3:HL:-!Z6I8T:#
MTM2QJX@8Z2A3)FVF X& 0^@P#J _P#U#+<:U/F%.\BBKE%-\GH<Y %-VE_.(
MC_*%$!UT,GN$Q1_BFT^CK%.AL>E7/"L,&YD_,P55*8BB9E6K@=1T*B8#@7M[
M"Z:[@^CVAV'IUU'2IJTF0QT7#1P)2'0\9B*G#738?8!#G 1U2'R=C=]-?JZF
M]]:>^K;,3[7K5R82D(B.T1)O.AM53,&G?44Q$0$0#77VAU4PM:U1]]#<%6[U
M!,1*)%#@!@#WDU2#]TY1_A[&#N'L^OJ!T/MI6&J0Q \R)Q%+?H4?8HD<.X$/
MIW P?0;V#IV^H) %1?\ .LQX0')FX:Z.?3MS#J.A7&Y,IA H]@(MJ;M]!OT^
MV%TO[*FK;,PE:O05*)R&703,F83$T[G$PE]@E4 ">T0_3U+6!%O94VOI5H[8
M"F3,0=Z:AP!,X=C .H?AG* ^XH C[/8/M#MU%S;W4K*<%1=.%@4V%6!4Y$UN
MQ2*%*8Q2IJ_0!NWNG_@'Z^@9@+"H*CJ:H2 [5NKH&PQETTS%,74!!,BIC)J$
M'[Q#"8-0Z@FYN:FU]#5L[9-8/*W+](>1'74R(F]W<3OJ9$1[!])?8/U]3<U%
MK:5=75 5UB*%WH>302!]XOC*"0*)"(>ZH!2_PAV'J+VZ5-KZUYX/3MW2A# 9
M-0B9$U"^P^Y3>8H@.HE.4$QU ?\ M:=3>Y%ZC6]6"*$<%*BX$ ,4 !)P;]@
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MON7:A8[A:X6JZ04Z_!)B@S:B2&C""VCE07CVPE9(!X&*X**@LS1TVI'W&W$
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M;<QDE%3(W%,WO*E(=58"GGB'5V'.<I0-M-X@3[%44,F6Z.-XX#1<R_\ R/\
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M0]$5_3KAJ5,R>T"#[VTZ8B0P:_282Z"(_3KU'NH"!5;-,J1BF5$/[044DTQ
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MO"->KCA)FQ=6^Z-_3BX8&74) P93JK;ECQI39LF:J<"TN7AHYE4QQ(8@LCV
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M\5S/+S]R9W*28\G*X:<A_+^.X_,;&Q<48TA$$63-89.1,ZR3".S1/&1N:?\
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MKWW#0A5Q\W$^A)R1#@+$<#(EP+2ODY44D*2Y>5%FVA^8G">A!' P,LDX;?\
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M4$A_"*&H[P/[P*F'MN,</U>SI4@"K[8H&;JBJF)RIF\R1-=!5.0!!0@ /<2
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MA9*$D"TL;;9:KE2R7B.?O*ZV@"3<55P9C#-BQA7K)X59%X<[A0RX*%<%!99
MM63R7%XSLHQV60%]BM$J$!BUBU[ZV(L5TTM;0&LSN#Z@?3GM[)R(8N!R8>2B
M.9\KCY/&8^'(B9#3F&3)W^JWJ;'B*O$%10A0Q$QQRLKRW'S.,LTL,<QO2M><
MJ7&^V"*L)KQ:7_Q"*DD+ZG0X@S-DZ9/XD(3X[&@*AE%@9':@=-)SX2$/:CYC
MBHW1WB#KZ<:E?346(]/U#<W!W;6]E[ZD7-:_ ^J_TSP,C$R\GC%RX1Q^#!+
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MD2.<\21/$<\.AQ58;GW*%#CQ()ZJ=#H=;BXL=N(89(Y!C/'(,EUNJV8G8;7
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M%%\OB*L<DT:")V]>-6D:-%>S-<JGZ=U%P;$FWV+B]Z<%W?SW=>9VQQ?&\8O
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M</:#RQAN14A9+]CFJ5RUJ4+*.4KG;(:UK/+8WB+5CMSBVVNI2I-(NQP)U&R
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MF+8-KHIQ*L1P4_5W+])6.+D 22MK)$J^HS$KH2J[R00"-;]+:6M5K%5Y ,F
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M&+SC!A!%\\*Q#^^1@8[50\4YF2N'B:EH.W8"P;*)@IZXQ?%N4$4T]V\0$2@
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M\ 2W\8H13C /.!-S+/V3JQ<,B2TPW<L'\\E6A0Y XP9.A40091ZLJK'&1%=
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MNBGC()=ZA3$*8!]A^@ZENZ<X"0Q'^29FHL+^5=/,"-?]E>:?6=]G;6(=@?\
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MH IQ /M[@'1"+D>ZHI(ZKJNCI2CI2CI2CI2CI2CI2CI2O=!'J*@D4X1$Q&!
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MN:S5A\:!4PT ZFU933MH Z^(@AKJ'NCNT^WJ*580**B@$U^\(:C]10U$QOX
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M KQT,]O@$>(>ACRG(N:G:/[:;\SS:RH2!Q)9"9XD48)BC9$YZOK,N/@95O\
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M6/#-WKB10_)]:!%^Y!8%7B85V&V.?[0HJOM7+[WOF$X"(@;OKU\/<Q?^9SW
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MQ@4 T#3N'2IK,(PBVIE4$&#!J*QDU7*[9BU0.H]*)C@X7%)(@K'3.H(;C:B
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MCU_%QZC5)!B[<(*&%VF7P^>+U4$UL?&I;IWS%,41\O"XQST1'%>;GJD1&6V
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MCEA=-RG=(%(D!5=H!-M#6</*A9<-<^;%FC O#EHC%%MY7BE5R&!5=P*$$W)
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MS"/DJO%L4WR;XJ"C@G6NXB$Y'&-&(8I5]<EKE5D4;+@AV%D%Q90VY968H5N
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MH"%/@#J MK5RW(NTB19*?I(\"JL+:LB*-BM]S:L/$CJ3>]?<%A@$0PSC$4%
M5*:D5(QS@H*H"J:K0XG_ !A H+:ZZ[P  -KKH'7P9SY8\YD[NOKR?^(U?;W
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M<:;MOC^,W*)<S'QX0"0+AHT,C:W'E52+'2Y -M"/FR:/(BYW.S[$QXN1/+N
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M9F;W.*K]CD*#5J%98+!=3CTG55L$7DW**=S7.P]>FL_9M8AUMB'SDIT$A8U
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M(DR9_P 0%.>0<6(AXQHW*NL=8RKI3>4PGU,!CB;K;<U)A/W%VX6;?BMRL@N
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M6B[?XS'Y&2:3+D:+&@C#%PR+8E@HN6]I( MK>O%OH=].>![\S.6SNZ,Z;C.
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M4L>7Q0RUA;%3IEH.9Q42[[6@4D&^,*U8)O)OL*0!N9!N#5R!.X=;GMQ2W<.
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M9"P6U\>7;I'KY8S"67'DY>*<UB)>S)7VH1S&AJS=ZQ3'0$.[?_&XXCJ&;H$
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MAPF9UEZY3#R!G(:0D(:[/%/WCGG6US?)N[95&3&S5@)?(%K"TM;96X.,-:9
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MKERR<1ODBFR:92,D?*W!#G4D;B\ULK$RI\CF,J1T,F1$^R--VZR)'^F2JQH
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MZ1<IDX<V5!W1%F9K77D\7&Q7OA1KB#,Q\[E(L3Y:.9GFEDEXO)W^F@,KQI)
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M8S0ZE[J=-/8Y,V;K!-I31XBRX,D;1CC#S][8H-[%UZS5>HVJ)*-MB$'L29Z
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MR'2AX)^A0J7<*]6:HTC%TVR38T4(F4*K(R: )D">/Q>?SL%^3Y6=3QDT*?\
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M5)(]XW"Q0A1YBY(^>99(H>8R<O,59)L/*F<1ON*NAD8W4 W+(^TV-]XW'0*
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M/-.+W6VPPC^$N.5)5HE_>>-K]-QNNG7<JW&8O&Q9_:,]N(0Z!A>3UF'G:=2
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MF9X[UU<K53L?P TH5D9]/(3$@R7$SAN\0%-5+GNUU[VY#DY8^W<7&;M8MO\
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MN6J3CU**;M%\T>D=HMG7XR:9P,!%?>* &[]5&,G2PJD&QKQTLFNH*:B4<N"
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M+F!%,4E@3 3;2AN-K2\;,_E!(]]5*ZA=35I+1ZL4I$WDZ(*% #%,:)<I&$P
M0 ()F6H@(_1L_AZO.+(1H-/OJVMBP)K*=*IHK>%N>,1,W(5'T<MN,_#9V4VK
M%135, JF$0$?, CWW=]>K<2-U8&Q'456["VG6]9T;) F85%EW:(H 90I48T2
MHJK;=J1$G:H+MC[EC (>^!NWLZIE0LUAKI[:E#Y?QJT8R@B)A^)& 1U 57+5
ML A]6B1B& 0#Z=/X>KH'EMI>U4'XKZVO66LHDFS(F @!W"WG$B\\ON\2("D7
M\/\ %* ;CF'N/<=.K,:D/<C]E7)-5K$3$JBB:1 0.<YRE(!9E4IMVX #00)K
MKWZNO\/]U4Q^(%9;T1.Y6\2;WQ);$"&1D@7U(@4J6H"LO[#"77Z^HC%D -K_
M '52P\U5LG7IP<+F>OFW@04$HNV9%T@45_!3W*I):!W.(A^(&NG5MU9F%@*N
MGX?=:L(^UR4#@G&R!0$ WI:)J!H&@::^H+N[_P X7JM 5.MQ5DU9WI)&* +.
MV!O84C@V] 3:Z !3+BNW'4?XIRCU=ZCP-4UE;G"9M5DRKE[&%1MJ53Z]1:G$
MV[4/XBAA'Z ZITMI4UQH^=TR&:X^8G(R%NJN3-48LAY0)^&+>D9$,Y*LBMXS
MG Y! /&(@(@!MNI@ I_:OH)(<?NR9S?_ ,DP/W&2,?WUXS];HO7[;QX_;F+^
MR.2N">, ) 7;C<XE6K!S/URY6BS)0TJW;RL57\)6:#E7,_8;$1ZV?M8FNMG3
M&2=JD:H$<+L'BYUU2(@U35^ANX5>;CN8:-F3%D@12XTWY4;J4"B]RVTHMR;
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M:DU,)=!]0N93(Y2'M7AIH55\GY2&5_X4,:-L]+8J%EU\I.N\V9C6^['X=L;
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M'IMOD8*1BTRN(QD3W%8<S<C%VJ0R:PU\I%E1<GAQI\P^;K?<45M_KR7"LI=
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MA O<X[2C]WJV_F&T=3]]$-KU@))I*[C)HQ[H2#[_ (0.Q<$$ ]@E 5?&;MV
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M.1BHJM0P$>G*\.R043WKO3AW^-B8O;7'39W<D8DY#,5H5CC(8JA!'HQBUP
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M!Z"OLGQ<DA^[3'3A!!5F0:=6$4X]4!W1I?@$2=1D)AT,H*&A$]QBE,)4P 0
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M'5IMI%AH;U<0$'S7M:O%P$[MF52*$!*#A<03(Y2U B8( (![Y0#<YT]G4K8
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M 5;@G^*4H!H'T^P>A Z+>G32J9))!!#SEC!=';';NC&*9<6NU!8BIM U,HJ
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MAQ6<+F(4'SLB(EV)I(@*A6J:KHY!V_B+*:#KI[.J5&_SMJ?95QF4"P(!I.,
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M:EAJ&W*HN;  D'8Y4N-S<B2/C-%R8]0/)-8Q,I;^,1Y9&VG0@AB=+D]:5)N
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M3;?_ '2YM:U):,+ 5BTO+OD.GP699AVG;D85]A9C!UAI/72UL@CH>K6FO3C
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M'! 'QG^PVN@IJ!])! !#[0[] 0>O7V52J:4SKWD^I8RJKJT9!>OFM?8KLH]
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MKH*(E(V*@**QAV)F$RZR)BG*11 ZY]H& /V-! ![=0RD :"U1O!J^95NH\3
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M1N!UUK4[E[3I#(.**5#1]!F<P,*_G[!UKO6-8YM7%W=JH5,NS:2M3,(VVV*
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MT'Z.2-S2B3JQ=E(+JX!4J1M%P0--6 ZQIREBY5U3)+(W']2=;RK&B+0R]\Q
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M+*.%:L9$XD.K7((++F6LF$<T8FLM'L\,F=N9LY@XO+\]BV\L':A5O&\:/F1
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M5KER2@8F*=5Z1MK=C/S0P9(F M)ZY#N)!M /5V\XN@B?8T$3%UI78?B?0U6
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MR.A-S<ZW-;/AG]7A\23U$EW8T1WHNQ'NBG<JV&U6ZJMA8$"PM:N,GSSEV3;
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MN!1,<OO:D5-M'4-0ZJLX/ID_[:?[U7$DF"R!I+U;AFY,!E=Z[4#^%),-@,'
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M]T0^X7WP[B7J-DB'=<>[WTZZ5X1VT0 (U-J<SQ(A"I*&7 J9&@")4GJA2(E
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MRBY;\/''PN1)-C8\RX./RO\ -'$F299_E @Q?5^8CD5H4VM;>_*40>P8QR-
M)QC^:4FZ);XA.&BGC..E)8\E7Y!D6,C9"11<1[%^_,MXD5ETSHI*' QRB4!
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M,A?LZ^X7(V+&>I!5T#]9$ARP(@MS?0G[?W_UT+7^^HAROPKBLF6VT7!7)L]
MQMRL(6-6OPM:9L&#V0CYVH2:C'(9(N>A&V1H:*)3"@U2<-V,P1LLLBM)N4D4
M$R5^D&+ DWL/N]WW^R@>UM*N.?EU8Z?1#J DKQ-/F!8:R1T-*&JM:"\,)*RU
M-Y5AGI7(*IG%GLSFLI/E @DUEDBQ,><S),QBF\P6/3'MJO>:;SWY:E1=&8^D
MRU885)*1KL[(DAZ7"-W3F?KLU&3#9]%3+B9=6"(8II1*;!JQ5=OV[./673 %
M#F04;/3'MIZAJ>,'<:5L'9)F+)596%BZ(2 I5,K5)9,3"DTA:_18N*M]D9(L
MVD+'5*T9,N]>AG\NF@60163A 4\@+OE_%*H![Q4$W&O6LG /%Q+ K3,T8URA
M:;K#YF<N922C)Z+CVB<#9Y-E-,+/>F;EJ\7=R%VR 663<V)VH=-"1D&A%D6[
M0AC(]4B(#H30M>WM%0_D;@=C:R/J:]2N5KA[+ *UARI.,V489U(Q>/L:8IQY
M! Y.BX8+-Y"(_=8E(Q[I4[Q"/7EY1,K10CH1ZKBA.K7T'N]OV_;4%_"F- ?+
M1JL,^*_89SM))0Q915B[&E0[,ZZLM5XVM>ZR4DY"*C851_ HS#]!)$BSA=0Z
M;9=@@NHB<48  WTZ_;[:U)D\+4[5/ERU25<QS]?)]@>W5O?Y>Z6FWL8V+BG,
MRK)N85WZ1JA%3,<ZAUXB0A1<0"AG#LL021>@"*PN#'$53XVO;KT_9]U1O\ !
M6[>,,?(XZQC2\4U9JLUKU(K$55_*VCFC/SKQ+5-J_?F:,$BM"3<U(D4>O52%
M$QG*ZAS&%0XFZFT2ZW'N\*I))]M/@KB0?MA9BS3*W3*=E(F^'HD*!D1%%=F@
M<K<HAJ(#N,'\F4= ][[HK&IW;KMX:U&I^ZK;=ZZ.F:.3;-2&9"#5TY*Q(02$
M*0AD2H[0 OJ56YBB(]P2'7VCH'4E$^.Y-^FOV\:52BZ5;J'BF+!B'C %4C>D
M,<C)HMKN P"H(JK)JZ[""/<#E$WN^V2BD;F)M]_4TZ:5=\[ABX20:,&ZBCX!
M $_1E,;U28;A>.E#$,8"K)@8#&]IS$*4H?53MC(NQ.GO\/8*C0'[ZR3HR;8"
M/$VIA424$[I8(]%,5DEA*18/Y#:4B!0 Y"ZZ$ G;VB(P/3.E^OOJ:S7*,NNB
MHB*JK?70Q#BN@V!-=,0.BJ "HGH*:H /LZ*4!OUJ35A(B[I%-9Q(-2BH750B
MCHS@2J%$2J)B5(JV[:H40^WJ"0#8 U&E8S5!HB"K=5Z=3TZ@D(#=JH/X!R^5
M#4RYF_W2'V>S]CJHDG51:]!;PK+ T<0 V-W*HAJ&JZQ$P'0?:)4DQ-_X_4>?
MVBIUK2#G=;FD12<(P;U>HPT)8.2>/[%9GEPEDZ]4"5? -9OG*61&YV5^1ZA
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MP,1BS-CU>-+-0S.*D:Y:[#)UIQ9XA9)Q' _;D(X*NEJ8I5"F&!.I-B"*DQ$
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M2K.1?-&KMP9KMA (VB'(KJ/O3)-#('(N9,X;>K\?%\A-D28L43-D1*691:X
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M')O4%6*W27639QJK<ZNW:Y4B9#N\V2O&YK661(8%FSFN=Z^K(RWB5T\MAJ6
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M_'+/=5#M$N^5Q?U2G07 ;PNM^#''&8QP^ GAR.:R(U]22/58X[,2H<[8T/\
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M$0&2JAK,-#]M*#V^-8[-TY=(%7*Y<H/Q\BRGD54,<OJ3BJ"2Y 4#U#0X:;!
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ME\Y5628\?,4JQ+F2:.T\WP2K5\V3\H@]6I^1DS&$2>-073A<C<I2:@CX]P&
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MOICZ<]K]K]R=DXL_<:<;'-'G9$2/R&0,!)8[0,4P9,<Q2YF0C.?5^::2.'?
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M13,J;:BV3VZE* ]5Z#ITJGK7+_ 2[;-'+MCDB,-%OJU!5W*7)?XS3\]S.?\
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M\W<!R>ORLWE4L#M7W 6N??4\;,,GAN?$NU(_Y3;R@=!D1:D"US^VPK[.^(8
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M+CQ *1N])%#NI(4[)'4W-]ET) )%?/9B&5S<BHPQ\>;,FCFD)((3U'8JI +
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M.XQ41$ $-W<X@'<WT=0;[2%T6_VO4W%]:R%]-[3V_P"N$]G_ +PX_P '?JD
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M,18Z1<=)BL-\N1R,3+5B+E;9CR;^.XV@, 4S%4[5YB E(.17"]&C+?8+E$3
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MD\;E:9AMB']!],HW%L<_]>;C]+=K2U70$*_!@(1Q1"'C $L0(&B0$&2':,,
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MCR'<-WD6-!(NW<H8,I)VLP4E58WVU\WRY&0>;S..#$">65-#;SEVV$&S;;,
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M.N]$07DLA7^!;O;+0:GCBK<%,88VQ;&JYTX@L(YV^< \*X/:J,5,&4\U(?\
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ML>1JTSC'N/L:M<FF,Z5+.Q7YXC:9,-&!$RF27@2S<4XA)M^JIJ7P.G\6D4
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M.(&LG=[-,,4KU1GMA&."MP9:K9YV36:3@M%F;65<R$,T9,B/RHM@=R"2+I5
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M$(0A:#42D*4VH&3"LQ )J;1T,4#E+V 0Z^#^6O\ SG+O_P!O)_XC5]M<,?\
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M";'\_P"BFOCTJVCM#:9!PZ;B!0VD73,")=N@:%D9,"JD+WT'T^G;N =2>MB
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MU\WW4$5 ,H;[A 'N(:#T]1#[?R_OJ1J+UXEG1BN)?'39LP&W[3?$(P$Q!,7
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M_.Y>1K=8XJ@;<L@F<?>(40;HATO^5-YI1HK3!-MG0A(O!U'B%S-9F1\YJ?4
M0_M($&5)XFL:3O*BMJOVT6'N?</4KZ;:+_14AR?;4VJ8RQN9C!Q*F/:,I%UD
M'WY<C3U* .P@0E!$TF$.T/'BWCOB1QW./$4OG. &/N, #U( (Z"A)]O6J!QA
MC,P30'QQ03EL9E36$IZ=7#EG16<-WBWQ<IHT0D05>M4US KO 5R%4^^&[IM7
MV"FYO::S)*@T28:2<?+TBGRC&:;L6DPSD*S"NVLJUC 8%C6\B@NR.F\1CBQ;
M4&Y5 ,"(-DMFWQDVS84W'VUAO<8XWD58QP\HE15<PAS*0K@:Y#"I$'.[</SC
M&;F8E8 =^\67$$@* K*G/]XYA&J]^H!'O% 2/;3P427/KO51<@.NH.FY!$=?
MK.GM+J/^9U5N7P!'W&HO5LJ!RAJ#82!N -6CTY0#M]"2@(%#[.PATW ^/YC_
M &U(JHICEUT4E$Q#M[R*3@ #V:@8A%QT_2/0V_W;??;^RIO]]>BL?00!ZN3V
M>\I'*#II[>YDDR^]]G3:/8/SI0*VH>\^.(]@#8T* B/Z!14#0?K^CI;7X?VU
M%_?5&B9M=5))4!_9*FY2#Z![^-%KJ&OVC_"'07\-H_+^^EA[ZK2 4P,+9AXQ
M]HJ*G31,.NG<QB'77./Z0Z&Q^-K_ &_"@JKQKG_E%P3+_-M2B3V>P!7.8ZFG
M^:!.@*@Z"Y]]0=17,3YLE@<4S"&'YR%*W0F&><(AQ&JN45%B [;4W(3LCDCD
MBY%H]9H*.WU&H* HY3 ATQW&Z]0^C^*N;W+E8TY_X9\%PVMCM,D?A:Q^[H0#
M7E?U=ROE.#QLF(7R%RTVZ7&X(Y_#W$=#7$FL25OQ/CMU8ZK5U;CC.7?OY;,&
M.)XDF=)A+0<+D99<9 :+9X&3&#OU"L,VV/)'A'Q6<BLR!4QW3)LH?VWE,;C>
M=Y88F?+Z'*1@+BSI8;E8QBUG5@6C=4.W>OEW%;!B*\8P)^0XGC3DXD?KX$C%
MLB)]0&3>;^4@[70L"P0Z[;W(!ISR$'>L"/V^4L,938QN*K.6YED'$M.URZPJ
M36N2,1'3]/M]?QH^FXBS+IQR1'B(JQK&12"1\IH^(5!(%+$.;QG<D X;N#$+
M\W"8P-JO&[;Q<2+)*%,=B!N.XIY;!G%79,/D^!R/YGPF7Z?#SB2^YE=5"&Q1
MHX]P>XOM!4/8W*H:MN[4M=7)K^;"^8N0TB^9M(J4R->(_'^+:=(T2.9.W=2K
MN-*,PB'T%78A.N9!2]&*:TQ+M!1<F3.1TFJ09BX\8,#<8G(XG'0JY/HP&7(D
M]0Z/)/.6!9MT9W"RQZB^AJ)LXYLJYTF)EY\Q07EF$<";!<HD,(4JJ[7%C=GL
M#;44F-)R(E&C2\5#C5E"'AH'?::!D+!2]?@+K%V5D_/)0ESB*3+MKC+-V);[
M'L4&C*8/*((R)51;.BD2,9.M\*;'W8&7R^)+DR 1SP9(8PNK:&,R+M&[T[EI
M$VMM.JZZVTR8'/SN)Q>3'!&=\4T%O45AKZ@0WN ]@J-==W1K#14>RF7>2TD$
M$SS*WG,;5E&^/9%X2$@L.-8MY36:KE]8+?25;#6<<R$_)V!%,A5@EQB"IF02
M0?,&ZA3*6HTX/L_$$S8 '+2H@0%FR5;U#94BE&Z18U4VV;0YU8JQ%7VFYCN:
M8019A;CD9S)^FL#*4%V:2,E4,C$7W;B@T (O5\7SVS15JQI0H92K<:Z<F+2R
M6-)ZA9'N1"5><D[4P;/9X+- 8\M5@RA9"QH+IQ,))M$&$HH<QW+5F95:U!'#
M#F0<OG.N1W7. R1&Z+ '&TL$V,Z)"F\;G=2746 +6":1Y\6?CL2/TNVXCM>0
MZF5E.\*6WJCO(^TV16 5CU"ZM2K2*KCC9S?B+,G(L8>E<.6%9(E'O8MM/HUI
M+->+E'$8G*2"#6+%['/7CC\(6X-TC/!%%%+=XS[O*@$7=G;N1B,GJS\R[L#?
M89#CR^:PN;$>^_37QK!P<C?V[S<$@)2#B$4=-VWUHM+GK;\O=7V'\1/#_=1X
MR^F16;M_[O\ AP$$'!4RN$D0QY70237*D)DBK%)H!P*.W=KIVZ^,>[+_ .:N
M2W$%OG\CIT_BO7UCVO8]L\?86'R,'_A+6Q'6@K>T=*4=*4=*4=*4=*4=*4=*
M4=*4=*4=*4=*4=*4=*4=*4=*4=*4=*4=*4=*4=*4=*4S,CMA>8\OC0(R,FA=
M4RT-@AII]\+AI85X-\D$9+2?J&GPZ,?B;Q+K^5+PI',?>734-SVY((>X<"8R
MRP!,V ^I&N^2.TJG?&EFWNOQ*NUMS "QO:N9[TA.3V=RV.((,HR<9E+Z,TGI
M0R[H''I2R[D].*2^V23>NQ"6W+:X6JZGX:_!)"V;,A2AHM,6;)?U3-IL9(%]
M,T<^1;U#9#3:FIO-O* #J.NO6%R+;^0G?<SWF<[F&UFNQ\S+868]2+"QTL*V
MG#)Z?#XD>Q(MN-$-B-N1+(HVHUSN5>BM<W !N>M:F<W^)SKF'C2F8[:W]KCK
M\JY9IN35Y9W1XJ_IR3>J)RJ2T"6%FG[!BU5D22@[7NXZC42;B%W" ATW8_=P
M[,Y2?DOECE&;"E@VB0Q6]7;YB0"3:WP]#XFM'WGVL>[>.AX\3B#TLN.;=LWW
M]._EM<6O?KX5I9+?)<Q4]LLW:8[.^8HR1LDS-V":%5K17X.)&6>K2*)45/RZ
MT518LG2A1%(PJ"J4@!O* CUVF-];.:BQ8L.3 PVA@15363<-H N3O-R1ITM8
MG2N/G^CO$23RY,>;EK+,S,W\,KYB38#8+"^O7P%4R/R9,?V0K+\Z<B<S6=:!
M46<U1XJG7FKN!>&3CS,UU!%LZ:RR$4[CBF:MUD?3H)+KD(0IU"JIL;ZU\K@1
MF+ P,".)S^HNTV<>:XT((ONZ@WNJ^^\S?2'C,N439^=F2R(/TR2+J=+'6X-K
M: BPN?<0\X'Y5$37H-M6(K/EO@:RB[<K'K54J43$02B,GX33XG3DYB?EW$E9
M'*/J7SIR\<BJZ$3@0H 0A=3/]4IY<@9<V%"^5IYW=F8VOM&@50JC0!5! '74
MWV<7TW@BA./'F3) ?W450->IU)8D]3=B"?#I2.7Y1\2G#R=;1Y(9!)7926^*
M+Q(TZGJ(%_M;-\+),%0,D+-=U$,%%P,F)UU&H*&-O!(R.9_]%R=\A,P\;BF=
M$V@[G'ML>O47-K: $BUJQ_\ Z%^/Z1QQGY(A+;B-J:]+B]NAL+_=>EQY\JZ,
M<PLA5C<@KH_J+])!DXIEAJ<'+U9]# HW=O(*48MI&)>N(][)MB.!%LY9N"B0
MH>4VTI@QO_HH9"Y2Y\.!#%G*2PD1B'5];."01>Q(LRLI]GA60?IOBOBG"ES)
MI,-A8HX!4KUVFQ!M?70@^^F-%?)@QU7%UY6K<@LP5ZR2S5FSLDVS)#*&?H-"
MHH$3B6ZNX\&#>.:I,D%/*Y<BS%5-TJZ%8YNMG+];>6R(UQ\S!PY,-'W!+$:^
M)<BY8D^8]!NL0%M:M4OT>XF)C+BYF7'DN+,X()\ -O\ AL!8:G2]R;WI.>_)
M)Q1.%.2QY]S') #4/ JUCZ%'NFLOYDU!EF[@:Z],43D)H=,0'<<=PG]H#=B^
MN'-8K!L7 PE6UK?J$;?9_$4?LZ53)]&^&G4C(S,MF-C<>F#?VW*$FNK</BIK
M!5^ KK*7=*LZ[$,(5DH[034<'9QS)JP;BL=,Z9#*BBT 3"!0 3&'0 #MUY+/
MR3Y$\F0R!6D<L0/:23_77K&)BIB8R8REF5% !/6P ']59?[N0_Y5-_L@?\(Z
MM_/M_@_;5WTD]_V_"C]W(?\ *IO]D#_A'3Y]O\'[:>DGO^WX4?NY#_E4W^R!
M_P (Z?/M_@_;3TD]_P!OPH_=U_\ #8W^RA_PCJ/GF_P?M%/23W_;\*/W<A_R
MJ;_9 _X1U/S[?X/VT])/?]OPH_=R'_*H_P"R!_PCI\^W^#]M/23W_;\*/W<A
M_P JC_L@?\(Z?/M_@_;3TD]_V_"C]W(?\JC_ +('_".GS[?X/VT])/?]OPH_
M=R'_ "J/^R!_PCI\^W^#]M/23W_;\*/W<A_RJ/\ L@?\(Z?/M_@_;3TD]_V_
M"C]W(?\ *H_[('_".GS[?X/VT])/?]OPKTN.@*8#?%![#K_J@?1_]7Z?/M_@
M_;4B)!KK]OPK6]YPU0=O'CO]X3A/U;MRZ\?Y<1-X_4+G6V;AEPW;-^FN@:Z=
M6SE:W M?WU3Z*>TUC?W+6_\ UB./^C:/_/'4?->X?G3T4]]']RUO_P!8CC_H
MVC_SQT^:]P_.GHI[Z/[EK?\ ZQ''_1M'_GCI\U[A^=/13WT?W+6__6(X_P"C
M:/\ SQT^:]P_.GHI[Z/[EK?_ *Q''_1M'_GCI\U[A^=/13WT?W+6_P#UB./^
MC:/_ #QT^:]P_.GHI[Z/[EK?_K$<?]&T?^>.GS7N'YT]%/?1_<M;_P#6(X_Z
M-H_\\=/FO</SIZ*>^C^Y:W_ZQ''_ $;1_P">.GS7N'YT]%/?1_<M;_\ 6(X_
MZ-H_\\=/FO</SIZ*>^JB\+D"B!@R(N(E$! #5EN8HB Z^\4TN)3!]8" @/3Y
MKW#\ZGT4]]*I^)3M02[\EJF BIE2E&I,-I3&:D9'*'_&>[QJ-4P(8HB(&#]/
M3YKW"I])+>->(\27C<$P;Y-<-_"90R0HU5DF8GD,L8R91"3U\0>H. %]@ 80
M]@]/FO</SIZ2>%ZPO[G)@*!0R2X I6SEF4H5=J4"M7BBJKE( +*E  446,.O
MM#Z-.GS1]@IZ2>^K:W#,B_C\V1W*@I(I-R":MH>Z@@4$TD@VRY?=33#:'TZ?
M3T^:]P_.H,2'VUGEXCO"I.$/WFKF1=F2.Z2/5&2B:QT1:BD8Q#R@@ E!DD';
M3L4?XQM7S1]@_.I]*/WUY_=%=@X]43)SM-<%5UB*)UEL0Q%7#4C)0Y!++ ("
M#5,"@/M#37774>H.3<:@5/I)[ZK/Q(<J)^$^25#HB54IDS5)@)% 4.10/*3X
MEM4\)TRBGJ&A-.W4#(MK87IZ:>^L,O#HQ"@4N2G10!J#,-*TV 0;%7!R"0&^
M+:AHN &U^]]NG4_->X?G4&)#[:SAXEO13<H#DY?P/$RIN4/RFP\*I2K%<=TO
MB6P!,N7>80 -PB;7[P]4_,:WTO\ ?3TDM;6L0_#TZCSUY\D+BY]@F_*S3QF)
MX/3"D=+XJ)#I&;CL, A[P>T=>JOFO8!4>BGOJXZXAN'C?TKG)CE1N#@'14OR
MNT*4JX X 3EVR@"4!!R;L Z::?4'3YKW#\ZDQ(?;58<1G8( V_><Y,@#0S$B
M2E69J$(T-X-Z! /*&VD,9L0W^<&OM$=9^:/L'YT$2#VU;'B"N9)1 V3')TE4
M&;8Q3U=H?\&/ X- *8TH(E.CY##N^\(B(CKT^:/L%3Z:>^LK^Z<_\RCD<G+B
MY5.BHHY-5&1ES&;JIK(ZG-*" @F=(NFH#H!0 -.H^:]PIZ:>^DE3ABBJH=0^
M1%@,<QCFV5AN0NXPB(Z%++@ =QZGYH^[\ZI,*$^-6_[EK?\ ZQ''_1M'_GCI
M\U[A^=1Z*>^C^Y:W_P"L1Q_T;1_YXZ?->X?G3T4]]']RUO\ ]8CC_HVC_P \
M=/FO</SIZ*>^C^Y:W_ZQ''_1M'_GCI\U[A^=/13WT?W+6_\ UB./^C:/_/'3
MYKW#\Z>BGOH_N6M_^L1Q_P!&T?\ GCI\U[A^=/13WT?W+6__ %B./^C:/_/'
M3YKW#\Z>BGOH_N6M_P#K$<?]&T?^>.GS7N'YT]%/?1_<M;_]8CC_ *-H_P#/
M'3YKW#\Z>BGOIY43BVC2)\LZ6ZK20E8O&7I3P:;4!]6"0>3S%DEA 4_'[-O?
M7JM,PKJ *D0H/;4SCCH!'7XJ/^R!_7AU(SF&FR_XU)B0^W[?A7G[N0_Y5'_9
M _X1U/S[?X/VU'I)[_M^%'[N0_Y5'_9 _P"$=/GV_P '[:>DGO\ M^%'[N0_
MY5'_ &0/^$=/GV_P?MIZ2>_[?A1^[D/^51_V0/\ A'3Y]O\ !^VGI)[_ +?A
M1^[D/^53?[('_".GS[?X/VT])/?]OPH_=R'_ "J/^R!_PCI\^W^#]M/23W_;
M\*/W<A_RJ;_9 _X1U'SS?X/VT])/?]OPH_=U_P##8W^RA_PCI\\W^#]M/23W
M_;\*/W<A_P JC_L@?\(ZGY]O\'[:>DGO^WX4?NY#_E4W^R!_PCI\^W^#]M/2
M3W_;\*/W<A_RJ;_9 _X1T^?;_!^VGI)[_M^%:[\G>$E*Y54BO4.]76YU^'KU
MI;VLAZ<,*U<OG;:/F(Y-L[--1DVCZ8$I@YO<(4PG(741#MUTG:W>O(=I<A)R
M7'PPR3O"T=I Q #%3?RLNH*Z:VKF>Z.T<'NO#CP<^26.*.42#TRH)(!%C<,+
M$'V5IE%_)OK< F7X!R>S#&+;#IJF+"4X6KIOO3 D>^9MV;,'D0=L4Z2S50PI
M+D4$I_<$Q#=K/]9\S)%LKC<)A>_5[[@0P8$EK$$#I7'1?27#Q[_*\AF(2+=$
M(VD%2I  N"#5</\ )BQ=5)A"PU',E\;3I)5Q81EK-#Q=J=Q=N%ZBX976L%.^
MBV45:6;1$&P*.T9)H1/4R+9 YCF/3F?6SFL^$XV;B8_HE=A"73?%:WI2:'<E
M_-Y=C7T+$:5.+](N(PI!-C9,_JAMP+V<K)?^)'J-K6T\V];:A0:>$[\J:-GS
M(.W7)/)_Q:-EFTE!RRD#65W<(DS60>MVS+> >!4DBW*MYT12.F'9($A #!KL
M3ZK28P*)QV(0R[6%W .A&HZ6L3H;W\;UGY/TU@R"K-G9(=&!!LMQ8WZV_HM[
MK5;+\J6.";?V?^\AD0MD7;L6L?+-:K562T.WC4B,FC=@+84U2M4XX!)X_(!2
MJ&%0FS42C+?5.3Y08;<=C''%[@LQ!)UN1TW ZWM[C>J%^F4*Y/S@S\GU_: H
ML.EM/"VEJ0[;\G>@9$DRN\@YJNUB0!FSC%7C> BX:VO(&,*FXBZ@_L;22.R<
M5-C,I^L(0(\DFD910B+](I^U[COJ_P CQ*$<?AXZ:D@$LT8=C<R!-/U"OE^+
M9;JA-6LSZ5\;R+[L_*GDT N+*Y4#1-X-M@.OP[[_ +XK$_\ F.E6,U:1:G)K
M,YX:):),H2+&.J2J,>FVC&K)L\,#UB\;+S!W3,B[ER"29G?<AR[=HER3]9\X
MR-,W'89RY&N[7<%ANW%;J0=GAMOT\;WK&'TBX\(L(SLKY=% 1?*=MA8-Y@07
M\=UKU;3^31CJ$QMFZGU#-EY0L6:L:M,>O[!<*K2;;7H55K<ZG<!L#>DDCH5K
M).5AJ*#047+LZ7B5.;43;=*S]:>6FY;C^0S,'',''Y1F5(V>-F_3>/:9"SD
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M._PK./*EX4SB?>734-SVY+Z'<.!.99,<)FP-ZJ)ZCQVE4^HD=FWLGQ*FUMQ
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M_D(YC^[_ /(KR%][[O\ ZI2_WO\ )^OKJNQ?_LWX;K_\UQ/_ .HCK@?JM_\
M\N[DZ?\ R#D.O3_RDW7W4ZZ-_P"I5/\ 9_ZK5_V>S_S2T]GV=:GG/_G>9_\
MC4O_ (C5T':O_P!C'&__ (AC_P#A)3IZU=;ZCI2CI2CI2CI2CI2CI2CI2CI2
MCI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2
MCI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2
MCI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2
MCI2CI2CI2CI2CI2CI2CI2CI2CI2FI</_ #:C_P"M?^N)_P#J?_YR_DEOY;_Z
GS_C?Y>WJ#2HC_P#U[_\ SS_\T?\ >?Z[_P"[_P#H=1^=3X>%?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
